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Abstract 
This thesis explores contrasting perspectives on what constitutes ‗good governance‘ for 
human embryonic stem cell (hESC) research. It asks whether there are systematic 
differences between perspectives of UK and US policy actors and what kinds of patterns 
are discernible. 
Biomedical technologies like hESCs generate complex interactions between public 
values, institutional interests, societal expectations and technological uncertainties. 
These pose serious governance challenges. Under such conditions, diverse aspects and 
implications of risk, ambiguity and uncertainty come into focus. We need appraisal 
processes that address these issues by combining quantitative and qualitative 
dimensions to ‗open up‘ divergent governance framings. The research framework 
employed here uses and further develops one such elicitation and analysis process called 
Multicriteria Mapping (MCM). MCM combines qualitative sensitivity with quantitative 
precision, while also aiding transparency and reflexivity in documenting and 
understanding diverse stakeholder perspectives. We therefore address ‗good‘ 
governance both as an analytical subject and as a rationale for testing a novel form of 
appraisal.   
The analysis discerns systematic patterns in perspectives on good governance across 
national contexts and between stakeholders, identifying several points of convergence 
and divergence. We examine underlying rationales behind individual perspectives, 
obtaining empirical support for recent theoretical arguments concerning technology 
appraisal and democratic deliberation. We find national policy literatures make greater 
use of moral and ethical language to frame governance challenges, by comparison with 
stakeholders‘ emphasis on institutional and socio-political factors. This suggests a more 
critical and cautious stance is needed towards the legitimatory language of ‗bioethics‘ in 
policy making. Finally, we explore some of the normative implications for governance 
of culturally sensitive and scientifically uncertain issues. 
By providing reflexive explanations of factors influencing perspectives of policy actors, 
this thesis makes a number of interlinked theoretical, methodological, empirical and 
normative contributions to understanding of how good governance of biomedical 
technologies is and should be conducted. 
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“If human embryonic stem cell research does not make you at least a little bit 
uncomfortable, you have not thought about it enough.”  
  
Professor Jamie Thomson
1
, creator of the first human embryonic stem cell line 
 
 
 
 
 
 
 
 
                                                 
1
 From an interview given to the New York Times on 22 November 2007 (Kolata, 2007).  
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1. Introduction 
1.1 The background context: November 1998 
In the week commencing the sixth of November 1998, the field of regenerative 
medicine took a major step forward. In the journal Science, Professor Jamie Thomson 
and colleagues published a three-page paper entitled ―Embryonic Stem Cell Lines 
Derived from Human Blastocysts‖ (Thomson et al., 1998). The paper concludes, 
―Progress in basic developmental biology is now extremely rapid; human ES cells will 
link this progress even more closely to the prevention and treatment of human disease‖ 
(ibid., p. 1147). In the journal Proceedings of the National Academy of Sciences, 
Professor John Gearhart and colleagues published a seven-page paper entitled 
―Derivation of pluripotent stem cells from cultured human primodial germ cells‖ 
(Shamblott et al., 1998). Their paper concludes that human pluripotent stem cells 
―would be invaluable for studies of some aspects of human embryogenesis and for 
transplantation therapies‖ (ibid., p. 13730).  
Human pluripotent stem cells are unique cells of the body that have the ability 
for both self-renewal and differentiation into any specialized type of tissue. It is these 
dual capacities which offer the greatest therapeutic hope for those suffering from 
debilitating conditions such as Alzheimer‘s disease or spinal cord trauma. For this 
reason, human embryonic stem cell (hESC) research is among the more exciting areas 
of biomedical science – attracting widespread public and political attention. However, it 
has also unleashed a fierce battle in many countries around the world as to the moral 
and ethical acceptability of this area of research. What is left unsaid in the conclusions 
of the Thomson and Gearhart papers is that in order to realise the promised therapeutic, 
biological and medical benefits, human embryos must be destroyed.  
This thesis investigates the implications of technological advance in this 
promising area of biomedicine by exploring contrasting perspectives on what constitutes 
‗good governance‘ for hESC research. It asks whether – and what kinds of –systematic 
patterns are discernible between perspectives of UK and US policy actors. Therefore, it 
critically examines how different understandings and determinations of good 
governance are constituted when scientific facts are uncertain, values are challenged and 
the political stakes are high. 
  
2 
1.2 Theoretical underpinnings 
In the field of hESC research, the building blocks of human life are literally 
taken apart and reconstructed for scientific study. Because of this, the research comes 
up against socially and culturally constructed boundaries about how we define ourselves 
as human, posing challenges to policy-makers and societies alike. This is readily 
apparent when the technology is considered in a comparative context. For example, 
despite having similar scientific capabilities, the UK and the US have contrasting policy 
environments around hESC research. The issue is particularly politically charged in the 
US, where restrictive federal funding policies have prevailed
2
 since the first forays into 
embryo and foetal tissue research in the mid-1970s. Conversely, the UK has one of the 
most permissive, yet highly regulated climates for hESC research in the world. The 
scientific details of hESC research and the relevant policy backgrounds in each country 
are reviewed in Chapter 2. 
While these divergent policy environments are easy to observe, a singular focus 
on different mechanisms of government does not tell us about how and why different 
policy approaches come to exist in each country. As Kooiman argues,  
the growing complexity, dynamics and diversity of our societies, as ‗caused by 
social, technological and scientific developments‘, puts governing systems under 
such new challenges that new conceptions of governance are needed (Kooiman, 
1993, p 6).   
This suggests a more holistic approach to analysis with a wider governance focus is 
needed: one that looks at, and beyond, the institutions and instruments of government, 
to the wider social processes and discourses that influence the development of 
governance trajectories. By adopting such a ‗socio-political‘ view on governance, we 
argue one can more readily analyse observed differences in policies, regulatory regimes 
and collective social problem-solving in contested areas of the biosciences. Governance 
is thereby positioned as a lens through which to understand how perspectives on good 
governance are constituted and constructed among different segments of society.  
 The theoretical literature on governance is reviewed in Chapter 3, in which an 
understanding of governance for this thesis is developed. In particular, normative 
conceptions of governance within the theoretical and academically oriented literature 
                                                 
2
 Despite the fact that in July 2009, US President Barack Obama overturned some aspects of the federal 
funding policy for hESC research established by his predecessor, President George W. Bush, there are 
still restrictions on federal funding of the research. In addition, many US states have restrictive regulatory 
policies banning research on embryos or embryonic tissue of any kind, including hESCs.  
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are explored. Based upon this review, three central dimensions of governance are 
developed and their different axes and orientations are applied within the 
methodological component of the thesis.   
1.3 Empirical approach 
The central research question of this thesis builds on the argument presented 
above that advances in the biosciences (or arguably in science and technology as a 
whole) have resulted in complex, value-laden controversies in modern societies (Davies 
et al., 2003). These controversies serve both to reinforce the notion of risk as a 
culturally embedded phenomenon (Beck, 1992) and to challenge traditional modes of 
political and social governance as we grapple with an increasing entanglement of 
cultural values and technological issues. This thesis is therefore concerned with how 
perspectives on ‗good governance‘ for hESC research are constituted. It asks whether – 
and what kinds of – systematic patterns emerge between the perspectives of UK and US 
policy actors. The hypotheses below follow from these questions:   
• It is possible to discern discrete perspectives on good governance, and 
systematic differences in these between and within groups of policy actors in the 
UK and the US. 
• Among these perspectives, patterns and regularities can be elucidated and 
analysed between and within national and cultural settings.  
• Methods of empirical analysis can allow us to understand how the perspectives 
on good governance are constituted and the kinds of patterns that emerge 
between them. 
• Distinctions between, and patterns within, perspectives on good governance 
from policy actors can be compared with the formal policy literature in each 
country and discernible distinctions can be analysed. 
• Conclusions made may have normative implications for understandings of how 
good governance of biomedical technologies should be conducted under 
conditions of risk, uncertainty and ambiguity. 
In order to test these hypotheses, a methodological approach is needed that appreciates 
the contingencies and sensitivities shaping contrasting perspectives. 
Technologies like hESC research have a powerful potential, both therapeutic and 
scientific, but this potential is uncertain, and to a large extent unproven, with unknown 
biological and long-term consequences. Conditions of scientific risk and uncertainty 
abound where the stakes are high, the assumptions vary and technological futures are 
unknown (Funtowicz and Ravetz, 1993). A range of approaches exist which, their 
proponents claim, enable us to arrive at robust decisions in such contexts. These more 
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established approaches to risk management have long enjoyed the standing of objective, 
‗scientific‘ methods, but their authoritative status is increasingly coming under question.  
In particular, there is growing recognition of the role that social sciences have to 
play in decision-making (Fineberg et al., 1996). Amongst other insights, work in the 
field of science and technology studies has shown how expert-based and ‗technocratic‘ 
decision analysis processes are subject to various framings and interpretations. These, in 
turn, can influence the ultimate policy choice (Jasanoff, 1990; Stirling, 1998; Wynne, 
2001). More to the point, they can effectively ‗close down‘ decision-making processes 
around particular sets of assumptions, while ignoring the alternatives associated with 
others (Stirling, 2008). This highlights the importance of acknowledging the diversity of 
views on risk, the ambiguities over the merits of alternative decisions, and the inherent 
uncertainties and ignorance that are ever present (Stirling, 2003). Procedures that can 
address these issues by incorporating quantitative and qualitative dimensions can ―open 
up‖ divergent socio-technical framings of risk in order to explore their wider 
implications (Stirling, 2004, 2008). 
Using hESC research as a case study, the research framework combines qualities 
of reflexivity, transparency and accountability in eliciting the views of divergent groups 
of stakeholders and analysing the perspectives for systematic patterns between groups 
and across national contexts. By reflexivity, we mean the framework engages 
symmetrically with different normative and epistemic positions, including that of the 
researcher. We address this by allowing for multiple units of analysis to be considered 
such that the central research question can be asked from, and of, multiple perspectives. 
This occurs at two levels, first through the eliciting of perspectives on good governance 
from national policy actors, and from academic and policy literatures. Second, in the 
analysis of these perspectives, the research question is asked of different analytical 
subjects and is repeatedly interrogated at each analytical step. Thus, each configuration 
of the data is reflexively examined in such a way that the contingencies and sensitivities 
framing contrasting perspectives on good governance can be explored. This reflexive 
approach will become clearer as it is employed in different stages of the thesis.  
The particular research method used, Multicriteria Mapping (MCM), is a novel 
elicitation and analysis process incorporating elements both of qualitative sensitivity 
and quantitative precision (Stirling and Mayer, 1999). With it, one can document the 
nature and implications of divergent framings in appraisal – in this case, those 
concerning the governance of technological advance. It allows participants freely to 
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characterise and evaluate an unconstrained array of governance frameworks (as 
‗options‘) and to identify their respective strengths and weaknesses under contrasting 
notions of ‗good governance‘ (as evaluative ‗criteria‘).  
As the methodology itself is so centrally intertwined with the theoretical 
approach of the thesis, significant attention is given to it in Chapter 4. However, it is 
worth pointing out here that though the unit of analysis in this thesis is ‗perspectives on 
good governance‘, and both the elicitation and analytical methods are focussed on 
discerning patterns within these, this is not meant to imply that a particular, fixed set of 
perspectives exist that we will somehow definitively identify in this thesis. Rather, 
within these perspectives various elements, ideas and notions of, as well as underlying 
rationales and motivations for, good governance may exist that contribute to the ways in 
which the perspectives themselves are constituted. It is these aspects that will be 
referred to throughout the text. More precisely, then, it is our belief that a continuum of 
perspectives exists and the point is to try and understand what this set of continua might 
be, the patterns that exist between them, the implications for wider theory-building and 
the understandings of good governance that result.  
1.4 Empirical findings and contributions 
 The findings of this study are presented in four main empirical chapters. The 
first of these, Chapter 5, presents a detailed review of a subset of the UK and US 
national policy literatures. Four themes of good governance are identified as pervasive 
in both sets of national literatures. These themes concern the extent to which good 
governance: i) advances scientific and technological outcomes and addresses related 
issues in hESC research; ii) encourages moral and ethical awareness of hESC research; 
iii) establishes appropriate institutions and instruments of oversight for hESC research 
and iv) is identifiably grounded in social and cultural bases. Within these themes, we 
find that patterns emerge between UK and US contexts. These include: a) contrasting 
framings of the nature of hESC research in relation to desired scientific and 
technological outcomes (or the governance trajectory), b) divergent presentations of the 
embryo coinciding with similar use of moral and ethical language to discuss governance 
issues, c) contrasting institutional perspectives on governance in terms of outcome or 
process-based characterisations of policy approaches, and d) similar levels of reliance 
on bioethics as a legitimatory policy advisory tool. 
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 These four themes of good governance are used to frame comparative analysis 
of perspectives on good governance across national cases and empirical contexts. 
Chapters 6 and 7 present these findings from the 57 MCM interviews conducted for this 
study. Chapter 6 presents the findings as analysed in terms of aggregate national UK 
and US perspectives. Chapter 7 presents the findings as analysed according to various 
groupings of socio-political stakeholder perspectives across each national context.  
We find first that systematic variations in perspectives on good governance can 
be discerned across and within different national settings and various groupings of 
stakeholders. MCM was found to offer a robust elicitation and analysis method, in that 
it proved capable of engaging diverse participants from contrasting national and 
stakeholder settings; characterising their complex and (often) divergent perspectives; 
and securing participants‘ agreement with the ‗results‘ of their interviews. These aspects 
suggest there is broad applicability of the findings across the national contexts and 
diverse perspectives. We find that the patterns in interviewee perspectives can be 
analysed and interpreted according to the four themes of good governance discussed 
above. In addition, when compared against the patterns identified in the policy 
literature, distinct differences emerge between these respective literatures and national 
interviewee perspectives.  
 In the final empirical chapter, Chapter 8, the theoretical, methodological, 
empirical and normative strands of the research are joined together and contributions are 
made in four areas. We find that underlying rationales and motivations for perspectives 
on good governance can be distinguished according to similar imperatives to those 
presented in recent theoretical literatures. This lends empirical support to an emerging 
area of theory concerning technology appraisal and democratic deliberation. A contrast 
is observed between the moral and ethical characterisation of governance discussions in 
national policy literatures and the noticeably more socio-political and institutional 
characterisation of governance issues in perspectives elicited directly from stakeholders. 
This raises questions over policy reliance on bioethics and interdependencies between 
the two. The findings suggest a cautious and critical evaluation may be called for of the 
legitimatory language of bioethics. Finally, we argue that the systematic patterns in 
perspectives on good governance at both national and stakeholder levels suggest that 
while national comparisons are useful for identifying broad cultural tendencies, they 
risk overlooking the richness and complexities that exist within societies, as well as 
between them. 
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2. The science of human embryonic stem cell research 
and its policy context 
2.1 Constructs of Life: Stem cell science explained 
2.1.1 Overview 
At the US Democratic Party National Convention in 2004, Ron Reagan Jr asked 
the assembled audience a simple question: ―How‘d you like to have your own personal 
biological repair kit standing by at the hospital? Sound like magic? Welcome to the 
future of medicine‖ (Reagan, 2004). With this statement, he drove home a point about 
the high stakes which rest upon policy decisions in an area riddled with expectations, 
uncertainty and controversy. Proponents of human embryonic stem cell (hESC) research 
promise it has the ability to provide therapies for a range of illnesses, as well as insights 
into the process of basic biological development. Such insights may, themselves, lead us 
to further therapies and technologies. Many opponents see hESC research as an affront 
to human dignity, believing that the use of the human embryos for research purposes is 
not justified and/or that scarce resources should not be spent on this area of science 
when more pressing issues of national health still remain.  
The technologies and biomedical therapies that may enable realisation of Mr. 
Regan‘s promised future are born out of controversial scientific developments that are 
pervaded by social values, institutional interests and cultural norms. This intensifies the 
challenges for policy-makers and governance, more generally. While this latter point is 
the broader subject of this thesis, this chapter sets the stage for the discussion. It reviews 
the salient scientific, technological, political and regulatory aspects of hESC research 
with a specific focus on the US and the UK. This background will be used in Chapter 4 
to justify why the US and the UK were selected as case study countries.  
2.1.2 The basics of stem cell science 
Developmental biologists have been studying stem cells and steadily making 
new discoveries about the process of embryonic development and the behaviour of stem 
cells since the 1950s (as described in detail by Parsons, 2004; Scott, 2006). Incremental 
developments (such as perfecting the culture medium, or ‗soup‘, on which cells are 
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grown in the laboratory) and radical innovations (like the first successful nuclear 
transfer experiment) moved the field forward. But – until the 1980s – there was still a 
feeling that the great potential of stem cells had yet to be unlocked. 
In 1981, a major step forward was taken when two different laboratories 
successfully cultured mouse embryonic stem cells (Evans and Kaufman, 1981; Martin, 
1981). Three years later, Steen Willadsen, a rather unknown scientist working at the 
British Agricultural Research Council‘s Unit on Reproductive Physiology and 
Biochemistry, cloned a sheep working with embryonic cells (Scott, 2006, p. 45). This 
latter achievement went unpublished and barely made the newspapers, but the scientific 
technique it employed laid the groundwork for the work of Professor Sir Ian Wilmut‘s 
lab at the University of Edinburgh. In 1996, his lab became the first to clone a mammal 
from an adult cell (Campbell et al., 1996). Resulting pictures portraying ‗Dolly‘ the 
clone with her genetically-identical mother made front-page headlines worldwide.   
In 1998, the field‘s scientific glass ceiling was broken. In publications appearing 
in the same week, the laboratories of Jamie Thomson at the University of Wisconsin, 
Madison, and John Gearhart at Johns Hopkins School of Medicine in Baltimore, 
Maryland, announced two scientific breakthroughs that would alter the landscape of 
their fields, both scientifically and politically. Thomson announced the derivation of the 
first pluripotent hESC lines from human embryos (Thomson et al., 1998), while 
Gearhart‘s lab had derived pluripotent human stem cell lines from foetal germ tissue 
(Shamblott et al., 1998). The eyes of the world were opened to this astounding area of 
science. Regenerative medicine suddenly seemed less the stuff of science fiction and 
more a medical reality. In Congressional testimony given in December 1998, former 
NIH Director Harold Varmus commented that the discoveries of Thomson and Gearhart 
were ―unprecedented‖ and that it was ―not too unrealistic to say that this research has 
the potential to revolutionize the practice of medicine and improve the quality and 
length of life‖ (Varmus, 1998). 
But what are these cells and how do they function? Why are they so critical to 
human development, and why do scientists and others think they have such great 
potential? The next two sections will review the scientific characteristics of stem cells 
and discuss their use and potential in science and medicine. Establishing these scientific 
principles will be critical to understanding the nuances of policy and governance 
challenges in this area.  
  
9 
2.1.3 Characteristics of stem cells 
Stem cells are unique cells that have two defining characteristics: they are able 
to self-renew and they are, to varying degrees, undifferentiated, meaning they have the 
potential to develop into at least one other type of specialised ‗descendant‘ cell. This 
dual capacity of stem cells is what offers the greatest hope and potential for applications 
in regenerative medicine (NRC and IOM, 2005), but, as we shall see, it is also what 
leads to the controversy surrounding further research in this area of biomedical science. 
Figure 1.1 (below) illustrates these two defining characteristics, plus a third specific to 
embryonic stem cells—their origin in the pre-implantation embryo. 
Figure 2.1
3
: Characteristics of human embryonic stem cells 
 
 
There are three main types of stem cells: embryonic stem cells, adult stem cells 
and foetal stem cells. Adult stem cells are considered to be multipotent. They have a 
limited developmental potential as they have already gone some way down a cell-
specific developmental pathway, but they have not fully differentiated. Thus while a 
blood stem cell can further differentiate into a white or red blood cell, it cannot, to our 
                                                 
3
 Figure 2.1 is from an article entitled ‗Embryonic Stem Cells‘, published in the NIH publication 
Regenerative Medicine (Yu and Thomson, 2006, p. 2). 
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knowledge, differentiate into a skin cell
4
. Adult stem cells are found in differentiated 
tissues of the body including the brain, umbilical cord and placental blood, skeletal 
muscle, teeth, skin and liver.   
Unlike adult stem cells, embryonic stem cells are pluripotent, meaning they have 
the ability to develop into any cell of the three main tissue layers of the body, the 
endoderm, ectoderm and mesoderm (shown above in Figure 2.1). Pluripotent stem cells 
can divide indefinitely in culture and are considered extremely malleable, that is, 
researchers can manipulate them and coax them to become different tissue types without 
the cells losing any cellular function. Embryonic stem cells are derived from a 
primitive, undifferentiated state of development: the pre-implantation embryo (NAS, 
2006). Herein lies much of the controversy surrounding hESC research as, currently, the 
only way to derive and study ES cells results in the destruction of a developing embryo 
(described below). The final class of stem cells for which there is a scientific 
classification are totipotent stem cells. These have the potential to form a whole new 
organism in and of themselves (an ability pluripotent cells do not possess) (Holland et 
al., 2001) and they would have to be derived from the very early embryo, or zygote 
stage (see below). Researchers do not derive embryonic stem cells from such an early 
stage of development and most embryonic stem cells are, therefore, discussed in terms 
of pluripotency.  
Finally, foetal stem cells are derived from the gonadal ridge
5
 of foetuses in an 
early stage of development (NRC and IOM, 2002). These stem cells are technically 
multipotent in character and so are not as easy to work with as ES cells (NRC and IOM, 
2005). However, they have been shown to give rise to cells of all the main tissue layers, 
proving they retain some features of pluripotency. Much of the remaining discussion in 
this chapter will focus on embryonic stem cells, but there will be some space devoted to 
recent developments in the science that relate to alternatives to embryonic stem cells. 
2.1.4 Deriving embryonic stem cells 
 Embryonic stem cells can be derived in two main ways: from the inner cell mass 
of a developing blastocyst, or by nuclear transfer (NT). Both methods require that the 
embryo be destroyed at an early stage in its development, usually around the fifth or 
                                                 
4
 However, recent developments in the science have shown that fully differentiated cells, such as skin 
cells, can be induced to return to their pluripotent state. These cells, known as induced pluripotent cells 
(iPS), will be discussed later in this chapter. 
5
 The gonadal ridge eventually develops into eggs or sperm in the adult human being.  
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sixth day after fertilisation. However, we need to have a basic understanding of the 
development of the embryo, from the point of fertilisation through to implantation of the 
embryo in the uterine wall, before discussing how these derivation processes work. 
Figure 2.2
6
: Preimplantation development of the embryo 
 
 
 As shown in Figure 2.2, in its earliest stages the ‗embryo‘ is not referred to as an 
embryo, but by a series of terms that describe the different stages of development. In 
fact, before the embryo is considered to be a foetus, it passes through over 20 stages of 
embryonic development that are scientifically distinct. At the earliest stage, immediately 
after fertilisation of the oocyte by the sperm, the embryo is referred to scientifically as a 
„fertilized egg zygote‟, or simply a zygote. The zygote then enters a cleavage stage 
where it divides approximately once per day, with no net growth in its size. Cleavage 
continues until Day 3 or 4, at which point a ball of cells called the morula begins to 
form. At Day 5, the morula has hollowed out and is now a blastocyst. The blastocyst has 
two distinct cell types—an outer layer of cells called the trophectoderm (which becomes 
the placenta) and an inner layer of cells called the inner cell mass (ICM). Throughout 
these early growth stages, the developing embryo is no bigger than the dot above an ‗i‘ 
on a piece of paper.  
 It is the pluripotent cells of the ICM that will eventually grow, multiply and 
differentiate into all the cells of the human body. However, the cells of the ICM only 
exist in this state for a brief period of time. At Day 6, the blastocyst is implanted into the 
uterine wall and the placenta begins to develop from the trophectoderm. At this point, 
the cells of the ICM begin further differentiating into the cells and tissues of the foetus, 
forming first what is known as the embryonic disc. At about two weeks after 
fertilisation, ―the first recognisable features of the embryo proper will appear‖ 
(Warnock, 1985). The first of these, and most significant for regulatory purposes as will 
                                                 
6
 Figure from the NAS Guidelines for Human Embryonic Stem Cell Research (NRC and IOM, 2005, p. 
30) 
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be shown later in this chapter, is the primitive streak. This appears as a grouping of cells 
at one end of the embryonic disc at the fourteenth or fifteenth day after fertilisation. It is 
one of the earliest recognisable features of the developing embryo. One month after 
fertilisation, cells in the developing embryo begin to work together, a primordial heart 
begins to beat, and by two months after fertilization, all the major organ systems have 
developed (Scott, 2006). It is at this point, approximately seven or eight weeks after 
fertilisation, that the ‗embryo‘ phase is considered to end and the foetal stage of 
development begins. 
 As alluded to earlier, it is at the earliest stages of embryonic development that 
embryonic stem cells are derived. The derivation process (see Figure 2.3) first requires 
extracting the cells of the ICM from the blastocyst just before it would (in theory) be 
implanted into the uterine wall, usually around Day 5 or 6.
7
 Once the ICM is removed 
from the blastocyst, the cells are transferred to a special culture medium that contains 
the right set of nutrients for the cells to continue growing. This medium is meant to 
simulate the environment the cells would experience in the developing blastocyst if it 
were frozen in time. Therefore, the culture medium allows the cells to grow in their 
‗stem cell‘ state indefinitely. Scientists can then take stem cells from this medium and 
stimulate them to differentiate into specific tissues for scientific study. 
                                                 
7
 We say ‗in theory‘ because the process of derivation is actually conducted in vitro, not in utero, so there 
is no ‗real‘ uterine wall for the blastocyst to attach to when ES cells are derived in the laboratory. 
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Figure 2.3
8
: Derivation of embryonic stem cells from a fertilized embryo 
 
Pluripotent embryonic stem cells can also be derived through a process called 
nuclear transfer (NT). Figure 2.4, below, illustrates the most commonly known NT 
process called somatic cell nuclear transfer (SCNT). In SCNT, a single cell is taken 
from an adult somatic (or fully differentiated) cell and the nucleus of that cell is then 
removed. This nucleus is then placed into a separate ‗donor‘ egg which has also been 
enucleated. The newly created cell is given a stimulus to encourage it to begin growing 
and dividing as a blastocyst. As above, at the appropriate time the ICM is then removed 
from the blastocyst and a culture of embryonic stem cells is made that are genetically 
identical to the original adult somatic cell. Nuclear transfer can also take place using 
other types of cells, for example donated cells from another developing blastocyst. 
                                                 
8
 Figure 2.3 is from an article entitled ‗Embryonic Stem Cells‘, published in the NIH publication 
Regenerative Medicine (Yu and Thomson, 2006, p. 1). 
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Figure 2.4
9
: Somatic Cell Nuclear Transfer 
 
 
By using the NT processes, the embryonic stem cell line that is created is 
genetically identical to whatever ‗donor‘ cell it came from. This is one reason why this 
technique is commonly pointed to as having a great potential to lead to actual therapies 
from stem cell research. SCNT is the technique that was used to clone Dolly the sheep 
and it is one you could envision being used to create patient-specific stem cells that can 
then be injected back into the patient with the hope they will replace the damaged tissue. 
For this reason, SCNT is sometimes referred to as ‗therapeutic cloning‘. However, to 
date no one has been able to clone a human embryo, nor derive a human embryonic 
stem cell line, in this way or through any other procedures.
10
  
For both methods of deriving embryonic stem cells, there are three main sources 
of hES cells: blastocysts remaining from IVF clinics or fertility treatment centres and 
donated for research; blastocysts generated from donated gametes; or products of NT. 
                                                 
9
 Figure 2.4 is from the National Academy of Sciences publication Understanding Stem Cells (NAS, 
2006, p. 6) 
10
 In November 2007 a primate embryo was successfully cloned for the first time (Byrne et al., 2007). 
This development allayed many fears that there was some unknown characteristic of primate embryos, 
and hence human embryos, that would prevent successful cloning at any point. Then, in January 2008, 
Stemagen (a San Diego, CA based embryonic stem cell research company) published a paper claiming 
they had created human blastocysts using SCNT. These blastocysts were only viable up to various stages 
of development and never reached a stage where the ICM could be extracted. See (French et al., 2008) for 
further details. 
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Out of these three sources, egg donation, in particular, is a recent topic of much debate. 
There are divided camps on whether women should be paid to donate their eggs to 
research, and, if so, how much. Some argue this is a necessary scientific resource and 
women should be compensated for the difficulty and hardship associated with egg 
donation. Others argue this will create an unwanted market for women‘s eggs and will 
pose too great a risk to the health of the woman. Recent legislation in the UK has made 
it legal for scientists to use animal oocytes as the ‗vessel‘ in which to grow the 
blastocyst to the appropriate stage for removal of the ICM and derivation of an 
embryonic stem cell line. Scientists argue that the creation of so-called ‗cytoplasmic-
hybrid‘ embryos is a welcome alternative to egg donation in the light of egg donation 
problems, but opponents argue this would amount to egregious ethical violations and 
could lead to the creation of ‗Frankenbunnies‘ (Watts, 2009). 
 In addition to the methods of deriving hES cells from blastocysts, scientists have 
had some success in identifying possible alternative sources of embryonic stem cells 
that do not require the destruction of an embryo. However, there is some debate as to 
how viable these alternative methods are and the quality of the hES cells they produce. 
For example, in 2007, Dr. Anthony Atala and colleagues isolated hESCs from amniotic 
fluid and showed they grow just as fast as embryonic stem cells and exhibit strong 
pluripotent characteristics (De Coppi et al., 2007). In the wake of that announcement, 
however, it was the researchers themselves who stressed their findings should not be 
used as an argument for discontinuing embryonic stem cell research (Weiss, 2007). 
Their point was that all scientific opportunities should be pursued and different methods 
had different advantages. 
 In November 2007, research groups in Japan (Takahashi et al., 2007) and at the 
University of Wisconsin (Yu et al., 2007) reported they had successfully de-
differentatied somatic cells, meaning they had literally ‗wound back the clock‘ on adult 
somatic cells. These induced pluripotent stem cells, or iPS cells have (so far) exhibited 
many of the traits that characterize embryonic stem cells
11
, but with none of the 
controversy surrounding the destruction of an embryo. Since this is such a new area of 
stem cell biology, studies are ongoing to compare them to pluripotent hESCs, which 
                                                 
11
 Mouse iPSCs show important characteristics of pluripotent stem cells, including expressing stem cell 
markers, forming tumors in all three germ layers, and being able to contribute to many different tissues 
when injected into mouse embryos at early stage of development (Takahashi and Yamanaka, 2006). 
Human iPSCs also express stem cell markers and are capable of generating cells characteristic of all three 
germ layers (Takahashi et al., 2007; Yu et al., 2007). 
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continue to be described as the ‗gold standard‘. However, creating iPS cells requires 
using viral vectors. These vectors carry genes that reprogram the original cell to its 
pluripotent state, which is useful for the science, but one of these viral vectors is known 
to cause cancer, which means the cells could not be used for medical therapy. 
Nonetheless, many disease-specific stem cell lines have already been created and 
scientists are able to study their behaviour in vitro. It is seen by many scientists and 
non-scientists alike as an exciting development; one that could potentially obviate the 
need to use embryos in research, but that day is still a long way off. 
2.1.5 Human embryonic stem cell technologies 
 As has been alluded to in the preceding discussion, the pluripotent characteristic 
of embryonic stem cells suggests they may have wide-ranging uses. As illustrated in 
Figure 2.5, there are generally three main applications wherein lies the greatest potential 
for the application of embryonic stem cell technology.  
Figure 2.5
12
: Some of the Promises of Stem Cell Research 
 
 
 First, it is claimed hESC research can lead to improvements in our 
understanding of basic biological development. Such improvements could lead to 
insights into treatment of fertility problems or prevention of birth defects. Second, 
embryonic stem cells can be used by the pharmaceutical industry to test the properties 
                                                 
12
 Figure 2/5 from an article entitled ‗Embryonic Stem Cells‘, published in the NIH publication 
Regenerative Medicine (Yu and Thomson, 2006, p. 3).   
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of new drugs, thereby providing ways to improve their safety and efficacy. Currently, 
many new drugs are tested on animal models because no human cells exist for the study 
of drugs at the pre-clinical trial stage. If, for example, a stem cell line of human heart 
cells were developed, researchers could use these cells to better understand how the 
drugs work. Efficacy and safety could be improved and tested even before clinical trials 
on humans began. This would be a major improvement in the pharmaceutical industry‘s 
testing model and we are indeed already beginning to see the positive effects of stem 
cell science in this regard (Baker, 2010).  
 Finally, and perhaps most widely hoped for, is the development of hESC 
technologies for use in medical therapies. Such ‗regenerative medicine‘ technologies 
could be restore or repair damaged tissue in the body, such as heart, neural, pancreatic, 
or spinal tissues. Stem cells have already been used in such a regenerative way for many 
years in the use of haematopoietic stem cells (found in bone marrow) to treat blood 
cancer patients. A successful bone marrow transplant can mean regeneration of all the 
cells of the haematopoietic system, including red blood cells, platelets, lymphocytes, 
etc. (Domen et al., 2006).  
 However, though haematopoietic stem cells have been proven to work in 
therapeutic contexts, they are adult stem cells and thus have limited (or no) therapeutic 
potential for other tissue types. Embryonic stem cells, on the other hand, are more 
versatile and could be used, for example, to generate cardiomyocytes for heart disease, 
neural cells for neurologic diseases, islet cells for diabetes, skin grafts for burn victims, 
and so on. The list is long and the hopes of patients afflicted with debilitative and 
degenerative diseases are high. From the period 2006-2009, the US National Institutes 
of Health (NIH) spent $343 million on human embryonic stem cell research, and $3.78 
billion on stem cell research overall. Estimates for spending in 2010 are $1.182 billion 
for stem cell research and $137 billion for hESC research (NIH, 2010). US states active 
in funding stem cell research are estimated, as of 2007, to be spending $528 million per 
annum (Fossett, 2007). Private funding estimates are difficult (if not impossible) to 
obtain, but one estimate done in 2007 calculates $1.7 billion was spent by a small group 
of major US advocacy groups, philanthropic foundations, and others (ibid.).   
 Across the Atlantic, the 2005 UK Stem Cell Initiative report called for an 
increase of £200-272 million in basic stem cell research over the 10 year period from 
2005-2015 and a further increase of £83-87 million in clinical and translational research 
over the same 10 year period, coupled with a concurrent rise in National Health Service 
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(NHS) research and development (R&D) funding of £36m per annum. These sums are 
large and serve to underscore the weight and importance accorded by national 
governments and funders of research in this area. However, they do not tell the whole 
story of how research is carried out in each country, nor the policies that are in place to 
oversee it. The remainder of this chapter sets out the policy histories pertinent to human 
embryonic stem cell research in the US and the UK, identifying the social, cultural, 
historical and legal contexts in which policy has developed over time. 
2.2 Governance of human embryonic stem cell research in 
the United States 
2.2.1 Overview 
 In the US, the history of embryo research seems marked by continued 
uncertainties, political contention, and mixed regulatory environments. Until recently,
13
 
federal and legislative regulations restrict federal funds for the majority of hESC 
research, but there are a variety of approaches being adopted at the state level and 
within individual research institutions. This inconsistent and rapidly changing research 
and policy landscape has been described by several commentators as akin to a 
‗patchwork quilt‘ (see, for example, NRC and IOM, 2005). The next section looks at the 
history of foetal tissue and embryo research policy in the US, as it is this history that has 
had a significant impact on the current policy and regulatory climate for hESC.   
2.2.2 History of foetal tissue and embryo research policy in the US 
Many would argue that the debate over hESC research is ―inextricably linked 
with the abortion debate‖, which has polarised American society (Wertz, 2002, p. 143) 
since the 1973 Supreme Court decision ‗Roe v. Wade‘. The politics of abortion clearly 
play a major role when it comes to the status of the embryo and hESC research, but we 
will not be addressing the full scope of that debate in the discussion here. This is partly 
because a recounting of the policy history of that debate, specifically, is outside the 
scope of this thesis. Though the issues shaping the abortion debate do intersect with the 
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 See footnote 1 on page 2 related to the recent changes to federal policy under President Obama which 
occurred during the course of writing up this thesis. All empirical research conducted for the thesis was 
undertaken during the term of President George W. Bush, when more restrictive federal policies 
prevailed, and so these will be the focus of policy history text below. 
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issues around embryo research (for example, concerns over the moral and legal status of 
the embryo), the purpose of this thesis is to consider multiple and symmetrical 
perspectives on hESC research. Therefore, we need (quite deliberately) to avoid the 
polarisation that is present in the abortion debate, but still allow for the views which 
frame that debate and, subsequently, those on hESC research, to be addressed. The 
methodology employed in this thesis can address this, and does not require a full 
recounting of the policy history of abortion to do so. 
Instead, we will start our story in the late 1960s when the American scientific 
community, as well as the national public, were shocked to learn about the human rights 
abuses in the Tuskegee Syphilis Trial. In order to understand the long-term effects of 
syphilis, researchers with the U.S. Public Health Service denied treatment to 399 poor 
African American men and instead talked them into participating in a study of which 
they were told little. The researchers were simply interested in studying the progression 
of the disease and so withheld all treatments from the men (Fairchild and Bayer, 1999). 
When the study was exposed in the national media, outrage followed. It was, in many 
ways, a final straw in a list of growing concerns about the conduct of research on human 
subjects and in the early 1970s the US government set out to reform and overhaul the 
regulatory system for human subject research. A few years later, the U.S. Congress 
passed the National Research Act of 1974, which established the National Commission 
for the Protection of Human Subjects of Biomedical and Behavioural Research. This 
Commission was to make recommendations on the ethical conduct of human subjects 
research in the US, including foetal tissue research. In this latter area, the Commission 
recommended that an ethics body be established to oversee and advise on federally 
funded research in this area.
14
 
The timing was apt. Just as the newly created Ethics Advisory Board (EAB) was 
coming into existence, the world‘s first ‗test-tube baby‘, Louise Brown, was born in 
1978 through the help of in vitro fertilisation (IVF) technology. With this birth, the need 
to specifically address the use of embryos and foetal tissue in research became more 
immediate. Under Federal regulations (45 CFR 46), the EAB was to oversee and 
approve all federally funded research on foetuses and foetal tissue that originated from 
abortions. The EAB also considered the ethical issues of the research, recommending 
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 Due to the nature of federal funding for biomedical research in the US, restrictions on federal funding 
are generally respected by institutions that are recipients of federal funds, even for research funded in 
other ways, to prevent the risk of losing eligibility for federal funding of other research projects. 
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that federal funding of research aimed at increasing the safety and efficacy of IVF and 
embryo transfer would be acceptable, provided ethical safeguards were followed (NIH, 
1994). However, in 1980 the charter for the EAB expired and President Reagan never 
renewed it, an action that resulted in a de facto moratorium on all federally funded 
foetal tissue, IVF and embryo transfer research for the next 13 years. 
Federal regulations (45 CFR 46) remained on the statute books until 1993 when 
the National Institutes of Health (NIH) Revitalization Act of 1993 was passed and the 
regulatory requirement for EAB review was removed. With this Act of Congress, it was 
made explicit that funding of ―peer reviewed and approved research proposals involving 
assisted reproductive technologies‖ would be permitted (from NIH, 1994, p. 1). 
However, before funding any research of this nature, NIH commissioned an expert 
panel to study the moral and ethical issues that were involved. The Human Embryo 
Research Panel (HERP) recommended that federal funds should be used to fund human 
embryo research, including the creation of human embryos, provided they were not used 
for human cloning (NIH, 1994). After receiving thousands of letters expressing unease 
with the idea of federal funding of embryo research, President Clinton rejected the 
panel‘s findings on this latter point. 
In 1995, the U.S. Congress created a more permanent barrier to federal funding 
of embryo research. The Dickey-Wicker Amendment was passed in 1995 as a rider to 
the annual NIH appropriations bill. It essentially states that no federal funds can be used 
to create human embryos or to conduct research in which they are destroyed. This 
amendment has been attached to every single appropriations bill since, seeming to 
create a permanent roadblock to federal funding of any embryo research, including 
hESC research.  
With the derivation of the first hESC line in 1998, however, the NIH requested a 
legal opinion on whether the Dickey Amendment precluded them from funding such 
research. Harriet Rabb, General Counsel to the Department of Health and Human 
Services in the Clinton Administration, concluded that the amendment does not 
explicitly prohibit research on embryos once they have been destroyed (Rabb, 1999). 
This essentially gave the green light to the NIH to begin funding research on hESCs, so 
long as the initial creation of the stem cell lines was done using private funds. The NIH 
began to develop guidelines for hESC research and published them in final form in the 
Federal Register on August 25, 2000 (Kirschstein, 2000). After a period of consultation 
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and further revision, the NIH began receiving the first grant applications for hESC 
research in the spring of 2001.  
By this time, however, President George W. Bush had been elected and his 
campaign rhetoric suggested he was not supportive of hESC research. Nonetheless, the 
NIH Human Pluripotent Stem Cell Research Group was set to meet on 25 April 2001 to 
review the first stem cell research grant applications. However, the meeting was 
abruptly cancelled so that a full scientific review could be conducted (Weiss, 2001). 
Three months later, President Bush used the first nationally televised speech of his 
presidency to declare that no federal funds could be used for embryo research where the 
embryo would be destroyed or harmed. Therefore, federal funds could only be used for 
research on embryos or embryonic stem cell (ESC) lines that were created on or before 
the date and time of his speech (9:00pm EST on 9 August 2001).  
President Bush presented his declaration as a compromise, claiming that 
approximately 78 hESC lines already existed and these would be sufficient for 
researchers to be able to continue research in what he acknowledged was a promising 
field with medical potential. However, it quickly became clear that only 23 of these 
lines were available for use by researchers, and none of them could ever be used to 
develop medical treatments because they were originally grown on mouse feeder cells, 
making them unsuitable for use in humans (Scott, 2006). As time went on, the number 
of viable cell lines decreased further, and researchers were left looking elsewhere for 
funding and guidance as to the conduct of the research itself. 
2.2.3 A regulatory patchwork for hESC research? 
Aside from President Bush‘s restrictions on federal funding for hESC research 
and the Dickey Amendment, there were no federal regulations or legislation specific to 
hESC research at the time this thesis research was conducted. However, it would be 
misleading to say it was an unregulated area of research as federal regulations broadly 
covering the field of biomedicine apply to both privately and publicly funded hESC 
research. These include:    
• Human subject protections for donors of oocytes, somatic cells and embryos; 
• Medical privacy protections; 
• Laboratory standards laws enforced through the Clinical and Laboratory 
Amendments of 1988 and the Fertility Clinic Success Rate and Certification Act 
of 1992; 
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• The Public Health Service Act that imparts statutory authority to the U.S. Food 
and Drug Administration (FDA) to regulate biologics,
15
 including embryonic 
stem cells, should it choose to; 
• Institutional Review Boards (IRBs) set-up to oversee federally funded research 
at individual research institutions across the country; and 
• FDA standards of laboratory practice for any research supporting applications to 
the FDA for regulatory approval (NRC and IOM, 2005). 
In addition, many states have passed legislation designed to either restrict or to fund and 
support hESC research. Thus, as we pointed out before, many liken the US policy 
situation for hESC research to a regulatory ‗patchwork quilt‘. In this regard, it is 
important to note two things. First, although FDA regulations do not apply until one has 
moved to clinical trials of stem cell therapies, publicly and privately funded researchers 
involved in basic research still consider the regulations to be applicable, where possible. 
This is because if acceptable derivation practices are not followed in laboratory 
research, hESC lines will not be eligible for use in clinical trial.  
 Second, President Bush‘s federal restrictions and the Dickey Amendment, only 
apply to publicly funded research in the US. Privately funded research is, strictly 
speaking, unregulated unless it involves human subjects or clinical trials, at which point 
FDA regulations would apply. This distinction between publicly and privately funded 
research is important to keep in mind throughout the discussion of hESC governance in 
this thesis. 
 Though the regulations listed above broadly apply to hESC research, they are 
not comprehensive and were not designed with hESC research in mind. Partly for this 
reason, the National Academy of Sciences (NAS), widely seen as the informal advisor 
to the US government on issues of science and technology, released a report in 2005 
setting out suggested guidelines for hESC research (NRC and IOM, 2005). The main 
recommendation is that all institutions involved in hESC research should establish local 
Embryonic Stem Cell Research Oversight (ESCRO) committees comprised of scientific, 
legal, and ethical experts, as well as educated members of the public. These ESCRO 
committees are meant to act as Institutional Review Boards
16
 and approve applications 
to conduct hESC research, regardless of the source of funding. In addition to this, the 
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 The term ‗biologics‘ is used to refer to a range of biological products regulated by the U.S. FDA, 
including vaccines, blood and blood components, somatic cells, gene therapy, tissues and recombinant 
therapeutic proteins. 
16
 Institutional Review Boards, or IRBs, are a central component of the US federal funding system of 
oversight. Each institution that receives federal funding must have an IRB approval process and all 
research, regardless of its funding source, must receive IRB approval prior to commencing. 
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guidelines also recommend that a national panel should be formed to oversee the main 
issues involved in research on a continuing basis. These guidelines were generally 
welcomed by the scientific community in the absence of any concrete federal guidance, 
but have also been criticized for being incomplete and a poor substitute for NIH-like 
guidance (Phillips et al., 2006).  
Completing the regulatory patchwork ‗picture‘ of patchwork regulations is the 
role of individual states in the US federal system of government. Some states have 
banned embryo research, while others have passed multi-billion dollar bond initiatives 
for state-of-the-art research centres (NRC and IOM, 2005).  However, as pointed out in 
a report by Fukuyama and Furger (2007), attempts by states to act in this area are often 
through narrow legislative bans or targeted legislation that is tightly defined. Where 
legislation is broader or includes provisions for research oversight, there are still 
overlaps and gaps between state and federal regulations (Winickoff, 2006; Fukuyama 
and Furger, 2007). Annex A contains details of initiatives and policies in individual 
states. In all, 12 states have passed legislation actively supporting stem cell research and 
have provided funding for the research to be conducted.  
To summarise, the US policy history for hESC research and current mechanisms 
of oversight seems to be a process marked by inconsistencies, political minefields and 
regulatory ‗thickets and gaps‘ (Baker, 2008). We will now look at the UK which has, in 
contrast, a rather more straightforward policy history, which has resulted in a relatively 
permissive regulatory framework. 
2.3 Governance of human embryonic stem cell research in 
the United Kingdom 
2.3.1 Overview 
Human embryonic stem cell research was explicitly permitted in 2002 by an act 
of the UK Parliament after a report by the House of Lords recommended that the 
Human Fertilisation and Embryology Act of 1990 (HFE Act) be amended to include 
hESC research in its remit. In the same year, the National Institute for Biological 
Standards and Control (NIBSC) opened a stem cell bank, which provides stem cells to 
any company or institution that demonstrates the appropriate ethical, peer review and 
informed consent procedures are in place. In the Chancellor‘s Budget report in March 
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2005, the UK Stem Cell Initiative was announced to great fanfare, with the claim that it 
would pave the way for the UK to become a world leader in embryonic stem cell 
research (UK Stem Cell Initiative, 2005).  
These are just a few examples of recent policy and political moves in the UK, 
but they underscore a generally more actively supportive government attitude to hESC 
research. The reasons for this will be discussed over the course of this thesis, but below 
we will review the UK policy history, starting with the initial regulation of foetal tissue 
and embryo research.  
2.3.2 History of foetal tissue and embryo research in the UK 
The birth of Louise Brown in 1978 was ―a considerable achievement‖ that 
simultaneously raised both hopes and anxieties amongst the British public: 
long sought, at last successful, [it] opened up new horizons in the alleviation of 
infertility and in the science of embryology... However, there were also 
anxieties. There was a sense that events were moving too fast for their 
implications to be assimilated (Warnock, 1985, p 4).  
Sentiments like these were pervasive and prompted the UK Government‘s Department 
of Health and Social Security to launch an inquiry in 1982 in order to consider the 
social, legal and ethical consequences associated with reproductive technologies, 
including the use of embryos in research (Mulkay, 1994). The Committee of Inquiry 
(the ‗Warnock Committee‘) was chaired by Mary Warnock. Its final report to 
Parliament (the ‗Warnock Report‘) left a lasting legacy on the field of embryo research, 
both nationally and internationally, through its recommendation of the ‗14-day rule‘ for 
embryo research (discussed in more detail below). Moreover, the deliberations, 
arguments, and recommendations presented in the Warnock Report form the 
cornerstone of all subsequent UK legislation and national dialogue regarding the 
regulation of IVF technologies and embryo research, including hESC research
17
. 
Therefore, it is important to look at its approach in some detail
18
.  
The Warnock Committee‘s remit was:  
to consider recent and potential developments in medicine and science related to 
human fertilization and embryology; to consider what policies and safeguards 
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 As pointed to in many Government reports on the subject since. See for example, the report from the 
House of Commons Science and Technology Select Committee, Human Reproductive Technologies and 
the Law (2005) and the Department of Health‘s Review of the Human Fertilisation and Embryology Act 
(DoH, 2006).  
18
 Though the Committee deliberated on the full range of issues relevant to fertilization and embryology, 
the focus here will be on their discussions concerning the use of human embryos in research. 
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should be applied, including consideration of the social, ethical and legal 
implications of their developments; and to make recommendations (Warnock, 1985, 
p. 4). 
On the issue of using human embryos in research, the Committee started by going 
―straight to the question of how it is right to treat the human embryo‖ (emphasis in 
original, ibid., p. 60). In order to determine this,, the Committee considered ethical, 
legal and scientific views on the embryo. The ethical considerations centred around 
three principal views on the embryo: 1) considering the embryo as equivalent to a 
human life and, therefore, entitled to full human rights, a view adopted by the Catholic 
Church; 2) a point of view roughly equivalent to that of the Church of England and 
Judaism, which see the development of personhood as a gradual process; and 3) a view 
which sees the embryo as no more than a collection of cells. The Committee found the 
second point of view to be the most appropriate and supported this finding with legal 
and scientific considerations (discussed below). 
In considering the permissibility of embryo research, the Committee looked at 
the current legal framework for the embryo and any protections afforded to it. Though 
protections existed for the embryo in vivo, there was very little in the law to protect the 
in vitro embryo that was to be used in research. They found this to be unsatisfactory and 
concluded that the ―the embryo of the human species ought to have a special status‖ and 
that this ―status of the embryo is a matter of fundamental principle which should be 
enshrined in legislation‖ (ibid., p. 63). 
In regard to scientific considerations, the Committee received evidence from a 
number of sources, including the Royal College of Obstetricians and Gynecologists, the 
British Medical Association, and the Medical Research Council on the scientific status 
of the embryo. The Committee wanted to fully understand the biological issues 
surrounding human development and what the technical distinctions were in the stages 
of development. Largely because so much was, and is, unknown about the development 
of the embryo, there was little consensus among the different professional bodies as to 
the point at which the embryo could be said to ‗become‘ a human individual.  
The Committee members themselves, however, were agreed that a cut-off point 
for research be established. In light of the ethical, legal and scientific inputs, they 
arrived at the point at which the neural system begins to develop because, they felt, the 
presence of a neural system suggests the early embryo might then be capable of feeling 
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pain
19
. This point is believed to happen around 14-15 days after fertilization with the 
formation of the ‗primitive streak‘, as discussed earlier in this chapter. The primitive 
streak gives rise to many cell types, including the neural groove from which the entire 
nervous system later emanates. Thus, the Committee felt that the development of the 
primitive streak ―marks the beginning of individual development of the embryo‖ 
(Warnock, 1985).  
Taking the legal, ‗special status‘, of the embryo together with a gradualist 
approach to the development of personhood and the scientific views on biological 
development, final recommendations on the use of embryos in research were made. The 
Committee concluded that: i) research using in vitro human embryos should only be 
conducted with a license, ii) that the ‗special status‘ of the embryo require careful 
ethical and regulatory oversight, iii) that research on human embryos should not be 
conducted past 14 days of development, and, iv) that oversight of research should be 
conducted by the same licensing body recommended to regulate all human fertilization 
and embryology (Ibid). 
In 1990, five years after Mary Warnock and her committee issued their report, 
the Human Fertilisation and Embryology Act of 1990 (HFE Act) was passed. This Act 
sets out the rationale for embryo research and establishes an independent Human 
Fertilisation and Embryology Authority (HFEA) to regulate and license, on a case-by-
case basis, all reproductive technologies and practices, including embryo research. 
Under Schedule 2 of the Act, a license cannot be granted to conduct research using an 
embryo ―unless the Authority is satisfied that any proposed use of embryos is necessary 
for the purposes of the research‖ (UK Government, 1990, paragraph 3(6)). There are 
five purposes under which the HFEA can authorise research:  
a) promoting advances in the treatment of infertility, 
b) increasing knowledge about the causes of congenital disease, 
c) increasing knowledge about the causes of miscarriages, 
d) developing more effective techniques for contraception, 
e) developing methods for detecting the presence of gene or chromosome 
abnormalities in embryos before implantation, or  
f) for other such purposes as may be specified in regulations (UK Government, 
1990, paragraph 3(2)).  
                                                 
19
 However, as pointed out by many scientists and doctors in evidence to the committee, we have no way 
of scientifically determining whether the embryo is capable of feeling pain at this point. 
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Though the Act has undergone changes in recent years, as will be discussed below, the 
six research purposes, the respect for the special status of the embryo, and the case-by-
case consideration of licenses are still central to the HFEA‘s oversight of embryo 
research and reproductive technologies. 
The importance of the Warnock Report reaches far beyond its initial advisory 
role. Though contentious at the time,
20
 the Committee‘s findings established ethical and 
moral principles on which subsequent legislation and national discussion could rest. We 
will now look at how recent policy developments, in light of advances in hESC 
technology, have played out against this background context. 
2.3.3 Permissive regulations for hESC research? 
With the announcement in 1998 of the derivation of human embryonic stem cell 
lines, the UK government, like the US, began to think about what regulatory context 
this research might be conducted within. It became apparent that the current remit of the 
HFE Act, though covering human embryo research, was ambiguous when it came to 
human embryonic stem cell research. As an example of this, a strict interpretation of the 
definition of the embryo in the 1990 Act—―a live human embryo whose fertilisation is 
complete‖—raises questions about the permissibility of nuclear transfer technologies 
where no fertilisation occurred.  
In 1999, a special Expert Committee, chaired by the Department of Health‘s 
Chief Medical Officer, was asked to ―undertake an assessment of the anticipated 
benefits of new areas of research using human embryos, the risks and the alternatives 
and, in light of that assessment, to advise whether these new areas of research should be 
permitted‖ (DoH, 2000, p. 2). The Committee ultimately concluded that ―the great 
potential to relieve suffering and treat disease meant that research was warranted across 
the whole range of possible sources of stem cells in the first instance, including 
embryos‖ (ibid., p. 9). In light of these findings, the Government drafted legislation 
which was debated in Parliament and eventually passed on 19 December 2000 as the 
Human Fertilisation and Embryology (Research Purposes) Regulations 2001 (2001a). 
These regulations added three new research purposes to the existing six in the original 
HFE Act: 
g) increasing knowledge about the development of embryos, 
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 This was acknowledged by Mary Warnock, herself, in a special introductory chapter published with the 
final report in 1985 (Warnock, 1985). 
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h) increasing knowledge about serious disease, or 
i) enabling any such knowledge to be applied in developing treatments for 
serious disease (ibid.). 
Following the enactment of these regulations, the House of Lords Select 
Committee considered whether an additional law was needed to regulate human cloning 
techniques, namely, nuclear transfer techniques. After much deliberation among peers, 
the report by the House of Lords found nuclear transfer techniques to be ethically 
acceptable, provided they were never used to clone a human being. To this end, the 
Human Reproductive Cloning Act of 2001 was passed, which officially outlawed 
human reproductive cloning (2001b).  
In 2005, the House of Commons Select Committee on Science and Technology 
reported on their year-long review of human reproductive technologies and the law 
(DoH, 2005b). They expressed views on a variety of issues related to the Act, including 
whether a legal definition of the embryo should be incorporated into the Act, the 
robustness of the decision-making processes of the regulator, and whether a single 
regulatory body for all reproductive medicine and human tissues (with the suggested 
title of the Regulatory Authority for Tissues and Embryos, or RATE), should be created. 
In late 2006, the Department of Health published a White Paper on the review of the 
HFE Act, which was to become the basis for the Draft Bill. Following a concerted 
opposition effort mounted by several scientific and medical professional bodies of 
science and medicine during the consultation period on the Draft Bill, the RATE 
proposal was dropped from the final Bill that was introduced in Parliament in 
November 2007.  
Almost a full year later, and four years after the initial review of human 
reproductive technologies and the law took place, the Human Fertilisation and 
Embryology Bill 2008 was passed by Parliament. It makes a range of amendments to 
the 1990 Act to take account of new scientific developments, to reflect changes in 
societal attitudes, and to update the HFEA‘s ability to regulate according to principles of 
better regulation (UK Government, 2008). Under the new Act, research utilizing 
embryos is permitted under the following criteria: 
a) increasing knowledge about serious disease or other serious medical 
conditions, 
b) developing treatments for serious disease or other serious medical 
conditions, 
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c) increasing knowledge about the causes of any congenital disease or 
congenital medical condition, 
d) promoting advances in the treatment of infertility, 
e) increasing knowledge about the causes of miscarriage, 
f) developing more effective techniques of contraception, 
g) developing methods for detecting the presence of gene, chromosome or 
mitochondrion abnormalities in embryos before implantation, or 
h) increasing knowledge about the development of embryos (2008).  
Despite the comprehensive set of regulations applying to the derivation of hESCs, once 
the stem cell line has been created, any research conducted on it falls outside the 
regulatory authority of the HFEA. However, a condition of an HFEA research license to 
derive an embryonic stem cell line is that one must also commit to depositing the 
derived stem cell line in the national stem cell bank. An independent Steering 
Committee oversees the operations of the bank and all national research on embryonic 
stem cell lines. The bank provides stem cells to any company or institution that 
demonstrates the appropriate ethical, peer review and informed consent procedures are 
in place. Though there are no statutory regulations in place, there is an implicit 
expectation that individuals will adhere to the Code of Practice that is published (and 
regularly updated) by the UK Stem Cell Bank.  
2.4 Conclusion 
 Like many new areas of science and technology, the scientific breakthroughs 
and potentials of embryonic stem cell research are not without controversy. We have 
shown how national conversations about hESC research began to take shape in the US 
and the UK almost 20 years prior to the publication of the Thomson and Gearhart 
papers. It is the nature and characterisations of these conversations and dialogues, the 
facts utilised and employed, the historical contingencies, the positioning against wider 
social dialogues, and the eventual conclusions (policy and regulatory outcomes) that are 
of interest to this doctoral study.  
This chapter set out to describe the science of hESC research, the issues it raises, 
the policy history of embryo and hESC research in each country and the current 
mechanisms of oversight and regulation. What it has not done, however, is provided an 
analysis of how processes of governance are characterised and carried out in each 
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country. The following chapter will look to the theoretical literature to discuss what is 
meant by governance in the context of this research. After discussing the methodology 
of this thesis in Chapter 4, Chapter 5 will turn back to the processes of governance and 
their socio-political nature in relation to hESC research in the US and the UK. The 
discussion will build on the policy histories set out above, but will employ the concepts 
introduced in Chapter 3 as a theoretical lens on ‗good‘ governance.   
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3. Governance of science and technology: Dimensions 
of analysis 
3.1 Introduction 
The previous chapter introduced the scientific background of human embryonic 
stem cells (hESCs) and its policy history in the US and the UK. It is a technology with a 
powerful therapeutic and scientific potential, but it is uncertain and unproven in many 
ways, with unknown biological and social consequences. It thus carries with it inherent 
and intractable elements of risk and uncertainty. These are more than risks and 
uncertainties associated with the technology itself, but extend to social, cultural and 
political arenas. With these come implications for the ways in which we deliberate on 
such risks in a society and make related policy choices (Fiorino, 1989, 1990; Fineberg et 
al., 1996; Pellizzoni, 2004).   
Such implications are played out in examples such as the contrasting policy 
approaches of the US and UK in the area of hESC research described in the previous 
chapter. While the details of the different policies and regulations themselves are of 
interest, a singular focus on these specific policy and regulatory differences, as is often 
seen in the literature (Knowles, 2004), tells us about different mechanisms or 
instruments of government that might be used, and not about how we might deliberate 
and engage with them as a society. Each policy approach has developed for particular 
historical reasons and by different means in each country. It is precisely the 
development of these different policy approaches that serves to underscore the attention 
that might be paid to the processes behind the development, and indeed, the ways in 
which these processes have come about and interact with each other.  
This idea is reinforced by the early work of Kooiman and colleagues who, in 
developing their concept of ‗social-political‘ governance, point out that  
the growing complexity, dynamics and diversity of our societies, as ‗caused by 
social, technological and scientific developments‘, puts governing systems under 
such new challenges that new conceptions of governance are needed...Why not 
take them seriously and put them in the centre of new ways of thinking about 
how to govern, steer, manage, control and use them? (Kooiman, 1993, p 6).   
This suggests a more holistic approach to analysis of this area is needed, one that looks 
at, and beyond, the institutions and instruments of government, to the wider social 
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processes and discourses that influence the development of governance itself. Indeed, it 
has been argued that the ―entanglement of social, cultural, scientific and political 
values‖ in the biosciences raises challenges for a ―new governance‖ that must 
acknowledge the cultural context of new technologies (Davies et al., 2003).  
As a concept, ‗governance‘ is used widely throughout various literatures ranging 
from political science to development studies. It is generally agreed to be a useful 
―organising framework for understanding changing processes of governing‖ (Stoker, 
1998). But what is meant by ‗new governance‘ in light of the entanglement in the 
biosciences, as suggested above, or ‗new conceptions of governance‘ as suggested by 
Kooiman? It is clear that before we explore contrasting perspectives on governance, we 
must first unpack the term ‗governance‘ itself. In doing so, we hope to illuminate the 
complex interplay of socio-political interactions and discourses that characterise 
decision-making processes in complex areas. In Section 3.2, we define what governance 
means in the context of this research and how it might be used in a comparative context. 
This discussion will be informed by a review of comparative policy studies as a means 
of gaining insights into overarching principles of comparison and theory. This will feed 
into a discussion in Section 3.3 of the wider literature on decision-making under 
conditions of risk and uncertainty. This is intended to bring us to an understanding of 
how governance might be affected under such conditions. The aim is to understand how 
governance in a context of risk and uncertainty is affected by, and might respond to, the 
challenges to ‗new governance‘ raised by the biosciences.  
3.2 Governance: Developing the concept 
3.2.1 Overview 
Governance is a very broad concept and is employed in various ways in the 
wider literature. A subset of this literature, sufficient to clarify how the term 
‗governance‘ will be used in this thesis, will first be reviewed in Sections 3.2.2 and 
3.2.3. Section 3.2.4 will then discuss how governance might be thought of in a 
comparative context. 
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3.2.2 In search of a definition 
It is difficult to find a standard, or commonly utilised definition of ‗governance‘. 
Indeed, it seems the driving imperative for the introduction and use of the term is itself 
determined by the plurality of perspectives on the issues at hand. A ‗formal‘ definition 
from the Oxford English Dictionary assigns the following primary (i.e., non-obsolete) 
definitions to the term governance: ―1) ‗the action or manner of governing‘; b) 
‗controlling, directing, or regulating influence; control, sway, mastery‘‖ (Oxford 
English Dictionary, 2009). This definition focuses attention first on the actions of 
governing, which tells us little about the substance of the term, but goes on to use words 
like ‗controlling‘, ‗directing‘ or ‗sway‘ as means to assert influence over something. 
This is striking as the words can have apposite interpretations when used in conjunction 
with government actions. While the first two invoke images of direct government 
intervention, the latter implies a lighter touch.   
Though a dictionary definition may seem a rather juvenile starting point for 
exploring governance, interestingly, the use of the term governance in the academic 
literature also employs both of the dictionary interpretations, as well as many more 
depending on the particular disciplinary tradition involved.  Starting in the political 
science literature, Rhodes‘ work Understanding Governance (1997) provides a 
comprehensive overview of the history and use of the term in studies of politics and 
government. He builds on a textbook definition of governance that is similar to the OED 
definition above, but introduces the notion of „process‟ into the act of governing. He 
argues governance implies a ―change in the meaning of government‖ where it refers to a 
―new process of governing; or a changed condition of ordered rule; or the new method 
by which society is governed‖  (Rhodes, 1997, p. 46). Though the introduction of 
notions such as ‗new‘ and ‗process‘ add layers and more nuanced meaning to our 
dictionary definition, Rhodes is correct in pointing out that there is confusion about 
what precisely is meant by the terms ‗process‘, ‗condition‘, ‗method‘, or, we even 
argue, the term ‗new‘.  
At this point, it is helpful to look at the use of the term ‗government‘ in 
comparison with governance. In the tradition of Anglo-American political theory, 
government is used to ―refer to the formal and institutional processes which operate at 
the level of the nation state to maintain public order and facilitate collective action‖ 
(Stoker, 1998, p. 17). Here we see echoes of the stronger image of governance discussed 
above. In this sense, government is taken to imply a ‗top-down‘ process of control 
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where, for example, behaviour might be regulated in specific ways in order to achieve 
specifically desired ends (Renn and Roco, 2006). By contrast, governance can be taken 
more broadly to imply a move from a ‗powers over‘ perspective to a framework that 
grants ‗powers to‘ institutions and people and aims for more enabling types of policy 
and regulation (Lyall and Tait, 2005). Others pick up on this and make explicit 
reference to the distinction that must be made between government and governance. 
While government can refer to a model of governing through coercion, governance 
focuses on the power of influence to accomplish specific governing ends (Murphy and 
Yanacopulos, 2005). As Stoker points out, it is ―rather a matter of a difference in 
processes‖ (Stoker, 1998, p. 17). In other words, a difference between the means, but 
not the ends. 
The literature reviewed so far is suggesting a move into a realm that focuses on 
the practices of governance. It is now becoming more clear what is meant by the earlier 
terms of process, condition, or method, and, moreover, why these are seen as distinctly 
‗new‘ in relation to older conceptions of government. These distinctions call attention to 
the role of diverse actors, citizens, and even individuals in the governance process, 
where there is an integration of multiple interests ―into structures of action and political 
decision-making‖ (Gottweis, 2005).  Using the concept of governance in this way can 
encourage us to look beyond state actors to the societal interactions that occur within the 
processes of governing. In this light, governance can be said to be about the ―the sum of 
the many ways individuals and institutions, public and private, manage their common 
affairs‖, including both ―formal institutions and regimes empowered to enforce 
compliance as well as informal arrangements that people and institutions either have 
agreed or perceive to be in their interest‖ (Kazancigil, 1998, p 70). Here, governance is 
given substance and meaning through the references to both ‗formal institutions and 
regimes‘, as well as ‗informal arrangements‘ that might be entered into. Societal 
interactions are represented at multiple levels with reflection on their inherent diversity.  
This use of governance in reference to a ‗social-political‘ (Kooiman, 2003) or 
‗social-cybernetic‘ (Rhodes, 1996) system is perhaps best known through the work of 
Kooiman and colleagues in a collection of essays published in 1993 entitled Modern 
Governance: New government-society interactions (Kooiman, 1993) and further 
developed by Kooiman in later work (2003). When employed in this way, governance is 
taken to be the sum of a set of societal interactions that express the diversity, dynamics 
and complexity of the governing process itself (Kooiman, 2003). The concept draws 
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attention to ―the patterns that emerge from governing activities of social, political and 
administrative actors‖ (Kooiman, 1993, p. 2) and highlights the role of interactions in 
this ―two-way‖ traffic model (ibid.).   
By stressing interactions in this way, Kooiman and colleagues arrive at a 
conception of governance that allows us to think about its utility as it applies to the 
issues of this thesis. Kooiman points out that when one is able to recognise the inter-
dependencies of all the actors and their interactions, one sees that ―no single actor, 
public or private, has all the knowledge and information required to solve complex, 
dynamic and diversified problems‖ (ibid., p. 4).  Policy problems are often complex and 
dynamic, but perhaps particularly so when we are considering technological and 
scientific advancements. This lends support to the observation that, when dealing with 
uncertain, and perhaps also controversial and contested, developments in science and 
technology, one must pay attention to the wider interactions amongst and between 
policies and politics, technologies and associated artefacts, discourses and social values, 
and the manifestations of all of these in the governance process (Stirling, 2008). Hence, 
with a clearer idea of what the term governance means, we can embark on a discussion 
of how governance can be used as an analytical tool, or ‗lens‘, for addressing problems 
of governance facing society. 
3.2.3 Governance as an analytical lens  
We have shown that the term governance is used variously, and sometimes 
ambiguously. It can be expected, then, that different perspectives and uses of 
governance will emphasise different aspects of governing styles and the processes that 
emerge. Rhodes (1997) distinguishes six distinct uses of governance within the 
literature, including references to ‗the minimal state‘, corporate governance, the ‗new‘ 
public management, ‗good governance‘, a socio-cybernetic system, and self-organising 
networks. These highlight, respectively, governance as characterised by a hands-off 
approach to the marketplace; the practices of corporate oversight; the use of private 
sector management methods in the public sector; efforts at government reform, 
especially in developing nation-states; the interactions of social and political actors; and 
the broader realm of public and private sector services. Each use is employed under 
different theoretical guises or analytical traditions. Similarly, state-centred perspectives 
on governance focus on the interactions of the state with other actors in crafting public 
policy (Smith, 2006), while a reflexive governance perspective explores the extent to 
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which governance is co-constructed and conditioned by previous institutional structures, 
social discourses or political manifestations (Voβ and Kemp, 2006). Thus, regardless of 
the theoretical perspective or use, the point is that governance can be ordered or broken 
down, interpreted or analysed, employed or conceived of in many different ways, 
thereby leading to various implications for the study of the social, political or 
technological issues at hand. 
In order to study these issues in a robust and systematic way, a range of 
typologies, modes, orders, or hierarchies of governance are employed in a wide variety 
of literatures to give structure and analytical consistency. In essence, each of these 
represents a different way of providing an analytical framework for either applying 
governance as a tool for problem-solving, or for enabling a deeper understanding of 
‗governance‘ as a theoretical concept. Inevitably, some frameworks prove more useful 
than others depending on the context within which they are applied. For example, 
Stoker (1998) uses governance to explore current dilemmas facing governments today 
and how they might be approached, while Kooiman (2003) offers a more theoretical 
exploration of the ―utility of the governance concept as an instrument for conceptualis-
ing‖ key issues within society (ibid., p. 8). These and other approaches will be 
investigated below in order to identify overarching principles that might be employed in 
the context of this research. We find that despite the varied levels of complexity in 
breaking down and applying the concept of governance to real-world analysis, each has 
a certain utility and contribution to make to our understanding of governance and its use 
in this thesis.   
 As alluded to above, Stoker develops a practical approach to governance by 
pointing out five central propositions for how we might think of and consider 
governance. The five propositions relate to different features of the governance process 
and are as follows: the set of institutions and actors that comprise the process; the 
blurring of formal and ‗traditional‘ boundaries for societal and economic 
responsibilities; the power dependencies and relationships between institutions and 
actors; the autonomous and self-governing nature of networks of actors; and the 
secondary role of government in achieving collective change or accomplishing 
governing tasks (Stoker, 1998).  
Stoker‘s propositions draw our attention to several issues. His presentation of 
governance as an ―analytical lens‖ illustrates the disconnect between the realities of 
decision-making and the normative codes used to justify traditional government roles. If 
  
37 
we recognise that there are complex sets of institutions and actors that operate within 
and outside government, then we are encouraged to accept the limitations of formal 
institutional perspectives on government as argued for earlier. This acceptance allows us 
to better understand and identify the multiple centres of influence and diverse links 
utilised between actors when appealing for legitimacy in political power. The picture 
becomes all the more complex when new actors emerge, when new governing 
challenges shake the foundations of the system (the economic crisis of 2008 being a 
particularly apt example here), or when new technologies and scientific trajectories are 
introduced into society. Thus, through Stoker‘s use of governance, we can gain an 
insight into critical issues facing government and governance systems, thereby 
providing new perspectives on how those issues might be addressed by practitioners and 
scholars alike. 
While Stoker‘s use of governance is fairly straightforward, others have posited 
more complex dimensions and frameworks. Treib et al., (2007) aim to clarify the 
concept of governance by articulating different ‗modes of governance‘. They first 
identify three core dimensions of governance in the literature—politics, polity and 
policy—and then offer interpretations of governance under each of these dimensions. 
For example, under the politics dimension, governance focuses on the relationships 
between actors, while under the polity dimension, governance is a system of rules 
shaping the actors‘ actions. In contrast, governance under a policy dimension 
emphasises the role of ‗political steering‘ and the instruments of policy making.   
It seems to us that these dimensions of politics, polity and policy relate to 
elements of Stoker‘s propositions. If politics is about the relationships between actors, it 
directly corresponds to the actor relationships and power dependencies Stoker discusses. 
Polity relates to the formal rules that structure the actions of social actors, so the idea of 
power and control is reflected, especially the locus of authority that governs the 
behaviour of actors. The final dimension of policy relates to the actual instruments and 
mechanisms of governing. Thus, we find that two entirely different uses and 
conceptions of governance eventually can be seen as reinforcing each other.  
Such mutual reinforcement of different authors presentations of governance is 
also found when we look at governance as a social-political set of interactions (as 
proposed by Kooiman and discussed above). In his theoretical development of this idea, 
most completely discussed in his widely cited work Governing as Governance (2003), 
he begins with the proposition that social-political interactions exist between the state, 
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market and civil society. The locus of each of these interactions is inherently diverse, 
dynamic and complex. Kooiman believes these types of interactions lie at the heart of 
every society. Thus, if governance is about collective problem solving and opportunity 
creation, then these interactions are where any analysis of governance must begin.  
His framework for analysing governance is through the presentation of orders of 
governance. He argues that while first order governance places an ―emphasis on 
governing as a process‖, second-order governance gives attention to the ―structural 
aspects of governing interactions, controlling or enabling problem-solving‖ (Kooiman, 
2003, p. 153). The final order of governance can be found at a ‗meta‘ level, where the 
focus is on the ―continuous dynamic (re)construction of societal elements (diversity) in 
their interrelations (complexity)‖ (parantheses in original, Kooiman, 2003, p. 171). 
Through these orders, Kooiman illustrates how governance as a concept can be used as 
an instrument of analysis. In other words, he shows us how to make operational the 
abstract propositions, elements and dimensions discussed so far.     
Importantly, Kooiman points out that the ―creation and development of societal 
institutions are the result of historical ‗path-dependent‘ processes‖ even though we see 
―institutional settings designed, created, maintained, reformed and even ended all the 
time‖ (Kooiman, 2003, p. 153). It implies that historical contingencies and path 
dependencies shape both how we currently define governance and how we attempt to 
change it. This insight will be important to bear in mind throughout this thesis as we 
explore how stakeholder perspectives on governance are constituted, and the variety of 
social, political, cultural and technological factors that impinge upon these perspectives 
and help to shape them. 
At this point it can be reasonably argued that core elements of governance are 
emerging from the review of the theoretical governance literature presented above. 
First, there is a focus around the nature, type and extent of actor and institutional 
relationships, including the power dependencies that affect them. Second, the locus of 
government responsibility and control emerges as a central element important to 
analysing governance processes. Third, the mechanisms of governing are discussed, 
and, through these, the tangible realisation of the first two elements are borne out. As 
governance in the context of this thesis entails a focus on the process of collective social 
problem-solving, the first and the second elements appear to function as inputs to this 
process, helping to shape and define its trajectory. The third element is concerned with 
the practical work of putting the governance system into place. Drawing these elements 
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together, I will introduce here the idea that various ‗dimensions of governance‘ can be 
developed from this analysis. These include: 1) processes and types of negotiation, 
engagement, and deliberation between society and the state; 2) the nature of institutional 
(de)centralisation; and 3) types of mechanisms used to govern. Attention to the 
reciprocal relationships between all three reflects the importance of Kooiman‘s ideas 
about social-political contingency and interactions. These dimensions will play a 
foundational role in developing the methodological structure of the empirical 
component of this research and will thus feature prominently in the analysis and 
normative policy implications identified. They are introduced here, though, to accustom 
the reader to their use and language. A more thorough argument for them and their 
relevance to perspectives on good governance will be developed at the end of this 
chapter and over the course of the thesis.   
The discussion thus far has taken us through some of the governance literature 
and has allowed us to arrive at a broader understanding of governance that will guide 
the theoretical development of this thesis. If we adopt a ‗social-political‘ view on 
governance as described above, we are able to analyse observed differences in policies, 
regulatory regimes and collective social problem-solving in contested areas of the 
biosciences, such as hESC research. In this sense, ‗governance‘ provides a lens through 
which to understand how perspectives on good governance develop and are constituted 
in wider society. Therefore, for this thesis governance is taken to refer to the entire 
process of defining, developing, engaging, deliberating, negotiating, establishing, 
implementing and reviewing the policy frameworks, regulatory structures, and other 
mechanisms of oversight for hESC research. These various processes can happen within 
and between many spheres, for example the public and private, scientific and political, 
ethical and practical, and moral and economic spheres. In other words, governance in 
this context is about the interactions between these multiple processes that are involved 
in governing hESC research. The question now becomes one of how to investigate these 
processes in a comparative context. To answer this, we will briefly consider some 
comparative policy approaches and their respective strengths and weaknesses in the 
context of analysing science and technology policy. 
3.2.4 Governance in a comparative context  
There is an enormous challenge in comparing processes of governance across 
nations in a way that enables progress and theory-building (Heidenheimer et al., 1990). 
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Comparative policy analysis began to emerge over the last few decades as a specific 
area of study to address this challenge (Leichter, 1979; Heidenheimer et al., 1990). The 
field has been defined in various ways, but the following is a useful starting point:  
Comparative public policy is the study of how, why, and to what effect different 
governments pursue particular courses of action or inaction (Heidenheimer et al., 
1990).   
Within this statement, important parallels with the governance concepts described above 
can be found. The ‗how‘ looks at the structure and processes of making government 
decisions, or specific mechanisms of governance. ‗Why‘ might involve analysing the 
effect of historical contingencies, political cultures or actor relationships on change and 
evolution in government styles, hence a new form of governing processes. The notion of 
‗to what effect‘ underscores the consequences of these changing processes, or the 
normative implications associated with how governance ‗ought‘ to occur. Thus, 
although this overview of the literature begins in the tradition of comparative policy 
studies, it is amenable to analysis under an organising framework of governance.   
   Recent developments in the field of comparative policy analysis make use of 
what might be thought of as ‗synthesis‘ approaches (John, 1998) to explain policy 
variation and change.  These incorporate aspects of traditional approaches into more 
holistic explanations of public policy variation that provide a guide for identifying 
important influences on the policy process as it evolves. For example, the policy 
advocacy coalition framework (ACF) (Sabatier, 1991; Sabatier and Jenkins-Smith, 
1993) and policy network analysis (PNA) (Rhodes and Marsh, 1992; Marsh, 1998) both 
highlight the importance of inter-organisational alliances and relationships within policy 
sectors (John, 1998), but emphasise different aspects within these relationships when 
explaining policy change (Smith, 2000). Other approaches, such as Kingdon‘s policy 
streams (Kingdon, 1995), look at the lifecycle of policies and treat the entire political 
system as a dynamic entity. Similarly, policy agenda studies give quantifiable ―attention 
to the dynamics of how new ideas...may or may not be accepted in the political system‖ 
(Baumgartner et al., 2006).   
What is most important about these approaches is the insights they provide into 
the mechanisms of policy configurations and inputs to policy interactions within the 
governance process. For example, the role of power in the PNA approach emphasises 
the importance of dependent relationships and hierarchies in a political process, while 
the ACF approach highlights the importance of competition between coalitions as a 
component of technical and policy-oriented learning. A policy agenda approach might 
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attribute governance differences to changing levels of national and political attention to 
an issue over time, highlighting the importance of historical contingencies. Each 
approach can, in theory, offer a distinctive explanation for different policy and 
regulatory configurations. 
However, all of the approaches discussed so far are situated in a political science 
tradition that, while useful as an introduction for studies of comparative politics, does 
not explicitly take into account the unique influence of science and technology issues on 
policy making. In fact, for many years political science scholars discounted the need to 
compare technical, science-based policies because science was seen to be universal and 
beyond doubt (Jasanoff, 2005, p. 16-28; see also Banchoff, 2005).  As this ‗Mertonian‘ 
ideal of science started to be challenged, however, the field of science and technology 
studies (STS) branched out (Rip, 1999), and with that came fresh insights on 
comparative studies of science and technology policy (Jasanoff, 1997). 
These insights from STS can acquaint us with the unique effects that cultural, 
political and scientific concepts may have on the ‗framing‘ and ‗bounding‘ of policy 
problems. This is particularly important for the socio-political lens on governance that 
has already been introduced. ‗Framing‘ makes explicit the notion that particular cultural 
or social viewpoints on a policy issue cannot be discounted (Jasanoff, 2005), while 
‗boundary making‘ (Gieryn, 1983) is concerned with the way issues are presented as 
discrete objects with a particular set of ideological norms. Thus, the creation of 
politically significant ‗boundary objects‘ (Star and Griesemer, 1989) has important 
ramifications as policy-makers, scientists or the public might try to relate to pre-existing 
framing assumptions, or to ―ethical and social sensibilities concerning the products of 
biotechnology‖ (Jasanoff, 2005, p. 26).  
Furthermore, awareness of the ‗social construction‘ of technology and scientific 
facts has become increasingly important. Seminal works by Latour and Woolgar (1979) 
and Bijker (1995) introduced these ideas by showing that scientific practices, in addition 
to knowledge and progress, cannot be divorced from the particular socio-cultural 
situations in which they are developed and embedded.  
As a social practice mediated through symbolic means, scientific knowledge 
emerges as a socio-technical construction set in specific historical and linguistic 
contexts of conjecture and refutation (Fischer, 1999, p. 301). 
These situations not only affect how ideas come to dominate in a particular field, but 
also how the very practice of science can be affected by social and behavioural norms. 
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Many have shown how conducting studies from an STS or science studies 
perspective can provide fresh insights into studies of comparative policy. Abraham and 
colleagues (Abraham and Sheppard, 1999; Abraham and Reed, 2002; Abraham and 
Davis, 2005) focus on the role of science in the regulation of pharmaceutical drugs. 
They point out the effects of professional and disciplinary interests on the framing and 
presentation of the regulatory science itself, thus introducing a distinct sociological 
interpretation of regulatory actions in the US and UK. Parthasarathy uses a ‗co-
productionist‘ approach21, balancing the simultaneous interactions of science, 
technology and society, to demonstrate differences in the way genetic risk is defined 
and regulated in the US and the UK (Parthasarathy, 2004; 2005). Her finding that  
―national styles of politics not only lead to very different approaches to regulation, but 
also very specific understandings of our bodies and ourselves‖ (2004, p. 349) reinforces 
the reciprocal relationships of politics and policies, social and cultural influences, and 
boundaries and framing in our socio-political understanding of the governance process. 
Though differences in governing structures across countries have been observed 
and analysed for STS issues, they are often conducted with a targeted focus on 
explaining specific policy outcomes or institutional structures. Observed differences are 
variously attributed to divergence in institutional structures (Bleiklie et al., p. 281), 
styles of regulatory decision-making (van Zwanenberg and Millstone, 2000), political 
cultures (Parthasarathy, 2004; 2005), national systems of innovation (Casper and 
Matraves, 2003), changes in global dynamics and policy ‗scenographies‘ (Gottweis et 
al., 2009), or ‗civic epistemologies‘ (Jasanoff, 2005). These attributions are significant 
and shed light on particular explanatory factors for different social and political 
problems arising from new technologies in the sciences. However, the authors do not 
always comment on the normative implications of their findings, that is, how best to 
address these problems in a governance context. Some have gone so far as to observe 
that in addition to neglecting state-level governance issues, there has also been more of 
an emphasis on ―interpretive‖ rather than ―explanatory‖ analysis in the STS tradition 
(Banchoff, 2005). For the purposes of this study, it will be important to draw out how 
these normative implications differ depending on whose (e.g. academic theorists) point 
of view they are coming from and at what level of governance (e.g. national or 
technological) the analysis is being conducted.  
                                                 
21
 The term ‗co-production‘ is discussed in detail by Jasanoff and other STS scholars in many works (see 
in particular, Jasanoff, 2004).   
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The next section will embed these views within the theoretical literature on 
decision-making under conditions of risk and uncertainty. It will discuss a variety of 
methodological, theoretical and practical insights which prompt us to think about the 
principles and analytical tools needed to understand how stakeholders in contested 
policy debates in the biosciences develop ideas about good governance. These insights, 
in turn, will help us to better understand how a governance lens can shed light on the 
processes of decision making in areas of complex technologies where goals and values 
are in conflict.  
3.3 ‘Good governance’ in a context of scientific risk and 
uncertainty 
3.3.1 Overview 
New technologies may open up a realm of possibilities, but they bring with them 
new risks and uncertainties. This has led to the argument that certain policy problems 
are seemingly intractable, and conflicts between different values and belief systems may 
be irreconcilable (Pellizzoni, 2001). For example, hESC technologies may have the 
potential to treat incurable diseases, but this potential is unproven and the technology 
itself poses risks to individual and collective social values. Such contexts of risk and 
uncertainty must be considered in ways that address the scientific risks inherent in the 
new technology, and the associated social, cultural and moral risks. It is these latter 
components that pose particular challenges to governance in this area and create new 
imperatives for critically assessing the utility and insights provided by methods of risk 
analysis, science advisory processes, legislative practice, stakeholder engagement and 
public participation. However, in order to ensure legitimacy, this re-examination of 
processes of decision-making, and governance more widely, must be a collective one 
(Jasanoff, 2003). The question becomes one of how to both understand and effectively 
engage at political and social levels in these fundamental questions of decision-making 
under seemingly intractable conditions of risk and uncertainty.   
However, the answer to this question lies not only in exploring its wider 
implications, but perhaps more fundamentally in making a crucial conceptual move 
within the theoretical framework of this thesis. We are concerned not only with the 
governance of hESC research, but specifically with good governance of hESC research. 
It is therefore critically important to move from the previous discussion regarding the 
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theoretical basis of governance, to a more normative one that looks specifically at the 
ways in which good governance is characterised within the literature.  
In Section 3.3.2 we will first consider technological risk and the theories, 
insights and methods that have evolved to understand its implications. We will then 
discuss other approaches to decision-making that have been employed by governments 
in an effort to make complex decisions about science and technology, and the critiques 
that have been leveled at them. Moving from within the sphere of government 
institutions to the network of social and political actors that shape its workings, in 
Section 3.3.3 we will review the ways in which the literature presents ideas about the 
possible ways to engage the public and wider actor networks in governance processes. 
In an effort to reconcile the social and political spheres of governance, and to move us 
towards a more complete understanding of good governance, we will look at how best 
to answer the analytical and theoretical questions raised by this thesis. To do this, more 
recent insights from the theoretical literature will be employed to understand how the 
processes of governance may be conditioned by the interactions they promote.  
3.3.2 Risk, uncertainty and technocratic governance  
Risk and uncertainty 
Regardless of the type of risk, it is accepted that conditions of risk and 
uncertainty pose considerable problems for rationalistic decision-making (Stirling, 
2008). This is a perennial dilemma confronted equally in research governance, 
technology policy, and corporate strategy, and a range of methodologies exist for the 
express purpose of testing the robustness of decision-making in such cases. But what is 
meant by ‗risk‘ in these contexts? What implications does this have for methods of 
decision-making, and how do they help address the problems of governance for 
contested technologies? 
Interestingly, there is no shared or commonly accepted definition of the term 
‗risk‘ (Renn, 1998). A variety of academic, methodological and disciplinary traditions 
have distinct approaches to the concept of risk, and in many fields such as welfare 
economics (Arrow, 1970), anthropology (Douglas and Wildavsky, 1982), psychology 
(Slovic, 1987), and sociology (Fischoff et al., 1984), risk analysis plays a central role. 
Fischoff and colleagues argue that the definition of risk is inherently political (Fischoff 
et al., 1984) and one that is affected by individual values and perceptions (Slovic, 1987). 
In his seminal work The Risk Society, Beck argues the concept of risk can only be 
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understood within the context of society‘s technologically driven process of 
modernisation. In this sense, risk is defined as the ―systematic way of dealing with 
hazards and insecurities induced and introduced by modernization itself‖ (Beck, 1992, 
p. 21). Renn, in his review of three decades of risk research, points out that risk need not 
be a negative concept, and instead focuses on the causal effects of risk. In his view, 
―risks refer to the possibility that human actions or events lead to consequences that 
affect aspects of what humans value‖ (Renn, 1998, p. 51). Though it could also be 
argued that natural risks would fit into this category, the point is that risk can exhibit 
both descriptive and normative characteristics. This allows one to account for more 
subjective, cultural and context-dependent situations that may affect the way risk is 
handled and thought of by the public and policy-makers alike.   
While these social science influenced definitions are more widely accepted 
today, for many years the dominant risk analysis methods reflected the origin of the 
concept of risk in the insurance and decision science fields (Starr, 1969). Technical 
approaches to risk assessment dominated, where quantitative methods attempt to 
measure, in numerical terms, the likelihood of different hazards and the ways to 
mitigate them. The methods ranged from cost-benefit analyses, life cycle assessments, 
decision analysis, ―technical perspectives‖ (including actuarial, environmental and 
technological analyses) (Renn, 1998), and multi-criteria approaches (DTLR, 2001). 
These methods are largely quantitative in nature with ―magnitudes and likelihoods held 
to be readily characterized on a cardinal numerical scale‖, holding in common ―a 
tendency to treat the concept of risk , at least in principle, as an objectively determinate 
quantity‖ (Stirling, 2003, p. 36-37). It is not hard to see why this concept of risk 
assessment as a strictly quantitative, measurable entity appealed to policy-makers. The 
variables that require consideration when assessing risk in a decision-making context 
are diverse and complex (see, for example, Collingridge, 1980) and often leave those 
responsible for the decisions struggling with the various options. Thus, when faced with 
policy issues that hold a large degree of uncertainty and whose impacts, whether 
positive or negative, concern public safety, health or economic growth, it is far easier to 
justify decisions with numerical answers based on lives saved or money earned. 
Perspectives from the social sciences, including sociology, anthropology, 
psychology and science and technology studies have raised serious criticisms against 
the use of such technical risk assessment methods. They have pointed out that 
quantitative approaches are not as objective or value-free as they might appear to be, if 
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at all. Early contributions from Fischhoff and colleagues pointed out that interactions 
between human activities and their consequences are far more complex than the average 
probabilities used in technical risk analyses are able to reflect (Fischhoff et al., 1984). 
Moreover, values are inextricably linked to every part of the risk analysis process, from 
characterisation to interpretation (Fischhoff, 1995), a finding that calls into question the 
claim that analysts of risk are themselves objective, much less the methods themselves. 
Others have made a related point when arguing that technical approaches to risk fail to 
account for differences in how, for example, the concept of ‗magnitude‘ can be 
conceived differently by different parties (Stirling, 1998, 2003; Renn, 1998, p. 53).  
In addition to problems with the techniques of risk assessment, a related, but 
distinct strand of critical work emphasises the sociological perspectives on risk. 
Attention is drawn to the processes of social learning and social construction that affect 
individual and collective definitions of risk (Renn, 1998). Insights as to how the 
interactions between society and the technologies introduced into them structure and 
condition perceptions of risk are particularly important. They highlight the need to 
account for the social construction of risk in decision-making (Renn et al., 1993) by 
developing new methods that take this into account. The point to note here is that the 
risks associated with any policy choice will take the form of many related, but distinct 
issues, and the value judgements placed on each will vary according to different parties. 
Moreover, the ways in which people perceive of a risk as ‗hazardous‘ or ‗harmful‘ will 
also vary by individual (Dietz et al., 1996, cited in Renn, 1998). Thus, failure to 
consider the wider social and cultural interactions can undermine the legitimacy of the 
whole risk analysis process, serving  
to render less visible the fundamental social questions embedded in the very 
design of technological research. By underplaying the questions of health or 
social consequences, they [risk analysis methods] hide the basic normative 
questions essential to democratic decision-making in the mystique of statistics 
(Fischer, 1999, p. 297). 
Each of these critiques serves to underscore the fundamental conditions of 
ignorance and ambiguity, as well as risk and uncertainty, that are ever-present when 
considering what, precisely, our knowledge is in relation to the likelihoods and possible 
outcomes of risk. Such ―dimensions of incertitude‖ (Stirling, 1998; 2003) encompass 
many of the insights from the social sciences on the assessment of risk and show that 
these insights do not just amount to footnotes or theoretical musings, but have real 
practical implications for our treatment of risk in a decision-making context. For 
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example, the true comparability of risk metrics across different circumstances (for 
example, mortality metrics) has been questioned, as has the ability to develop 
comparable metrics or decision tools under conditions of uncertainty (Collingridge, 
1980). When conditions of ambiguity and ignorance are added into the mix, further 
complexities abound. Ambiguity is concerned with the variety of framing assumptions 
that might be applied to a set of possible outcomes, which necessarily hinge on a range 
of social values, while ignorance is a state of ‗unknown unknowns‘, where one cannot 
even fully characterise the parameters of the problem. 
Though critiques of formal risk assessment methodologies began in the 1970s, 
and in some cases earlier (see Slovic, 1987, for a review in the area of risk perception), 
evidence was not seen of the uptake of the ideas into policy circles until the mid-1990s. 
In 1996, it appeared that the US government was beginning to understand and recognise 
the need to account for social and cultural influences in the process of risk analysis, as 
well as the need for more participatory approaches to assessing, managing and 
communicating risk (Fineberg et al., 1996).
22
 These insights not only relate to the need 
to think about risk assessment in new ways, but also the ways in which experts 
themselves should contribute to decision-making processes in areas of technical risk and 
uncertainty. Slovic observed (albeit almost a decade before the publication of 
Fineberg‘s work) that ―risk communication and risk management efforts are destined to 
fail unless they are structured as a two-way process. Each side, expert and public, has 
something to contribute‖ (Slovic, 1987, p. 285). The concept of ‗expert‘ in this quote 
suggests we might take a closer look at a less overt, but nonetheless important, 
component of technical risk assessment: the contributions of expert advisory 
committees. These bodies are set up to advise on the scientific and technical data 
involved in policy decision-making, and, hence, risk analysis processes. However, as we 
have shown the case to be with the methods themselves, technocratic advice has serious 
short-comings.  
Technocratic expertise 
Policy-makers have often relied heavily on expert-based, technical inputs to 
decision-making, leading some to observe that ―there has been a universal assumption 
(however superficial and laced with cynicism) that scientific expertise is the crucial 
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 Fishhoff (1995) points out that Vice-President Gore‘s White Paper Reinventing Government also 
recognised that quantitative risk assessments needed to be clarified in terms of their uncertainty and 
inherent subjectivities. 
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component of decision making, whether concerning Nature or society‖ (Funtowicz and 
Ravetz, 1993, p. 741). Much of this is based on the belief that the pursuit of scientific 
truth is itself an entirely objective, empirically driven process (Polyani, 1962). In the 
face of polarised politics, science seems to offer a neutral middle ground that could be 
used to ―de-politicise public issues‖ (Nelkin, 1975, p. 36). The so-called ―dilemma of 
expertise‖ has been around since the days of Plato and Socrates (Nowotny, 2003), but it 
has not become any clearer how best to employ expert advice in processes of decision-
making. Much the same as in the field of risk assessment, many have called the 
objective role of science into question. They argue that not only is the pursuit of 
scientific progress a socially constructed phenomenon (Latour, 1983), but that science 
itself can offer multiple answers to the same question (Collingridge, 1980; Collingridge 
and Reeve, 1986).  
As Jasanoff has pointed out, the use of expert committees became especially 
prevalent in the United States in the 1960s and 1970s. However, as their strength in 
numbers grew, so did concerns that expert committees were rapidly becoming a ‗fifth‘ 
arm of the US government (Jasanoff, 1990). As an abstract notion, this may merely 
raise eyebrows, but it becomes more troubling when coupled with the realisation that, 
just as technical risk assessments are affected by different value judgements, social 
constructions, or framing assumptions, so too is the scientific ‗evidence‘ used to feed 
into risk analysis and other types of decision-making. Whether the medium is a 
technical risk assessment or a panel of expert deliberators, the influences and outcomes 
are still the same, leading Millstone and van Zwanenberg to note, ―it is not possible to 
construct a risk assessment from available scientific data without embedding it in some 
prior, socially derived framing assumptions‖ (2001, p. 101). 
In terms of the practical implications of such a so-called ‗politics of expertise‘, 
Fischer has contributed considerable empirical and theoretical work in this area, 
especially in combining insights from the political science literature with ideas about 
expert-based decision-making (Fischer, 1990, 1993, 2003). He argues that in today‘s 
postindustrial societies, science and technology are central to economic growth. Policy-
makers realise this and are often faced with competing priorities and policy goals. In 
this context, ―governance devolves to a consideration of what is feasible‖, and 
technocracy itself comes to refer ―to the adaptation of expertise to the tasks of 
governance. It gives rise to a theory of governmental decision-making designed to 
promote technical solutions to political problems‖ (Fischer, 1990, p. 16-18). The 
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problem with this lies in the realisation that such ‗technical solutions‘ become the 
preferred manner of side-stepping the complex social and political problems posed by 
rapid technological advancement. Nowotny and colleagues echo this argument by 
positing that although expertise can provide reliable knowledge, it perhaps does not 
provide ―socially robust knowledge‖ that captures the wide range of culturally specific, 
locally contingent, and publicly deliberated ‗knowledges‘ that exist in technical and 
scientific policy debates (Nowotny et al., 2001; Nowotny, 2003). The idea is that we 
should move towards a more ―pluralistic expertise‖ that captures the variety of 
knowledge types that impinge upon the debate.  
In these arguments, we can see theory and practice moving closer to responding 
to the demands for greater accountability and legitimacy that are invoked when 
academics and the public alike call for a greater ―democratisation of expertise‖ 
(Nowotny, 2003) in decision-making and governance processes. Thus, throughout this 
discussion of quantitative and qualitative models, inputs and approaches to risk 
assessment and technocratic decision-making, several themes begin to emerge. Terms 
like ‗accountability‘, ‗legitimacy‘, ‗trust‘, ‗local knowledge‘, ‗social values‘, ‗lay 
perspectives‘ and many more are all invoked in various ways. Taken individually, they 
are intended to inform ways in which, for example, risk assessment techniques might be 
made more reflective or expertise more democratic. Taken as a whole, they make clear 
the normative principles that can inform the discussion of how good governance might 
operate under conditions of risk and uncertainty.  
As Beck‘s theory of reflexive modernisation has shown us, we live in a society 
characterised by the continued proliferation of risk and uncertainty. New technologies 
carry with them significant unknowns and it is our job as a society to participate in 
policy-making processes as we collectively consider the best ways to deal with them. 
Singular approaches that employ only technical, quantitative answers fall short, as do 
purely expert-based approaches as they fail to include the more ‗social‘ dimensions that 
are needed. In this context, the problem posed to the governance of science, and 
particularly good governance of science, is how to put into practice such methods and 
ideas. There is a need for ‗technologies of humility‘ in decision analysis that will  
make apparent the possibility of unforeseen consequences; make explicit the 
normative that lurks within the technical; and acknowledge from the start the 
need for plural viewpoints and collective learning (Jasanoff, 2003, p. 240).  
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With this in mind, attention now shifts to the deliberative turn in studies of government 
and decision-making and the ways in which public engagement can, or should 
according to many normative perspectives, influence wider governance processes.  
3.3.3 Deliberative democracy and public engagement 
In a widely cited, early contribution to the literature on risk and democratic 
decision-making, Fiorino points out that 
Entirely new fields like genetic engineering pose substantial scientific 
uncertainties where a political consensus has not even begun to emerge. 
Affected publics demand a role in technically based decision making, while 
administrators grope for ways to involve them constructively... A major question 
is whether democratic institutions and processes can keep pace with these 
changes (1989, p. 501).  
This nicely encapsulates many of the issues that are raised by the advances in the 
biosciences, where risk and uncertainty prevail as conditions under which decisions 
must be made. In response to criticisms of technocratic and quantitative risk analysis 
approaches as described above, calls like Fiorino‘s have been made from a variety of 
places for more qualitative, participatory and deliberative methods of decision-making. 
These are proposed as a way to ensure the cultural and social implications of new 
technologies and policy decisions are taken into account. A widely acknowledged 
definition of deliberation in this sense comes from the US, where the National Research 
Council defined deliberation as  
any formal or informal process for communication and collective consideration 
of issues. Participants in deliberation discuss, ponder, exchange observations and 
views, reflect upon information and judgements concerning matters of mutual 
interest and attempt to persuade each other (Fineberg et al., 1996, p. 73).  
Thus, deliberation refers to the ―discourses in which political debate is conducted, 
together with their limits and achievements‖ (Jasanoff, 2005, p. 285) and can be linked 
to the governance concern with the characterisations of socio-political interactions. 
Central to discussions about participation and deliberation is a concern with the 
democratic legitimacy of policy-making in the absence of public input and engagement. 
Much of the theoretical foundations in this area come from the work of Habermas and 
discussions of the principles of democratic decision-making and engagement 
(Habermas, 1975). Building on this, early participatory theorists claim that 
―participation engenders civic competence by building democratic skills, overcoming 
feelings of powerlessness and alienation, and contributing to the legitimacy of the 
political system‖ (Fiorino, 1989, p. 536). The aim of deliberation and participation is 
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thus similar to those discussed earlier: to increase legitimacy and trust in the conduct of 
democratic decision-making. It includes the idea of ‗participatory policy analysis‘ 
(Fischer, 1993) that seeks to ―open the process to a wider range of interests and 
concerns‖ and to ―integrate more fully the normative aspects of the inquiry process‖ 
(Fischer, 1999, p. 300). In doing so, it thereby allows for the incorporation of social 
values in the policy development process (as discussed in Pelletier et al., 1999), a 
feature sorely lacking in the quantitative and technocratic techniques discussed above. 
The term ‗deliberative democracy‘ has been coined as a wide-ranging reference to many 
of these ideas. It is defined as a process that refers to ―the idea that legitimate 
lawmaking issues from the public deliberation of citizens. As a normative account of 
legitimacy, deliberative democracy evokes ideals of rational legislation, participatory 
politics, and civic self-governance‖ (Bohman and Rehg, 1997, p. iv). 
Specific methods for achieving such democratic aims are wide-ranging. Public 
deliberation exercises held at local, regional or national levels are one such example of 
these efforts and can include citizens‘ juries, public hearings, consensus conferences, 
and focus groups that elicit a range of views on an issue (Rowe and Frewer, 2005). Each 
method can help achieve different goals, but it is precisely this point that serves to 
underscore the different aims that each method seeks to foster. Consensus conferences 
help participants to reach a consensus on a given issue, while focus groups elicit a range 
of views and facilitate discussion and deliberation. The question becomes one of 
determining how to most effectively address the risks inherent in today‘s 
technologically advanced societies (that is, in a way that minimises potential harm to 
society), while still allowing for the views of the general public to be heard and 
considered, even when their inclusion might pose political and institutional difficulties. 
The aims of such qualitative and ‗participatory‘ approaches ―should be broader than the 
instrumental objectives of the agency or key clientele groups. Its ethical basis should 
reflect democratic values and the intellectual contributions of democratic theory, not 
just the need to satisfy opposition demands as they arise‖ (Fiorino, 1989, p. 546).  
Pellizzoni‘s work on processes of deliberative decision-making offers an 
additional take on how participatory deliberations might play out in a policy debate 
where irreconcilable values dominate (Pellizzoni, 2001, 2003). Like others, he points to 
the shortcomings of expert-based approaches to policy development, stating that  
the debate on deliberative democracy has been undoubtedly stimulated by the 
inadequacy of strategic or elitist approaches to an increasing number of [policy] 
problems characterised by extreme complexity (Pellizzoni, 2004, p. 60).  
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However, he questions Habermas‘ claim that it is through deliberation and democratic 
process that every problem can find a solution. For Pellizzoni, some conflicts are 
intractable and values are in irresolvable conflict. Faced with situations where there is 
no ―universal reason‖, he argues we must look beyond traditional democratic processes 
and deliberation to the motivations and cognitive aims behind the decision-making 
process itself. In other words, when values are inextricably intertwined with the policy 
debate, we must be more attuned to the motivations of policy actors and their strategies 
for engagement in participatory process.  
In a much expanded discussion on such motivations, Stirling offers a subtle, yet 
important distinction in analytical starting point (Stirling, 2008). He argues that rather 
than singularly focussing on the differences in participatory approaches to appraisal as 
opposed to technocratic ones, we might find more useful analysis in considering the 
motivations for engagement as revealed in different appraisal strategies. Building on the 
work of Fiorino and others, (Fiorino, 1989; Fineberg et al., 1996), Stirling has argued 
that we might consider the implications of different normative, instrumental or 
substantive imperatives for engagement in different types of participatory or expert 
appraisal exercises. These imperatives can be used to explain stakeholders‘ motivations 
for participating in engagement exercises, or to examine the intentionality behind 
different analytical or participatory approaches to policy appraisal. Thus, these 
imperatives can affect the way in which stakeholders engage in the participatory or 
appraisal process, as well as having effects on the strategic choice of appraisal processes 
in the first place. The questions below thus take centre stage:  
Are there commonalities, synergies, or tensions transcending the apparently 
simple dichotomy [between expert analysis and participation exercises]? Are 
there conditions under which specific expert-analytic processes might potentially 
be more conducive to enhanced social agency or (conversely) particular 
participatory procedures less so? (Stirling, 2008, p. 268)  
If we address each in turn, normative imperatives manifest themselves in a 
variety of ways, but they are all concerned with the processes (rather than outcomes) of 
appraisal (Pellizzoni, 2003). In this sense, appraisal strategies are designed with a 
concern for embodying normative, democratic principles and being the ‗right thing to 
do‘, with little concern for specific ends being achieved. Under normative democratic 
perspectives, the process of evaluation or appraisal is one that might, alternatively: 
invoke ―the scope, resourcing, openness, representativeness, accessibility, facilitation, 
transparency, or accountability of engagement‖; hinge on ―capacities for social 
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empowerment‖; and be a ―self-evidently good thing‖ (Stirling, 2008, p. 269). By 
contrast, instrumental imperatives are characterised by a considered (and often 
considerable) interest in the outcomes of appraisal or evaluation processes (Pellizzoni, 
2001). Thus, appraisals designed from an instrumental perspective are concerned with 
―efficacy in realizing particular favored ends. The grounds for favoring such ends are 
simply assumed... Efforts thus concentrate on the interests of specific constituencies, 
institutions, or technological systems, irrespective of wider normative values‖ (Stirling, 
2008, p. 269).  
Finally, substantive imperatives are also concerned with the outcomes of the 
appraisal, but not in the way instrumental imperatives are in terms of particular ―values 
and ends‖. Instead, substantive imperatives have a ―focus on explicit, socially 
deliberated, publicly reasoned evaluative criteria for the outcomes themselves‖ (Stirling, 
2008, p. 271). Early evidence to support this interpretation can be found in the work of 
Fiorino, who argues that though the participation movements of the 1960s and 1970s 
promoted ―substantive democratic values‖ and discussion about what public 
participation in the democratic process would mean and could achieve for society, it 
―did very little to promote the procedural ends of democracy ... It substituted litigation 
for discussion, joint problem-solving, and a search for common ground‖ (Fiorino, 1989, 
p. 504). In other words, appraisal processes might be designed in order to facilitate 
wider discussion about the quality of desired outcomes and how that quality might come 
to be agreed on and judged. Thus, while adding a critical layer to the analysis of the 
deployment and use of public participation methods, these three imperatives may also 
have important explanatory power in understanding how and why perspectives on good 
governance differ amongst stakeholders in the hESC research debate.  
Insights such as these which call into question the imperatives behind different 
engagement methods, are not necessarily attempting to pass judgement on which means 
lead to normatively ‗better‘ ends. The point is merely to show that though public 
engagement or deliberative exercises might allow for a plurality of views to be 
expressed in a way technical assessments cannot reflect, once unpacked they may be as 
equally subject to human agency, contending framings, implicit agendas or hidden 
assumptions (Stirling, 2008). Rayner points out that though participatory methods have 
potential, their use in the social science literature, or even employed in policy circles, 
are subject to irreconcilable ―political-cultural‖ constraints (Rayner, 2003). Thus, 
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qualitative methods may just as easily serve to ‗close down‘ decision-making processes 
and policy trajectories towards particularly desired ends.  
This may appear to be a dilemma with no way out. Traditional approaches to 
risk assessment have been shown by the social sciences to be unsatisfactory, but 
equally, new qualitative and participatory approaches can mask hidden agendas and 
instrumental shaping of policy choices. How can these be reconciled? Returning to the 
challenges discussed at the beginning of this chapter, scientific progress today is rapid 
and there are, often unknown, societal implications. Funtowicz and Ravetz term this a 
situation of ‗post-normal science‘, where although science and its future implications 
are characterised by uncertainty, these uncertainties are embraced and ―not banished, 
but managed, and values are not presupposed but are made explicit‖ (Funtowicz and 
Ravetz, 1993, p. 740). Under these conditions, we must look anew at processes of 
decision-making and engagement. Analysis should emphasise the diversity, complexity 
and dynamism of social-political interactions and their effect on the processes of 
government. Similarly, analysis of good governance must give consideration to how 
policy decisions can be made in such a way that acknowledges and makes explicit the 
culturally contingent, uncertain and risky context of hESC research, in particular, and 
science and technology more generally. 
3.4 Conclusion: Dimensions of governance 
A challenge of this research is to not only distinguish what is meant by good 
governance, but also to analyse whether distinct and discernible perspectives on this 
concept exist amongst different groups of stakeholders in the UK and the US. 
Overcoming this challenge will depend, in part, on our ability to address this in a robust 
and systematic way. Just as we have now seen how the governance literature has 
developed systematic ‗lenses‘, ‗modes‘, ‗orders‘ or ‗hierarchies‘ which contribute to 
theoretical development, so we too must identify an organisational framework that can 
both draw together the theoretical strands identified above, but also inform and structure 
the research approach. This approach must not only address core elements of 
governance drawn from the literature above, but it must also incorporate important 
theoretical and empirical insights from STS in relation to ‗good‘ governance.   
Particularly relevant to this discussion, then, are the ideas introduced above that 
can acquaint us with the unique effects that cultural, political and scientific concepts can 
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have on the ‗framing‘ and ‗bounding‘ of policy problems. In particular, these insights 
can be used to flesh out the dimensions of governance introduced earlier. These can 
now be described in a more concrete way with implications of ‗good‘ governance 
explained for each axis. That is, within each dimension, various perspectives on what 
qualifies as ‗good‘ may exist. While it is these perspectives are explored through the 
empirical methodology of this thesis, it is important to ground the basis of this 
methodology in the theoretical ideas about governance, and especially good governance 
presented above. Therefore, to sum up, the dimensions are: 1) the nature of institutional 
centralisation, 2) the processes and types of negotiation, engagement, and deliberation 
between society and the state, and 3) the types of mechanisms used to govern. A brief 
description of each dimension follows the schematic drawing below.  
Figure 3.1: Schematic representation of dimensions of good governance 
 
The first dimension, institutional oversight, refers to the institutional structure 
and locus of authority that is used to govern a biomedical research programme. Within 
the political science literature, the study of institutions, or institutionalism, has a specific 
meaning and analytical approach associated with it. Institutions are defined as the 
―formal rules, compliance procedures, both formal and conventional, that bind the 
components of the state together and structure its relationship with society‖ (Hall, 1986; 
cited in, Gottweis, 1998, p 14). However, this is not the way in which it is used here, 
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although we do draw on the notion by identifying the locations of formal rules and 
procedures as either ‗centralised‘ or ‗decentralised‘.   
Our use of institutional oversight as a dimension of governance acknowledges 
the importance of identifying a locus of decision-making and formal authority within a 
given governance structure. This may also inherently reflect the overall structure of the 
country, for example, a federal or unitary state. In addition, some governance structures 
may have both centralised and de-centralised elements. It will be important to be able to 
reflect these aspects and their impact, if any, on the perceived ability of the governance 
system to function appropriately (however this may be defined).   
 The second dimension, mechanisms/instruments of control, relates to the 
regulatory environment and the mechanisms or instruments of government that are used 
to maintain and shape that environment. Juxtaposed on this axis are targeted regulations 
and passive steering mechanisms. The latter might include market-based mechanisms of 
professional self-regulation or federal funding guidelines. Targeted regulations include 
legislative acts, laws or regulatory statutes that may set boundaries and impose 
restrictions on how research can be conducted or therapies developed. The extent to 
which one instrument is preferred over another may reflect particular views on, for 
example, the nature of scientific autonomy and its relationship with government, itself.   
 The third dimension is about the processes of deliberation, negotiation and social 
engagement that may lead to the emergence of new governance systems or policy 
decisions. The poles of this dimension are characterised as either technocratic or 
democratic. As has been discussed throughout this chapter, the former may include 
expert-based, scientific procedures involving quantitative analysis, technical inputs and 
solicited advice from expert advisory panels. It is characterised by the science-led 
model of expert inputs to policy-making. The latter addresses the recent trend seen in 
the rise of democratic and participatory methods of discourse, where citizens and non-
experts are brought into the process to establish a lay perspective in decision-making.   
These three dimensions will form the basis of the empirical methodology 
presented in the following chapter. We have now established the scientific background 
of hESC research, reviewed the policy histories in the US and the UK, explored the 
theoretical foundation of governance, and introduced implied bases of ‗good‘ 
governance within the academic literature. We will now move to the heart of this thesis 
and a discussion of how all of these components will be analysed through a two-part 
methodological research strategy.  
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4.  Methodology: An introduction to Multicriteria 
Mapping 
4.1 Introduction 
The previous two chapters provided the contextual and theoretical foundation for 
this thesis. We must now consider how to use these foundations to explore the primary 
research question regarding the ways in which perspectives on ‗good‘ governance are 
constituted among different groups of stakeholders in the US and the UK. Two 
independent sources of evidence are used to compare and analyse these perspectives. 
These arise through i) a literature-based review of policy documentation and ii) direct 
elicitation from specialist experts and representatives of key stakeholder groups. In light 
of the theoretical aspects of governance outlined in the previous chapter, it is of 
particular importance that the elicitation methodology be one that can systematically 
and reflexively elicit notions of good governance in a way that retains accountability 
and transparency. 
This chapter will first introduce the case study strategy employed in this thesis 
and justify the chosen countries and technology of study. It will then review each 
methodological approach in relation to the two independent sources of empirical 
evidence. The chapter will necessarily focus more on the novel methodological process 
of eliciting and analysing stakeholders‘ perspectives, entitled Multicriteria Mapping 
(MCM). We will first justify the selection of MCM before describing the elicitation and 
analysis in detail in Sections 4.3-4.5. 
4.2 Case study selection and methodological framework 
4.2.1 Overview 
 This research combines a case study approach with a particular elicitation 
methodology. According to Yin, a case study is ―an empirical inquiry that i) investigates 
a contemporary phenomenon within its real-life context, especially when, ii) the 
boundaries between phenomenon and context are not clearly evident‖ (Yin, 2003, p. 
13). They are most useful for exploring research questions of ‗how‘ and ‗why‘ when the 
researcher does not want, or does not need, to control the behaviour of participants or 
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research subjects and when the events being studied are contemporary, as opposed to 
historical (Yin, 2003, p. 5-9). Multiple methods can be used in a case study to explore a 
given research question and the findings arising from such independent methods can 
usefully be triangulated. Thus, the two-pronged approach to the research strategy was 
adopted, with a literature-based review of policy documentation and a direct elicitation 
methodology with key specialists in the field of hESC research, in order to provide two 
empirical bases for comparison. Such relative flexibility in the types of methods 
employed are an advantage when time and resources are limited. This was the case in 
this doctoral research study and early on a decision was made to limit the study to only 
two countries and one technology due to existing resource limitations. We will first 
briefly justify the case study selection in the chosen countries – the US and the UK – 
and technology – human embryonic stem cells, before moving on to discuss the 
literature review and elicitation methods in turn. 
4.2.2 Case study selection 
Human embryonic stem cell research was selected as the case study technology 
for reasons that build on the overarching theoretical ideas discussed in the previous 
chapter. That is, the technological area of study needs to be one where governance 
stakes are high, future applications uncertain, assumptions varied and conditions 
unknown. It must be one in which risk and uncertainty exist not just from a scientific or 
technological standpoint, but from a cultural and social one, as well. This is necessary if 
we are to understand perspectives on good governance in such a way that allows us to 
explore wider implications for socio-political governance. In other words, the aim is to 
look beyond the institutions and instruments of government to the wider social and 
political processes and interactions which characterise governance.  
On the basis of the above, the selection of a case study technology was guided, 
in part, by the following criteria: 
• the chosen area of research or technology must be at similar levels of 
development in different countries;  
• the chosen area of research or technology must be politically and socially 
salient in various national settings; and 
• the chosen area of research or technology must lend itself to sufficiently 
different perspectives on good governance amongst a variety of policy actors in 
a variety of national settings.  
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For reasons that are apparent in the scientific review in Chapter 2, hESC 
research fulfils all of these criteria. It is ‗global‘ in the sense that the capabilities and 
capacities for conducting the research are present in several countries around the world. 
Though it is politically and socially salient in a variety of national settings, there are still 
important differences in the ways in which the research comes to be salient and the 
specific differences in culture and national context thereby reflected. The myriad of US 
state laws that have been passed in relation to embryo and hESC research reflect the 
diversity of views that can exist within one nation, let along between nations. Our 
attention now turns to the selection of the two countries within which this variation 
might be compared.  
The policy histories described in Chapter 2 substantiate the observation that 
differences in policy exist between the UK and the US for hESC research. This suggests 
that ‗sufficiently different‘ perspectives on good governance may also exist in each 
country. However, this observation alone is not enough to justify the selection of these 
two countries as the case study locations. The criteria used for this selection have 
different emphases to those above, given they are concerned with the location of the 
case studies as opposed to the topic. Thus, in each case study country the following 
conditions should be satisfied:  
• similar political structures should exist (e.g. Western democracies); 
• hESC research should be at a similar level of scientific development; 
• hESC research should be politically and socially salient; 
• hESC research and associated governance considerations should inspire active, 
diverse and sophisticated civil society discussions; and 
• hESC research and associated governance considerations should raise, as a 
result of the civil society discussions and other interactions, sufficiently different 
notions of good governance.  
Since the policy histories of each country were discussed earlier, we should be able to 
understand how the UK and the US fulfil these criteria. Though each country has 
different policy and regulatory frameworks, the science is sufficiently advanced in each 
country and both are arguably at the forefront of the field. The policy histories reviewed 
in Chapter 2 show embryo research, and more recently hESC research, has been a 
socially and politically salient issue for more than thirty years. The discussions in the 
UK and the US have been active, diverse and sophisticated over this time, beginning 
with debate over the permissibility of embryo and foetal tissue research and continuing 
through to the present state of embryonic stem cell research.  
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In addition to these more theoretically grounded selection criteria, the two 
countries were also selected for reasons of feasibility. The author is located in the UK, 
and so travel for interviews and access to information in the UK were both 
straightforward. The author conducted MSc research on the topic of hESC research 
policy in the US, and so had a ready network of contacts which could be mobilised 
there. The next section discusses the method employed to analyse the first source of 
independent evidence: the policy literature. 
4.2.3 Policy literature analysis 
A policy literature analysis is central to the research strategy of this thesis as it 
not only informs the wider context in which the research is occurring, but it also 
provides the basis for one strand of the empirical findings. As could be seen in Chapter 
2, the policy literature on the two case studies is a vast dataset in itself. In this research, 
the policy documents will be used for two main purposes. First, a wide-ranging review 
is used to contextualise the issue and inform the elicitation methodology through the 
identification of, for example, the main policy and institutional actors in the debate, the 
distinct viewpoints held by those groups, and the different governance scenarios in 
countries around the world.   
Second, a subset of the formal policy literature is analysed as an independent 
source of evidence in order to discern whether perspectives on good governance emerge 
from the policy literature and, if so, in what ways. Thus, inductive reasoning is used to 
provide the basis of comparison for the deductive component of the research, i.e., the 
stakeholder interviews. This provides a ‗baseline‘ that is independent from the elicited 
stakeholder views and thereby provides a critical reference point.  
In order to be confident in the ‗baseline‘ of perspectives emerging from the 
policy literature, the review itself must be conducted in a robust fashion. Though a full-
scale content analysis (Krippendorff, 2004) is beyond the scope of this thesis, and, 
moreover, is not necessarily called for by a research strategy employing mixed methods 
(Smith, 1996), the literature review was conducted using basic principles of content 
analysis. Content analysis is, at its simplest, ―a systematic analysis of texts‖ 
(Krippendorff, 2004, p. 3). It is further elaborated as ―a method by which we may 
summarise fairly rigorously certain direct physical evidences of the behaviours of, and 
the relationships between, various types of political actors‖ (Manheim and Rich, 1995, 
p. 184-185). Conducting a full content analysis, then, is a systematic undertaking, that 
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requires (at least): i) the definition of a population of texts or communication records; ii) 
the establishment of a ‗dictionary‘ set of criteria for coding; iii) the determination of a 
unit of measure; and iv) the establishment of several ‗coders‘ to work with the texts and 
reduce potential bias.  
The modified content analysis approach employed in the review of the policy 
literature addresses, to a small extent, each of these four points. A population of texts 
was defined through the identification of policy documents that were ‗formally‘ 
produced by governments or government-sponsored entities in the UK and the US. 
Initially, 12 possible texts were identified before the final selection of six policy 
documents (three in each country). This selection process is reviewed in greater detail in 
the following chapter.
23
 Analysis of the six chosen texts was conducted in an iterative 
fashion which allowed for themes of good governance to emerge through systematic 
analysis according to: i) organisational structure, ii) content in terms of issues addressed 
and iii) relevance to governance according to social, political and scientific themes. In 
relation to this latter point, as they emerged, themes of good governance
24
 were further 
used to categorise and ‗code‘ sections of text according to their thematic relevance. The 
findings were recorded in such a way as to allow for relative determinations of coverage 
according to each theme and within each text to be identified.
25
 Thus, though the 
procedure did not amount to a full content analysis, it did comply with underlying 
principles concerning use of ‗criteria‘ and ‗codes‘ by the analyst. 
Having now described the basis for the first source of evidence used in this 
thesis, we will turn our attention to the second, methodologically independent, source of 
evidence: stakeholder interviews. Before describing the interview elicitation process, we 
will discuss the theoretical basis on which an appropriate elicitation methodology was 
selected.  
4.3 Selection of an elicitation methodology 
4.3.1 Overview 
Various methodologies exist for the social appraisal of contending regulatory or 
policy interventions. As discussed in the previous chapter, technically based risk 
                                                 
23
 See the discussion in Chapter 5, p. 94-99. 
24
 While it is not necessary to identify these themes here, it is important to justify the way in which they 
were identified and preview their centrality to the empirical analysis. 
25
 This was the basis for the ‗shading‘ in Table 5.1, p. 98, of the themes of good governance. 
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analyses were a preferred method for many years in policy analysis, where quantitative 
approaches used ―scientific‖ and ―technical‖ models of risk assessment including cost-
benefit analyses, life cycle assessment, environmental valuation and others (Stirling, 
1998, p. 97-98). These ‗expert-based‘ analyses result in quantitative values that give a 
definitive ‗answer‘ to a policy question. A more recent trend has seen the rise of 
democratic and participatory methods of discourse, where, for example, citizens and 
non-experts are brought into the process to establish a lay perspective in decision-
making. However, these efforts might also be subject to distinctive framings and 
interpretations of a kind that could serve equally to ‗close down‘ decision-making 
processes as much as they seek to ‗open‘ them up (Stirling, 2008).   
It seems that both quantitative and qualitative approaches have important 
contributions to offer to decision-making. Quantitative components allow for traditional 
appraisal methods to be expressed, while qualitative components allow for an explicit 
acknowledgement of the possibility of divergent framings that might impact the 
ultimate ‗decision‘. Thus, the methodological design of the elicitation component of this 
research might usefully take advantage of qualitative sensitivity and quantitatively 
precise analysis of different governance options in a contested technological area. Such 
a design would also allow for the recognition that any decision is impacted by both the 
historical policy and technological circumstances in each country, as well as the unique 
socio-political context of each individual stakeholder. However before going any 
further, we must establish some basic criteria against which the particular methodology 
chosen was deemed preferable to others which operate under similar principles. 
4.2.2 Using criteria to inform the methodology selection  
As alluded to above, ‗participatory‘ decision-making techniques can be critiqued 
from a variety of angles. Perhaps equally important to evaluating how effective they are 
in a given context is consideration of how we might select different approaches in the 
first place. Indeed, some have argued that the methods by which we should select and 
evaluate ‗democratic‘ approaches to participation and appraisal have been under-
researched as a whole (Fiorino, 1990; Beierle, 1999; Rowe and Frewer, 2000). For 
theoretical and empirical reasons, then, it is important to critically understand and 
validate the selection of a given appraisal methodology.  
Since this research is comparing the views of actors across countries in a 
contentious technology area, a methodology is required that enables accurate and 
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nuanced elicitation of perspectives on good governance, such that any associated 
(and/or) systematic patterns may be identified and robustly analysed. Based on this, the 
following criteria have guided the selection of an appropriate methodology:  
i) it must be able to incorporate multiple views in a symmetrical fashion that does 
not unduly privilege one type of perspective;  
ii) it should allow one to distinguish the criteria through which perspectives on 
„good governance‟ are constituted as they relate specifically to possible real-
world scenarios; 
iii) it should elicit a rich body of salient background information concerning the 
contextual conditions, qualifications and uncertainties related to the 
applicability and interpretation of these criteria;  
iv) it should allow expression of normative judgements (within and across 
perspectives) concerning overall evaluations of particular governance 
scenarios; and 
v) it should elicit this information in a fashion that is convenient and accessible to 
participants, allowing them to validate key aspects of the outcome, rather than 
leaving this solely to interpretive analysis.  
Considering both the limitations of this research and, more importantly, the criteria 
above, Multicriteria Mapping (MCM) and Q Methodology are the two methodologies 
that stand out for consideration.  
MCM is a type of multi-criteria decision analysis tool, but is distinct in that its 
aim is not to identify a single, normatively ‗best‘ course of action, but instead to identify 
the different underlying reasons, or criteria, that influence people‘s perceptions of 
different options (Stirling and Mayer, 2001). It does so by systematically eliciting 
stakeholder viewpoints on the different options and mapping these diverse perspectives 
out (DTLR, 2001, p. 128). Q methodology is a type of discourse analysis that was 
developed in 1935 by the British physicist-psychologist William Stephenson 
(Stephenson, 1953; Brown, 1996). It shares with MCM the systematic identification of 
collective views, but in a way that is initially framed by the research investigators and 
based on responses to textual prompts rather than decision options (Dryzek and 
Berejikian, 1993; Yearley, 2001). Both methods involve qualitative and quantitative 
elicitation, but as pointed out by Yearley in his review of MCM, there are distinct 
advantages to the use of each in different situations (2001). The discussion below will 
consider how well each of these two methods fulfils the five criteria outlined above. At 
the end, we expect to establish a more robust, theoretically and empirically grounded 
justification for the elicitation methodology selected for this thesis.  
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Criterion i): it must be able to incorporate multiple views in a symmetrical and 
transparent fashion that does not unduly privilege one particular perspective 
MCM was originally conceived to allow stakeholders to assess different policy 
options for a given issue, with the aim being the construction of a literal ―sensitivity 
map‖ where the technology and policy choices preferred by individuals, constituencies 
or agencies at any particular moment, or point of view, could be determined (Stirling, 
1997, p. 195). Q methodology was developed with the intention of ―providing a way to 
reveal the subjectivity involved in any situation‖ from political attitudes to personal 
judgements (Brown, 1996). Q methodology can reveal patterns in how ―elements of 
different perspectives are related‖ (Tuler et al., 2005), but in a manner based on the 
analysis of particular features of discourse, not on the assessment of different 
governance options. On this criterion, then, Q methodology and MCM equally meet the 
requirement of systematically, transparently and impartially incorporating multiple 
points of view. 
Criterion ii): it should allow one to distinguish the criteria through which perspectives 
on „good governance‟ are constituted as they relate specifically to possible real-world 
scenarios 
Q methodology begins with a set of statements about a particular issue. The 
statements are pre-selected by the researcher from a wide variety of literatures in order 
to represent the range of discourses on the topic of research (Swedeen, 2006). They are 
then presented to the participant for ordering in various ways based on how strongly 
they agree or disagree with the statement. These ‗Q-sorts‘ are statistically analysed to 
determine what patterns of discourse exist among the participants.   
MCM begins with an open-ended set of ‗options‘ that vary depending on the 
context of the research. For example, they might be specific policy options or different 
‗scenarios‘ of options where a wider range of variables can be brought in. Participants 
must consider a set of ‗core options‘, but can define new options if they wish. The 
participant is then asked to define criteria that are used to evaluate (quantitatively and 
qualitatively) each option‘s ‗performance‘. The criteria represent the individual factors 
that underlie and influence a participant‘s views on the topic at hand. Once the 
evaluations are completed, a literal ‗map‘ of the range of views that can be expressed 
for a given option when considered against different criteria is produced. In this way, 
the criteria and their evaluative use provide a window into the perspectives on ‗good 
governance‘ that the research seeks to illuminate. As Q methodology has no such 
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established way of eliciting similar ‗criteria‘ in such a user-defined manner, MCM 
seems to be a preferable method under this criterion.  
Criterion iii): it should elicit a rich body of salient background information concerning 
the contextual conditions, qualifications and uncertainties related to the applicability 
and interpretation of these criteria 
This type of information is critical for the research as it will enable an 
explanation of why different interpretations of good governance exist. Through the 
MCM interview, a vast array of verbal information is collected from the individual as he 
works through the different criteria definition and option scoring stages. In addition, the 
analysis package for MCM allows multiple criteria, scores and other sources of 
information to be tested and analysed in different ways. Thus, MCM allows the full 
context of the evaluations of governance options, in terms of how the criteria are 
developed and defined, to be revealed and explored. Q methodology has no similar 
mechanism for drawing out a similar level of background information. Once the 
participant has sorted the statements, the final analysis is done at a statistical level and 
overall conclusions about the way each stakeholder‘s views relate to the overarching 
factors are made. Thus, the inability of Q methodology to elicit background information 
and detail is a critical shortcoming in light of the requirements of my research. 
Criterion iv): it should allow expression of normative judgements (within and across 
perspectives) concerning overall evaluations of particular governance scenarios  
Yearley‘s review of MCM concluded that though MCM was not explicitly 
developed for the purpose of delivering prescriptive policy recommendations, it can 
easily be utilised to do so (Yearley, 2001). More importantly, MCM can deliver the 
―reasons for differing views‖ as well as the ―practical implications for the overall 
performance‖ of different governance options for the technology being considered 
(emphasis in original, Millstone et al., 2006, p 60). Similarly, it can aid in the 
identification of points of disagreement or synergy that may not otherwise be readily 
apparent between the criteria. Though Q method can be interpreted to deliver normative 
judgements, these are not identifiable in a way that can be interpreted according to the 
different criteria. That is, the results of a Q sort can only be interpreted in the context of 
the responses to all the Q statements. MCM, on the other hand, is able to accommodate 
different perspectives on the options as they may vary according to individual criteria. 
Thus, normative judgements can be gathered both at the level of overall governance of 
an institutional configuration, and at the distinct level of the criterion. 
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Criterion v): it should elicit this information in a fashion that is convenient and 
accessible to participants, allowing them to validate key aspects of the outcome, rather 
than leaving this solely to interpretive analysis. 
 Q methodology leaves much interpretation to the analyst. From the initial stages 
of the research and the identification of the Q statements to the ongoing analysis of the 
empirical data after the interview is conducted, there is a certain degree of interpretive 
flexibility afforded to the researcher. This is particularly the case in the final stages of 
the analysis, the aspect that is most crucial for this fifth, and final, criterion. After a Q 
sort is completed, it is the analyst who conducts the validation, assessment and final 
interpretation of the research results in order to determine which views, framings and 
assumptions are revealed and the implications for the wider research question. 
 With an MCM analysis, the participant is able to validate the performance 
rankings of each assessment made, both under individual criterion and at the aggregate 
level under all criteria. This step is particularly crucial at this latter point in the 
interview when the final performance ranking ‗map‘ for all the options is considered. If 
there are any aspects of this map that do not seem ‗right‘ to the participant, he is able to 
explore why this is the case and make changes to any part of the evaluation, if 
necessary. The intention is that by the end of the interview, the participant must be 
satisfied that the final performance ranking is consistent with his ‗worldview‘ in relation 
to the options. If any changes are made, the analyst is aware of any points that may or 
may not have originally reflected the views of the participant and why. This information 
serves as a rich source of information and data in the analysis.  
In conclusion, based on the analyses above, it is clear MCM provides a more 
appropriate elicitation methodology for the particular aims and objectives of this 
research. It can transparently incorporate multiple views, identify synergies between 
competing options, elicit criteria for governance configurations, assign weights to value 
preferences, and lend itself to normative judgements about the constitution of ‗good 
governance‘ for hESC research. The remainder of this chapter will focus on a detailed 
discussion of the MCM methodology, including the interview process and data analysis.  
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4.3 Multicriteria Mapping in Detail 
4.3.1 Overview 
Multicriteria Mapping (MCM) is a software-assisted, multi-criteria decision 
analysis-based technique used to assess different ‗options‘, or ways forward, for 
contested areas of science and technology policy. This assessment is done through 
analysing the respective strengths and weaknesses of different options under participant-
defined, evaluative ‗criteria‘. It is distinct from other decision analysis techniques of this 
type in that its aim is not to identify a ‗best‘ decision, but instead to identify the 
different underlying reasons, or criteria, that influence people‘s perceptions of different 
options (Stirling, 1997, 1998; Stirling and Mayer, 2001).  
The MCM process is based in a recognition of the limitations of more complex 
multi-criteria, cost-benefit, or other risk analysis approaches which try, and fail by the 
conditions of Arrow‘s impossibility theorem (Arrow, 1970, as explained in Stirling 
1998), to identify singularly, normatively ‗best‘ decisions on the basis of a complex 
series of calculations and considerations. Rather, MCM aims to enrich our 
understanding of how and why different decision options may appear favourable under 
some conditions and less so under others. Thus, it allows exploration of divergent 
framings and interpretations through a transparent, reflexive and iterative appraisal 
process. The result is an array of open qualitative, and structured quantitative, 
information which yields a rich picture of the conditionalities and framings associated 
with each perspective. This information takes the form of literal ‗sensitivity maps‘ that 
can be evaluated to expose key features and perceptions of governance frameworks that 
are favoured under particular socio-political viewpoints (Stirling, 1997). 
In its entirety, the MCM process can be broken down into six distinct phases: 1) 
designation of technology area, 2) research into scientific and policy literature, 3) 
identification of participants, 4) definition of options, 5) individual interviews, and 6) 
analysis. The first two of these steps are covered in the general case study approach and 
the policy literature review discussed above. The remaining phases are specific to the 
MCM process. Much of this is covered in the sections below, however, for purposes of 
space and clarity, some of the more detailed methodological discussions are provided in 
relevant Annexes.  
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4.3.2 Identifying interview participants 
An MCM process aims to capture the ‗envelope‘ of expert and stakeholder 
views and relevant dimensions of a policy debate. In other words, one must include 
views in the ‗centre‘ of the debate, as well as those on the periphery. Based upon the 
initial review of the policy, scientific and historical literature discussed above and 
presented in Chapter 2, several stakeholder perspectives were initially defined as 
important to ‗capture‘ within the envelope. These include: 
1. Patient advocacy groups 
2. Scientific advocacy groups 
3. Religious advocacy groups 
4. Opposition policy advocacy groups  
5. Scientists 
6. Professional body representative groups 
7.  Industry Executives 
8. Policy-makers and Regulators 
9. Bioethicists 
Each group has an important role to play within the socio-political governance context 
in which decisions about hESC research are made. All four types of advocacy groups 
are relevant because they represent key points of view in the debate and each has an 
interest in particular governance strategies for hESC research. Scientists are the ones 
conducting the research and so have first-hand, technical experience in the challenges 
science can pose to governance and policy-making. Industry executives, like 
professional body representative groups, have a market or related professional interest 
and so can be said to hold a unique set of views on aspects of governance most relevant 
to them. Policy-makers and regulators are ultimately responsible to the public for the 
governance decisions that are made and related ramifications. Finally, bioethicists are a 
relatively newer entrant to policy advisory circles but are important in this field. Their 
deliberations are said to provide a forum for more nuanced social, cultural and ethical 
governance considerations.  
As it is important to capture both a range of depth of views, at least two or three 
people will be interviewed per group, with some adjustments made depending on 
resource constraints and national context. For example, in the US, it was important to 
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explore whether regional differences existed between individual states. A full table of 
the final numbers of interviewees per group is provided in Chapter 7 (Table 7.1).
26
 
Interview participants were identified through a range of methods, but all were 
initially contacted in a standardised manner through email or phone call.
27
 Initial contact 
with potential interview participants in the US was first made by reconnecting with 
interview participants who had participated in a previous study of the authors‘ using 
MCM in relation to hESC policy options in the US (Morgan, 2004). In an email,
 
these 
participants were reminded of this earlier research and the new research topic was 
introduced. Of these eleven participants, seven agreed to participate in this doctoral 
research. The remaining individuals either referred us to someone new or were not 
reachable as they had moved positions. Contact with new individuals was made through 
‗cold‘ emails or phone calls. Of these ‗cold‘ contacts, a positive response rate of over 
50% was achieved, with either the individual agreeing to be interviewed or referring me 
to a colleague. Participants were also identified through references given at the end of 
MCM interviews.
28
 This ‗snowballing‘ effect was a rich source of new interviewees. 
However, participants were identified equally through ‗cold‘ contacts and 
‗snowballing‘. This allows me to remain reasonably confident that there is not too much 
overlap in my dataset in terms of shared perspectives.
29
  
4.3.2 Defining the Options 
An MCM interview begins with an open set of options. These options provide 
alternative ‗ways forward‘ for the problem being evaluated and can be of many types, 
for example specific policy options (Stirling and Mayer, 2001; Millstone et al., 2006; 
McDowall and Eames, 2007), or diverse pathways (Leach et al., forthcoming; 
Thompson et al., 2010). Regardless of the type, it is important that each option is 
sufficiently distinct from the others in that it addresses different aspects of the issue, in 
this case, the governance of hESC research.  
Options feature in an MCM interview in three distinct ways as core, 
discretionary and additional options. The core options are pre-defined by the 
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 The table of interviewee codes in Annex E also provides this information. 
27
 With the caveats given below about ‗cold‘ emails versus those the authors had prior contact with, all 
emails were of a standard format and content. A sample of both types of emails are provided in Annex D. 
28
 At the end of an MCM interview, a participant was often asked to recommend colleagues who might be 
interested in participating. 
29
 One might expect that mutually referred colleagues might share similar perspectives on good 
governance, especially if they are part of the same actor network.  
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interviewer and evaluated by all participants. Because they are evaluated by everyone, it 
is the core options that enable systematic and structured comparison across all 
interviewees. Thus, great care is taken to ensure these options are sufficiently 
representative of the key features of governance.
30
 Discretionary options are also pre-
defined by the interviewer, but participants have the option of choosing whether to 
evaluate some, all or none of these options. In the case of this thesis, discretionary 
options are used to ‗round out‘ the scope of the options. Finally, if the participant feels 
that none of the pre-defined options capture an aspect of governance he believes is 
important to discuss, he is able to define his own ‗additional‘ options. These can take 
any form or structure, but are usually modelled on an existing option so that they can be 
evaluated in a consistent manner. 
The MCM options for this thesis are structured according to the ‗dimensions of 
governance‘ presented at the end of the previous chapter. These dimensions revolve 
around the questions: 1) Is the principal governance mode centralised or devolved? 2) 
Do mechanisms for regulatory oversight provide detailed prescriptions or general 
guidance? 3) Are associated deliberative processes ‗democratic‘ (participatory) or 
‗technocratic‘ (expert-based)? The option definition process addresses these dimensions 
by proceeding in an iterative fashion through two independently conducted stages. A 
description of these stages is provided in Annex B, but a brief summary is given here. 
The first stage involved developing eight ‗abstract‘ options based on the 
potential combinations of the three central dimensions. The second stage was to review 
national governance frameworks and develop country-specific options. Once two sets of 
options had been prepared, a ‗matching process‘ commenced through which a core set 
of options were identified that were based upon the abstract dimensions, but grounded 
in ‗real-world‘ examples. We decided to base the governance options on country-
specific examples so as to simplify the ‗conceptualisation‘ of the options by the 
participant. Due to the fact all participants were specialists in their field, it was 
reasonable to assume they would have at least a working level of knowledge about 
different country‘s governance approaches. Eventually, six core options and three 
discretionary options were arrived at, covering seven countries. The full description of 
the options that were used in the MCM interviews and an accompanying summary table 
are given in Annex C, but their titles and short summaries are listed below. The 
countries indicated in parentheses next to the titles are those the option was based upon. 
                                                 
30
 The process by which the core options were identified for this thesis is discussed later in this section. 
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Core Options 
1. Detailed Centralised Oversight (UK): Centralised governance with detailed 
regulations implemented by an expert statutory body that is empowered by 
legislature and is informed by occasional public involvement initiatives.   
2. Expert-led Framework (Sweden): Devolved ethical, expert-based oversight 
subject to central general laws. 
3. Detailed Expert Oversight (Germany): Centralised, expert governance through 
detailed regulations established by legislature and carried out by central 
scientific institution. 
4. Devolved Authority (Australia): Devolved legislative authority subject to central 
detailed regulations and expert review with occasional public participation. 
5. Mixed Central/Devolved (US): Centralised expert governance with detailed 
regulation of federal public research funds, and a variety of devolved 
governance frameworks. 
6. Ethics-led Governance (Israel): Centralised, expert governance through general 
laws with ethical oversight.   
Discretionary Options 
7. Devolved Democratic Governance: Devolved democratic governance through 
general laws. 
8. Centralised Democratic Governance: Centralised democratic governance 
through general laws. 
9. Centralised Regulatory Authority (Canada): Centralised detailed regulation by 
expert statutory body subject to oversight by legislature. 
Three additional options
31
 were defined by participants over the course of the 57 
interviews and no discretionary options were evaluated.
32
 When asked, all participants 
indicated a satisfaction with the coverage of the six core options and thought they 
comprehensively covered relevant dimensions of governance.  
                                                 
31
 The definition of these options as defined by the participants can be found in the summary overview of 
MCM findings given in Annex F. 
32
 An important methodological point should be made here. The MCM interview process began with only 
the first five of the six core options listed above. After an initial set of interviews had been conducted, the 
sixth core option, which was previously a discretionary option, was added. Some individuals had already 
chosen to evaluate it as a ‗discretionary option‘ and had commented that the option filled an additional 
‗dimensional space‘: that of (largely) self-governance. As it was added ‗late‘, so to speak, 12 individuals 
in the US and eight individuals in the UK did not evaluate the sixth core option. It was felt that returning 
to these individuals and conducting a single option assessment at a later stage would potentially bias the 
results as the participant might not be in the same frame of mind for the later assessment. During the 
analysis, great care was taken when making any judgements about the sixth core option given fewer 
participants evaluated it than others. No claims were made about the significance of any findings from 
this option where insufficient numbers of participants had evaluated it relative to the whole. 
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4.4 The MCM Interview Process 
4.4.1 Introducing the MCM Interview 
 An MCM interview is an open, reflexive, transparent and relatively simple 
process (in theory) which takes the participant through what is essentially a decision 
analysis process, from selecting options for consideration to evaluation of those options 
under different, evaluative criteria. The stages of an MCM interview are summarised in 
Figure 4.1 below. An MCM interview is mediated through the use of a computer 
software programme, which allows one to record the qualitative and quantitative 
information in real-time. This feature also allows the participant to validate their 
evaluations throughout the interview. The discussion of the MCM process below will be 
aided by the inclusion of screen shots from the software programme, MC Mapper.
33
  
Figure 4.1: Stages of an MCM Interview 
 
 
Each stage is discussed in more detail below, but can be summarised as follows:   
1) Choose options: the set of options the participant is asked to consider during 
the interview are discussed, and any discretionary or additional options are 
identified,  
2) Develop a set of criteria: he is then asked to define evaluative criteria that 
will be used to evaluate each option‟s performance,  
3) Score options under each criterion: he evaluates the options under each 
criterion,  
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 MC Mapper is an open-source software programme developed by Professor Andrew Stirling and 
colleagues at the University of Sussex. Details about the software algorithms can be found in Annex G. 
2. Develop  
a set of  
criteria 
5. Reflect on  
outcome 
1. Choose  
Options 
3. Score  
option under  
each criterion 
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weight to  
each  
criterion 
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4) Assign weight to each criterion: he assigns relative weightings to the criteria, 
and  
5) Reflect on final outcome: the final „map‟ of performance rankings, as well as 
the whole process, is reflected on.  
It is important to note that though these stages are presented in a sequential order, and 
the interviewer must follow a specific protocol in going through them, the participant is 
free to return to earlier stages of the interview at any time. For example, the participant 
may add new evaluative criteria, select a discretionary option for evaluation or change 
an assessment score at any point. This is one example of how MCM provides an open 
and reflexive evaluation process whereby they are able to continuously reflect back 
upon previous assessments in light of new insights throughout the process.  
Before the formal interview stages commence, a description of the research 
project is given and the participant is introduced to the MCM process.
34
 Participants are 
also explicitly made aware of the scope of the research. This is essentially two-fold: 1) 
the governance options are restricted to hESC research and do not, therefore, extend to 
clinical applications and associated governance considerations;
35
 and 2) the use of the 
term ‗governance‘ in this research context (see definition in background document and 
in the previous chapter). Finally, participants are assured that the views they express in 
the interview will be presented as their own and not as officially representative of their 
respective organisations.
36
 However, in the MCM analysis, the organisational 
affiliations of each individual are taken to indicate a particular shared point of view, or 
perspective, of the participant as a result of these affiliations. Thus, though individual 
organisations are not officially represented, the professional fields the individual is a 
part of are taken to be indicative of a given perspective they hold.  
4.4.2 Choosing the options 
This stage of the interview is relatively straightforward. The options are 
discussed with the participant, who is encouraged to ask questions or seek points of 
                                                 
34
 Though participants are given two briefing documents prior to the interview, most participants 
generally have not read through these in their entirety. The two briefing documents and a sample covering 
letter/email are provided in Annex D. 
35
 For example, were the scope of the research to extend to clinical applications, clinical trials and other 
regulatory procedures would need to be included within the governance options. As mentioned earlier in 
this chapter and at earlier points in the thesis, this research was specifically bounded as looking at good 
governance in the context of hESC research and not the clinical aspects, per se, although these 
necessarily factor in to governance discussions as the future clinical and therapeutic promise of hESC 
research is a key factor in this wider socio-political context.  
36
 Though the majority of participants did not request anonymity, for purposes of confidentiality all 
responses and participant identities have been made anonymous for this thesis. 
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clarification at any time. During this stage participants are also asked if they would like 
to consider any of the discretionary options or define any additional options. Generally, 
participants had not read through the options in great detail prior to this time, but, in 
about 25% of the interviews, the participant had read through the options and made 
notes or comments in the margins of their introduction pack. Some had gone so far as to 
generate an initial list of criteria. Though helpful in the sense that the participant had a 
good grasp of the interview methodology, this did not always mean the interview more 
accurately or authentically reflected their personal view. Each participant proceeded 
through the interview at their own pace and regardless of their preparation beforehand, 
their unique set of views, framings and judgements still emerged.  
Figure 4.2: Screenshot of Option Definition Stage of MCM Interview 
 
 
The figure above shows a screenshot of the MC Mapper software at the option 
definition stage. All the option titles are listed on the left hand side, while their 
definitions are displayed on the right-hand side of the screen. 
4.4.3 Defining criteria 
The second stage of an MCM interview is the definition of the evaluative 
criteria. Criteria are the different judgements, assumptions, technical views, personal 
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beliefs, and so on that a participant uses to evaluate the options. Participants can define 
as many or as few criteria as they like.
37
 They are also able to define ‗criterion of 
principle‘, meaning a criterion that reflect views on which there are moral absolutes or 
ethical thresholds against which no trade-offs can be made. Definition of a criterion of 
principle means the participant is able to rule out one or more of the options on the basis 
that it violates such ‗absolutes‘.  
The figure below shows a screenshot from the MC Mapper software at the 
criteria definition stage. As participants define their criteria, a new criterion in the upper 
left-hand corner box is created and notes are taken on the way the participant defines it 
in the larger box on the right-hand side of the screen under the ‗Notes‘ panel.38 
Figure 4.3: Screenshot from Criteria Definition Stage of MCM Interview 
 
 
To date, most MCM projects have been primarily concerned with the final 
analysis of policy options and the views and framings that influence the relative option 
performances (see Stirling and Mayer, 2001; Davies et al., 2003; Millstone et al., 2006; 
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 Full details about the number of criteria defined in all MCM interviews, including any ‗criterion of 
principle‘, can be found in the summary data of MCM usage in Annex F. 
38
 Though not shown here, a screenshot of the MC Mapper software when a criterion of principle is 
defined can be found in Annex F.  
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McDowall and Eames, 2007). However, this research is concerned with notions of good 
governance. Therefore, the criteria are of primary importance, not only in how they are 
defined, but also in how they are used to evaluate the options in terms of scores given, 
uncertainties expressed and associated nuances illuminated.   
Due to the central importance of the criteria themselves, it is of utmost 
importance that all participants share a common understanding of what a criterion is. 
Past experiences with MCM have revealed that participants can struggle in the criteria 
definition stage (see Morgan, 2004). They may not understand what a criterion is or 
what the criterion will be used for and often ask for examples to aid their thinking. 
Methodologically, such examples are difficult to give. Examples given to one 
participant would need to be given to all without running the risk of unduly biasing the 
results. Though participants are provided with a worked example of an MCM exercise, 
including criteria examples, of an entirely different scenario (the case of energy 
provision),
39
 this is not always helpful. In considering the central topic of this research, 
whether distinct perspectives on good governance are discernible, and the hypotheses 
that follow, in discerning these perspectives one can probe the diversity of framings, 
conditionalities and viewpoints that affect how the perspectives are constructed, the 
importance of eliciting meaningful criteria in a consistent way becomes paramount.      
In order to address this, a ‗thought bubbles‘ handout was developed and given to 
all participants (see Annex D). Of course the danger in using a ‗prompt‘ sheet like this 
is that it risks increasing the criticism of interview bias that it is meant to address. In 
order to mitigate this, several steps were taken. First, only single words are given in the 
‗thought bubbles‘. Thus, participants have to elaborate on them in a meaningful way in 
order to use them as criteria. To further emphasise this, the instructions at the top of the 
handout clearly state the bubbles ―are only prompts‖ and if the participant would like to 
use them, they should ―define them in a way that is meaningful‖ to them. Thus, if the 
handout is used, the participant is only drawing on single words and each interpretation 
is unique to an individual. 
Second, not only do the written instructions indicate the bubbles are only meant 
to be a guide, but the verbal and physical interaction with the participant attempts to 
minimise reliance on the bubbles. When the criteria definition stage in an interview is 
reached, the definition of criteria is reviewed and the handout is briefly shown to the 
participant. It is explained that it is a list of ‗ideas‘ or ‗thoughts‘ that might help them to 
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 See the example given in the background information documents included in Annex D, p. 306. 
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think about criteria. After being given enough time to read the instructions at the top and 
glance through the bubbles, the participant is asked if any criteria occurred to them 
while preparing for the interview or while discussing the options. As this is said, the 
thought bubbles handout is discreetly, but purposefully, moved to the side and out of the 
participant‘s line of sight. The aim is to verbally and physically distract the participant 
from using the prompt sheet before developing his own ideas.  
Third, and finally, approximately 45 ‗thoughts‘ bubbles are included in the 
handout. This is about the same number of discourse statements that are used in a Q-sort 
and so might in this broad sense be considered methodologically valid in terms of the 
requisite levels of refinement of the literature required in order to avoid bias. Moreover, 
each issue listed on the prompt is ‗grounded‘ in wider policy literature specific to hESC 
research, theoretical literature in a variety of academic disciplines specific either to 
hESC research or biotechnologies, and wider governance and STS literatures. The aim 
was to ensure, as comprehensively as possible, that the majority of the issues discussed 
in the wider literature and policy discourse, were covered within the bubbles.  
The results from the interviews suggest that this approach was successful in 
minimising bias and producing meaningful criteria. Less than half of the participants 
interviewed for this research actively used the prompt sheet, but the use of the sheet 
varied. Some used it only for defining the first few criteria, but once they became 
comfortable with the idea of criteria they would put it to the side. Others started with 
their own criteria, but would look to the sheet after an initial brainstorm as if to seek out 
additional ideas. Even when different participants based criteria on the same thought 
bubbles, the definitions of the criteria were unique and, in some cases, completely 
divergent in their meaning. Thus, we can be reasonably confident that the prompt sheet 
did not bias the criteria definition in any significant way.
40
  
4.4.4 Evaluating the options 
This stage is, by far, the most complex and time consuming part of the MCM 
interview. Participants are asked to evaluate each of the options based on how well it 
‗performs‘ under individual criterion. To do the evaluation, participants are asked to 
give a pessimistic and optimistic score to each option on a scale of the participants 
choosing (usually 1 to 10, or 1 to 100). These scores are recorded in a table as shown in 
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 Further detail of the relationship between ‗freely-defined‘ criteria and those in the prompt sheet is 
provided in the summary of MCM interview findings in Annex F. 
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the screenshot below, with ‗minimum‘, or pessimistic, scores recorded on the left and 
‗maximum‘, or optimistic scores, recorded on the right. Notes are taken in each of the 
‗pencil‘ boxes (which pull up a dialogue box when clicked on) about the participant‘s 
reasons for assigning particular scores. These reasons might include the assumptions 
being made about optimistic or pessimistic conditions, the conditions themselves, or the 
relationships between evaluation assessments. The bar rankings seen in the top half of 
the screen come up automatically, so the participant is able to see the relationship 
between options at all times. 
Figure 4.4: Screenshot of Scoring/Assessment Stage of an MCM Interview 
 
 
As pointed out earlier, we are most interested in the way participants use the 
criteria to evaluate the options (as expressions of good governance), as opposed to what 
they think of the options themselves. In this regard, it is important to note two distinct 
ways the participants evaluated the options. Some were comfortable evaluating the 
options in the ‗abstract‘, that is they understood the options were only based on different 
country models for illustrative purposes and they rely on these abstract dimensions to 
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conduct the evaluations. The second pattern is where participants based their evaluation 
more on their knowledge of the country the governance option is related to.   
With regards to the research question, these differences do not significantly 
affect the findings. As has been repeatedly stated, the interest of this research is to 
understand perspectives on good governance. We expect these perspectives to be 
culturally, politically and individually contingent in ways that will emerge through the 
definition and weighting of the criteria and the respective option assessments. Thus, as 
long as the qualitative information about the criteria and the assessments are elicited, 
variations in the interpretation of the options should have little impact on the overall 
research question as it relates to understanding how perspectives on good governance 
are constituted. Nevertheless, the point about interpretation is methodologically 
important, and one that was considered throughout the analysis.  
4.4.5 Weighting 
The final stage of an MCM interview is the weighting of criteria. Here 
participants can express the relative importance of each of the criteria they have defined. 
They are encouraged not to think about the ‗rank order‘ of the criteria, but the relative 
importance of the criteria in terms of the assessments of options themselves. In other 
words, it is not just which criteria are more important, but the ‗amounts‘ (in relation to 
minimum and maximum option scores) by which each criterion might be traded off 
against others.
41
 In the software, weighting is done using a sliding scale of 0-100 
(pictured below). The weights are normalised and the final performance rankings of the 
options under all the criteria can be seen. The figure below shows a screen shot of the 
weighting bars and final performance rankings. 
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 Recall that criteria that are identified as not being susceptible to trade-offs are addressed in the MCM 
methodology using ‗principles‘. 
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Figure 4.5: Screenshot of Weighting Stage of an MCM Interview
42
 
 
 
Importantly, as the participant adjusts the weightings, he sees the aggregate 
performance of the options under all the criteria he has defined. That is, the final 
performance ‗map‘ of the different options as expressed through the length and relative 
position of the bar charts moves in real-time as the participant adjusts the weightings. 
This allows the participant to understand how the weightings affect option performance 
and aids in the crucial ‗validation‘ step that was discussed in Section 4.2.2. For 
example, if the participant‘s initial rankings are found to be inconsistent with their 
views, the we can discuss why this might be the case. If the participant is simply 
surprised, reflections are made on why he is surprised and how the final rankings differ 
from any expectations. However, if the participant is unhappy because the final rankings 
are incompatible with an organisational or personal view, we might again explore these 
reasons and, if necessary, adjust scores or weightings.
43
 Such transparency in 
understanding the framings and socio-political views affecting the final performance 
map is not something easily found in other methodologies and provides a rich source of 
material for the later analysis, as well as an important validation step in the method.  
                                                 
42
 The reader may note that in the above example all the weightings are equal. This reflected the view of 
the interviewee that all criteria were equally important, however this was not usually the case with most 
interviewees. 
43
 In such instances, both versions of the MCM weightings and options scores are saved so that they can 
be referred to by the interviewer in later stages of analysis. 
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4.4.6 Discussion of performance rankings 
 Finally, at the end of the interview the final ‗map‘ of the performance rankings 
of the options is discussed with the participant. Most participants find the map 
accurately reflects their views they initially had about the different options, but there is 
often surprise at the extent of the uncertainty ranges or the relative performance 
rankings. In this study, no participant asked to change any scores at this stage, but some 
did want to return to earlier scores to understand which assessments were affecting the 
final performance rankings and in what ways.  
We have now completed our description of the MCM interview process. The 
next section will discuss how all of the MCM interview data was analysed.   
4.5 Analysis of MCM Interview Data 
4.5.1 Introduction to the MCM Analysis package 
In total, 57 MCM interviews were conducted where a full set of MCM data was 
collected.
44
 Three interviews were conducted in which the participants declined to 
participate in the full MCM interview. In one instance this was due to unexpected time 
constraints on the interview with no opportunity to reschedule. In the other two 
instances it was because the participants felt uncomfortable with a certain aspect of the 
interview process. In one case the participant was opposed to hESC research on 
religious grounds and so he was not willing to discuss the governance of such research 
at all. Though the participant was given the option of defining a criterion of principle to 
address this, he declined. In the other case, the participant did not feel comfortable 
making judgements on governance options in the abstract or even when considered in 
their nationally-based context. In all three cases, semi-structured interviews were 
conducted. In two of them, the participants defined the types of criteria that were 
important to them in thinking about governance issues for stem cell research (including 
non-embryonic stem cell research).
45
  
                                                 
44
 In two of these 57 interviews, the participants worked together for a US state policy department. They 
conducted the MCM process sitting together. Upon sitting down to conduct the interview they found they 
had each defined similar criteria, and so they each used the same criteria names, with slightly different 
definitions. For some options different scores were given and each individual gave different weightings. 
This detail is given here because in some of the supporting Annex material it may appear to the reader 
that one interview was counted twice, however this was not the case. 
45
 As they did not complete a full MCM appraisal, these criteria were not included in much of the analysis 
of interview-generated empirical data. However, they are included in the table of criteria in Annex H. 
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In order to ensure completeness of the database before beginning the analysis, 
all interviews were recorded and listened to after the fact in order to ensure all 
information from the interview was accurately recorded in the interview database.
46
  
The 57 MCM interviews resulted in a dataset composed of 310 individually 
defined (and fully evaluated
47
) criteria and 1,815 individual option assessments. This is 
obviously a vast amount of information, all of which must be qualitatively and 
quantitatively analysed for content, themes and insights. Generally speaking, the 
analytical strategy (Yin, 2003) of an MCM analysis is one that is driven by a process 
termed ‗hypothesis-testing‘. Through a process of systematically generating testable 
hypotheses and applying them to the data, one is able to develop a sophisticated and 
structured understanding of the large amounts of quantitative and qualitative data 
generated. This process of ‗hypothesis-testing‘ requires several analytical steps and 
proceeds through a process summarised in Table 4.1 below.  
Generally speaking, the analysis process can be summarised as first grouping the 
data into meaningful, ‗analysable‘ units, or categories, and then generating quantitative 
and qualitative representations of the data according to those categories. Quantitative 
data are shown as performance ranking charts of the governance options according to 
the particular categories defined, and qualitative data are criteria definitions and 
associated option evaluations and weightings. By looking for systematic patterns in the 
quantitative option performance rankings and qualitative characteristics of different 
categories, a type of ‗heuristic-based‘ analysis is used as a starting point. One can then 
dig deeper into both the quantitative and qualitative data underpinning areas of 
analytical interest to understand why and how particular patterns emerge. 
                                                 
46
 This was done either through transcribing parts of the interview into a Word document and then pasting 
relevant notes, ‗nuggets‘ or additional information which was not captured in the interview into the 
database, or simply directly inputting material into the database while listening to the recorded interview. 
While the former method was the initial process the author followed, she was afflicted with a serious case 
of Repetitive Strain Injury halfway through the analysis for which medical attention was needed. At this 
point it was recommended that the stage of transcribing into a Word document was skipped and the 
updates made directly into the database. This was approved by both supervisors as the outcome of either 
path was deemed to be the same – that is, updating of the database with all relevant interview material. 
47
 A total of six criteria were defined in six different interviews that were not fully evaluated under all the 
options. However, these criteria were assigned weights. The implications of this for the analysis of the 
rankings are negligible, however in a few instances there are small implications for the analysis of the 
weightings. Where this is the case, this is noted in the text in the following pages. 
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Table 4.1: Analysis of Stakeholder Interviews
48
  
MCM Interview 
Stage 
MCM Analyst Stage
49
 
Analysis of Stakeholder Interview 
Data
50
 
Identification of 
stakeholders 
Grouping of stakeholders into 
meaningful ‘perspectives’  
Qualitative analysis of interviewee‟s 
background and any other pertinent 
information that may provide insights 
into their framings and views 
Governance 
option definition 
  
Grouping of options with similar 
features into ‘clusters’ 
Qualitative textual analysis of 
discussions around the policy options  
 
Qualitative textual analysis of additional 
options defined by participants  
Identifying and 
weighting 
criteria 
  
  
Grouping of criteria addressing 
similar themes into ‘issues’ 
Qualitative textual analysis of criteria 
definitions and discussion around 
criteria definition  
Quantitative analysis of issues by 
numbers of criteria, numbers of 
participants defining criteria within 
the issue and relative distribution 
of issues among perspectives. 
Generation of ‘weighting extrema’ 
charts under different issues for 
different perspectives 
Qualitative textual analysis of criteria 
weighting amongst individuals and 
across „perspectives‟  
Assessing 
option 
performance 
  
  
Generation of ‘performance 
ranking charts‟ for: all criteria for 
each individual; all criteria under 
various perspectives; individual 
issues under various 
perspectives.  
Qualitative textual analysis of the option 
assessments under individual criteria by 
individual stakeholder and at the level of 
issues by perspective 
Generation of ‘uncertainty’ and 
‘ambiguity’ charts for various 
combinations of issues and 
perspectives. 
Quantitative analysis of the option 
assessments across and within 
perspectives, including analysis of 
pessimistic and optimistic scores by 
both ‘rank means’ and ‘rank extrema’ 
Generation of textual reports 
based upon different 
configurations of perspectives 
and issues. 
Qualitative textual analysis of the 
conditions and assumptions specified 
under pessimistic and optimistic 
conditions 
Quantitative analysis of the option 
assessments under various issues 
across and within different perspectives 
Evaluation and incorporation of 
methodological scoring differences 
across and within stakeholder groups. 
Review of final 
option rankings 
  
Generation of performance 
ranking charts as above. 
Qualitative textual analysis of thoughts 
on final performance scores. 
Qualitative assessment of procedural 
and methodological issues and 
implications. 
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 This table builds on those in (Morgan, 2004) and (Davies, et al, 2007) as well as guidance found in the 
Multicriteria Mapping Analyst Handbook, accessed at www.multicriteriamapping.org. 
49
 All terms indicated in „italics‟ will be described in more detail in the sections below. 
50
 All qualitative textual analysis is based on information entered in the MC Mapper software and 
subsequently uploaded into the MCM Analyst database as well as additional information compiled 
through the review of the interview recordings.  
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In order to begin organising the MCM data into more manageable units of 
analysis, the MCM Analyst package was employed.
51
 This software first facilitates the 
transfer of all the quantitative and qualitative information from the interview into a 
Microsoft Access database. The database is structured so that the interview data can be 
displayed in various forms, tables and queries. This structure enables one to group the 
interview data in a dynamic and iterative way so that multiple hypotheses can be tested. 
Examples of groupings are described below and further elaborated on in the empirical 
findings presented in the next two chapters. The database is also linked to a set of 
Microsoft Excel spreadsheets. This facilitates the generation of performance rankings 
and other analytical charts for heuristic analysis. Finally, the MCM Analyst software 
also allows for generation of textual reports that contain relevant qualitative information 
pertinent to a particular configuration of the data one is testing. Thus, the combination 
of quantitative data in the spreadsheets and qualitative data in the textual reports allows 
for side-by-side comparison of the heuristic indicators and the detailed textual data. The 
sections below provide additional information about how each of these stages proceeded 
for this thesis study.  
4.5.2 Groupings of data: clusters, perspectives and issues 
As pointed out above, the hypothesis-led analysis of MCM data is done through 
identifying patterns or points of comparison in the option performance rankings. 
However, in order to analyse the data in a meaningful way, the data need to be grouped 
and ordered according to the hypothesis being tested. There are many ways to ‗cut‘ the 
empirical data and the different types of ‗cuts‘ are dependent upon the hypothesis. 
These cuts of the data into analysable categories take the form of clusters of options, 
perspectives of individual participants and issues emerging from related criteria.  
Clusters are groupings of options that share similar features. While full use of 
clusters as a unit of analysis was not useful for this thesis due to the small numbers of 
options, they are a useful analytical unit when the number of policy options exceeds a 
manageable number (see, for example, Millstone, 2006).  
Perspectives are a grouping of viewpoints that may be seen on the basis of 
MCM analysis to display certain features in common. There are different, cross-cutting 
                                                 
51
 This software complements the MC Mapper interview software and was designed specifically to 
facilitate the analysis of MCM interview data. 
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ways to group participants into perspectives and, indeed, the participants were originally 
recruited on the basis of some provisional ideas in this regard (see earlier discussion in 
Section 4.3.2). However, the exploration of a variety of different perspectives is a 
central focus in MCM analysis. 
Issues are groupings of criteria that may be seen on the basis of MCM results to 
display certain features in common. Issues are, in principle, potentially relevant across 
all perspectives, although in reality only some perspectives may actually invoke any 
given issue. Nevertheless, useful analysis can be conducted on the basis of how 
different types of issues are evaluated and defined across different perspectives. As with 
perspectives, there are different ways to group criteria into issues.  
The process of defining issues or perspectives and grouping criteria or 
participants, respectively, is done through a relatively ―inductive‖ process (Stirling and 
Mayer, 2001, p. 537) of ‗pattern-matching‘ (Yin, 2003) and other qualitative analysis 
techniques. For example, criteria could be qualitatively analysed in several ways: i) in 
the way they are defined, ii) in the associated discussions around the definition of the 
criteria and iii) in the additional comments and insights as to the nature of the criterion 
made by the participant during the assessment process. Obviously criteria and 
participants could be grouped according to many different parameters.
52
 This was where 
the importance of the analysis being hypothesis-led comes to the fore. New hypotheses 
lead to new understandings of the data, which require new configurations and questions 
to be posed. This process continues until diminishing returns set in. Thus, the analysis, 
like the elicitation, is an iterative and reflexive process from start to finish. 
4.5.3 Quantitative and qualitative analysis: towards heuristic 
understanding 
For each hypothesis that is generated, a particular configuration of perspectives 
and issues is determined and analysis proceeds according to the summary table above. 
Various performance ranking charts are generated and qualitative and quantitative 
analyses proceed according to heuristic-based analysis of the performance ranking 
                                                 
52
 In many cases there was some uncertainty as to how an individual criterion might be grouped according 
to the hypothesis being tested. In these cases, ‗uncertain‘ criteria were either included or excluded from 
the analysis and two different sets of analyses performed. If the ‗uncertain‘ criteria did not seem to affect 
the performance rankings in a significant manner, then they were usually included in the issue group. If 
they did affect the performance ranking, more detailed analysis was undertaken to determine why and 
how they were affecting option performance. A decision was made after this analysis was done from a 
more informed perspective as to the nature of the criteria and where it most appropriately was to be 
situated within the analysis. 
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charts. Where such heuristics indicate points of interest, further qualitative (or in some 
cases quantitative) analysis was conducted in order to gain insight and understanding 
into the underlying patterns. To aid in this process, performance ranking charts can 
display the quantitative data in several different ways. The most relevant charts for the 
analysis that will be presented in the main text of this thesis are underlined below. 
Detailed algorithms for each of the calculations used to generate the charts are given in 
Annex G. 
• Rank means: these charts display option rankings as an interval (or ‗range‘) 
between two averages: (i) all optimistic scores and (ii) all pessimistic scores. 
These intervals can be generated in two ways: 1) for a specified subset of 
interviews (a ‗perspective‘) and criteria (an ‗issue‘) or 2) for a specified subset 
of interviews and all issues together (thus indicating the overall ranking of the 
options in question). Generation and comparison of both sets of charts enables 
exploration of how and why option performance varies between different 
perspectives and under different issues . 
• Rank extrema: these charts display the performance rankings for each option as 
an interval between the highest extreme optimistic score and the lowest extreme 
pessimistic score for a given set of interviews (a perspective) under all criteria. 
• Mean interval uncertainty: these charts display the absolute scale of the 
difference between the mean optimistic and pessimistic scores, averaged for a 
given option over all relevant interviews (a perspective) and/or criteria (an 
issue).  
• Mean ratio uncertainty: these charts display the same basic property of 
uncertainty, as that addressed in mean interval uncertainty (above). Here, 
though, it is expressed as the ratio of the absolute difference (as above) to the 
underlying values of the scoring ranges themselves. In other words, mean ratio 
uncertainty is calculated by taking the median of the pessimistic and optimistic 
scores and calculating the ratio between this and the corresponding interval 
uncertainty as defined above. Again, the calculation can be performed for any 
grouping of interviews (a perspective) and/or criteria (an issue).  
Charts of ratio uncertainties can be used in conjunction with those for interval 
uncertainties to understand potential divergences of implications for the scale of 
uncertainty across perspectives, issues and options, depending on whether 
participants are held to be expressing this in absolute terms or in relation to the 
magnitudes of the scores themselves. 
• Mean ambiguity: these charts display the scale of the differences between 
individuals in their option assessments. Such ambiguity is expressed here as the 
mean difference between optimistic scores and the mean difference between 
pessimistic scores for all interviews within a perspective under a set of criteria 
(issue).  
Thus, whilst mean interval uncertainty displays the scale of uncertainties as 
expressed by individual participants, mean ambiguity displays the scale of the 
differences between different individuals included in the same perspective. It 
therefore reflects the degree of collective disagreement rather than individual, or 
average, uncertainty. 
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• Median ambiguity: this corresponds to mean ambiguity in that it reflects a 
measure of collective disagreement between individuals in a perspective. 
However, these charts display the average scale of the differences between the 
medians of each interview‘s option scores under a set of criteria (issue). 
• Issue weight extrema: these charts display the highest and lowest criteria 
weightings expressed in a given set of interviews (a perspective) over different 
groups of criteria (an issue). 
• Issue mean weightings: though not expressed as charts, these numerical values 
indicate the mean aggregate weightings in a given set of interviews (a 
perspective) over different groups of criteria (issues).  
Each type of chart provides a way to analyse different features of the 
quantitative data and they feature in different ways in the analysis that follows in this 
thesis. We will now briefly comment on the issue of statistics within an MCM analysis, 
before concluding this chapter. 
4.5.4 A note on statistics 
 MCM is a hybrid methodology, symmetrically incorporating quantitative and 
qualitative elements. However, if either were to be judged to take precedence, it would 
be the qualitative aspects – which address the reflexivity and openness that is a feature 
of both the interview and analysis process. While the quantitative features in an MCM 
analysis might in some ways be seen as complementary to statistical methods, the form 
of MCM data does not fit well with the strict parameters required in statistical analyses. 
Quantitative measures are used in MCM primarily as a heuristic to identify points of 
potential interest and provoke hypotheses, which in turn provide a guide for structured 
analysis of the qualitative material. Conclusions are drawn and tested on the basis of the 
full set of MCM data. Nevertheless, use of quantitative metrics and data in this 
methodology inevitably raises questions over the statistical robustness of some of the 
findings. Therefore, it is worth devoting some attention to considering this issue before 
proceeding to the empirical chapters. 
  The main point is that MCM is not designed, and has not previously been used, 
as a methodology that produces statistically significant findings. Nor does it need to be. 
As discussed above, MCM aims to capture the ‗envelope‘ of key dimensions in a given 
policy area. Specifically, these include a range of perspectives, option assessments and 
ranks, criteria descriptions and weights, and expressions of uncertainty and ambiguity. 
This range of dimensions is more suitable to the type of analysis provided by MCM 
than aggregated parameters derived in statistical analysis would be (for example, 
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variance, standard deviation, confidence intervals, etc.). In addition, interviewee 
numbers in an MCM study are typically on the low side for high confidence in 
statistical generalisations, and the distribution of other data cannot be assumed to take 
the conventional normal form necessary for much statistical analysis. This is because 
we cannot assume that the main categories involved in MCM analysis (e.g., clusters of 
options, groups of issues, shared participant perspectives) display the homogeneity 
necessary for statistical generalisations. Moreover, to adopt such an approach would 
risk obscuring the crucial focus on qualitative differences and reflexively shifting 
framings within categories. Therefore, an MCM analysis is more comparable with 
qualitative, interpretive analysis such as that used in discursive or text-based research. 
Given this, we can offer several points (positive and negative) about the 
positioning of MCM analysis in relation to statistical and qualitative approaches. First, 
in comparison with conventional quantitative methods, MCM is more sensitive to the 
participant‘s own framings and expressions. The interpretation of the ‗results‘ are not 
solely reliant upon the interpretations of the analyst: the interviewee himself has the 
opportunity to amend or explain for his results so as to be consistent with his own point 
of view. This transparency and openness are also present in the MCM analysis process. 
An MCM analysis is more flexible and rigorous in terms of the constituting of the 
categories (‗perspectives‘, ‗issues‘, ‗clusters‘), which condition it. In other words, the 
categories are not conceived ‗outside‘ the realm of the analysis and then imposed on the 
data as ‗objective‘ analytical constructs, but instead are more reflexive in that they are 
continually interrogated in relation to the findings. Moreover, they are presented to the 
reader as subjective categories and open to judgement as such. Therefore, the dynamic 
and fluid nature of the analytical parameters becomes a strength of the analysis. It is one 
that enables the reader and analyst, alike, to become equally aware of the conditional 
nature of the findings and the basic data that underpins them. 
Second, in comparison with other qualitative methods, MCM is able to offer a 
more detailed, transparent and verifiable approach to elicitation and analysis. 
Methodologically, the most direct comparators with MCM are qualitative, interpretive 
methods like semi-structured interviews or deliberative appraisal. In either case, the 
interpretations drawn by the analyst are not always reproducible, or arrived at in a 
transparent fashion. With MCM, the bases for conclusions are presented to the reader in 
the form of the ranking charts and tabular data, as well as the associated, qualitative 
evidence provided in the criteria definitions and weightings, option assessments and 
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other analytical ‗nuggets‘. Thus, there is a clear ‗evidence trail‘ which any reader could 
use to reproduce the findings (subject to use of the same interpretive conditions and 
assumptions as the analyst). In addition, and perhaps most crucially, though the number 
of individual viewpoints in an MCM study are perhaps not as numerous as would be 
required of conventional statistical methods, they are more numerous than many other 
qualitative methods. Thus, with appropriate caution in both analysis and elicitation (see 
below), we can be reasonably confident that the intensity and depth is strong in 
comparison to other qualitative methods. 
Third, and finally, alongside its strengths we should also point out some of the 
associated weaknesses of MCM. The principal danger in any MCM analysis is that of 
over-interpretation. In order to minimise this, this study adopts principles of disciplinary 
rigour in MCM established and developed in previous studies (Stirling and Mayer, 
2001; Davies, et. al, 2003; Davies and Burgess, 2004; McDowall and Eames, 2007). 
Crucially, the findings presented in the following chapters are based only on those 
‗signals‘ and patterns that are the most prominent and unqualified. In each case, the full 
relevant data are reproduced alongside the point being made so as to allow contrasting 
and critical reflections. Where qualifications do exist, we point out and actively explore 
alternative explanations. This is done through the testing of alternative hypotheses, 
internal triangulation between MCM parameters (ranking patterns, criteria definitions, 
weightings), and the testing of uncertainty and ambiguity. Therefore, the conclusions 
made are open to judgement of plausibility by the reader. Although it is possible that 
separate subsequent research might identify ways in which certain specially-configured 
statistical analytic techniques might be integrated with some aspects of MCM (see 
conclusions), such a methodological innovation lies beyond the scope of the present 
study (and the entire contemporary MCM literature as a whole). Against this, we can 
say with some degree of confidence, that when judged against more conventional 
quantitative and qualitative methods, the findings and conclusions of an MCM study 
grounded in analytical and empirical rigour. 
4.6 Conclusion 
 It should now be apparent that the methodology underpinning this thesis is a 
theoretically and empirically demanding construct in its own right. The amount of data 
that is generated in one MCM interview, let alone 57, is enormous and to a certain 
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extent unwieldy. Thus, the findings that are presented in this thesis do not represent the 
full breadth and depth of the analysis conducted. For example, identifying the 
perspectives and issues which form the basis of the analysis were based upon the testing 
of countless hypotheses, groupings and orderings of data, in addition to detailed 
qualitative and quantitative analyses. The findings used to support the main hypotheses 
of this thesis and to answer the central research questions only reflect a small proportion 
of the richness of the data collected. 
 Nevertheless, the following pages will cover broad analytical ground. The next 
chapter is the first of four empirically-grounded chapters. It reviews a subset of the 
formal policy literature on hESC research in the US and the UK, and an analytical 
framework for the findings is presented. Chapters 6 and 7 present two sets of empirical 
findings from the 57 MCM interviews, the first according to national groups of 
stakeholder perspectives in the US and UK and the second comparing perspectives of 
policy actor groups as defined within the analysis by shared points of view. Chapter 8 
draws the policy- and interview-based empirical findings and the theoretical strands 
together. 
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5.  Good governance of human embryonic stem cell 
research: a review of the policy literature 
5.1 Introduction 
This thesis is concerned with whether divergent stakeholder perspectives on 
good governance for human embryonic stem cell (hESC) research are, first, discernible 
within different socio-political and national contexts and, second, whether systematic 
patterns between different perspectives emerge from this examination. Previous 
chapters have reviewed the scientific and country-specific policy histories in the field of 
hESC research and theoretical concepts of ‗good governance‘. What has not yet been 
accomplished, though, is an integration of these two strands into an account of how 
good governance for hESC research is constructed by policy actors in the UK and the 
US. In order to address this, we must look to wider literatures. This will allow us to 
become familiar with the variety of technological framings, analytical viewpoints, social 
issues and cultural dynamics that bear upon the hypotheses of this thesis.  
This chapter will begin the process by analysing how good governance is 
characterised and interpreted within a subset of the formal policy literature on hESC 
research in the US and the UK. It aims to identity systematic patterns in the ways in 
which governance is characterised in these literatures and, from this, determine how 
perspectives on ‗good‘ governance are constituted within different socio-political 
realms. The significance of this chapter to the overall thesis, then, is to establish a 
‗baseline‘ against which the views on good governance uncovered in the empirical work 
of the thesis can be compared. The analytical policy literature review presented here 
amounts to a ‗top-down‘ account of good governance, which aims to deconstruct 
notions of good governance as they are ‗officially‘ discussed in a policy context. This is 
in contrast to the empirical results and analytical findings that will be discussed in later 
chapters and amount more to a ‗bottom-up‘ account of good governance.  
The structure of this chapter is as follows: it will first build on the governance 
theories introduced in Chapter 3 in order to ground good governance in the context of 
biomedical technologies. It will then present a subset of the core policy literature in the 
area of hESC research. Overarching themes of good governance are identified within 
these literatures and are used to structure the analysis. Evidence for the interpretation of 
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good governance within each theme is given and additional support is identified in 
wider academic and stakeholder literatures. The chapter will conclude by reviewing the 
themes of good governance and any variations uncovered between the US and the UK.  
5.2 The problem of biotechnology governance  
5.2.1 Overview 
An aim of the theoretical chapter on governance (Chapter 3) was to ―understand 
how governance in a context of risk and uncertainty is affected by, and might respond 
to, the challenges of ‗new governance‘‖ that are posed by advances in the biosciences 
(specifically) and the associated risks and uncertainties (of many types) associated with 
them. The chapter reviewed how various understandings of these challenges are arrived 
at by governments and policy actors. These understandings are never straightforward 
and can hinge on many factors and competing priorities. For example, the notion of 
science as the seemingly objective bastion of certainty (as invoked by ‗sound science‘ 
rhetorics in policy making) has been shown to be something that can vary depending on 
how it is constructed (Latour and Woolgar, 1979). Competing values and subjective 
experiences shape the ways in which ‗scientific facts‘ are presented and interpreted 
(Levidow and Carr, 1997; Wynne, 2001). This all serves to underscore the importance 
of understanding the social, technological, economic, political and cultural components 
of emerging areas of science and technology. This has long been known to scholars of 
STS, who argue that with the development of new technologies comes a variety of 
influential interactions between technological and social processes. The nature of these 
interactions plays an important role in influencing technological development and 
render it ―a fundamentally social process open to sociological analysis‖ (Martin, 2001, 
p. 195; see also, Bijker et al., 1987; Bijker, 1995; Williams and Edge, 1996). 
This analysis can take many shapes and the relative importance and influence of 
the related social processes, be they political, economic, cultural and so on, will vary 
according to the nature of the technology being discussed and the nature of risk and 
uncertainty associated with it. This recalls Beck‘s thesis that risk is a culturally 
embedded phenomenon (Beck, 1992). He argues that the nature of risk in today‘s 
society is characterised by the continued introduction of new technologies. It is in 
appreciating how such a conception of the (rather reflexive) relationship between risk 
and technology comes to exist that we find resonance with the ideas in this research. 
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From here, the question becomes one of making the link from technological 
risks more generally, to medical biotechnologies – and stem cell research – in particular. 
In this task, it is not the intention to adopt Beck‘s theoretical framework, but rather to 
appreciate the relatively uncertain context in which new biomedical technologies 
emerge and the associated implications for governance. Many have commented on the 
fact that new technologies emerging from advances in the biosciences are particularly 
pervaded, and corresponding governance issues particularly influenced, by entangled 
cultural and social values. It is the ‗biological‘ nature of these technologies that gives 
the distinctive character to what some have termed ‗biopolitics‘ (Jasanoff, 2005), as 
they pose difficult questions about ―the character of our human/nonhuman identify‖ 
(Brown and Webster, 2004, p. 2). Weale (2001) argues that it is these characteristics 
that introduce difficult policy problems, particularly when it comes to assessing how 
scientific advice and public input might feed into the policy-making process. In this, it is 
hard to disagree with Weale‘s sentiment that ―incommensurable values produce 
complex political problems‖ (2001, p. 420). For the present authors, though, the key 
question lies not just in understanding how these complex problems are produced, but 
also in how they ought to be addressed.  
One of the aims of this thesis is to draw out the implications of these issues in a 
way that will enable us to make an empirically-based contribution to knowledge of 
relevance to a variety of different literatures, as well as a normative contribution of 
potential relevance to policy-making. The following sections will demonstrate that there 
are different ways of interpreting what policy actors believe good governance of hESC 
research should look like and the components it might entail. Thus, the review in this 
chapter amounts to a systematic examination of key perspectives on ‗good governance‘ 
of hESC research as they emerge from the national policy documents. 
5.2.2 Good governance of hESC research: reviewing the policy 
literature 
To a certain extent, broader changes and new modes of governance are already 
emerging to deal with the increasing pressures that society and governments are faced 
with in the context of scientific and technological advances in the biosciences. This can 
be seen through the rise of ethics committees as bodies of expertise (Levidow and Carr, 
1997; Wynne, 2001); public participation experiments in deliberative democracy 
(Rayner, 2003; Davies and Burgess, 2004); changes in the nature of political discourse 
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(Brown and Michael, 2002); and the emergence of a global ―moral economy‖ of 
bioethics (Salter and Salter, 2007; Gottweis et al., 2009). As it becomes clear that there 
are many ways in which governments and publics try to address conflicting values, we 
also see that there is no straightforward answer as to which modes and approaches will 
be most appropriate, and under which circumstances.
53
 Scholars and stakeholders would 
argue that a variety of factors must be brought into consideration such as the 
acknowledgement of social values and wider cultural risks outside the ‗technical‘ ones, 
increasing openness and transparency, a greater inclusion of broader ‗publics‘, and 
changes to the nature and content of the policy debates. The relative ‗amounts‘ of each 
of these in different approaches will vary as they may privilege some interests over 
others, or favour particular political ideologies. 
One of the first places one might expect to see evidence of this is in the official 
policy literature itself. Within each country, core policy documents can be found which 
form the basis for policy development. These documents review the issues, draw 
conclusions and make recommendations for policy-making. Since these 
recommendations are underpinned by a review of the relevant social, scientific, medical, 
political, legal and/or ethical issues, we can reasonably expect they may be interpreted 
and analysed for the views on good governance that are being expressed by the 
government or official body that produced the report. As introduced in the previous 
chapter,
54
 six primary policy documents (three each for the UK and US) were identified 
and systematically reviewed for content with an eye to identifying common themes and 
rationales of good governance specifically in relation to hESC research. The documents 
were selected according to the following selection criteria: i) they were produced after 
the announcement of the derivation of the first human embryonic stem cell line in 
1998,
55
 ii) they are relevant at a national level,
56
 iii) they focus on a range of issues 
specifically relevant to hESC research and iv) they can generally be considered to be of 
primary importance as a basis or formal rationale for policy initiatives within each 
national context. A brief summary of each of the documents reviewed is discussed in 
Table 5.1 below.  
                                                 
53
 See the discussions in Chapter 3 for additional detail on particular ‗modes‘ or ‗approaches‘. 
54
 See the discussion in Chapter 4, p. 60-61. 
55
 It should be noted that no documents published prior to 1998 were included in the review. This is 
because the first scientific breakthroughs in the production of an hESC line were announced in 1998. 
Though many more general issues bearing on human embryo research were discussed in both countries 
going back to the 1970s, the specific governance issues raised by human embryonic stem cell research 
were focussed on in more depth and brought to the fore after the 1998 breakthroughs.  
56
 As opposed, for example, to covering specific regions of the UK or individual states in the US.  
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Table 5.1: Summary of ‘core’ formal policy documents 
US Policy Documents 
Ethical Issues in 
Stem Cell 
Research (1999) 
(hereafter referred 
to as the NBAC 
report) 
This report was requested by President Clinton from his National 
Bioethics Advisory Council (NBAC). Clinton requested that the Council 
examine the implications of recent developments in hESC science 
following the development of the first hESC line. It is one of the first 
official US government policy documents to review the scientific, 
medical, ethical, legal and social issues at stake. The report makes 
recommendations on how and under what circumstances hESC 
research might be supported in the US. 
Monitoring Stem 
Cell Research 
(2004) (hereafter 
referred to as the 
PCBE report) 
This report was produced by the President‟s Council on Bioethics 
(PCBE) and was officially requested by President George W. Bush in 
2002. Its aim was to report on developments in the field of stem cell 
research since the President‟s policy for hESC research was 
implemented in 2001. The report did not contain any policy 
recommendations, but rather aimed to “shed light” on the current 
scientific, ethical, legal and medical state of the field. 
Guidelines for 
Human Embryonic 
Stem Cell 
Research (2005) 
(hereafter referred 
to as the NAS 
Guidelines) 
The US National Academy of Sciences (NAS) is not an official 
executive body of the US government, but it is seen as the de-facto 
advisor to the government on a variety of scientific and related policy 
issues. In the absence of any national guidelines on hESC research, 
and in response to requests from the scientific community, the NAS 
sought private funding for a blue-ribbon commission to develop 
voluntary guidelines on the conduct and oversight of hESC research. 
These have served as „unofficial‟ official guidelines for hESC research 
in the US and provide important insights into the views of the national 
scientific community on issues of good governance. 
UK Policy Documents 
Chief Medical 
Officer’s Report: 
Medical Progress 
with Responsibility 
(2000) (hereafter 
referred to as the 
Donaldson Report) 
This report was produced by an Expert Group set up by the 
Department of Health and chaired by the Chief Medical Officer, Sir 
Liam Donaldson. Its remit was to advise the government on whether 
research using embryos should be permitted and what the associated 
scientific, technical, therapeutic, and regulatory issues might be if it 
was allowed to proceed. It is one of the first official government reports 
released after the 1998 development of the first human embryonic 
stem cell lines and it was in light of the recommendations offered in 
this report that the UK Government introduced extended regulations 
for the purposes of embryo research. 
Stem Cell 
Research: Report 
from the Select 
Committee (2002) 
(hereafter referred 
to as the Report 
from the Select 
Committee) 
In 2001 the UK Parliament passed the Human Fertilisation and 
Embryology (Research Purposes) Regulations, which extended the 
regulations for which research on human embryos is permitted under a 
license from the HFEA. In light of these new regulations, the House of 
Lords Science and Technology Select Committee was asked to 
“consider and report on the issues connected with human cloning and 
stem cell research” that arose from the new regulations. The report 
comprehensively addresses the issues related to stem cell research 
and makes recommendations on how the government should proceed 
with future legislation and governance. 
Human 
Reproductive 
Technologies and 
the Law (2005) 
(hereafter referred 
to as the HRT and 
the Law report) 
This report was produced by the UK House of Commons Science and 
Technology Committee in 2005. It marked the beginning of a four-year 
review of both the HFE Act and the „state-of-the-art‟ of human 
reproductive technologies in the UK. It assesses whether advances in 
human reproductive technologies have raised new social, legal or 
scientific issues that would require revisions to the original legislation. 
Many concepts first introduced in this report are reflected throughout 
policy documents issued both by Parliament and the UK Government 
until November 2008, when the final version of the Human Fertilisation 
and Embryology Bill 2008 (essentially a revision of the Human 
Fertilisation and Embryology Act of 1990) was passed. 
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After identification as a ‗core‘ policy document, each report was reviewed 
systematically and coded
57
 for organisational structure, content and thematic attention 
paid to different governance issues related to hESC research.
58
 However, conducting 
such an analysis on a narrow range of documents could lead risk selecting out some 
documents that may introduce a different perspective, and thus lead to a different set of 
conclusions. As a means to appraise and mitigate this risk, ‗the next most suitable‘ 
policy document(s) were considered according to the same analytical framework. This 
step also served to check the basis for prioritisation of the core documents.  
In the UK, the next most suitable policy document was the ‗UK Stem Cell 
Initiative‘ report, which was published in 2005 and presented a future investment 
strategy for stem cell research in the UK. If followed, it was claimed it would be 
capable of enabling the UK scientific community to become world leaders in stem cell 
research. The strategy focuses largely on commercialisation and investment and so is 
skewed in its presentation of relevant governance issues. Nevertheless, it covers similar 
themes to those discussed below and no significant differences in content were 
discerned. The next document to be considered was a workshop report on stem cell 
therapy by the Nuffield Council on Bioethics. This document was ruled out primarily 
because it focuses specifically on stem cell therapies and does not consider many issues 
related to the fundamental nature of hESC research. In addition, the document was a 
summary report of a workshop, and so only covers material from the day.  
In the US, the next most suitable policy document for inclusion was a report of 
the National Research Council published in 2002 and entitled ‗Stem Cells and the 
Future of Regenerative Medicine‘. This publication was the report of a workshop 
convened by the NAS that brought together several leading stem cell scientists, 
philosophers, ethicists and legal scholars. The report did not raise new or significantly 
different points from those in the three other US documents. In addition, it was a 
workshop report and so only covered material discussed on the day.  
                                                 
57
 For a discussion of the methodology employed in this respect, see p. 60-61 of Chapter 4. As pointed out 
there, 12 policy documents were originally considered and this was narrowed down to the six core 
documents presented in this chapter. The text below describes the steps taken to mitigate the risk that the 
‗next most important‘ document in each country should not also have been included in the analysis. 
58
 The majority of the documents are specifically concerned with stem cell research, but one of the 
documents, Human Reproductive Technologies and the Law, covers the entire field of human 
reproductive technologies that fall within the purview of the HFE Act. Thus, the report covers embryo 
and hESC research, but is not exclusively dedicated to hESC research, as is the case in the other policy 
documents. 
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In the analysis of the core documents, attention was paid not only to which 
issues were given attention, but also to how they were discussed, the particular 
problems identified, the solutions suggested and the implications of all of this for good 
governance. It is on the basis of broad similarities within the way the issues are 
presented that four themes of good governance are identified as featuring in the majority 
of the documents. The fact these four themes do emerge suggest they might be useful as 
an overarching framework within which we can identify systematic patterns, points of 
comparison and areas of synergy throughout the analysis. Thus, using this framework, 
we can build an understanding of the ways in which governance is constructed, framed 
and interpreted as ‗good‘, and how this may (or may not) differ between the two 
countries. The themes of good governance (indicated in bold) and associated sub-
themes are:  
• Scientific and technological issues in hESC research, with sub-themes of 
scientific „outcomes‟ (e.g. autonomous research environments or therapeutic 
aims); research support; and technological development. 
• Ethical issues in hESC research, with sub-themes concerning research 
principles of conduct and the moral status of the embryo. 
• Institutions and instruments for hESC research, with sub-themes of policies for 
oversight and funding; policies for regulatory activities; and qualities of 
deliberation (inputs and interactions of publics and experts).  
• Socially and culturally-based aspects of good governance, with sub-themes of 
the maintenance of policy continuity, and the bases of trust and legitimacy.  
Table 5.2 below provides an interpretive summary of the extent to which each report 
covers issues within each of the broader themes. The narrative indications of the 
different shadings in the table are only meant to provide an illustrative overview, not 
something that has been comprehensively ‗calculated‘ or additive values. Nonetheless, 
they present a comparable picture across all the core documents, themes and cases study 
contexts taken as a whole. 
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Table 5.2:  Themes and issues in good governance of hESC research59  
Theme 
Advances scientific & 
technological outcomes 
& addresses related 
issues in hESC research 
Encourages 
moral & ethical 
awareness for 
hESC research 
Establishes 
appropriate 
institutions & 
instruments for hESC 
research 
Identifiable 
social & cultural 
bases of good 
governance  
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US: NBAC 
Report (1999) 
    
 
              
US: PCBE 
Report (2004) 
    
 
              
US: NAS 
Guidelines 
(2005)     
 
              
UK: CMO 
Report (2000) 
    
 
              
UK: House of 
Lords Report 
(2002)     
 
              
UK: HRT and 
the Law (2005) 
    
 
              
Shading Key 
  Sub-theme is extensively covered and is central to the perspectives on good governance 
  Sub-theme is reasonably covered and features prominently in perspectives on good governance 
  Sub-theme is mentioned, but is not a prominent feature of the perspectives on good governance 
  Sub-theme may be mentioned within literature, but does not feature in perspectives on good governance 
 
Within each of these themes and sub-themes many features of good governance 
of hESC research are identified and discussed. However, presenting the features in such 
a structured, schematic way invites an array of possible criticisms, such as over-
simplification of the complex interactions among many of the governance processes 
represented or cultural contingencies upon which they may rest. Indeed, such criticisms 
resonate strongly with the thrust of this present thesis and the sympathies of the authors. 
If we were to treat each theme and sub-theme as if in a ‗vacuum‘, it would be in conflict 
with the broad socio-political definition of governance adopted for this thesis and the 
emphasis on the interactions and feedbacks between various processes, networks and 
                                                 
59
 See discussion in the methodology chapter, p. 60-61, for detail as to how the analysis of the documents 
occurred. As indicated there, recordings were made as to the relative ‗coverage‘ of each theme within the 
policy documents. From this basis, determinations of shading were made which reflected relative levels 
of coverage as indicated by the key above. 
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actors. Rather, by grouping the perspectives that emerged from the policy literature into 
similar sub-themes and, then, overarching themes, we are able to develop a type of 
analytical tool with which we can systematically unpack and understand how extant, 
individual perspectives on good governance are articulated and assembled (or re-
assembled) within the policy literature chosen here. It is hoped this will enable a richer 
characterisation and interpretation of good governance within the different national, 
political and cultural domains that are being explored for this thesis.  
With this in mind, the simple presentation of the sub-themes and the respective 
coverage of each within the academic literature seems to indicate that each is reasonably 
prominent in its own right. This underscores the suitability of the analytical framework 
for identifying not only areas of, but perspectives on, good governance. Each policy 
document covers, at least to a certain extent, the majority of the sub-themes identified 
above, it not all of them. Intriguingly, an initial glance indicates that there do seem to be 
systematic differences in emphasis across the US and the UK, such as in the framing of 
scientific outcomes, the moral status of the embryo and the nature of oversight policies. 
The implications of this and other analytical points of comparison will be explored 
throughout the remainder of this chapter. 
5.3 Advancing scientific and technological outcomes; 
Addressing related issues 
5.3.1 Overview 
This section will consider how the six policy documents address scientific and 
technological issues in the context of good governance. It will first compare the ways in 
which the literature highlights the scientific nature and trajectory of hESC research, and 
thus reflects different framings of desired scientific outcomes. It will then go on to 
discuss the mechanisms and processes that should be in place to support the realisation 
of these outcomes. Finally, it will consider the ways in which the literature frames 
perceptions of technological, social and cultural risk. As was alluded to above (and will 
continue to be pointed to throughout this chapter), it is precisely which issues are 
discussed, how and by whom they are discussed, and under what conditions the 
discussion takes place that are of interest to our analysis. Thus, the role of framing
60
 in 
                                                 
60
 See discussion in Chapter 3, p. 41. 
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the analysis of good governance will be a recurring theme within the work presented 
below.  
5.3.2 Outcomes: scientific autonomy and therapeutic goals 
The ‗trajectory‘ (Williams and Edge, 1996) of the field of hESC research is 
presented differently and to different effect in the US and UK policy literatures. This 
has important implications for the framing of scientific outcomes within the overall 
narrative of good governance. Within the UK policy literature analysed below, there 
seems to be a greater emphasis on the therapeutic outcomes of hESC research. When 
the science is discussed in the UK policy documents, it tends to be framed in terms of 
current problems with medical technology and/or incurable diseases and the potential 
that stem cell technology has to overcome this. Within the US policy literature, the 
emphasis seems to be on scientific autonomy as a key enabler of good scientific 
outcomes, be they therapeutic- or basic research-oriented. In other words, there seems to 
be more of a tendency to present the issues as a matter of preserving scientific 
autonomy so that the scientists are free to pursue multiple paths towards ‗successful‘ 
scientific outcomes. These ‗successes‘, then, are defined by the scientists themselves 
and may include therapeutic outcomes, but may also simply broaden our understanding 
of basic scientific knowledge and biological development. The evidence for each of 
these claims is discussed in turn below, beginning with the UK.  
In the 2000 Donaldson Report, the chapter reviewing the scientific background 
of hESC research begins with a ―simple overview of the complex techniques which 
could yield cells capable of repairing diseased or damaged organs‖ (DoH, 2000, p. 16). 
It then goes on to outline the problems with organ transplantation in the UK, thereby 
establishing from the start a medical and public health problem for which stem cell 
technology could be a solution.  
A new prospect of widely available human tissue that is biologically compatible 
with the recipient has now been opened up by greater scientific understanding of 
the growth and development of animal and human cells (Ibid, p. 17). 
The report goes even further in its claims of the promise of stem cell technologies, 
stating on the next page that ―the scope for stem cell therapy in the future could be 
enormous‖ (Ibid, p. 18). The reader is left with little doubt is left as to why this area of 
research is worth being pursued. Similarly, in the Stem Cell Research report from the 
House of Lords Select Committee, the report immediately addresses (after a brief 
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introductory section) the potential of stem cells in developing new medical therapies. In 
the first paragraph of this section, the committee lists a range of degenerative diseases 
that ―affect millions of people in the United Kingdom alone‖ and claims that ―stem cell 
treatments, unlike most conventional drug treatments, have the potential to become a 
life-long cure‖ (House of Lords Select Committee, 2002, p. 11).  
In both of these examples there is a great amount of certainty with which it is 
claimed that hESC science will one day lead to treatments for a variety of diseases and 
solutions to public health problems. This is especially remarkable given that both of 
these reports were published less than five years after the first hESC lines were 
developed. Nevertheless, in the case of the UK policy documents, the framing of hESC 
research in terms of public health and medical technology solutions is clear.  
In the US policy literature, hESC research is first described in historical terms. 
The field of stem cell research, and thereby hESC research, is presented as one that 
scientists have been working in for many years and has been long recognised for its 
potential to explain many developmental, biological and disease-specific questions. By 
presenting the science in a detailed and technical way with a focus on its history, the 
policy documents seem to be suggesting there is a particular importance to the 
preservation of scientific autonomy as an aspect of good governance. This will lead to 
the advancement of scientific knowledge, as history has already proven, and perhaps 
one day to therapeutic and technological developments. However, it is for the scientists, 
not policymakers, to determine how and when this might happen.  
The NBAC report only mentions the therapeutic potential of hESC research after 
accounts of the past and current state of hESC research are given. When any therapeutic 
potentials are mentioned, the tone seems one of exploration, rather than direct intent: 
this research might, for example, lead to the discovery of new ways to treat a 
variety of conditions...and would build on investigations conducted over the last 
decade, in which laboratory animals have been used to determine whether ES 
cells can be used to re-establish tissue in an adult organism (NBAC, 1999, p. 8).  
The passage refers specifically to examples of how science ‗builds‘ on previous 
investigations. This leaves one feeling as though possible treatments and therapies are 
simply a natural progression of yet another field of scientific inquiry. This reinforces the 
idea that hESC research is not a new area of science, but rather, one where new 
findings, such as the derivation of hESC lines in 1998, are merely the result of a natural 
progression of scientific inquiry.  
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The NAS Guidelines also reflect the notion that respect for scientific autonomy 
is an important part of good governance. Like the NBAC report, hESC research is 
framed so as to establish its legitimacy as a long-standing area of scientific inquiry. 
Desired scientific outcomes are described in reference to the research merits of hESC 
research itself. Though it does point out in the executive summary and introductory 
chapters that it is the ―dual capacity of stem cells for self-renewal and for differentiation 
into particular types of cells and tissues [that] offers great potential for regenerative 
medicine‖ (NRC and IOM, 2005, p. 15), this comes across as a tangential comment. 
Whereas in the UK‘s Donaldson Report, hESC research was introduced by discussing 
the problems with medical transplant technology, in the NAS Guidelines it is introduced 
via a detailed scientific account of the history of the field. Only after this are the 
prospects for its application discussed. Thus, we see a similar pattern to the NBAC 
report where the scientific background is presented in great detail and it is only within 
this detail that references are made to therapeutic and technological prospects. 
 Though the PCBE report was produced under the presidency of George W. Bush 
(whose restrictive funding policy on human embryonic stem cell research was reviewed 
in Chapter 2), we still find a similar framing of hESC research. The report gives a 
detailed account of the science of stem cell research in the final chapter, but it refers 
throughout the text to several appendices which go into great detail about various types 
of stem cell research, the historical development of the field, and possible therapeutic 
applications of both adult and human embryonic stem cells. It is the case that more 
caution is present within the text about the ‗hype‘ surrounding hESC research, but this 
could be due to the policy context under which the report was produced. In other words, 
though scientific autonomy frames the discussion of the science, the tone does suggest 
that autonomy does not equate to free reign.  
 To sum up, the point is not to claim that the US policy literature is unconcerned 
with the therapeutic benefits of hESC research, but rather that the discussion emphasises 
how well the science has developed on its own. Good governance, then, should seek to 
preserve this autonomous nature. This is in contrast to an emphasis on the future 
therapeutic outcomes of hESC research in the UK. The implications for good 
governance here are the need to actively support this type of research because of the 
medical benefits to society which may result.  
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5.3.3 Issues: Research support processes 
The next area to consider within this theme is the ways in which it is argued that 
the realisation of the scientific outcomes should be facilitated and the research 
enterprise supported. The discussion below will highlight how the perspectives on this 
element of good governance complement and further reinforce the framing of hESC 
research and related scientific outcomes.   
A key feature of research support in each country is about standardisation of 
research practice. Standardisation is believed to be necessary to advance the research 
and move towards therapeutic products (Harvey, 2009), facilitate researcher 
collaboration and sharing of information (Baker, 2008), promote a philosophy of 
‗governance-by-standards‘ (Webster and Eriksson, 2008) and manage uncertainty 
around new regenerative medicine technologies (Gottweis, et al, 2009). The argument 
for establishing these links is made differently in the policy documents of each country. 
In the UK policy documents, good governance is concerned with how best to facilitate 
the realisation of desired therapeutic outcomes through government-mediated 
mechanisms of support. In the US documents, processes for research support are less 
about direct interventions in the science and more about the establishment of indirect, 
enabling frameworks within which the science can autonomously develop.  
The respective processes of research support in the policy documents reinforce 
the framings of hESC research discussed above. According to one UK policy document, 
the aim is to ensure ―that legitimate medical and scientific applications of human 
reproductive technologies can continue to flourish‖ (DoH, 2007, p. 1). More to the 
point, though, it is argued that the science can move towards therapeutic benefits 
because of ―the enabling and consistent regulatory environment‖, which ―is currently 
one of the strongest assets to UK stem cell research‖ (UK Stem Cell Initiative, 2005, p. 
43). This ‗enabling‘ regulatory environment is believed to be a crucial aspect of good 
research support processes and is mentioned in all three UK policy documents. Specific 
processes that result from direct government support include: the establishment of a 
national stem cell bank; the writing into legislation of the need for basic research; and 
the balancing of regulatory oversight with an open commercial environment.  
Standardisation is also discussed in the US-based policy literature, but in a way 
that emphasises harmonisation of indirect oversight practices, not centrally managed 
government initiatives. The emphasis on harmonised oversight reinforces the historical 
framing of the science. Harmonisation has in the past facilitated autonomous research 
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activities, while still ensuring the responsible and ethical conduct of research. It is 
argued in the NAS Guidelines that the ―patchwork‖ of regulations in the US serves to 
undermine not only the progress of the research, but also the ―integrity‖ of all types of 
hESC research being pursued. ―Some standard protections may be lacking and the 
implementation of protections is almost certainly not uniform throughout the country‖ 
(NRC and IOM, 2005, p. 19). The implication is two-fold. First, the lack of a 
harmonised ‗space‘ for science might result in ―less efficient and less powerful science‖ 
(Webb, 2007). It also suggests that standardisation as a feature of good governance is 
especially important to ensuring scientific integrity in the eyes of the public.  
Thus, in both country‘s policy documents, the nuances in the perspectives on 
good governance for research support lie both in the references to ideas about the 
scientific trajectories as discussed previously and the way this links to ‗responsibility‘. 
With the UK policy literature there is a greater emphasis on standardisation to actively 
facilitate and manage aspects of the science (whilst ensuring it is done in a responsible 
manner), whereas within the US policy literature the emphasis is firstly on 
standardisation to foster scientific autonomy so that the responsible conduct of the 
science can be ensured.  
5.3.4 Issues: Perceptions of risk (technological or social) 
As we have seen in the analysis so far, the nature of hESC research means that 
the potential benefits of technologies that may arise from it are part and parcel of 
discussing related components of good governance. With this comes a discussion of the 
perceptions of technological, social and cultural risk associated with developments in 
hESC research. In the previous chapter the ways in which risk is determined and 
factored into policy decisions was shown to be subject to different framings that, 
themselves, are constituted by different perceptions and values. Thus, alternate framings 
of risk can affect regulatory, or governance, choices. Examples arise in the case of 
genetic testing in the US and the UK (Parthasarathy, 2004, 2005), or in consideration of 
future regulatory regimes for hESC therapies (Liddell and Wallace, 2005).  
In both sets of policy literatures from the US and the UK, risks are presented and 
framed in one of two contexts: first, in the therapeutic context, as technical and safety 
risks and, second in an ethical context, as social and cultural risks. In the former, the 
main safety issues are around possible therapeutic applications of stem cell research 
technologies. Each set of national policy documents emphasises the need for future 
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governance frameworks to ensure patient safety, incorporate informed consent 
mechanisms and work with or within existing mechanisms of regulatory oversight for 
drugs and clinical therapies. These elements are addressed fairly similarly in each set of 
national policy documents. 
However, it is in discussing the social and cultural risks posed by the 
technologies implicated in embryo research that we see differences in the framing of 
risk emerge. These risks are tied to fundamental ethical and moral questions about 
embryo research, issues which are more fully discussed in the next section. What is 
noteworthy for the discussion here is that in presenting the ‗social‘ risks of embryo 
research, the framing of public health and therapeutic outcomes of the science in the 
case of the UK and scientific autonomy in the case of the US are seen. For example, in 
discussing the special status of the embryo in the Stem Cell Research Report, the House 
of Lords Science and Technology Select Committee addresses the issue of respect for 
persons and concludes: 
respect may take the form of developing treatments for serious degenerative 
diseases, and there can be few causes more worthwhile than to relieve the 
suffering caused by these diseases...It would be wrong not to seek therapies for 
such diseases, which necessarily involves undertaking the fundamental research 
that may make those therapies possible (House of Lords Select Committee, 
2002, p. 22).  
The Donaldson report uses even starker language when describing the issue of using 
leftover embryos from infertility treatment in stem cell research, arguing that ―the only 
options at this stage are to let the embryos perish or to use them... as part of the effort to 
enhance future fertility treatment and human lives‖ (DoH, 2000, p. 38). This sends a 
strong signal that social risk of hESC research does not lie with the pursuit of the 
research, but rather with the failure to pursue the research.  
Conversely, in the case of the US policy literature, social risk seems to lie with 
how, or whether, the research is conducted. In the NAS and NBAC documents, the risks 
posed by the technologies and scientific practices of hESC research are presented as 
risks to scientific autonomy and the freedom to pursue research. In the case of the PCBE 
document, which was produced under a policy environment less favourable towards 
hESC research, the social risk lies more heavily with the use of embryos in research and 
the threats to human dignity that this poses.  
These differences in the characterisation and framing of social risk within each 
set of national policy documents illustrate that in each country the social risks of the 
technology are framed in a manner that correlates with previous perceptions of the types 
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of activities or mechanisms good governance would help achieve. The next section 
addresses perspectives on good governance in relation to ethical and moral issues in 
hESC research, beginning first with perspectives on the moral status of the embryo, and 
second discussing how this status might be protected through the ethical principles of 
research practice.   
5.4 Encourages moral and ethical awareness 
5.4.1 Overview 
Discussions of hESC research in the wider literature often begin with the status 
of the embryo. However, the moral and ethical principles wrapped up with hESC 
research and policy extend well beyond these considerations, to issues such as cultural 
pluralism, equity, justice and ethical conduct of the research in the laboratory setting. 
This section will look first at the wider ethical issues relating to the conduct of hESC 
research. It will then review the framing of the moral status of the human embryo in the 
policy documents. We will argue that the ways in which the embryo is presented has 
important implications not only for the structure of the policy debates (Kirejczyk, 1999), 
but also for emerging perspectives on good governance. 
While, overall, there is little difference in the types of ethical issues developed in 
each set of policy documents, what differs between the two countries are the ways in 
which it is argued that good governance should address these ethical issues. In the UK, 
it appears that good governance under this theme emerges through the institutions of 
law and regulation, such as the enforcement of ethical conduct and the preservation of 
the special status of the embryo through a legislative framework. Good governance, 
then, is an attempt to balance the ethics and the science. In the US good governance 
tends to be characterised by a confidence in the system of federal funding to uphold 
ethical principles of research. This reinforces the respect for scientific and market 
autonomy (in the absence of formal legislation), and places trust in the scientific 
community to police itself. However, what is notably absent from the US policy 
documents is a consistent treatment of the embryo. This leaves it an open question as to 
how good governance will (or can) address the status of the embryo. What is important 
to bear in mind throughout the analysis, though, is the centrality with which the ethical 
and moral issues seem to frame perspectives on good governance more widely.  
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5.4.2 Ethical principles underpinning research conduct 
In an area as entangled with ethical issues as hESC research, it is not surprising 
that there is a great deal of concern and discussion over the ethical conduct of the 
research and the extent to which the establishment of appropriate ethical conduct will 
help to mitigate a variety of perceived social and cultural threats posed by the research. 
These threats include an affront to moral values by destroying the early embryo for 
research; the related danger of ―instrumentalization‖ of the embryo through such 
research practices (NBAC, 1999), including the exploitation of woman; and the threat of 
human reproductive cloning becoming a scientific possibility through continued 
advances in research technology (PCBE, 2004; NRC and IOM, 2005). With some 
exceptions in the level of detail afforded to each, it is fair to say that each threat is 
covered within the respective national policy literatures. However, there are differences 
between the national policy documents in the mechanisms through which it is argued 
that appropriate and ethical research conduct might mitigate these threats.  
In the UK policy literature, the arguments employed in the Warnock Report 
(Warnock, 1985) about the acceptability of embryo research are always referred to first 
when discussing the ethical principles that must underpin hESC research.
61
 However, it 
is not just the principles that are referred to, but also the process through which they 
were developed. There were extensive deliberations, periods of reflective thought and 
public consultations undertaken by the Warnock Committee. The fact that the ethical 
principles rest upon such broad-based deliberative processes is always pointed to as 
illustrative of the legitimate basis on which the principles rest. Moreover, the central 
role the report plays in providing the basis for the HFE Act of 1990 and all other 
regulations and legislation, further reinforces this legitimacy and encourages acceptance 
of the Committee‘s findings.  
In terms of the perspective on good governance that emerges from the UK 
policy literature, it seems that there is a considerable emphasis on ensuring ethical 
conduct through a ‗hands-on‘ relationship between the regulated and the regulator. Such 
a relationship (it is argued) will assure public confidence in the fact that the research is 
being conducted in a responsible manner. Thus, in arguing for why the system of 
oversight should continue in its current form, the UK Government has argued that it 
has: ―engendered public confidence in the ethical development and use of human 
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 As the Warnock Report was the main locus of deliberation on the moral acceptability of embryo 
research in the first instance, it will be discussed in greater detail in the next section. 
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reproductive technologies‖; ―allowed medical and scientific progress to flourish within 
appropriate safeguards”; and ―achieved consistency across the country‖ (emphasis 
added, DoH, 2005a, p. 13). Each point italicised above reflects important notions of 
good governance that the regulatory system achieves.  
Two additional points are worth pointing out that reflect subtle variations in the 
perspective on good governance emerging from the UK policy literature referenced 
above. First, it is not just ethical conduct of the research, but ethical ‗development‘ that 
is referred to. This implies a continuous appraisal of the ethical situation as the science 
develops is an important component of good governance. Second, the statement 
suggests that medical progress has flourished because of the safeguards in place. This 
further reinforces the notion that good governance assures ethical principles are upheld, 
as well as facilitating scientific and medical advances.  
Like the UK policy literature, some of the US policy literature seems in favour 
of continuing existing systems of oversight in order to assure ethical conduct of hESC 
research. Unlike the UK literature, however, the perspectives on good governance that 
emerge from the US policy literature seem aimed at reinforcing ideas about scientific 
autonomy. The argument emphasises how ethical conduct already occurs through 
existing mechanisms within the system of federal research funding and the required 
local and national Institutional Review Board (IRB) procedures. With the exception of a 
few small additions, then, the NAS and NBAC reports suggest adoption of a rather 
similar governance system for hESC research to the one that has existed for many years 
for all of biomedical research.
62
 
This might at first seem curious, and perhaps even contradictory, given that 
much of the policy rhetoric emphasises the unique ethical and moral nature of hESC 
research and how this merits special attention. However, closer examination of the way 
in which the arguments are set out seem to clear up some of the confusion. In the NBAC 
report, ethical reasoning used to underpin the argument for federal funding is based on 
the principles of beneficence and non-maleficence. The former justifies the pursuit of 
research when the aim is to reduce suffering and the latter justifies the placement of 
safeguards on the practice of research (Cohen, 2005). It seems that there is significance 
in using ethical principles grounded in the medical profession for this reasoning.  
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 It is the same in principle, but the policy literature also includes recommendations for a national 
oversight panel which would monitor developments in the research. In 2005 it was also suggested that 
local Embryonic Stem Cell Research Oversight Committees (ESCRO) also be formed as a further 
oversight level. See discussion in Chapter 2, p. 22-23. 
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We would argue that such grounding in professional ethics serves to emphasise 
the nature of scientific research into human embryonic stem cells as a professional 
discipline in itself. Thus, in a neat parallel to the ideas of scientific autonomy discussed 
earlier, it seems intended to show that hESC research is something that is governed 
internally by the professional ethic of scientists. The NBAC‘s main recommendation 
that federal funding of research is the best way to both enable and monitor this 
professional ethic is internally consistent with the ethical reasoning adopted. A similar 
pattern can be found in the NAS Guidelines. This document has a whole chapter on the 
ethical issues in stem cell research and the associated implications for governance. This 
is noteworthy because it is a document specifically aimed at commenting on the 
scientific practice of hESC research. The fact it goes into such detail in relation to 
ethical principles of conduct seems to underscore the idea that the scientific profession 
is both cognisant and capable of upholding ethical principles. Thus, it emerges as a 
central perspective on good governance.  
Though adopting a different framing of the question of federal funding, the 
arguments in the PCBE report do not negate the above observations about the mutual 
reinforcement of ethical principles, professional ethics and scientific autonomy. The 
PCBE re-frames the issue as an ‗ethical-political‘ question about the nature of federal 
funding, itself.  
The decision to fund an activity is more than an offer of resources. It is also a 
declaration of official national support and endorsement, a positive assertion that 
the activity in question is deemed by the nation as a whole, through its 
government, to be good and worthy…[and is] therefore laden with moral and 
political meaning, well beyond its material importance (PCBE, 2004, p. 37). 
By calling attention to the morality of federal funding, the PCBE shifts the focus away 
from the professional norms of science and towards a question of whether common 
ground can actually be attained through federal funding if fundamental moral principles 
are at odds. The question being considered is not necessarily of the same nature, and, 
therefore, a direct comparison between the three reports cannot be made. We can only 
conclude by saying that while both the NBAC and NAS reports argue that federal 
funding is the way to ensure ethical principles are upheld, the PCBE argues the question 
should first focus on identifying a shared vision of what is being funded. The fact that it 
is then silent on how federal funding might enforce (or reinforce) ethical principles of 
research conduct neither supports nor refutes the earlier claims.  
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However, it does raise the question of how societies should arrive at shared 
moral values and ethical principles of research conduct. When ethical principles for 
research are discussed in the UK policy documents, it emerges that national discussion, 
and broad-based consensus, are important legitimating factors. In the US, these factors 
seem to vary. This suggests there is an interesting discussion to be had about how such 
ethically and morally challenging issues are and should be deliberated on within a 
society so that social and cultural views are respected. These issues will be the topic of 
section 5.5, but are worth linking to here. For the moment, though, we will complete the 
discussion under this theme by turning to the moral status of the embryo. 
5.4.3 Moral status of the embryo 
The moral status of the embryo is, for many, where the debate around the 
acceptability of hESC research starts. As pointed out by the PCBE, ―in the actual public 
debate, as it has developed, this question seems to have been most central and 
prominent and probably most responsible for shaping the different basic approaches 
pursued‖ (PCBE, 2004, p. 57). These ‗basic approaches‘ are arguably shaped by the 
framing of the embryo within the policy documents. This, in turn, leads to different 
views on appropriate governance constructs and so helps to shape associated political 
debates (Kirejczyk, 1999; Parry, 2003). We will find that while in the UK policy 
documents the embryo is consistently discussed in similar technical terms as the ‗early 
embryo‘ or ‗pre-embryo‘, its framing in the US policy literature is less consistent and 
more ambiguous as to its treatment within a context of good governance.  
It is clear in reviewing the policy literature on hESC research in the UK that 
‗closure‘ around the framing of the embryo in more ‗technical‘ terms came through the 
work of the Warnock Committee in the early 1980s (Warnock, 1985). The Warnock 
Committee reviewed a range of social, legal, moral, religious, ethical and scientific 
views related to the status of the embryo and the acceptability of embryo research. 
These views on the early embryo range from the belief that the embryo is a human 
being from the moment of conception, to claims that the embryo is just a ball of cells 
and is therefore no different from any other biological material. Complicating the 
situation even further is that representations of the embryo are often derived from 
particular religious principles and so grounded in specific moral systems (see Young, 
2001, for a further discussion). As was discussed in Chapter 2, the Warnock Committee 
adopted a position between the two views – according a ‗special status‘ to the embryo – 
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that was eventually enshrined in legislation and led to the establishment of the ‗14-day 
rule‘. This serves as a shared foundation on which wider governance issues for the 
science can be discussed, developed and debated. 
Though this shared foundation is now the basis of legislation in the area of 
embryo research, at the time it was delivered, the Warnock Report only went some way 
towards stabilising the framing of the embryo in a policy setting. A more complete 
sense of closure within the policy literature came through a shift in rhetoric that was 
employed over the course of the Parliamentary debates leading up to the passage of the 
Human Fertilisation and Embryology (HFE) Act of 1990. In his book, The embryo 
research debate, Mulkay (1997) shows how Parliamentarians in favour of passing the 
HFE Act succeeded in shifting the frame of the debate by repeatedly referring to the 
developing embryo as the ‗pre-embryo‘. By adopting a more scientific term, the embryo 
could be ―treated as un-problematically devoid of human traits, and hence as a suitable 
object of research‖ (Jasanoff, 2005, p. 278). Thus, by closing down the terminology, 
Parliamentarians in favour of embryo research opened up a way for the debate to focus 
on the issues we have been analysing above: how to respect the ‗special status‘ while 
still allowing for the potential medical benefits for society to be realised. 
Evidence of the permanence of this rhetorical shift is found in the fact that in all 
three of the more recent policy documents being reviewed here, the embryo is 
consistently referred to as the ‗early embryo‘. The ‗early embryo‘ is defined as covering 
―stages of development up to the appearance of the primitive streak‖63 (House of Lords 
Select Committee, 2002, p. 20). This definition is a rather ‗technical‘ framing of the 
embryo, akin to that of the ‗pre-embryo‘, which may enable policy discussions to move 
beyond the issue of the embryo to other governance issues, whilst being safe in the 
knowledge that the ‗special status‘ is enshrined in legislation.  
In marked contrast, the varied framings of the embryo in the US policy literature 
demonstrate how the debate has never reached such closure. This is readily observed in 
the various presentations of the embryo within the policy literature. In the PCBE report, 
the first chapter comments on how terminology is used variously in the debate, which 
can often lead to confusion or a misrepresentation of the issues. They point to the terms 
‗embryo‘, ‗spare embryo‘ and ‗moral status of the embryo‘ to illustrate this point. 
Looking, then, in more detail at the way in which the embryo is referred to in each 
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 See discussion in Chapter 2, p. 12, for a definition of the primitive streak and its significance in 
embryonic development. 
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document in the context of developing ES cell lines, we first see that in the PCBE report 
they are described as originating from  ―the inner cell mass of embryos at the blastocyst 
stage‖ (PCBE, 2004, p. 8). The description uses both scientific (blastocyst) and more 
mainstream (embryo) terms, thus doing little to clarify any ‗confusion‘ it points out.  
The NAS Guidelines do not use the term ‗embryo‘ at all in the description of the 
derivation of ES cells. Similarly, the NBAC report prefaces the description of how ES 
cells are derived with the sentence ―In mammalian embryonic development, cell 
division gives rise to differentiated daughter cells that eventually comprise the mature 
animal‖ (NBAC, 1999, p. 9). This, combined with the use of the term ―early cleavage-
stage embryo‖ seems to reflect a more technical framing of the embryo akin to that in 
the UK policy literature. Not only does the reference to ‗mammalian‘ seem to position 
the embryo as far as possible from ‗human‘, but ‗early cleavage-stage‘ is a rather 
technical description of the stage of embryonic development at which ES cells are 
derived. One could interpret this as seeking to position ES cells as more suitable for use 
in scientific research. Other interpretations also exist and we present these here not with 
the purpose of claiming analytical robustness, but merely to point out that we find three 
different presentations of the embryo within the US policy literature.  
This variation makes discussion of the governance framework and the related 
perspectives on ‗good‘ governance harder to identify as there is no foundational 
agreement on which the socio-political discussions can rest. In and of itself, this is not 
necessarily a problem and, indeed, disagreement over social and policy goals is part of 
the democratic process. However, it does raise questions when we consider it alongside 
the policy development in each country. One could argue that the relative stability of the 
status of the embryo has contributed to a clearer presentation of a governance approach 
in the UK policy literature. A more technical framing of the embryo in the UK policy 
literature allows for a perspective on good governance which readily seeks a balance 
between the dual needs to facilitate the science, on the one hand, and uphold the respect 
for the ‗special status‘ of the ‗early embryo‘, on the other. In the US, the framing of the 
embryo varies and is less consistent between the policy documents. This, it seems, 
results in a mix of perspectives on good governance. Without a consistent framing of 
the embryo, it is difficult to determine what is deemed to be acceptable treatment of the 
embryo within a policy and legal context, let alone a research one. The implications of 
the inconsistent treatment of the embryo, then, as well as the primary framing of 
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governance issues in ethical and moral terms, may extend far beyond this theme of good 
governance. 
5.5 Establishes appropriate institutions and instruments of 
governance  
5.5.1 Overview 
This section will review the different ways in which governance institutions and 
instruments – such as mechanisms, structures and features of the governance process – 
are discussed and how different perspectives on good governance emerge from the 
policy literatures. Section 5.5.2 will focus on the differences in the policy frameworks 
and policy instruments that are argued for in each set of national policy literature. In the 
UK, policy instruments are seen as ways to implement regulatory activities, whereas in 
the US the argument is made for policy institutions that subtly affect oversight through 
the distribution of research funding. In Section 5.5.3, the quality of the governance 
deliberations as presented in each set of policy documents will be discussed. Particular 
attention is paid to how these qualities reflect perspectives on good governance. These 
topics are discussed in significant breadth and depth in the wider academic literature on 
hESC research governance, and it is almost impossible to discuss the perspectives on 
good governance emerging from the UK and US policy documents in isolation from 
these other literatures. Thus, to a greater degree than in the previous sections, the 
following discussions will draw on academic and theoretical insights on good 
governance of hESC research where necessary for purposes of comparison, explanation 
and theory-building.  
5.5.2 Characterising policy approaches 
This section will discuss the differences in the UK and US policy documents in 
terms of the arguments made for policy frameworks that either involve institutions for 
oversight and funding (in the US) or instruments of regulation for research activities (in 
the UK). The emphasis on institutions or instruments is relative as both policy 
frameworks incorporate elements of each. However, it is the case that the UK policy 
discussion places greater emphasis on specific regulatory approaches to hESC research, 
while in the US the role of institutions in funding and overseeing ‗appropriate‘ research 
is emphasised. These distinctions, effectively in national governance strategies, are also 
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observed by others studying patterns in the science and technology policy arena from an 
interdisciplinary perspective and across many areas of regulatory science (Vogel, 1986; 
Jasanoff, 2005; Fukuyama and Furger, 2007; Gottweis et al., 2009). In particular, they 
claim that important differences do exist in areas where government must control the 
social behaviour of industries heavily reliant upon science (Vogel, 1986).  
In further support of this argument, I will claim that in relation to the governance 
of hESC research, these differences are reflected in a greater focus in the three UK 
policy documents on the regulatory processes of governance, and how it is that these 
processes come to characterise good governance. In this, we see attention paid to 
describing the ways in which actors are able to interact and provide inputs to regulatory 
decisions, the manner in which instruments and institutions operate in their regulatory 
capacities, and the means through which regulatory oversight is achieved. In the US, on 
the other hand, we find a focus on the research outcomes of institutional oversight 
strategies and how these outcomes amount to good governance being realised. These 
outcomes might include the types of research permitted, the principles of scientific 
autonomy or ethical conduct that are upheld, the ways in which both of these outcomes 
will shape the scientific trajectory, and, importantly, the types of institutions that best 
enable all of these ends to be met. Each of these claims will be explored in greater detail 
below, with particular attention paid to the types of ends that the institutions and 
instruments of good governance reinforce, such as public confidence, responsiveness, 
and scientific advance. 
In the UK there are three ‗effective‘ levels of oversight for hESC research: 1) 
license application and approval by the HFEA; 2) approval by a local Research Ethics 
Committee; and 3) receipt of funding by a research council or other funding body. In 
order to proceed with a research project, then, the researcher must receive approval at 
all three levels. The first two of these requirements are assured through formal 
regulatory mechanisms. The UK Government takes pride in the formality of these 
procedures, arguing that the regulatory controls themselves serve to ―promote public 
confidence in the development and use of human reproductive technologies‖ (DoH, 
2006, p. 5). The House of Lords Select Committee goes so far as to claim that the 
HFEA has been the ―lynchpin‖ of the regulatory system and 
it has the full confidence of the scientific and medical research community, and 
we believe that it has also been instrumental in reassuring the public that 
regulation in a particularly emotive area of public policy is carried out 
effectively and sensitively (House of Lords Select Committee, 2002, p. 38).  
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Here the regulatory activities themselves and the idea that good governance should 
promote confidence in all sectors of society are strongly linked. Thus, it is the use of 
regulatory controls and the way that they are employed which further demonstrates how 
features of the governance process are identified as characteristic of good governance.  
In addition to the notion of public confidence emerging out of the process of 
regulatory oversight, there is also evidence to suggest a belief that the best and most 
effective regulations will be those that help to advance science and technology. It is 
argued the regulatory structures must remain ―responsive to technological advances‖, 
apace with ―significant changes in public attitudes‖, and ―sufficiently flexible to remain 
effective‖ (DoH, 2006, p. 6). These reflect firstly the means (e.g. responsive 
regulations) and then the ends (e.g. desired scientific outcomes or positive public 
attitudes), or the process before the outcomes, of good governance.  
In the US policy literature, good governance is described more in terms of the 
outcomes various policies for oversight and funding help to achieve. Here, emphasis is 
placed on the role of institutions in carrying out indirect roles of oversight through the 
dispersion of federal funds for research. This mode of oversight, administered primarily 
through the institutional framework of the NIH and individual research centres around 
the country, enables particular, and desirable research outcomes to be achieved. In 
arguing in support of oversight through federal funding, the NBAC notes: 
one of the principal benefits of federal funding of biomedical and behavioural 
research is that it is relatively easy to put in place an effective system of public 
oversight and review...It is a policy strategy designed to provide the appropriate 
checks and balances and ensure ethically acceptable research protocols (NBAC, 
1999, p. 61).  
The approach not only favours existing systems, but also a lighter touch that is ‗easy‘ to 
put in place and amounts to a ‗policy strategy‘, not formal regulatory activities. In this, 
we note there are no recommendations that would force compliance in the private 
sector, indicating a more ‗hands-off‘ approach to the process of governance. Privately 
funded researchers and their sponsors are only ―encouraged‖ to ―adopt voluntarily the 
applicable recommendations of this report‖ (NBAC, 1999, p. 79).  
The NAS Guidelines make recommendations for oversight along similar lines to 
the NBAC, but with the caveat that further strength be given to institutional oversight at 
the local level as a complementary layer of review. According to the authors of the 
guidelines, this would serve to underscore the sensitive nature of the research and foster 
consistency across the country. Consistency, in turn, would presumably lead to faster 
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advances in the science. This is particularly relevant due to the timing of the NAS 
Guidelines‘ publication, when many initiatives for state-based support and oversight of 
hESC research were emerging. In both reports, then, we find that desirable policy 
outcomes are discussed in relation to the relative merits of a system that is already in 
place. In all of these, the outcomes of good governance seem to be of primary 
importance.  
The analysis so far has been interesting for purposes of identifying perspectives 
on good governance, but it still seems to beg the question of what the implications are 
for policy-making and contributions to wider literature. We can return to the tentative 
suggestion made earlier that where similar comparative observations in national policy 
styles have been made, notably in the case of Vogel‘s study of environmental regulation 
in the UK and US, further support can be found for the assertions being made here. That 
is, though Vogel‘s study was focussing on the environmental industry, we would argue 
that parallels can be seen in the case of hESC research. 
Both Great Britain and the United States may be early industrializers, but they 
have come to pursue markedly divergent strategies for controlling the social 
behaviour of their industries (Vogel, 1986, p. 266).  
Vogel argues that Britain‘s regulatory style is one where goals remain incremental and 
there is widespread use of non-governmental organisations to implement regulatory 
policies and close consultation with industry interest groups before and during the 
development of new policies. In the US, by contrast, Vogel characterises the American 
system of regulation as one that has become increasingly pluralist ―not only with respect 
to government regulation but in a wide variety of policy areas‖ (Vogel, 1985, p. 278). 
He asserts that the US relationship with industry is one that is marked by persistent 
strain and ―open, unstructured competition among interest groups‖ (Ibid, p. 279).  
Examples of both characterisations are seen in the case of hESC research and 
within the policy literature being reviewed here. However, for reasons that will become 
clearer after the presentation of the empirical findings, it is more appropriate to consider 
both those findings and the conclusions being drawn in the final chapter. The next 
section will look at perspectives on the qualities of deliberative inputs to good 
governance. 
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5.5.3 Qualities of deliberations: the role of publics and the nature of 
expertise 
 In the context of this thesis, the term ‗deliberation‘ refers to the ways in which 
discussions and decisions are made in a governance system. The qualities of these 
deliberations, the nature of the inputs and interactions that take place within them, and 
the various roles of those engaged in deliberative activities are considered below. In the 
UK policy documents, we will show that the qualities of deliberations characterising 
good governance include eliciting the views of the public (usually through some form of 
consultation activity); having lay representation on expert advisory bodies; placing a 
value on informed scientific and medical expertise as an input to governance; and 
ensuring wider expert inputs that are seen to be more ‗social‘ in nature, such as those 
provided through bioethics-based deliberations. In the US, the value of public input is 
also recognised, but the format through which this should be mediated is less clear. 
Though there is a value placed upon the role of expert advisory committees, both at the 
national and institutional levels, it is often through these structures that public input is 
sought or engagement is mediated
64
. Each area will be discussed in further detail below, 
under the sub-headings ‗the role of publics‘ and ‗expertise‘.  
The role of publics  
A full discussion of the theoretical arguments for why public engagement and 
deliberation are important in contexts of technological risk and uncertainty is provided 
in Chapter 3. One of the main points to take away from that nuanced debate and bring 
into the discussion here is the argument that because this is an area where risks extend 
beyond the technological and into the social and cultural, the representation of views 
needs to be broader than individuals from particular ―epistemic communities‖ on expert 
panels (Fukuyama, 2005). That is, engagement efforts must attempt to represent the 
entire ‗body politic‘ and their diverse views. However, this is not always a straight-
forward matter and, as Stirling has argued, even the act of designing public engagement 
and appraisal processes can be subject to different imperatives and motivations, which 
may serve to close down policy discussions before they begin (Stirling, 2008). 
Given the considerable attention paid to this topic in the academic literature, it is 
curious that there is comparatively little attention paid to the critical examination of the 
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issue of public engagement within the policy literature being analysed here. Though 
there are discussions in the HRT report about the problems associated with the expert-
based nature of the composition of the HFEA and the duty of the regulator to ensure 
public engagement, it is only in later discussion of the new legislation for embryology 
and fertilisation in the UK that discussion explicitly focuses on the ways in which full 
public representation might be assured. Even this seems lacking in critical reflection as 
it only points out that ―responses to public consultations often come from those with 
strong views which may not be representative of those held by the general public‖ (Joint 
Committee on the Human Tissue and Embryos (Draft) Bill, 2007, p. 14).  
The situation is made all the more curious by the fact that in the 2005 Human 
Reproductive Technologies report it adopted what it claimed to be a ―significant 
innovation in the use of e-consultation‖ where the main aim ―was to listen to and gauge 
the public‘s views, both to help us frame the inquiry‘s terms of reference and to allow 
new voices to contribute to the debate‖ (House of Commons Science and Technology 
Select Committee, 2005, p. 4). However, the findings of this consultation are not 
summarized in a single place in the text of the final report, only in a separate summary 
report listed on the e-consultation‘s forum website. Though various quotations and 
examples are used throughout the text, showing (at least) some responses were a source 
of evidence, this does little to demonstrate how the responses were evaluated and 
whether they made a real difference to the findings of the inquiry. This seems puzzling, 
given the comment made to the House of Commons Science and Technology Select 
Committee by the (then) Chair of the HFEA, Suzi Leather.  
The HFEA must respect and be seen to take on board the concerns of 
individuals and groups who invest huge amounts of time and resources in 
contributing to the debate, and yet often feel marginalized and excluded from the 
decision-making process (emphasis added, House of Commons Science and 
Technology Select Committee, 2005, p. 155).  
This statement makes it clear that the regulatory authorities recognize the importance of 
the public‘s opinion, yet the comment ‗be seen to take on board‘ is particularly 
ambiguous as to how it will be taken on board, and, moreover, how the public will be 
able to know their views have actually been taken on board. In the absence of any 
critical reflection on how one might know whether the aims of a consultation were 
achieved, and perhaps more fundamentally, articulating what these aims might be, any 
broad brush statements about the importance of consultation, though welcome, 
unfortunately come across as rather vacuous.  
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In the US policy documents, there is slightly more critical reflection on the 
purposes and meaning of public engagement in a broader context, but on closer 
examination it is also difficult to determine any specific information about what types of 
public engagement constitute good governance. As mentioned earlier, the NBAC report 
devotes several pages to the different ways in which morally contentious issues might 
be deliberated upon within a society and how public policy should, to the greatest extent 
possible, focus on ―ethical values that might be broadly shared‖ (NBAC, 1999, p. 51). 
This wider, consensus-based approach to their deliberations is grounded in writings and 
theories relating to Rawlsian ‗public reason‘ (Cohen, 2005), where reason emerges 
through the articulation of shared fundamental interests and collective political will.  
Laudable though this may be to some readers, the NBAC does not recommend 
specific engagement initiatives that might be undertaken in order to determine what 
these shared interests might be. Rather, they simply argue that such an approach should 
form the foundational principle of their own deliberations and recommendations.  
Our aim throughout these deliberations has been to formulate a set of 
recommendations that fully reflects widely shared views that, in our view, would 
serve the best interests of society (NBAC, 1999, p. 67).  
This seems to reflect a position that quality deliberations are not about facilitating 
broad-based public dialogue, but rather are about gathering ‗public views‘ specifically 
for the purpose of informing expert advisory panels. The dissatisfaction with this lies in 
the lack of clarity about how the public‘s views are first gathered, and second 
considered by such panels.  
The NAS Guidelines and PCBE report make reference to deliberative principles, 
but again neither offer tangible ideas about the role that public engagement might play. 
In its recommendation about the formation of a national oversight body to monitor 
developments in hESC research, the NAS Guidelines simply advise that such a body 
must also ―pay careful attention to evidence and argumentation in its deliberations, as 
well as taking into account the diverse views of the public on these sensitive and 
evolving issues‖ (NRC and IOM, 2005, p. 59). The PCBE report is even more 
ambiguous as to what might be needed in the way of public engagement. It points out 
that it is important to discuss the ways in which society deliberates on profoundly 
contentious matters and that the hESC research debate provides a ―valuable opportunity 
to think through the ways in which the American policy debates‖ such issues (PCBE, 
2004, p. 94). However, the discussion ends without giving any resolution to the 
dilemma or suggestions for improvement. As Cohen points out, for a body whose 
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empowering charter directed them ―to undertake fundamental inquiry into the human 
and moral significance of developments in biomedical and behavioural science and 
technology‖ (Bush, 2001), it seems strange that they do not offer any plausible 
suggestions about how society might structure its discussions about these issues, debate 
ways forward or indeed participate more fully in the democratic process (Cohen, 2005).  
Thus, although each national body of policy literature acknowledges the idea 
that good governance will involve making efforts to engage the public and ensure 
representativeness, little in the way of critical reflection on what meaningful public 
engagement should seek to achieve or be characterised by is presented. This seems 
remarkably unsatisfactory given the heightened attention paid to public engagement 
discussions and characterisations of its importance in terms of good governance in the 
wider academic literature on new biotechnologies.   
Expertise and bioethics 
While public inputs are viewed as important, albeit ill-defined and poorly 
reflected on, the role of expertise is widely discussed in much of the policy literature 
and, as we will find, has an interesting relationship with the role of the public in the 
context of hESC research. Though academic work discussed in the previous chapter has 
shown expertise and singularly technocratic approaches to governance to be flawed, we 
cannot deny the fact that when it comes to scientific policy issues, some expert input 
will be required. A tension manifests itself, then, when governments argue on the one 
hand that ―ultimate authority on issues of public concern should lie outside of the 
scientific and medical communities‖, while in the same breath reminding us that, 
nevertheless, ―it is important that any decisions are informed by science and medicine‖ 
(House of Commons Science and Technology Select Committee, 2005, p. 182). It seems 
that the appropriate role for scientific inputs to decision-making differs depending on 
one‘s point of view.  
In her book Designs on Nature, Jasanoff (2005) reminds us that the public often 
turns to experts when issues of risk and uncertainty arise. This gives experts a 
heightened importance in the decision-making process, and, thus, in the wider 
governance picture. ―In the politics of biotechnology, as on any issue of public moment, 
the credibility of experts is therefore as crucial to democratic governance as is the 
legitimacy of officials‖ (Jasanoff, 2005, p. 267). However, the way in which this 
credibility is established and subsequently conferred within different countries is less 
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certain. Jasanoff argues these features vary between cultures and are related to the 
different processes of knowledge generation in a society. She characterises such 
processes as a nation‘s ‗civic epistemology‘ (Jasanoff, 2005).65 Such epistemologies 
have different dimensions which contribute to their characterisation, one of which is the 
way ‗expertise‘ is collectively recognised within a society. Thus, in relation to experts, 
she claims that variations can be found in the balance between an expert‘s formal 
qualifications on the one hand and their personal or institutional experiences, on the 
other (Jasanoff, 2005). In the US, professional skills and standing in one‘s field are 
given much more weight than one‘s experiences. Skills and standing are seen to be 
more measurable qualities, and, thus, easier to quantify and prove. In the UK, on the 
other hand, personal experiences and institutional service are more important (ibid.). 
In the UK policy documents, the principle of lay representation on expert 
advisory bodies seems to be of fundamental importance. The main regulatory body for 
hESC research, the HFEA, is required by law to have a lay majority. This principle was 
argued by the Warnock Committee, as it believed an advisory body for embryo and 
fertility research should ―not exclusively, or even primarily, [be] a medical or scientific 
body. It is concerned essentially with broader matters and the protection of the public 
interest‖ (Warnock, 1985, p. 76). Therefore, those lay members of the body would be 
appointed because of their services to society in other areas and not for their 
professional skills or technical background in the area of human reproduction or 
science. A clear perspective on good governance emerges where the principle of lay 
representation becomes a part of the nature of expertise. 
In the US, similar calls have been made for members of the public to sit on stem 
cell oversight committees, but there is little or no guidance given as to how these 
members should be chosen. Though this is also the case in the UK, at least broad 
suggestions about composition are made in the legislative statute for hESC research, 
whereas in the US policy documents it seems there is only lip service to the notion. The 
NAS Guidelines call for membership of the national oversight body to be comprised of 
―nationally and internationally recognised authorities in the scientific, medical, ethical 
and legal issues, and representatives of the public‖ (NAS, 2005, p. 59). The NBAC 
states that its recommended national oversight panel should have ―a broad, 
multidisciplinary membership, including members of the general public‖ (NBAC, 1999, 
p. 76). Thus, though it is clear that respected experts in various professional fields 
                                                 
65
 Each epistemology is discussed in full in Chapter 8. 
  
122 
should be represented, it is less clear precisely how and in what proportions the 
members of the public should be represented on these bodies or the rationale behind 
their inclusion. If we are to accept Jasanoff‘s claim as to cultural differences in how 
experts are defined, we might expect members of the public with significant 
professional skills and standing to be selected. However, though the NAS report makes 
some reference to ‗recognised authorities‘, there is little other evidence of selection 
criteria in the policy documents to verify this claim. We are still left with a question 
mark as to the exact perspective on good governance in this area and what, if any, 
relationship to the role of the public in deliberative activities exists. 
Part of the answer might lie in the emergence of a new type of expertise that is 
coming to dominate the types of expert input seen as necessary by policy-makers: 
bioethical expertise. It is argued that the ‗politics of biotechnology‘ has given rise to this 
unique type of expert body, which serves as a deliberative mechanism able to consider a 
host of values and moral issues at stake. ‗Bioethics‘ has thus arisen as the language of 
choice for many expert-based discussions, at both the national and international level 
(Gottweis et al., 2009) and on a variety of different biotechnology issues. These range 
from GM crops, where it has been used to set a risk/ethics boundary (Wynne, 2001; 
Levidow and Carr, 1997); to xenotransplantation, where it might serve as a language of 
authenticity (Brown and Michael, 2002); to genetic technologies, where advances in 
research are seen to force a deeper ―political examination of personal and social values‖ 
(Knoppers and Chadwick, 2005, p. 75; see also, Salter and Jones, 2002; Kerr, 2003) 
and, of course, to hESC research, where the focus is on the moral status of the embryo 
and on wider issues of ethical conduct of the research (Robertson, 1999; European 
Group on Ethics, 2000; NBAC, 1999; Nuffield Council on Bioethics, 2000; Kelly, 
2003; Walters, 2004; PCBE, 2004; Salter and Salter, 2007). Due to the value of 
bioethics in different contexts, particularly national contexts, it has been argued that 
bioethics is a new type of ―global moral currency‖ that governments and publics can 
trade in (Salter and Salter, 2007; Gottweis et al., 2009).  
The question then becomes one of how this new arena of expertise has been used 
in UK and US policy documents to deliberate on the topic of hESC research. Jasanoff 
argues that in the US the language of bioethics was used to head off the growing fears 
of the risks posed by new developments in biomedicine, while in Britain it was seen as a 
way to protect science and the research community (Jasanoff, 2005, p. 187). As much of 
the analysis in this chapter has shown, in both the UK and the US, policy discussions 
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over hESC research have taken place with extensive reference to and framing within the 
moral and ethical language of bioethics. More importantly, the nature of these 
discussions has varied between national bodies. Thus, the relative impact of the framing 
of the governance issues within a moral and ethical context seems to have an effect on 
the perspectives on good governance emerging from the policy literature. For example, 
while in the UK the moral status of the embryo was established in 1990 in legislation 
and the framing of the embryo has remained fairly consistent in the literature since, in 
the US a process of re-framing seems to occur with each new national bioethics body 
asked to advise on the issue. In addition, though the UK does not have a single official 
body solely concerned with the area of bioethics, general deliberations over bioethics 
feature prominently in policy debates, whether mediated through specialist ‗official‘ 
committees (e.g. the HFEA, the Human Genetics Commission (HGC), the Agricultural 
and Environmental Biotechnology Commission (AEBC), etc.) or ‗unofficial‘ bodies 
with tacit government approval (e.g. the Nuffield Council on Bioethics). 
Thus, as Jasanoff argues in her review, in response to the challenges raised by 
advances in biotechnology, including hESC research, bioethics offers governments the 
―promise of bringing order and principle to domains previously governed by irrational, 
emotive and unanalyzed reactions‖ (Jasanoff, 2005, p. 172). In much the same way 
policy-makers looked to technical risk analyses or expert appraisal when confronted 
with scientific uncertainty, it seems they now look to bioethical expertise as a way to 
make sense of and in some way legitimise – in social and cultural terms – the use and 
applications of biotechnology. Indeed, it has been argued that in the absence of 
meaningful public engagement methods, as discussed above, a moral authority is 
conferred upon public bioethics bodies due to their location, expertise and composition 
(Kelly, 2003). It is within public bioethics bodies that concepts such as ‗consensus-
building‘ (Moreno, 1995) and ‗value pluralism‘ merge with deliberative principles from 
the democratic theory literature (Gutmann and Thompson, 1997, 1996). In this way, 
bioethics bodies are able to lay claim to both deliberative and representative authority.  
However, though the aims of consensus within bioethics are easily articulated, in 
much the same ways as we saw for public engagement in the policy documents, there is 
still a looming question as to whether, in practice, bioethics bodies come up short. Do 
they provide a full representation of the views of the public(s) they claim to speak for, 
or help to identify a consensus (Kelly, 2003)? In this respect, it is worth noting that the 
vast majority of bioethics bodies deliberating on issues of hESC research (be they 
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official bodies of nation-states or local Institutional Review Boards (IRBs)), are 
comprised mainly of medical scientists, lawyers, and laypeople, but not necessarily 
those trained in philosophy or ethics (Gottweis et al., 2009).  
This seems to suggest that although public engagement is believed to have a role 
in the context of good governance, it is still embedded within a role of expertise as the 
main deliberative focus for issues of scientific uncertainty. The policy and academic 
literature analysis above presents bioethics as a way to formally deliberate and articulate 
matters of public concern, perhaps bridging the ‗expert‘ and the ‗public‘. However, is 
this merely a new way of framing expert input? Just as with other bodies of more 
‗technical‘ expertise, the politicisation of the endeavour cannot be ignored as 
―bioethics‖ is just as easily susceptible to taking on elements of a ―biopolitics‖ 
(Callahan, 2006; Bishop and Jotterand, 2006). Though they may aim to either ‗canvass‘ 
(NBAC, 1999) or probe the moral basis of an ‗ethical-political‘ issue (PCBE, 2002), 
there is a strong argument to be made that ‗bioethics‘ cannot be a simple substitution for 
more broad-based mechanisms of public engagement and deliberation.   
5.6 Social and cultural bases of good governance 
5.6.1 Overview 
This section addresses the social and cultural aspects of good governance as 
raised in the policy literature. It touches on the importance of historical and political 
legacies in policy development, or the relative desires to maintain the ‗status quo‘, and 
from this, how conceptions of the social and cultural bases of trust emerge. In the latter 
area, there are clear links between the ‗status quo‘ and trust in introducing new 
governance ideas, but more nuanced references to the basis of trust in the context of 
good governance.  
5.6.2 The status quo 
It is nothing new to state that existing regulatory structures and political histories 
influence the current nature of policy debates and, in the case of this thesis, the various 
elements of good governance that are contained within the policy documents being 
analysed here. References to these histories and existing regimes are used in various 
ways within the literature in order to legitimise certain recommendations, courses of 
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action, presentations of the technologies or framings of the science. In a particularly 
insightful bridge between the political science and STS literatures, Banchoff (2005) 
argues that when it comes to value-driven policy issues, like stem cell research, a path-
dependent analysis of policy change and exploration is merited. His argument is similar 
to that being made here, that is, there is a relative importance of history and culture as 
they affect perspectives on good governance and shape emerging policy discourse.  
Insights such as these help to reinforce the argument that references to existing 
regulatory or policy authorities serve to complement, strengthen and confer legitimacy 
upon new notions about good governance. They reflect a desire that, for want of a better 
phrase, is about maintaining, or appearing to maintain, the status quo. For example, in 
the UK there has been a ―long-standing tradition of promoting scientific freedom‖ 
(Knowles, 2004, p. 160) and it can be argued that this frame of reference contributes to 
the increasingly permissive regulatory regime for hESC research. By showing how 
current regulatory controls have ensured ethical and responsible science while still 
allowing for scientific progress to be made, the UK Government has been able to make 
a case for new degrees of flexibility, transparency or consistency. This was seen in the 
case of the introduction of new regulations for research introduced in 2001 and the new 
legislative framework introduced in 2008.
66
   
Though the US also has a history of supporting the biomedical enterprise 
(Resnik, 1999), this is in a more ‗free-market‘ way through the provision of research 
funding. References to the success of this system and a history of self-regulation by 
scientists in new and advancing areas allow for good governance to be portrayed as 
something that does not upset the status quo, but still acknowledges public concern. In 
reviewing the arguments in favour of federal funding for certain types of stem cell 
research, the NBAC report points to: ―the enhancement of scientific progress‖ (NBAC, 
1999, p. 58); the benefits that would emerge from a system that ―encourages‖ both 
public and private support of the research (ibid., p. 59); the ―synergies‖ that would 
result from combined federal efforts (ibid., p. 59); the application of federal regulations; 
and the greater ability of the US to ―sustain a leadership position in this increasingly 
important area of research‖ (ibid., p. 60). There is clearly a balance being struck 
between emphasising the positive benefits to science and to society through ensuring 
appropriate levels of oversight. The NAS Guidelines make an even stronger case for 
relying on past precedents when arguing that self-regulation is entirely merited:  
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there is a precedent for self-regulation by the scientific community and research 
institutions... The initiative taken by the scientific community in the 1970‘s with 
regard to recombinant DNA research serves as a model for self-governance in 
hES cell research in the absence of involvement of the federal government (NRC 
and IOM, 2005, p. 47). 
Both examples from the UK and the US suggest that it is through appeals and 
references to existing processes of oversight that a certain legitimacy comes to be 
conferred upon the perspectives on good governance that emerge from the policy 
literature itself. Due to its grounding in the ‗status quo‘, such a legitimacy seems to have 
clear links to social and cultural bases. These are explored further in the next section.  
5.6.2 Bases of trust 
 Closely related to the issues discussed above are differences in the social and 
cultural bases of trust. In her comparative study of different cultural responses to 
biotechnology and the civic epistemologies they reveal, Jasanoff argues that the bases 
for trust come from the ways in which public accountability is assured in different 
countries (Jasanoff, 2005). Accountability is conferred in the US, then, through the 
judicial litigation process where one is able to establish credibility through the courts. In 
the UK, Jasanoff argues that accountability is conferred by the experts sitting on 
advisory bodies or making regulatory decisions. It follows that it is through the 
judgements of such ‗trustworthy‘ experts that the public deems decisions to be credible, 
acceptable, and, hence, accountable. 
However, the analysis in previous sections of this chapter seems to suggest that 
there are other bases of trust that are important to recognise. For example, though there 
is a high degree of import given to the deliberations and (claimed) representativeness of 
expert bodies in the UK policy literature, there is also great emphasis on the legislative 
principles that underpin regulatory practice. In addition, the practice of legal challenge 
is not mentioned in the US policy documents on hESC research, and so here, too, other 
bases of trust may exist.  
 One way to think about trust is to ask why trust is sought and by whom. In a 
review of the governance of human genetics in the UK, Jones argues that 
Although trust in a governance system may seem inherently ‗good‘, from a 
pragmatic policy perspective there are compelling reasons for its nurture—the 
strongest of which is the state‘s need for legitimacy...Principally, although trust 
and legitimacy cannot be equated, trust is a lynchpin of political legitimacy. 
(Jones, 2004, p. 252). 
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Thus, though not equal, trust and legitimacy seem linked. Jones goes on to explore the 
use of objectivity in decision-making activities as a basis for establishing rhetorical 
legitimacy, and hence, trust. Using Jones‘ approach, we will look for similar links and 
evidence of appeals to both legitimacy and trust in the policy literature. It seems to us 
that references in the policy documents to the ‗status quo‘ in governance processes (as 
discussed above) and/or support for current and past regulatory practices, are similarly 
used as ‗objective‘ statements to ‗stretch‘ (Jones, 2004) the arguments into a foundation 
for establishing trust and legitimacy.  
 In the 2002 Select Committee Report from the House of Lords, we find that in 
their description of the current framework within which hESC research is permitted and 
regulated, they refer three times in the same paragraph to perceived indicators of public 
support. They find that the ―majority public opinion‖ is supportive of stem cell research, 
that the regulatory authority for stem cell and embryo research enjoys ―public support‖ 
and, moreover, was ―enacted after a lengthy period of public and parliamentary debate.‖ 
They go on to point out that the legislation and regulatory authorities have ―been in 
force for ten years‖, which seems a direct reference to the importance of the status quo 
(House of Lords Select Committee, 2002, p. 23). It seems, then, that within this policy 
document a perspective on good governance emerges that emphasises continuation of 
the status quo precisely because it enjoys strong support, high levels of public 
confidence and is based upon ‗legitimate‘ processes of previous public debate, which 
include the morally and ethically-derived conclusions of the Warnock Report.  
In the US policy documents, trust seems to be sought in emphasising the state‘s 
established precedent in responsible scientific oversight. Since previous areas of science 
have been overseen through federal funding, the aim seems to be to convince the public 
that trust can be placed in government to ensure hESC science will be conducted in a 
responsible way. Further, more nuanced, appeals to legitimacy are found in the way this 
argument is made through references to the moral import of this activity. Thus, a link is 
made between the appeals to confidence in the system and the shared moral sensitivities 
of Americans. The following excerpt from the NBAC report is illustrative of this 
attempt:  
We concluded that sufficient safeguards can be put in place in order to prevent 
abuse and to ensure that any use of embryos...[this] embodies the kind of respect 
for the embryos that most Americans would expect and demand of any activity 
that is carried out with the support of the federal government (NBAC, 1999, p. 
67). 
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The report goes on to further appeal to the sensibilities of Americans in pointing out that 
―the development of such policy in a morally contested area is not a novel challenge for 
a pluralistic democracy such as that which exists in the United States‖ (NBAC, 1999, p. 
67). The reader is thus both reminded that these types of issues are not new and their 
government has successfully dealt with issues of similar moral import before.   
 To conclude, in the US the basis for trust seems to rest on a reference to 
established precedent in scientific oversight, which is reinforced by the legitimatory 
language of morality, ethics and cultural pluralism. In the UK, bases of trust seem to be 
more closely tied to the framework of regulatory oversight that has proven, over time, to 
protect the public, allay fears about violation of moral sensitivities, and enable scientists 
to move forward with the research. The differences between the two countries are thus 
subtle, yet important, and tie in with the wider perspectives on good governance of 
hESC research that the analysis in this chapter has sought to uncover. 
5.7 Conclusion 
In conclusion, this chapter has looked at the systematic patterns in perspectives 
on good governance that emerge from a sub-set of the national policy literature for 
hESC research in the US and the UK. These perspectives emerged across four main 
themes of good governance, concerning the extent to which good governance: 1) 
Advances scientific and technological outcomes and addresses related issues in hESC 
research; 2) Encourages moral and ethical awareness for hESC research; 3) Establishes 
appropriate institutions and instruments of oversight for hESC research and 4) 
Identifiable social and cultural bases of good governance emerge. Each of these themes 
were found to be covered to varying extents and in different ways within each of the 
policy literatures, with no significant additional issues emerging. This underscores the 
robustness of these four themes as an analytical framework for analysing perspectives 
on good governance within different national policy contexts.  
More specifically, the discussion above under each of the four themes 
distinguishes systematic patterns in the perspectives on good governance in the US and 
UK policy literatures. There are similarities in the ways both sets of policy literatures 
use moral and ethical language to characterise, describe, and in some cases frame, many 
of the governance issues relevant to hESC research. This is seen both in the central role 
played by the ethical and moral discussions, but also in the fact that the role of bioethics 
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has emerged as a dominant, and perhaps legitimatory, input to policy-making in both 
countries. The full implications of this observation in comparison with the findings of 
the MCM interviews will be discussed in Chapter 8.  
However, differences were found in the way the nature of hESC research was 
framed in both sets of policy literatures as well as in the characterisations of policy 
approaches. The UK policy literature has a greater emphasis on the realisation of 
therapeutic benefits of hESC research as soon as possible, and thus measures are 
outlined as to how direct government support may help to achieve this. The US policy 
literature, by contrast, displays a greater emphasis on an indirect governance approach 
that characterises scientific outcomes in relation to the relative degree of scientific 
autonomy afforded to researchers. This results in more outcome-based policies which 
seem to focus less on the processes of governance and more simply on letting science 
‗get on with it‘. Conversely, the UK policy literature seems to have greater concern with 
the processes of regulation and oversight as a means through which therapeutic 
outcomes of the science may be achieved.  
We will now turn from the findings of the review of core policy documents and 
associated literatures, to presentation and discussion of the first set of empirical data. 
The analysis in the next chapter concerns the national characteristics of perspectives on 
good governance arising from MCM stakeholder interviews. 
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6.  Perspectives on good governance: comparative 
analysis of the US and UK 
6.1 Introduction 
6.1.1 Overview 
The analysis presented in previous chapters has shown that human embryonic 
stem cell (hESC) research presents a classic case of scientific and technological 
uncertainty where facts differ and conditions are unknown, assumptions varied and 
stakes are high (Funtowicz and Ravetz, 1993). The reality, though, is that despite these 
circumstances, policy-makers, industrialists, scientists and publics alike must be able to 
shape ways forward (of whatever kind), build justifications for and legitimise their 
decisions, and integrate all of this in a wider governance context.   
This thesis is concerned with the question: Are there contrasting perspectives on 
what constitutes ‗good governance‘ for hESC research amongst different groups of 
stakeholders in the UK and the US and do systematic patterns emerge? Several sub-
questions fall from this, including how do such divergent perspectives differ across 
stakeholder groups and national contexts? Are perspectives affected by individual and 
collective ideas, assumptions and framings? How might these be empirically elicited? 
From these questions, the hypotheses for this thesis emerged:   
• It is possible to discern discrete perspectives on good governance and 
systematic differences in these between and within groups of stakeholders in the 
UK and the US. 
• Among these perspectives, patterns and regularities can be identified and 
analysed between and within the national and cultural settings. 
• Methods of empirical analysis can allow us to understand how the perspectives 
on good governance are constructed and the patterns that emerge from their 
comparisons. 
• Distinctions between and patterns within perspectives on good governance from 
stakeholders can be compared with the formal policy literature in each country 
and discernible distinctions can be analysed. 
This chapter and the next will address these hypotheses and discuss the analytical 
findings arising from the MCM interviews. Selecting among the many possible 
dimensions for analysis was one of the initial challenges for the research, as was 
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discussed in the methodology chapter.
67
 The remainder of this chapter will focus on 
discerning the differences between UK and US participants, while the following chapter 
will analyse the differences between multiple perspectives at the level of different 
groupings of policy actors across the two national settings. Throughout the discussion, 
we use the term ‗perspective‘ to refer to discernible distinctions and regularities that 
emerge in the analysis of these different stakeholder groups, rather than to imply reified 
discrete phenomena in the empirical fields themselves. Approaching the analysis in this 
way allows for a targeted approach to addressing the main hypotheses of this thesis, as 
well as a focused analysis of each of the main areas of exploration—that is, cross-
country differences in perspectives on good governance, as well as cross-stakeholder 
differences within specific national contexts. 
 The next sub-section will discuss implications arising from the high-level 
analysis of the empirical findings of UK and US perspectives on good governance. We 
will then ‗preview‘ the main patterns in divergent perspectives which emerge from the 
analysis presented in this chapter. Sections 6.2 and 6.3 will present the findings in full 
under two of the themes of good governance described in the previous chapter.
68
 A few 
points about the presentation and discussion of the findings are worth making before we 
begin. First, an MCM empirical analysis of stakeholder perspectives is informed both by 
attention to rankings, as well as more fine-grain framings that are evident in the defining 
of criteria and the detailed assessments of options. Thus, throughout this chapter and the 
next, the quantitative picture is supplemented with qualitative material in the form of 
stakeholder statements from the MCM interviews. Second, given previous comments 
about the depth and breadth of data, the analysis presented in some themes will be more 
detailed than others. This is to emphasise those areas where the conclusions were most 
robust in relation to the hypotheses under examination. Where data is not presented in 
full, the reader is referred to relevant Annexes as noted in the text.  
6.1.2 Analysing final performance rankings 
As set out in the methodology chapter,
69
 MCM is a heuristic tool that can be 
used to explore relationships between technological and socio-political factors in 
                                                 
67
 For example, many different permutations and classifications of both participants and their responses 
were made and analysed before the dimensions as presented here were settled upon. See the discussions 
in Chapter 4 for more detail on this point. 
68
 The other two themes of good governance are discussed more fully in Chapter 8. 
69
 See the discussion in Chapter 4, Section 4.2.2 and Section 4.5. 
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perspectives on good governance and decision-making. In the present analysis, option 
rankings will be the first point of reference for identifying potential analytical insights, 
followed by textual and qualitative analysis as discussed above. Figure 6.1 below 
presents the option performance rankings for UK and US-based stakeholder 
perspectives. The further the ranking ranges extend to the right, the higher the option 
performance. The horizontal scale in this (and all subsequent ranking charts) is 
normalised, such that a value of 100 indicates an option that scores consistently highest 
in every interview under all possible criteria, whilst a value of 0 indicates an option that 
scores consistently lowest in every interview under all possible criteria. As explained in 
the Methodology Chapter, the extreme lower and upper ends of the ranking ranges for 
each option, are (in this ranking chart as all others in this thesis, except where noted) 
represented as the means respectively of the pessimistic (minimum) and optimistic 
(maximum) rankings obtained in each case.     
Figure 6.1: Rankings under UK and US stakeholder perspectives 
 
 
An immediate general finding that is consistent with usage of MCM in other 
exercises where there exist highly divergent framings (see, for example, Stirling and 
Mayer, 2001; Davies et al., 2003; Millstone et al., 2006), is that no single good 
governance option ranks as unequivocally best or worst across all these perspectives. 
The scale of the overlapping ranges for individual options typically far exceeds the 
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incremental differences between the options themselves. Beyond this ambiguity, 
however, there is a notable similarity in the ordinal patterns (i.e.,: the relative orderings 
of options). In particular: i) the relationship is consistent across both UK and US 
perspectives among the first four options (from the top of the y-axis in the charts); and 
ii) there is a  relatively wide range of uncertainty and ambiguity evident in the mixed 
central/devolved option. This degree of congruence is particularly striking given the 
number of interviewees, the complexity of the options, the uniqueness of the criteria 
defined by each individual, the open-endedness of the possible framings each individual 
might adopt, and the degree of latitude each participant has in determining the final 
outcome of their respective interviews. Against this background, it might be expected 
that the pictures derived in this analysis would display multiple forms of divergence. 
Yet it is clear that there exists – at least at this level of analysis – a fairly consistent 
pattern in the perceived overall performance of the different governance options across 
the contrasting contexts of the US and UK. Moreover, subject to the caveats set out at 
the end of Chapter 4,
70
 the degree of consistency in the observed regularities suggest 
that they are not due to volatilities intrinsic to the method. 
It is tempting to conclude that these similarities imply that perspectives on good 
governance of hESC research across UK and US perspectives are more notable for their 
similarities than their differences. However, the analysis in the remainder of this chapter 
will argue that the ways in which perspectives on good governance emerge from these 
different settings do vary in several potentially significant ways. Though the aggregate 
pictures – as indicated by the ranking patterns – seem similar, there are deeper 
complexities, differences between perspectives, and variations in framings that are 
otherwise masked at the level of overall rankings.   
The basic similarities in option performance orderings across US and UK 
stakeholder perspectives are all the more intriguing when considered in light of some of 
the comparative literatures that aim to explain generic national differences in policy 
discourses through the identification of specific cultural, institutional and epistemic 
differences across nation-states (see for example, Jasanoff, 2005). While national 
comparisons are necessary and useful at a meta-level of analysis, my findings seem to 
suggest that these types of comparisons cannot always be assumed sufficient. In other 
words, despite the fact that the findings presented here reveal contrasts across national 
settings, there are nonetheless discernible differences between perspectives in each case 
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 See the discussion in Section 4.5.4, p. 87-89. 
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that suggest that the picture is much more complex and nuanced. This prompts a 
conclusion that broad comparisons and distinctions framed at a cross-national level may 
obscure underlying commonalities, variabilities and contingencies.  
In addition to the similarity in the ordinal rankings, three other distinct patterns 
emerge. First, there is a more extensive degree of uncertainty and/or ambiguity
71
 evident 
in the mixed central/devolved option in both national contexts. For UK-based 
stakeholders the range between the pessimistic and optimistic assessment scores for this 
option is about 46 (on an interval scale across all options, normalised to 0-100 as 
explained above). For US-based stakeholders the same range is about 49. In both cases 
this exceeds by some 10 base points (or at least 30%) the average scale of the ranking 
ranges for other options. This suggests there may be some intrinsic features of this 
option that make it more susceptible to uncertainty or ambiguity in appraisal, regardless 
of the stakeholder perspective. Contributing factors accounting for this are discussed in 
this chapter and the next.  
Second, there is slightly more differentiation between the performance orderings 
for the last three options (devolved authority, mixed central/devolved and ethics-led 
governance) under UK perspectives than under US perspectives. The optimistic 
assessments for the three options under US perspectives all display fairly similar ranks 
(around 70 base points).
72
 With the exception of the mixed central/devolved option, the 
other two options also have similar pessimistic assessment ranks between 38-40. This is 
in contrast to the rankings under UK perspectives, which exhibit greater variability in 
rank orderings across these three options. The one thing all three options have in 
common is a devolved structure of governance with varying degrees of expert input, 
public deliberations and regulatory oversight. Analysis in the following sections may 
reveal that UK perspectives find something in a devolved governance structure which 
renders it more susceptible to variable ‗performance‘.  
Finally, in both national contexts, there emerges a similar ordinal relationship 
between the rankings of the devolved authority and expert-led framework options. 
These options share certain features in common, such as a centralised legislative 
oversight and some degree of decentralised research oversight, but other features differ. 
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 The difference between measures of uncertainty and ambiguity is a subtle, yet important one and is 
discussed in the Methodology chapter on p. 86. In short, uncertainty is a measure of the difference 
between pessimistic and optimistic scores expressed by individual participants, whereas ambiguity is a 
measure of the differences between the option evaluations made by participants within a perspective. 
72
 The reader is referred to Annex G for a discussion of the mathematical computations behind such 
‗aggregate‘ scores and mean performance rankings. 
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A more detailed analysis will enable us to determine why and how these similarities 
emerge.  
We can see that the rankings and the associated reasons surrounding option 
performance are nuanced and varied. A more detailed exploration and analysis in light 
of the socio-political viewpoints, framings and assumptions that may affect option 
performance may therefore be capable of providing insights into how perspectives on 
good governance are constituted in each country. Table 6.1 below summarises the main 
patterns in UK and US perspectives that will emerge from this exploration and analysis 
over the coming chapter. These are presented within the same analytical framework of 
the themes of good governance that were identified in Chapter 5. There, the themes 
were found to be relevant and substantially represented in both sets of policy 
documents. In addition, the analysis revealed differences in framing within the 
documents and across the themes which were linked to a variety of perspectives on 
good governance. As one of the hypotheses of this thesis is that the stakeholder 
perspectives on good governance identified through the empirical analysis may differ 
from those identified in a formal policymaking context,
73
 it makes sense to employ the 
themes of good governance adopted in Chapter 5 to the interview-based findings. 
Moreover, in applying these themes to the MCM empirical data, we are able to further 
test the robustness of the themes as an analytical framework and ensure a consistent, 
systematic and structured probing of the material collected during the course of 57 
MCM interviews. 
The presentation of Table 6.1 below provides a preview of the findings that will 
be presented over the rest of this chapter. It is intended to give the reader a sense of the 
analysis to come and to help guide them through it. Each theme is presented along the 
horizontal axis and the areas of comparison are summarised along the three vertical 
columns. Broad summaries of the findings, and corresponding shadings, are given for 
each comparative area. These findings rest on the relative patterns of prominence in 
each case as determined by the respective comparative axis. For example, the analysis 
of the policy document-based perspectives in the previous chapter provides the grounds 
for comparison along that axis. The basis for the MCM-based stakeholder perspectives 
will be discussed in detail in this chapter. These were arrived at through the 
methodological process described in detail in Chapter 4. First, criteria are allocated to 
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 A ‗formal policymaking context‘ is here taken to mean those expressed in the ‗core policy documents‘ 
selected and analysed in Chapter 5. 
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themes on the basis of their definitions and, second, the associated assessments, 
weightings, rankings and other relevant qualitative and quantitative data-points (such as 
uncertainty and ambiguity) are explored. The analysis continues in an iterative fashion 
until the analyst is satisfied that all alternative explanations have been accounted for and 
a prominent perspective is identified.    
Table 6.1. Summary table of patterns in perspectives across all themes of good 
governance 
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Policy literature vs.  
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Shading Key 
 Noticeably divergent: Distinct differences across the two perspectives are clear and readily identifiable 
 Slightly divergent: Some differences across the two perspectives are clear, but similarities or unclear signals exist. 
 Slightly convergent: Some similarities across the two perspectives are clear, but differences or unclear signals 
exist.  Broadly congruent: Similar patterns across the two perspectives are clear and readily identifiable. 
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A few points from the table are worth noting. First, the reader will observe that 
some of the analysis within a theme is discussed in Chapter 8. This is because the 
findings were found to cut across both national settings and individual stakeholder 
perspectives in important and illuminating ways. In addition, though the four main 
themes remain the same, some of the sub-themes have been merged for the empirical 
analysis. This is due to the differing nature of the two sets of empirical findings and the 
fact that a one-to-one correspondence was not always found, nor was it always 
appropriate. For ease of reference, the reader will note that each ‗theme‘-related portion 
of the table is reproduced at the end of each section in order to summarise the analysis 
that has preceded it. The table is then reproduced again, in full, at the end of the chapter 
for the final summary. We will now move to discussing each of these patterns and the 
empirical evidence to support them in greater detail. We begin with the theme of good 
governance relating to ‗advancing scientific and technological issues in hESC research‘. 
6.2 Advancing scientific and technological outcomes 
6.2.1 Overview 
Chapter 5 discussed the patterns that emerged within and between different 
themes of good governance for a subset of the UK and US policy literature. Within the 
theme ‗advancing scientific and technological outcomes‘, it was argued there were clear 
differences between UK and US policy documents in the framing of hESC research 
outcomes and the elements of good governance that would be needed to achieve them. 
In the US policy literature, there was a prominent view that if a flexible space for the 
autonomous pursuit of science was created, a host of scientific outcomes could be 
realised. These outcomes included, but were not limited to, therapeutic ones. Research 
support, therefore, should serve to harmonise oversight frameworks and policies so that 
science can progress relatively ‗unfettered‘. By contrast, in the UK policy documents 
‗good‘ outcomes of hESC research were more prominently characterised in a 
therapeutic way. Processes of research support, then, should involve ‗direct‘ 
government efforts, such as creation of a permissive regulatory space, aimed at more 
quickly advancing hESC research.  
The question now arises of how stakeholders express perspectives on good 
governance in this area. Given the different nature of the empirical findings from the 
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policy literature, the analysis here will look simultaneously at the different perspectives 
on the framing of ‗quality scientific outcomes‘ of hESC research and the processes of 
research support. Discussion of the therapeutic and technological trajectories of hESC 
research will also be covered within this discussion. The section will conclude by 
summarising the most prominent patterns within the perspective for this theme.   
6.2.2 Scientific outcomes and research support 
In the analysis presented in this section, attention will focus on option 
performance and criteria definition as characterised specifically under the MCM 
analytical issue ‗advancing the science‘. The definition of this as an issue for MCM 
analysis arises both from consideration of the good governance themes previously 
introduced, as well as from systematic testing and probing of the empirical material in 
an open and transparent way.
75
 Thus, the criteria that comprise this issue reveal not only 
the ways in which qualities of hESC research outcomes are perceived as ‗good‘ by 
stakeholders, but also the ways in which these perceptions reveal particular framings 
about the nature of the science, the processes of research support that enable these, and 
the assumptions, judgements and values that affect these framings. With this in mind, 
the issue used for the analysis is defined in the following way:  
Advancing the science: Criteria in this issue are distinctive in their concern 
with fostering and advancing the science of hESC research itself. Often 
expressed in an instrumental
 76
 way, the criteria are concerned with the need for 
the  governance framework to facilitate, support and actively advance the 
research, technological and therapeutic trajectories of human embryonic stem 
cell research. 
Criteria falling within this issue were the most frequently mentioned by all 
participants across all perspectives.
77
 Thus, the following discussion will go into greater 
depth than later sections due to the detail that is required in order to explore nuances in 
the framings and perspectives on hESC research that emerge. The chart below shows 
the rankings under UK and US participant perspectives under the issue ‗advancing the 
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 The reader is referred to discussion earlier in this chapter on p. 135-136, as well as to discussion in 
Chapter 4, Section 4.5, p 81-87 as to how the analysis of the MCM empirical material was conducted and 
prominent patterns within the findings identified. 
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 Throughout this chapter and the next, use of the terms ‗instrumental‘, ‗normative‘ or ‗substantive‘ will 
be used according to the interpretations discussed earlier in Chapter 3, p. 52-53. A fuller discussion of the 
implications of the empirical findings for these theoretical concepts is given in Chapter 8 and cuts across 
both the analysis presented in this chapter and that in the next. In the case of the issue definition above, 
‗instrumental‘ refers to the fact that the criteria reveal instrumentally motivated concerns about particular 
research ends, or technological outcomes, being realised and correspondingly supported. 
77
 A full list of criteria defined for the MCM interviews is provided in Annex H. 
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science‘. As has been discussed previously,78 the various dimensions of option 
performance illuminated in MCM provide a heuristic framework that can be used to 
explore the relationships between technological and socio-political factors that 
constitute divergent notions of good governance. As part of this, an initial analysis of 
the patterns that emerge from the rankings above (that is the overall ordinal sequence 
and associated intervals reflecting uncertainty and ambiguity) can be used to guide the 
more detailed analysis. 
Figure 6.2. Rankings under UK and US perspectives for ‘advancing the science’ 
criteria
79
  
 
  
We can see that, on the whole, the option rankings are broadly similar. However, 
there are potentially significant differences in rankings. These include: i) the notably 
greater uncertainty/ambiguity in the ranking interval for the mixed central/devolved 
option for US and UK stakeholder groups; ii) the higher ranking of the expert-led 
framework option under US perspectives as compared to the higher ranking of the 
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detailed centralised oversight option under UK perspectives, and, iii) correspondingly, 
the higher performance of both the expert-led framework and ethics-led governance 
options under US perspectives. On this final point, the fact that the two options are more 
indirect, or ‗hands-off‘, in terms of oversight instruments than the other options may be 
significant. This seems to suggest that for US perspectives there is a discernible 
underlying pattern indicating a relative preference for less centralised and less regulated 
governance options under this issue. If this is the case, we expect to see confirmation of 
this in the qualitative assessments of the options under the issue, analysed below.  
In addition to the broad similarities of the ranking patterns for both UK and US 
perspectives, the relative distribution of the criteria within the issue is remarkable. There 
are notably
80
 fewer individual criteria under this issue for UK than US participants: 44 
individual criteria for the former as compared with 71 individual criteria for the latter. 
Moreover, all 30 US participants defined at least one criterion of this type compared 
with only 23 UK participants who defined at least one criterion in this issue. However, 
the differences in relative expressions of importance assigned to the criteria are not as 
great as the numerical differences suggest. UK participants designate an average 
importance of 32.5%, as compared with 44% for US participants.
81
 There is a slight 
difference, but perhaps not big enough to warrant full confidence in explaining for the 
numerical difference we observe. An alternative, or corroborating, explanation as to 
why US participants defined so many more criteria within this issue, is that they are 
responding, in some way, to the ‗patchwork‘ governance framework for hESC research 
which was in place at the time the interviews were conducted. Such inconsistencies may 
have led US participants to qualify their views on similar issues, such as advancing the 
science, with more criteria than UK participants. 
Finally, a less significant feature of the ranking patterns seen above is that there 
are differences from the rankings for each country as a whole (that is, under all issues as 
shown in Figure 6.1). This point could also be applicable to many of the analyses that 
will follow throughout this chapter. This underscores the ability of MCM as a method to 
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 The author is aware of the implications of using the term ‗significant‘ in an analytical context and the 
association with statistical ‗significance‘. The term, therefore, may be used throughout the analysis, but 
with the connotation merely as one of ‗noteworthiness‘ (as indicated by the choice of the term ‗notably‘ 
here), but not to imply statistical significance of any type. As discussed in Chapter 4 (p. 87-89), there are 
questions over whether qualitative/quantitative MCM data in a study such as this one would support the 
assumptions necessary for statistical analysis. 
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 A full table of weightings for each of the issues presented in this chapter is provided in Annex I. 
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distinguish among different perspectives and associated evaluations made under 
different sets of assumptions and contextual factors. 
These observations lead us to the following questions which guide the analysis. 
First, given the broad similarities in the ranking patterns under this issue, are the criteria 
that comprise the issue also similar, or are there different framings of the nature of 
hESC research and desired scientific outcomes? Are there different interpretations of 
option performance between each country and, if so, what does this tell us about 
differences in framing in option assessment? In other words, if there are differences in 
the characterisations of criteria, but similarities in option assessments, or vice versa, will 
this affect our understanding of the constituting of perspectives on good governance? It 
will be argued below that more noticeable differences are apparent between UK and US 
stakeholder perspectives concerning criteria and associated option appraisals. The 
distinctions evident between the stakeholder perspectives and policy literatures in each 
respective national context are more subtle, but nonetheless potentially significant.  
We will begin by looking at the two types of criteria evident within the UK 
perspectives.
82
 The first is about the qualities of scientific outcomes which stakeholders 
believe should be sought, and the second is about what processes of research support 
should be in place, or, in other words, how achievement of the outcomes should be 
facilitated. Amongst UK participants, there is a tendency to refer to the achievement of 
particular scientific outcomes in the context of regulatory support. Thus, the two are 
portrayed as being mutually dependent: without regulation, advances in hESC research 
may not occur. Though there is some implicit (and in some cases explicit) 
acknowledgement that regulation can be a negative force on these trajectories, most 
participants point out that regulatory forces can be of an ―encouraging‖ (UK bioethicist 
2, #C192),
83
 ―enabling‖ (UK professional body 4, #C329) and ―balancing‖ (UK policy-
maker 3, #C170) nature. They emphasise the more ‗positive‘ characteristics of 
regulation and not those where regulation is ―being restrictive, being the nay-sayer‖ 
(UK bioethicist 2, #C192). With ‗balanced‘ or ‗proportionate‘ (UK regulator 4, #C123, 
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 Here, and throughout the analysis in the following chapters, the reader is reminded that a full list of all 
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table in Annex H. 
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UK policy-maker 2, #C139) regulation, there is also discussion about ‗flexibility‘. Here, 
regulation needs to be ―protective enough for safety and responsive enough to take 
future developments into account‖ (UK industry executive 3, #C203). The dominant 
feature of good governance that emerges in terms of processes of research support is 
about creating a ‘protected, regulated space’ for scientific outcomes to be achieved in.   
However, there is a caveat that regulation should not be burdensome or 
inflexible so that it ―stifles the science‖ (UK policy-maker 2, #C140) or cannot ‗change 
as the science changes‘ (UK scientist 6, #C314). In this, an interesting framing of hESC 
research emerges where criteria about the quality of scientific outcomes seem embedded 
within and intimately linked to the regulatory framework. 
So the regulatory system has to look at the realities of the possibilities 
determined by the way the biology works, it has to be grounded in the science, 
and it has to be able to factor in the risk, or the perception of risk. ... It‘s not only 
about the best way of doing it, but is it an appropriate application of this type of 
knowledge. (UK patient advocate 5, #C309). 
Here, the stress is on the role of the regulatory system in ensuring that only the highest 
quality science is permitted. In the stress on the best way of doing things, we find a 
broader framing of the outcomes of science than was seen in the policy literature, where 
a more therapeutic orientation was seen in the UK. There is also an implicit link to the 
idea that science is advanced both as a result of regulations, in that they set a high 
standard for the science, and because of them, in that the regulatory framework itself 
assures that only the best and most appropriate types of science are being conducted. 
This latter point is especially important and is made more explicit by others.  
It's about having enough regulation, but no more, to keep the public on board, 
but still allowing science to get on with it (UK bioethicist 4, #C128). 
In this quote, we see a linking of ‗pragmatically‘ balanced regulation to the 
advancement of hESC research, but in a way which brings out another key facet of the 
link between regulation and scientific advance: regulation as a means through which 
public support for the science is gained. Since public support is seen as important for 
enabling the pursuit of specific scientific outcomes, part of the role of regulation is to 
reassure the public that the science is being conducted in a responsible way. This theme 
will also come up in later sections, but is worth previewing here. It reveals an important 
tension between regulation to protect the public and regulation to protect the science. 
Moreover, it reveals a type of instrumental motivation behind the appraisal criteria 
which is about the purpose of governance in attaining desired outcomes or ends, such as 
public trust or quality scientific outcomes.  
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The discussion and analysis presented thus far allows us to conclude that there is 
a difference to be found in the way that perspectives on ‗advancing the science‘ emerge 
between the UK policy literature and the UK-based participant perspectives. The 
therapeutic framing in the UK policy literature was strong as compared to the more 
varied characterisation of scientific outcomes as needing to be both ‗high quality‘ and/or 
therapeutic by UK participants. Moreover, though both the policy literature and the 
participants discuss the importance of regulation to protect a space for science, there is a 
clear instrumental link between three seemingly separate elements of good governance 
— scientific progress, regulatory oversight and public support.  
Overall, the more prominent regulatory framing of the science is supported by 
the performance rankings under the issue for UK perspectives. The most centralised and 
regulated option, detailed centralised oversight, receives the highest ranking among UK 
interviewees. This is supported by qualitative assessments asserting that if regulation 
were proportionate and balanced, this option would do well at advancing the science. 
However, the lower end of the assessment reflects concern that it could be too heavy 
handed, thereby stifling scientific creativity. This tension between centralisation with 
flexibility can also be seen in the relatively high ranking interval for the expert-led 
framework option under optimistic assessments and the comparatively low ranking 
interval for the mixed central/devolved option. The former option has a centralised 
legislative framework, but a more ‗hands-off‘ approach to regulation of hESC research. 
Thus, the pessimistic end of the ranking reflects a concern that there isn‘t enough 
regulation. Similar reasoning applies to the explanation of the low performance and 
wide uncertainty expressed in the mixed central/devolved option. Assessments for this 
option referred to the possibilities for ―huge polarisation‖ (UK policy-maker 1, #A115), 
―huge variability‖ (UK patient advocate 3, #A30), and ―wider swings in opinion and 
regulation‖ (US patient advocate 5, #A1751) as a result of weak centralised oversight.  
US perspectives on good governance under this issue revealed different framings 
of hESC research and the processes of governance in supporting hESC research as 
compared to UK perspectives. Criteria defined by US participants emphasise the quality 
of scientific outcomes as being dependent upon scientific autonomy and an indirect 
process of research support. However, the autonomy is different from that expressed in 
the US policy literature as discussed in Chapter 5. There, scientific autonomy was 
characterised by the need to leave scientists to determine the best outcomes to pursue, as 
suggested by the research. In the MCM interviews, US stakeholders defined criteria that 
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tend to be grounded in a firm belief in scientific autonomy, yet are more explicit in 
emphasising that ultimately scientific outcomes should be characterised by therapeutic 
aims. Thus, though autonomy is implied in, for example, the view that scientists should 
have ―freedom to perform research‖ (US industry executive 1, #C346), this is countered 
by the sentiment that this type of autonomy is necessary because of the need to move 
towards therapeutic outcomes.  
This area of research should advance medicine through its research... It‘s 
certainly interesting to know about embryos, but I think everyone involved in 
this is involved in the advancement of medicine, not just abstract knowledge 
about biology (US bioethicist 5, #C246). 
This criterion [‗advancing therapies‘] reflects that there is an urgency and 
overriding moral authority to help people through this research and move the 
research towards clinical therapies (US professional body 5, #C233). 
It is worth noting that criteria which express the desire for more therapeutic ends are 
more prominent among non laboratory-based scientists. Such points about inter-
stakeholder differences will be taken up in the next chapter, but it offers early indication 
of the presence of differences between national perspectives on good governance, as 
well as within them.  
In this more therapeutic framing of hESC outcomes, it appears that perspectives 
on good governance expressed by US stakeholders in the MCM interviews are 
diverging from the views on good governance under this theme in the US policy 
literature. This is seen both in the framing of the desired qualities of scientific outcomes, 
as well as in the rationales for why indirect processes of research support are needed to 
enable scientific autonomy. In regard to these latter areas, the criteria reflect a desire for 
an open and flexible space for science to advance within.  
Any regime has to be at a level high enough to be able to deal with fast moving 
science. You can't have detailed regulatory regimes... [We need] flexibility that 
allows science to move forward even in light of political restraints (US 
professional body 3, #C256). 
It is important to point out that this ‗flexible space‘ is not presented as limitless, but 
rather is one that works with the science to support it. In other words, US stakeholders 
stress that with flexibility to ‗follow the science‘, should come stability and consistency 
in the policy framework. 
[This criterion] comes from working with other states and wanting to be able to 
share lines.... [It‘s] about not impeding collaboration... [We want] uniformity 
and consistency across and amongst jurisdictions (US policy-maker 5, #C265). 
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Following from the analysis of the criteria that comprise the issue, we would 
expect to find stakeholders preferring options with governance frameworks that are 
more flexible, afford more freedom to scientists, and offer a stable environment for 
research. Thus, options such as the mixed central/devolved, ethics-led governance and 
expert-led framework have higher rankings overall (under the most favourable 
conditions), while the detailed centralised oversight, detailed expert oversight and, to a 
certain extent, the devolved authority options have lower rankings (even under the most 
favourable conditions).  
The ethics-led governance and expert-led framework options are the two highest 
performing options under this issue for US stakeholders. The two options have minimal 
regulatory or institutional oversight, and participants believe that science could be most 
easily advanced because these options offered both flexibility and uniformity. The 
ethics-led governance option had a slightly lower ranking, though, which could be 
attributed to  the dangers of too much flexibility. 
It's almost too much flexibility ... Where I worry about having too much 
flexibility is on authorising derivation research
84
 that might go beyond the pale, 
both violating ethical standards, but also creating a political backlash that would 
threaten the rest of the research.. (US professional body, #A1452). 
This was counter-balanced by optimistic assessments relating to, for example, the 
expert-led and non-regulated nature of oversight that is specified within the option. 
In addition to these higher ranking options, it is worth pointing out some of the 
reasons for the poor performance of the mixed central/devolved (the US-based) option 
amongst US perspectives. Although the optimistic rank of the option is fairly high, the 
ranking range also features high uncertainty and ambiguity and the lowest minimum 
rank. Under optimistic assessments, one participant describes his higher score as being 
down to the simple fact that ―it is able to be done in the end, even though the federal 
restrictions are in place. With your own money you can do anything‖ (US scientist 4, 
#A1679). However, under pessimistic conditions, the ―lack of harmonisation makes it 
difficult to figure out how the policies would move forward on a broad scale... it‘s hard 
for people to know what they‘re supposed to follow‖ (US industry executive, #A1685). 
Finally, we might also briefly reflect on the lower ranking amongst US perspectives of 
the UK-based option, detailed centralised oversight. Though the UK has one of the most 
permissive climates for hESC research in the world, it is also one of the most heavily 
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 In this quote the participant refers to ‗derivation research‘. This is a technical term referring to the first 
step in hESC research where the embryonic stem cell lines are actually derived, that is, the embryo is 
destroyed. 
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regulated. US participants aired concerns that regulation and centralisation would 
impede scientific autonomy by creating barriers to conducting research. They were also 
concerned about the regulatory implications for commercialising future hESC therapies.  
6.2.3 Discussion 
 We can now answer the questions posed at the beginning of this section in turn. 
The criteria that comprise the issue being analysed here do differ between US and UK 
stakeholders. Moreover, the analysis of the criteria reveals different framings and 
perspectives on good governance under the theme ‗advancing scientific and 
technological issues of hESC research‘. The table below summarises the prominent 
patterns of this aspect of good governance when we compare the UK and US 
stakeholders and the UK and US policy literatures: 
Table 6.2. Summary table of patterns under the theme ‘advancing scientific and 
technological issues in hESC research’ 
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Quality of scientific 
outcomes (including 
therapeutic & 
technological 
developments) 
Slight Divergence Slight Divergence Slight divergence 
Processes of 
research support 
Broadly congruent Broadly congruent Noticeably divergent 
Shading Key 
 Noticeably divergent: Distinct differences across the two perspectives are clear and readily identifiable 
 Slightly divergent: Some differences across the two perspectives are clear. Similarities or unclear signals exist. 
 Slightly convergent: Some similarities across the two perspectives are clear. Differences or unclear signals exist. 
 Broadly congruent: Similar patterns across the two perspectives are clear and readily identifiable. 
 
As can be seen in the table, a picture is emerging of the patterns in perspectives 
on good governance amongst UK and US stakeholders and the policy literature (as 
reviewed in Chapter 5) for this theme. Overall, both UK and US stakeholder 
perspectives emphasise the need for governance to create a space in which science can 
progress, but the characteristics and purpose of this space vary, as well as the nature and 
quality of scientific outcomes within it. UK participants tend to characterise scientific 
outcomes both in terms of therapeutic and basic research outcomes, but believe 
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outcomes are best pursued within a supportive regulatory environment that is 
‗enabling‘ of science and fosters public trust. US stakeholder perspectives are grounded 
in a belief in scientific autonomy within a flexible and harmonised environment, yet a 
majority of participants still emphasise the importance of therapeutic outcomes being 
an eventual aim.  
These findings highlight a distinction between stakeholder perspectives and the 
policy literature in relation to the characterisation of scientific outcomes. UK policy 
documents tend to reveal a therapeutic framing of hESC research outcomes while US 
policy documents tend to adopt a framing that emphasises scientific autonomy. 
However, the elements of research support are similar in both stakeholder-based and 
policy document-based perspectives in the case of each country. In the UK, the 
emphasis is on direct processes of research support, such as targeted regulatory support 
and state-led standard-setting initiatives, whereas in the US more indirect processes of 
research support aim to create a flexible space in which science can advance 
autonomously.  
The differences in framing between stakeholder perspectives and across the 
policy literature are all the more intriguing given the fairly similar patterns observed in 
the overall rankings of the governance options. This serves to underscore the point that 
in understanding how the perspectives on good governance are characterised and 
constituted, we can begin to gain an appreciation of their importance in a comparative 
context. The next section will now look at perspectives within the theme ‗establishes 
appropriate institutions and instruments of governance for hESC research‘. 
6.3 Institutions and instruments of governance for hESC 
research: qualities of deliberative activities 
6.3.1 Introduction 
In Chapter 5, a variety of governance institutions and instruments that are 
discussed in the UK and US policy literature were analysed and a number of elements 
of good governance identified. In the UK policy literature, it was found that good 
governance tended to be characterised in institutional terms by strong regulatory 
mechanisms and centralised, national institutional oversight. In the US policy literature, 
good governance tended to be characterised by flexible funding policies nationally and 
local institutional oversight. Perspectives on good governance in the UK seemed to 
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emerge through a focus in the first instance on the processes of governance and how 
specific processes are best able to lead to desired ends, or outcomes. In the US policy 
literature, by contrast, perspectives on good governance tended to be characterised by a 
primary focus on the outcomes of governance, followed by a discussion of the processes 
through which these outcomes might be achieved.  
The relative focus on outcomes over processes, or vice versa, may have 
important implications for the ways in which policy strategies are deployed and 
stakeholder-specific influences affect them. Because of this, they will be more fully 
discussed in the cross-cutting discussion of the empirical findings in Chapter 8. For the 
present discussion, though, whether the characterisations of good governance are 
process-based or outcome-based, is only one element of the wider issues under this 
theme of good governance. As introduced previously for the context of this thesis, 
‗deliberation‘ refers to the ways discussions are conducted and decisions made within a 
governance system. These can occur at a formal or informal level, thus echoing the 
definition adopted by Fineberg, et al (1996) and introduced in Chapter 3: 
any formal or informal process for communication and for raising and 
collectively considering issues... In deliberation, people confer, ponder, 
exchange views, consider evidence, reflect on matters of mutual interest, 
negotiate, and attempt to persuade each other (ibid., p. 73).  
Building on this, important factors to consider in analysing the quality of deliberations 
include the nature of the inputs and interactions to decision-making that take place, the 
roles of the actors engaged, and the (perceived) successes or failures of the outputs (e.g. 
policy-making) that result. In all of this, from the term ‗quality‘ all the way through to 
determinations of ‗success‘ and ‗failure‘, it should be clear that the perspectives 
themselves will be critical to the analysis and the ways in which the qualities of 
deliberative activities are defined, perceived and evaluated. 
 Criteria related to the qualities of deliberations were the second most frequently 
mentioned by all participants across the perspectives. However, distinctions were made 
about different types and/or qualities of deliberative activities, so two main analytical 
issues will be pertinent to this analysis. First is the role of the public and its perceived 
importance in contributing to – and participating in – deliberative activities. Second is 
the nature of expertise and its relationship and interactions with other features of good 
governance. Each analytical issue is defined as follows: 
Role of the public: Criteria in this issue are concerned with how the role of the 
public is conceived of and defined as a part of good governance. The focus is 
both on how public inputs and deliberations might feed into the governance 
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process, if at all, as well as the importance of public views on the institutions 
and instruments of governance itself. Thus, issues like public trust and 
confidence are addressed. 
Nature of expertise: Criteria in this issue are concerned with the features and 
characteristics of expertise within the governance framework. They focus on 
issues like the composition of expert bodies, the quality of advice that is 
provided, the types of deliberations that occur, and the qualities of the processes 
of input themselves as they reflect on the wider role of expertise in a context of 
good governance.  
In presenting these two issues for analysis, we do not intend to claim these are the only 
elements of deliberative activities worth considering. For example, one could also 
include ‗formal decision-making‘, such as legislative procedures. However, due to the 
volume of data collected for this research, a full analysis of every single line of inquiry 
cannot be presented here. These two types of criteria are believed to be most relevant to 
the main hypotheses being tested in this thesis and have the greatest potential to 
contribute to ongoing academic discussion. However, before considering each in the 
sections below, we will briefly consider the performance rankings of both issues 
combined under the broader heading ‗qualities of deliberative activities‘ to give an 
initial indication of the key areas of analytical inquiry.  
Figure 6.3. Rankings under UK and US perspectives for the issue ‘qualities of 
deliberative activities’  
 
As Figure 6.3 shows, there are some patterns to be found in the rankings. For 
example, the ‗stair-step‘ pattern of the first three options holds under both perspectives 
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and is consistent with the pattern found in the overall rankings under each perspective 
(as shown in Figure 6.1). In addition, proportionally more UK-based participants define 
at least one criterion in this issue than US-based participants, indicating a distinction in 
emphasis between the two perspectives. This is supported by the mean weightings 
between the two stakeholder groups: 38% and 24% for UK and US perspectives, 
respectively. It is worth pointing out not only the greater importance given by UK 
perspectives to these types of criteria over the previous ones (‗advances the science‘) 
but also the lesser importance given by US perspectives in comparison to both UK 
perspectives and the previous group of criteria.
85
 This reveals a potentially significant 
contrast between the two perspectives and the way features of good governance are 
characterised. We will now unpack this finding further and look at how these 
evaluations and rankings might differ in relation to the two ‗sub-issues‘ defined above. 
6.3.2 Deliberative activities: the role of the public 
 The analysis of the UK and US policy literature with regard to this topic showed 
that although there was acknowledgement of the importance of public engagement and 
participation in both sets of policy documents, there was very little critical reflection on 
what this engagement would look like in practice or how (e.g. in what ways) one would 
know that the outputs of any exercises had been incorporated within policy-making 
processes. Given this, it is interesting, but perhaps not surprising, to find that the role of 
the public as an element of good governance was brought up by a majority of the 
participants interviewed. However, there is an important difference in the way the issue 
was addressed in each country, with a greater relative percentage of UK participants 
defining this type of criteria (35 criteria defined by 21 UK participants) and a higher 
mean weighting of 24% attributed to it. In contrast, only 23 criteria of this type were 
defined by 19 US participants, with a mean weighting of only 13%. The implications of 
this will be explored throughout the analysis below. Looking to the picture of 
performance shown in Figure 6.4 below, we can see that the ranking patterns under this 
issue are fairly similar between the two perspectives, although there are some notable 
differences.  
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 Again, the reader is referred to Annex I for a table directly comparing all the weightings and criteria 
types analysed in this chapter. 
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Figure 6.4. Rankings under UK and US perspectives for ‘role of the public’ criteria 
 
 
First, UK participants seem to express a greater degree of either uncertainty or 
ambiguity under this issue, as indicated by the relatively longer length of the ranking 
bars compared to US interviewees. More detailed analysis
86
 shows that this is due to in 
part to a slightly greater use of uncertainty in the assessments compared to US 
participants, but is more prominently attributable to a higher degree of ambiguity 
expressed among UK participants across the options. Recall that ambiguity is a feature 
of disagreement between participants, so it does suggest that there are particular features 
of this type of criteria which are more affected by individual framings or points of view.  
Second, though the ranking patterns for both perspectives are roughly similar for 
the first three options (although there is a difference in the pessimistic ranking of the 
detailed expert oversight option), the second three options (devolved authority, mixed 
central/devolved and ethics-led governance) display different patterns across the two 
perspectives. Third, under US participant assessments, the mixed central/devolved 
option has a greater range of uncertainty and ambiguity
87
 relative to the other options, 
whereas for UK perspectives it is one of the first times we do not see such a wide range 
expressed for this option. Finally, there is a distinct difference in the evaluation of the 
ethics-led governance option between both national perspectives. This is intriguing 
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 Further analysis presented in Annex I confirms that the longer range seen in the rankings is a factor of 
both greater uncertainty expressed and ambiguity reflected for this option among US participants. 
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given that within the definition of this option there is no specified role for the public. 
Therefore, it will be interesting to see how UK and US participants differ in their 
interpretation as to which aspects of the option fulfilled criteria about the ‗role of the 
public‘ in this regard. 
Analysis of the criteria that comprise this issue reveals differences in the ways in 
which the role of the public is characterised. These differences cut across both 
perspectives. Criteria may be characterised in terms of the processes of public 
engagement or participation activities and the qualities which make them ‗good‘. These 
criteria variously address how a ‗space‘ for public deliberation should be created, what 
the role of society should be in ―setting the guiding principles‖ for research, and the 
need for there to be ―opportunities to express views‖ (UK scientist 3, #C196), including 
what the nature of these views might be, such as ―morality, religion and ethics‖ (US 
scientist, #C284). Alternatively, criteria in this issue may be characterised in terms of 
‗publicly framed‘ outcomes that might arise from good governance. In other words, 
these criteria draw on various features of good governance such as ‗transparency‘, 
‗acceptability‘ and ‗legitimacy‘, but present them as necessary features to ensure 
outcomes that are framed in relation to the role of the public or public perception. These 
outcomes are most notably (and frequently) concerned with public trust.  
Different emphases are placed on each of these features of the criteria across the 
two perspectives. Amongst UK perspectives, there is a greater emphasis on how 
governance processes can lead to public trust as an outcome of good governance. In 
this, many criteria relate to the reasons for employing various mechanisms of public 
engagement or participation activities because of the need to foster public trust. In the 
words of one participant, the governance option ―has to engage with the general public 
in order to avoid mistrust. It has to represent all opinions, not to edit what gets presented 
at the end‖ (UK professional body 4, #C331). Others discuss the need for an active role 
by government where, ―in terms of effective governance, it's about government 
promoting public confidence‖ (UK regulator 4, #C118). In this sense, public trust is 
gained through active demonstrations to the public. The role of the public, then, is to 
hold government accountable for this task.   
 Though the majority of criteria in this issue are instrumentally
88
 focussed on 
gaining public trust, some are more reflective on the qualities of engagement processes, 
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 See the discussion in Chapter 3 (p. 52-53)  and future discussion in Chapter 8 (Section 8.2) for the 
theoretical context in which this term is used. 
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usually without reference to any particular ends being achieved as a result. Thus, they 
reveal a more normative
89
 framing of how things ought to happen. One participant 
defined a criterion of principle, ―representation‖, to this end. She felt that a governance 
framework would be unacceptable if it did not include full and appropriate public 
representation. She ruled out the detailed expert oversight option on the basis that it did 
not have a clear mechanism for public engagement. Another commented more on the 
process of how the governance system should account for public views:  
[The criterion], ‗responsiveness‘ is about the readiness of the regulatory system 
to engage with the stakeholders, so there is an ongoing dialogue and a constant 
updating of the people's concerns and interests. Also that the regulatory system 
has a willingness ... a willingness to listen and engage and respond rapidly where 
it is required (UK bioethicist 1, #C152). 
This statement not only illustrates a more normatively motivated criterion about the role 
of the public, but also addresses some of the earlier inadequacies in the ways the UK 
policy literature dealt with public consultation and engagement. As was argued in that 
discussion,
90
 the literature fails to comment on how public views are taken into account. 
That is, although statements are made about the importance of ‗being seen‘ to take 
public views on board, they are lacking in critical reflection as to how this would be 
done and, perhaps more crucially, how the public would know it had been done.  
This point is worth further examination. Though not always couching them in 
such ways as the previous example, some UK participants did reveal normative 
considerations about the processes of appraisal in their discussion of the potential 
pitfalls of public engagement and consultation. We note two examples in relation to the 
option analogous to the UK, ‗detailed centralised oversight‘.  
It [public engagement] can be done on an alarmingly small scale. So I do have 
concerns it isn't done robustly enough (UK professional body 4, #A1909.) 
The option [assessment] is very mixed. You have to be quite determined to have 
your voice heard and keep the debate open. [But] it's certainly not closed to 
public debate (UK bioethicist 2, #A1034).  
Though ‗good‘ engagement was defined slightly differently by each of these 
participants, they all shared the belief that the important thing was that it happened 
robustly and with broad inputs. In this sense, the empirical findings are similar to the 
perspectives identified in the policy literature, but with a stronger sentiment about the 
importance of public trust coming from the empirical findings. 
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 As above, see discussion in Chapter 3 (p. 52-53) and future discussion in Chapter 8 (Section 8.2) for 
the theoretical context in which this term is used. 
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 See the discussion in Chapter 5, p. 117-120. 
  
154 
We commented earlier on the high ranking of the ethics-led governance option 
under this issue for UK-based stakeholders, despite the fact that this option does not 
include any provisions for public involvement in the same ways as the other high-
ranking options under this issue (the devolved authority and detailed centralised 
oversight). It seems that many UK participants believe that the ethics-led option would 
score well because it had a ‗shared vision‘ developed by a national bioethics body. 
Implicit in this assessment is the idea that the simple presence of a bioethics body 
corresponds to a full consideration of social and cultural views. One participant 
commented that despite the fact there was ―very limited engagement and scrutiny and 
very little involvement with anyone but scientists‖, one still had to think that there 
would be ―a lot of public confidence if everyone signs up to the rules at the top‖ (UK 
bioethicist 4, #A678). Another participant based his assessment on his view of how a 
bioethics committee deliberates, commenting they would ―take into consideration what 
the public thinks about by their very nature‖ (UK scientist 6, #A1818).  
These assessments lead to an interesting insight into the perceived role of 
bioethics committees. In Chapter 5 it was argued they have come to serve as a ‗new 
mode‘ of expertise, which is assumed to be more representative of the public by virtue 
of their ability (or mandate) to reflect on the shared moral and ethical values of a 
society. However, there are questions as to whether and by what evidence these claims 
are held to be true. The findings here suggest that these claims may be quite uncritically 
adopted by some stakeholders. Further comments will be made on this in Chapters 8 
and 9 where empirical, theoretical and normative implications are explored, but the 
issue is important to raise here. 
While the UK perspectives seem marked more by a concern with how to gain 
public trust through good governance, the US perspectives tend to focus on the mere 
presence of public engagement and the types of policy outcomes (not necessarily framed 
in relation to the public) it might lead to.
91
 One US participant defined the criterion 
‗space for public deliberation‘, which expressed his belief that such a space was 
important to create ―with a politically and socially charged issue such as this one‖ (US 
regulator 2, #C83). Another participant commented that there should be ―an opportunity 
for public discourse that‘s real... [where] public discourse is actually taken into 
consideration‖ (US bioethicist 3, #C39). These criteria seem to reveal a dissatisfaction 
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 There were comparatively fewer criteria about public trust as one outcome of engagement, only 7 out of 
23 criteria for US participants as compared with 16 out of 35 for UK participants. 
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with current governance in the US and a perception that there is no real opportunity for 
public input. Thus, any public input will certainly lead to better governance outcomes. 
However, there is a tension exposed between the desire to create a public space 
for discussion and the perceived dangers of including all the views that might be present 
in a culturally diverse society.   
I‘m not looking for totally democratically representative input. Not everybody 
needs to be represented in the system. We need people as part of the process 
who have something to contribute to the process. They‘re contributing skills or 
knowledge... (US professional body 3, #C259). 
Similarly, another participant commented that society needed to be involved in setting 
the standards and guiding principles for research, but society only as represented by 
political bodies (US scientist 4, #C287).  
 These criteria presented themselves in interesting ways in the option 
assessments. The three options that specifically stated there were provisions for public 
involvement within their definitions (the detailed centralised oversight, devolved 
authority and mixed central/devolved options), all had similar optimistic rankings, but 
there was a longer ranking range for the mixed central/devolved option. This latter 
finding was brought up earlier and analysis here seems to suggest it could be 
attributable to the tension discussed above. The public may have more input within 
‗individual jurisdictions‘, but this could be interpreted positively or negatively. As a 
result, participants used a wide scoring range, in some cases utilising the full range of 
their chosen scoring scales.  
Since it was discussed earlier, it is worth briefly commenting on the ranking of 
the ethics-led governance option under US-based assessments. As we have seen, the US 
perspective on the role of the public is more focussed on the processes of engagement. 
The ethics-led governance option does not have engagement mechanisms and so most 
participants felt that because there was ―no real avenue for participation‖ (US industry 
executive 2, #A1273), it would ―lack credibility‖ (US professional body 3, #A1470) and 
would not be ―open to democratic mandates‖ (US industry executive 1, #A2010).  
 In summary, under both national perspectives there is concern with the role of 
the public, but for UK perspectives the concern seems more motivated by a desire to 
ensure public trust is established as an outcome of good governance, while for US 
perspectives the concern seems more to do with ensuring good, democratically-based 
policy outcomes. However, ‗democratic‘ was not always used in a normative way, but 
instrumentally to ensure that individual policies, and wider governance approaches, 
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reflected the views of the majority. We will now look to the second component of this 
sub-theme, the nature of expertise.  
6.3.3 Deliberative activities: the nature of expertise 
As has been discussed previously, the role of expert input and advice is a 
necessity when developing policies for new and uncertain technologies – though 
sometimes problematic in the way it is articulated or interpreted. In Chapter 3, the views 
of various academic theorists were discussed concerning how technocratic decision-
making might be characterised in a context of ‗good‘ governance. Amongst other 
insights, it was argued that if expert input was combined with principles of 
transparency, democratic deliberation and participatory mechanisms, it might be able to 
overcome some of the pitfalls that academic analysis has highlighted over the years 
(see, for example, Jasanoff, 1990).  
In Chapter 5 we looked at the perspectives of the UK and US policy literature on 
the role of expertise in good governance. In the UK, balanced representation of experts 
and the inclusion of lay members on expert advisory panels were seen as fundamental 
components of ‗good‘ expertise. In the US policy literature there was discussion about 
including public views on oversight panels, but there was little guidance as to how these 
members should be selected or who they should be. While there is similarly little 
guidance on selection criteria, per se, in the UK policy literature, the proportions of 
expert versus lay members are explicit in the Human Fertilisation and Embryology Act, 
although the selection criteria for other expert bodies are more opaque.  
Figure 6.5 below shows the ranking patterns for the UK and the US under the 
issue ‗nature of expertise‘. On the face of it, there is a much greater degree of similarity 
between US and UK rankings with regard to this issue then for the previous one (with 
the exception of the ‗ethics-led governance‘ option92). However, we can immediately 
see there are fewer criteria defined within this issue among both groups of stakeholders. 
This means we might be more cautious about any interpretations made.  
Under these criteria we find relatively equal weightings across the two 
perspectives. While US participants expressed a similar mean weighting to those under 
the ‗role of the public‘ for these criteria, 11%, UK perspectives expressed a relative 
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 As was discussed in Footnote 32, p. 71, this is an example of where there were insufficient participants 
evaluating this option to merit full and robust analysis of the implications arising from this ranking 
difference. 
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importance of 15%, which is lower than the weightings under the previous issue. 
Despite the caveat about low criteria within the issue, the weightings do seem to 
confirm a lower priority assigned to this aspect of deliberative activities within each 
national perspective.  
Figure 6.5. Rankings under UK and US perspectives for ‘nature of expertise’ 
criteria 
 
 
 Under UK perspectives, half the criteria in this issue focussed on the 
composition of expert advisory bodies. The overriding concern is that expertise be 
multi-disciplinary and representative of wider society. In the words of one participant, 
―expertise should be broad, not reliant on a narrow scientific view, and should have 
different perspectives on the potential benefits, such as social benefits‖ (UK policy 
opposition 1, #C130). Another participant echoed this, defining expertise as ―people 
who have knowledge of the different areas that you might want to take into account‖ 
(UK patient advocate 4, #C180). These different areas included ethical, scientific, 
clinical and lay knowledge. This composition was analogous to that discussed by other 
participants defining similar criteria.  
It is worth calling attention to the criterion discussed above by the participant 
who is opposed to some or all aspects of hESC research policies. While she defines a 
criterion which is, at face value, similar to those defined by other UK-based 
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participants, another participant who opposes hESC research policies describes his 
views on expertise in the following way:  
membership of decision-making bodies is often dominated by scientists or 
people who are other experts who get to be on these bodies because they have 
adopted the scientific worldview and discourse, meaning a set of assumptions 
that scientific research equals progress and more knowledge is always a good 
thing. It is this scientific ‗expertocracy‘ that is a travesty and prevents any kind 
of real broad-ranging attempt to think about the issues that this type of research 
raises (UK policy opposition 6, #C343). 
Though this latter example reflects a particularly strong conviction, it is still expressing 
a similar point about the importance of including breadth of input and ensuring 
representativeness of diverse points of view. The examples show that even those on 
‗extreme‘ ends of the policy debate can find common ground. In addition, the 
perspective seems similar to the views expressed in the academic literature about the 
need to open expert-based processes in order to mitigate the risks of singularly 
technocratic inputs to decision-making.  
While lay involvement was often mentioned as ‗another‘ type of expertise, it 
was not emphasised as heavily by UK stakeholders as it was within the UK policy 
literature. Rather, it was only one feature of many that should be considered. Moreover, 
though acknowledging its importance, there was an air of dissatisfaction with the term 
‗lay‘. One participant felt that in including lay members on scientific committees like 
the HFEA, governments actually ran a greater risk of having the decision-making 
process captured by one particular scientific or disciplinary point of view (UK scientist 
6, #C315). This was because when lay people were included, there were less places at 
the table for a range of experts. Others commented that lay expertise was a fleeting 
concept because as soon as one joined a committee, he quickly became an expert.  
 In rankings under this issue, options with stronger centralisation, some type of 
regulation and a balance in expert and public deliberation components all perform more 
positively. The mixed central/devolved option has the widest range of uncertainty under 
UK perspectives, but one of the highest optimistic rankings of all the options. This is 
particularly interesting because this option has (under UK perspectives across all issues 
discussed thus far) been consistently assessed more pessimistically, with lower rankings 
and higher degrees of uncertainty and ambiguity. Here, though, participants interpret the 
devolved feature of the option to mean there might be more opportunities for broad 
expertise to play the ‗right‘ kind of role in deliberative activities. ―It‘s more 
empowering at the devolved level. But it will depend...on the resources and information 
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available to those at the devolved levels‖ (UK policy opposition 1, #A721). Another felt 
that the presence of two levels of governance (centralised and devolved), meant that 
there would be ―strong expert engagement across all areas... (like having) two levels of 
Parliaments in these options‖ (UK bioethicist 1, #A816). Thus, unlike the mixed 
central/devolved option, the devolved authority option resulted in a lower expression of 
uncertainty/ambiguity due to the clearer delineation between devolved and centralised 
oversight within the option. 
 US-based perspectives are similar in some ways to those of UK-based 
participants, but as with the previous issue, there are subtle differences and nuanced 
tensions. Most criteria within the issue are about the ways in which the processes 
through which expert-based inputs to policy-making occur. Criteria of this type define 
how expert input should occur in relation to its intended purpose (as perceived by the 
participant) in a wider governance context.  
Expertise is extremely important so that the laws can be realistic for what the 
science is doing, not just a way to scare the public. The policies need to be 
legitimate for what could happen (US scientist 5, #C62). 
Here the purpose, or outcome, of expert input is legitimacy in policy-making, which the 
participant implied was not happening. Others express similar concerns that the right 
‗outcomes‘, such as ‗objective‘ decisions based on ‗testable knowledge‘ (US bioethicist 
4, #C279), are not being realised because of poor types of expert input.  
No policy or scientific decision should be made without the input of all experts 
in hESC research present and with a voice in the conversation. You have to have 
highly trained, currently practicing scientific experts in the room at all times, 
especially for ethics review... Furthermore, we should have no clergy on the 
board, [we need] more scientists, more experts (US professional body 5, #C229). 
We need immunity of the deliberations to political influence versus scientific 
leadership. It's about the scientific integrity of the deliberations... Objectivity is 
relevant here (US industry executive 4, #C296). 
Even criteria less explicitly critical reveal a tendency to emphasise the way expert input 
is given in relation to the purpose. For example, some criteria discuss the need for a 
balance between expert and societal views in expert decision-making, where ‗societal‘ 
views are often equated with ‗ethical‘ inputs. This ties in with discussions about ethical 
deliberations being a part of the governance framework.
93
 However, the motivations for 
defining these criteria seem to be aimed at ensuring ethical deliberations occur, not as a 
normative feature of governance, but rather to portray the science as a ‗professional‘ 
discipline, capable of policing itself.   
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 See the discussion of this point in Chapter 8, Section 8.3. 
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 These types of nuances offer a partial explanation of why the detailed expert 
oversight does not score highly under US perspectives for these criteria, despite the fact 
the option relies so heavily on expert input to governance. The option does not specify a 
role for the wider public and so is perhaps perceived to be lacking in societal balance. 
One could say this reflects the original definitions of the options themselves, as they are 
worded in ways that might be interpreted to limit the types of expertise that are a part of 
the governance process. However, there was evidence of critical reflection across all the 
options on the ways in which the nature of expertise could vary, even within the 
constraints of the option definitions, so we feel more confident this was not the case. 
In summary, there are different types of criteria that characterise the sub-theme 
of ‗nature of expertise‘. These criteria reveal subtly diverging perspectives between UK 
and US stakeholders. UK perspectives are characterised by a concern over how broadly 
composed expert bodies are so good and balanced processes of expert input will ensue. 
With the emphasis on people and process, legitimate and evidence-based advice will 
ultimately occur. US perspectives reveal a different focus, with good input being the 
primary concern. There is a greater focus on which processes will enable the right 
outcomes and a lesser focus on the types of people required. As a result, a tension is 
revealed between the desire to have positive outcomes for one‘s policy agenda and the 
need for democratically representative and balanced input. Thus, we might propose that 
the UK perspective tends to believe that having the right people will lead to the right 
processes of governance, while the US perspective tends to believe the right processes 
are needed so that the right outcomes result.  
6.3.4 Discussion 
Table 6.3 below summarises patterns in US and UK stakeholder perspectives 
and the respective policy literatures on good governance in relation to the theme of good 
governance ‗establishes appropriate institutions and instruments for hESC research‘.  
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Table 6.3 Summary table of patterns in perspectives for the theme ‘establishes 
appropriate institutions and instruments for hESC research’  
 Perspectives from US 
policy literature vs.  
US stakeholders  
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policy literature vs.  
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US stakeholders vs.  
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 Slight divergence 
Qualities of 
deliberative 
activities: expertise 
Slight convergence  Broadly congruent Slight divergence 
Shading Key 
 Noticeably divergent: Distinct differences across the two perspectives are clear and readily identifiable 
 Slightly divergent: Some differences across the two perspectives are clear. Similarities or unclear signals exist. 
 Slightly convergent: Some similarities across the two perspectives are clear. Differences or unclear signals exist. 
 Broadly congruent: Similar patterns across the two perspectives are clear and readily identifiable. 
 
We can see that there is a divergence in the way institutions and instruments of 
governance are characterised. UK stakeholder perspectives seem to emphasise the idea 
that putting the right processes in place will, necessarily, lead to good governance 
outcomes. Perspectives on the role of the public are characterised by the idea that public 
engagement processes, or indeed general mechanisms of government, should be 
conducted because they will foster public trust. Putting the right balance of individuals 
on expert bodies will mean the bodies might function in a way that is robust. Either 
way, good processes will lead to good outcomes. 
In contrast, US stakeholders reveal a set of framings more focussed on the 
outcomes of good governance. The perception that greater public input into 
deliberations is needed seems less motivated by a desire to see public discourse as a 
normative good, and more instrumentally motivated by a desire to see particular policy 
agendas advanced. Similarly, the way expert input is conducted is expressed in relation 
to the purpose it ‗should‘ achieve. This seems to reveal a tension in the motivations of 
US participants in this area. Though there is a shared focus on outcome-based policy 
approaches, there is an inherent tension in the ways in which these outcomes might be 
achieved amongst different stakeholder groups. This is explored in the next chapter.   
 Throughout the preceding sections, normative, instrumental or substantive 
motivations have been pointed out where relevant. While a full analysis of these 
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 Though the patterns are identified as divergent, this is mostly due to the fact that there was a strong 
tendency to equate the role of the public with public trust under UK stakeholder perspectives. This feature 
was notably absent from the perspective identified in the UK policy literature. 
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motivations as criteria, themselves, is reserved for Chapter 8, their relevance to the 
discussion here can, and should, be explored. An examination of the findings above in 
light of the types of imperatives (either normative, instrumental or substantive), reveals 
some distinct patterns, both qualitative and quantitative,
95
 between stakeholder groups. 
First, normative values about the nature and quality of deliberations emerge 
which relate to good processes and features of deliberations as ends in themselves. For 
UK perspectives, criteria such as openness, transparency, and breadth of representation 
(both in terms of public engagement and expert advisory processes) tend to be of great 
importance and seem to be ways of expressing normative democratic values of 
deliberation. Normatively derived conceptions of the legitimacy of the governance 
process become linked to, and follow from, the implementation of these features. That 
is, when the process is seen to reflect normative values, it is variously described as more 
‗consistent with public opinion‘ (various participants, #C339, #C176, #C340) , 
‗objective‘ (various participants, #C345, #C135, #C197, #C174), ‗accountable‘ (various 
participants, #C120, #C9, #C205, #C148) and, perhaps, legitimate. 
 The US perspectives are more difficult to disentangle. Though there are 
normative imperatives identified within the criteria, it is less clear whether a common 
theme underpins them. Normative values about the processes of deliberation are 
expressed in different ways, either through criteria about minimising political influence 
and respecting the democratic process (various participants, #C164, #C249, #C232, 
#C41, #C42, #C209), creating a space for public input and discourse (various 
participants, #C284, #C251, #C39, #C84, #C83) or striking a balance between the role 
of expertise and societal values in decision-making. These findings do seem to expose a 
tension between the desire for science to advance and the views of a pluralist society to 
be respected. Legitimacy, then, seems more in the eye of the beholder and based on 
individually held normative values about democracy and pluralism.  
Instrumental imperatives are revealed under the perspectives that relate to 
gaining public trust and realising scientific goals. The latter was described in Section 
6.2 above. Trust is a particularly dominant theme among UK perspectives, as we have 
shown throughout the analysis. It is discussed in various ways, indicating that 
participants interpret trust according to their own set of assumptions and framings, not 
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 These patterns were tested by defining an issue and generating performance rankings under two MCM 
‗issues‘: ‗deliberations (normative)‘ and ‗trust (instrumental)‘. These charts can be found in Annex I.  
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those which might be publicly deliberated and, hence, more substantive in nature.
96
 
Overall, an instrumental UK perspective seems to emerge in both emphasising the need 
for public trust as an important component of good governance, as well as describing 
the ways in which public trust and confidence can be achieved. Of this latter group, trust 
is seen as arising from various governance features, such as regulatory oversight, 
centralised decision-making, transparent policy mechanisms and representativeness.  
Two points are worth commenting on further. First is the identification of 
‗representativeness‘ as both an instrumental and a normative issue within the 
discussions here. With some participants it reveals normative ideas about how the 
process ought to work, whereas with others it reveals an instrumental motivation to 
obtain public trust as a singular, privately-held, outcome of balanced representation. 
MCM analysis allows us to expose these different framings. The second point relates to 
arguments discussed in earlier chapters
97
 that the basis of trust (or public accountability) 
in the UK was seen to rest upon the types of experts who are at the centre of socio-
political governance processes. The empirical findings here do not necessarily support 
this view. Further comments will be made on this in Chapter 8.  
Trust as an instrumentally motivated consideration was less frequently found for 
US perspectives and thus the analysis here is more tentative. Of those criteria that do 
reveal instrumental imperatives about fostering public trust, they focus primarily on the 
actions of policy-makers in their role of ensuring public safety. A few participants 
mention the role of education in helping to promote awareness about how the science 
was being conducted safely and what the purposes of the science were (that is, the 
therapeutic and scientific goals it was working towards). Thus, there is a parallel here 
with work in the public understanding of science literature.
98
 This indicates that though 
much work has been done outlining the problems with a simple ‗public education = 
public acceptance‘ equation, there is further work to be done.  
6.4 Conclusion 
Returning to the main hypotheses that were set out at the beginning of this 
chapter, we can conclude that 1) it is indeed possible to discern discrete perspectives on 
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 See the discussion in Chapter 8, Section 8.2. 
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 See the discussion in Chapter 5, p. 120-121. 
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 We make this point to indicate we are aware of the parallels, but this body of literature is not directly 
discussed within this thesis. See in particular (Irwin and Wynne, 1996). 
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good governance between and within different groups of stakeholders in the US and the 
UK; 2) regularities in the ways in which perspectives on good governance are 
constituted have been identified and analysed, with certain patterns emerging as 
summarised in the table below; 3) as a method of empirical analysis, MCM has allowed 
us to develop an understanding of how these perspectives are constituted in an open, 
reflexive, transparent and verifiable manner; and 4) comparisons between the two 
national settings show notable differences between stakeholder perspectives and policy 
literatures concerning the nature of good governance. Table 6.4 below provides a 
summary of the key patterns identified in this chapter.
99
 
Table 6.4. Summary table of patterns in perspective across all themes 
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 This table is a replication of Table 6.1 presented earlier, but with the sub-themes and themes not 
analysed in this chapter removed for purposes of clarity. 
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 See discussion in related section(s) for caveats. 
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As the summary table shows, this chapter has analysed stakeholder perspectives 
on good governance in the US and the UK under a number of previously identified 
themes of good governance. In particular, some systematic contrasts have been found 
that distinguish key elements of perspectives in the US and the UK. This is most notable 
in two places. First, there is a distinct tendency for US and UK stakeholders to adopt 
contrasting perspectives on how good governance can best facilitate and foster advances 
in the science. US stakeholder perspectives on good governance tend to characterise the 
facilitation of hESC research in terms of creating a flexible, harmonised space within 
which the science may advance in a relatively autonomous fashion. UK stakeholder 
perspectives on good governance, on the other hand, tend to frame the facilitation of 
hESC research in terms of the construction of a regulated, protected framework around 
which the science can advance in a relatively structured fashion. 
Second, there is a difference in perspectives on the qualities of deliberative 
activities. UK stakeholders tend to characterise deliberative activities in a process-based 
way, with specific outcomes dependent on these processes. US stakeholders tend to 
characterise these activities more directly in terms of the outcomes they might achieve. 
While good processes of public engagement and other mechanisms of governance are 
seen as key to establishing public trust by UK stakeholders, US stakeholder 
perspectives expose a tension between the importance of assuring broad public input 
and expert, or evidence-based, deliberations among expert advisory bodies. Some US 
stakeholders believe ‗real‘ public input and representative, reflective expertise should be 
an integral part of deliberative activities for normative reasons (but provide little detail 
as to how this would happen). Others reveal an instrumental desire to see particular 
hESC research policies advanced and, so, express ostensibly ‗process-based‘ criteria 
about public inputs or experts in instrumental, ‗outcome-based‘ ways. Though more will 
be said in later chapters about these motivations, analysis of stakeholder views in light 
of discussions about normative, instrumental and substantive motivations behind the 
appraisal of good governance further enhances our ability to illuminate how 
perspectives on good governance are constituted.  
The analysis has also shown the ability of the elicitation methodology to uncover 
otherwise hidden framing assumptions and judgements about the options themselves. If 
we recall the option performance rankings under all issues for US and UK stakeholders, 
there was a fair degree of similarity in the overall structures in these rankings. 
Superficially, this might encourage a conclusion that the underlying framings are also 
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convergent. However, analysis of these framings has shown that similarities in the 
aggregate performance rankings actually conceal important differences between 
performance patterns under specific criteria. Analysis of these differences illuminates 
significant variations in the framings, assumptions and socio-political values that 
constitute perspectives on good governance. The next chapter will build on this 
observation, by exploring the differences in perspectives across different groups of 
stakeholders. Thus, it will provide a different ‗cut‘ of perspectives and allow us to 
compare across inter- as well as intra-national levels. 
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7.  Stakeholder perspectives on good governance: 
comparative analysis of multiple stakeholder groups 
7.1 Introduction  
7.1.1 Overview 
The previous chapter discussed the findings from the analysis of stakeholder 
perspectives on good governance in UK and US settings. It was argued that patterns and 
distinctions can be identified in the ways perspectives are constituted. This is true both 
of the empirical data, as elicited using MCM, and in the analysis of the formal policy 
literature. In themselves, these findings may hold implications for wider theory-building 
and policy analysis of the governance of science and technology. However, a robust 
discussion of these implications cannot be undertaken until a full analysis is completed. 
Specifically, addressing the research question requires not only an understanding of how 
stakeholder perspectives differ across national settings, but also how they might differ 
across and within different stakeholder groups. Building on the main hypotheses of this 
thesis, we suggest:  
• it may be possible to discern discrete perspectives amongst the different types of 
stakeholder groups extant in each national setting; 
• amongst these discrete perspectives, patterns, regularities and systematic 
differences can be identified and analysed; 
• distinctions and patterns within and across perspectives on good governance 
among different stakeholder groups can be compared in potentially illuminating 
ways; and 
• these patterns may have implications both for wider theory-building, as well as 
allowing for further explanation of technological and socio-political factors in 
decision-making under varying conditions of risk and uncertainty. 
This chapter will address these inter-related hypotheses and explore their implications 
for the thesis. As with the previous chapter, the perspectives will be discussed within the 
framework that has structured the empirical discussions thus far concerning distinct 
‗themes‘ of good governance. This allows us to continue testing the robustness of these 
themes as well as ensuring a consistent, structured and systematic probing of the 
empirical material.  
 The remainder of this introductory section will discuss the findings of the MCM 
interviews in a comparative light across multiple stakeholder perspectives, as opposed 
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to the two national ones discussed previously. Section 7.1.2 will describe the 
stakeholder groups as approached initially for the purpose of designing the research
101
 
and as resolved in later analysis of associated perspectives. The discussion in Section 
7.1.3 will move to the final ranking patterns for the contrasting governance options as 
obtained for each of the initially-identified stakeholder groups. This analysis will be 
used to identify points of convergence and divergence, emerging patterns and areas of 
analytical interest. The remaining sections will explore the empirical findings in further 
detail. Due to the sheer volume of data collected, not every theme can be explored at the 
same level of resolution. Where a particular analysis is not presented or discussed, 
reference is made to supporting Annexes.  
7.1.2 Analysis of general results and issues  
In the methodology chapter we discuss how the initial grouping of stakeholders 
was conducted for the purposes of establishing the interview cohort. We also point out 
how within an MCM analysis one is not necessarily constrained to analysing the data 
along such lines. In an MCM analysis, there are multiple ways to ‗cut‘ the empirical 
data—for example, by national setting or professional affiliation. Each ‗cut‘ is 
determined according to the hypotheses being tested and so each test must be reflexive 
not only about the conclusions that are reached, but also about the initial categories with 
which the analysis begins. 
The five main perspectives summarised in Table 7.1 and used throughout the 
analysis in this chapter were settled upon as the result of testing many such ‗cuts‘ of 
stakeholder perspectives. This is pointed out simply to be explicit that these were both 
the starting point for the analysis as well as the final end point. Therefore, it is not our 
contention that these groupings of socio-political viewpoints are in some way definitive, 
merely that they emerged as the most suitable for the analysis here.  
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 See the discussion on p. 68 in Chapter 4.  
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Table 7.1: Summary of initially-defined perspectives 
Perspective 
Name 
Total number 
of participants 
Total 
number of 
criteria 
defined 
Perspective definition 
Advocates 12 participants 
(6 US & 6 UK) 
64 individual 
criteria  
This perspective is broadly inclusive of advocacy 
groups working to advance a particular policy 
position related to hESC research. It includes 
participants in patient advocacy groups working on 
behalf of patients afflicted with a variety of medical 
conditions and policy advocacy groups, where the 
organisation takes a specific policy stance 
regarding hESC research in line with the members 
they represent. Further divisions are evident 
between those advocates who are broadly 
supportive of hESC research and associated 
governance structures, and those who are broadly 
opposed to them. 
Bioethicists 9 participants 
(5 US & 4 UK) 
50 individual 
criteria 
This perspective includes individuals who are 
working as bioethicists in a variety of capacities, be 
they academic, medical, advisory or policy-based. 
Importantly, all individuals in this perspective have 
some formal training in the practice and intellectual 
thought associated with bioethics as a „discipline‟, 
through either academic or professional training.  
Industry and 
Professional 
12 participants 
(6 US & 6 UK) 
65 individual 
criteria 
This perspective is comprised of individuals who 
are either industry executives working in companies 
involved in the commercialisation of stem cell 
related technologies or therapies, or executives 
representing a professional body that describes 
itself as acting on behalf of a commercial or 
industrial sector that has a vested interest in stem 
cell research. 
Policy-
makers and 
Regulators 
12 participants 
(8 US & 4 UK) 
65 individual 
criteria 
Includes policy-makers and regulators at state and 
national levels, in addition to science policy 
specialists in national funding or policy advisory 
bodies. It also includes those who are policy and 
regulatory specialists by virtue of their position as 
expert advisors on national or state policy advisory 
commissions or statutory bodies. 
Scientists 
(Labs) 
12 participants 
(5 US & 7 UK) 
66 individual 
criteria 
This group includes established and new 
researchers in the field of stem cell science, 
reproductive technologies or biomedicine (but with 
a particular expertise in stem cell research). It also 
includes scientists with a variety of research 
trajectories, including basic research, applied and 
clinical. All participants in this group work in 
research laboratories and the majority of their time 
is spent actively engaged in research. 
 
 A few points from the summary table are worth noting briefly. First, the 
distribution of the 57 participants across the five perspectives is fairly even. Second, and 
relatedly, the balance between UK and US participants in each group is relatively even 
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(except for policy-makers and regulators
102
). Third, all the groups defined 
proportionally similar numbers of criteria.
103
 All of these factors contribute to the 
decision to use this initial grouping of stakeholders as the foundational set of socio-
political viewpoints for the remaining analysis. However, as we will see, some 
variations within each group did emerge as relevant during the analysis and these are 
reviewed in the analysis below.  
Figure 7.1 shows the option rankings under each of the perspectives identified 
above. We can see that there are systematic similarities and differences in option 
performance across all perspectives. These are reviewed below.  
Figure 7.1: Rankings under initial stakeholder perspectives
104
 
 
                                                 
102
 As discussed on p. 68-69, this is due to the need to represent a range of state-based perspectives in the 
US. The eight individuals represent a mix of state and national policy-makers and regulators.  
103
 This in itself is not surprising as each individual was encouraged to keep their criteria within a certain 
range to prevent the process from either becoming unwieldy at one extreme (from too many criteria being 
defined) or ineffective at distinguishing amongst the options at the other (if too few criteria were defined). 
Nevertheless, the relatively balanced categories allow us to be more confident in the initial constituting of 
categories as an even starting point for analysis. 
104
 As explained in the previous chapter and the methodology chapter, the extreme lower and upper ends 
of the ranking ranges for each option, are represented as the means respectively of the pessimistic 
(minimum) and optimistic (maximum) rankings obtained in each case. 
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Analysis of the rankings shown above reveals a degree of similarity in certain 
features of the ordinal pattern across most of the perspectives, echoing the findings 
made under UK and US rankings in the previous chapter.
105
 As with all such MCM 
ranks, these patterns are qualified by significant ranges of uncertainty within individual 
viewpoints and ambiguity across perspectives – as displayed by the relatively extensive 
lengths and overlaps in the ranking intervals. But the patterns are nonetheless consistent. 
These include: i) the detailed centralised oversight option is consistently assigned a 
relatively high performance, ii) the expert-led framework closely follows the high 
performance of the detailed centralised oversight option, iii) the mixed central/devolved 
option is repeatedly portrayed as among the lowest performing, and iv) there is more 
variation in ranking patterns for the options with significant ‗devolved‘ components 
across the stakeholder groups. 
Though these patterns, especially the first three points, mirror those observed in 
the previous chapter, what is different here is the extent to which potentially significant 
variations are apparent within the ordinal patterns across the perspectives. For example, 
the extent to which the detailed centralised oversight option is the highest ranking 
option under optimistic scores varies, revealing significant differences in the 
assumptions made about good governance under different perspectives. Among 
bioethicists and laboratory-based scientists, the detailed centralised oversight option has 
the highest ranking by a factor of almost 50% of the full interval of the ranking range.
106
 
This seems to indicate a rather strong preference for this option amongst these groups. 
For other groups, however, the relative extent to which this option ranks higher than 
others at the optimistic end of the scale is not as large; moreover, for the industry and 
professional group it is not the highest at all. This suggests a closer relationship between 
the contingencies, nuances and (perhaps more) veiled assumptions which affect option 
performance under these perspectives.  
Just as the detailed centralised oversight option has a consistently high ranking 
across all the perspectives, so the mixed central/devolved option displays both a 
relatively low ranking and a consistently high expression of uncertainty and ambiguity 
                                                 
105
 See the discussions in Chapter 6, in particular p. 132-135 
106
 For example, for bioethicists the interval for the detailed centralised oversight option is approximately 
35 base points long and the next highest performance ranking is 14 base points lower than the highest 
point rank of the detailed centralised oversight option. Similarly, for laboratory-based scientists, the 
length of the rank bar for the detailed centralised oversight option is 24 and the next highest performance 
ranking option is 11 base points lower. 
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across all the perspectives. Considering the similar findings in the previous chapter, we 
might now be able to identify something inherent to this option, of a kind that 
transcends stakeholder perspectives, rendering it more susceptible to uncertainty and 
ambiguity over its potential to fulfil general notions of good governance. 
If we now turn our attention to each perspective, there are further features of the 
ranking patterns worth pointing out. These are apparent not only as displayed above, but 
also at more discrete intra-perspective levels. For each of the next five figures, the 
stakeholder perspectives resolved above will be taken as a starting point upon which 
further resolution of additional perspectives might be found. It should be noted that the 
following discussion purposely takes a systematic approach to discussing option 
performance for each stakeholder group. Due to the breadth of the findings, we feel it is 
important to give the reader such a structured overview of the aggregate ranking 
patterns and analytical issues that these suggest. The analysis in the remainder of the 
chapter is not always so systematic, instead emphasising important analytical 
‗storylines‘ and pointing the reader to corroborative details in relevant annexes.  
Figure 7.2: Rankings under UK and US policy-maker and regulator perspectives 
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 We can see in Figure 7.2 that there is a clear difference in the pattern of 
performance rankings across the two perspectives, with the UK group displaying greater 
distinctions between option performance than the US group. The highest ranking option 
under UK policy-maker and regulator views is the detailed centralised oversight option. 
Even under the most pessimistic scores for this option, it still performs better than the 
most optimistic scores given to the worst performing option, mixed central/devolved. 
This feature is notable. When the ‗worst of the best‘ and the ‗best of the worst‘ fail to 
overlap, it offers a clear indication that one option is more favourable under all sets of 
conditions as specified by the participants within that group. We do not see, however, a 
corresponding picture for US views in this stakeholder group. The greater overlap 
between ranking patterns suggests there may be more points of convergence in the 
circumstances under which different options are seen to perform well. This will be an 
area for further analysis and exploration in the following sections.  
Figure 7.3: Rankings under UK and US laboratory scientist perspectives 
 
 
In Figure 7.3, all perspectives display a minimal degree of overlap between 
options. There is a clear distinction in each case between the highest performing option, 
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detailed centralised oversight, and two of the lowest performing options, the mixed 
central/devolved and detailed expert oversight. Again, this situation where the ‗best of 
the worst‘ and ‗worst of the best‘ display little or no overlap gives a clear indication of 
preference for a particular type of option under all conditions. This is of particular 
interest because these highest and lowest performing options display opposing degrees 
of each of the three dimensions of governance employed in the option definitions.
107
 
The highest performing option, detailed centralised oversight, has detailed regulations, 
centralised oversight and a mix of technocratic and democratic deliberations. The lowest 
performing option, mixed central/devolved, has a greater emphasis on decentralised 
oversight and a mix of technocratic and democratic deliberative mechanisms. The 
option performance patterns, then, seem to suggest that for the scientists interviewed it 
is not just singular characterisations of governance, such as ‗central oversight‘ or 
‗detailed regulations‘, that affect option performance, but rather the ways in which the 
dimensions are seen to interact within a given framework.  
Another feature of these ranking patterns is the difference in expressions of 
uncertainty and ambiguity across the two national groupings of scientists. While  
accompanying charts displaying the relative degrees of uncertainty are provided in 
Annex J, for present purposes it is sufficient to point out that UK scientists seem not 
only to express greater uncertainty in the option assessments than US scientists (with an 
average interval uncertainty range across all options of 6.2 base points for UK scientists 
and 4 base points for US scientists), but detailed analysis shows the UK group as a 
whole displays greater ambiguity than the US group.
108
 In other words, there is a greater 
tendency for more disagreement about option performance amongst UK scientists than 
US scientists. It is this, alongside the greater uncertainty, that determines the wider 
ranges in rankings seen above.  
                                                 
107
 From the discussion in earlier chapters (p. 54-56 and p. 70) these three dimensions of governance are: 
i) decentralised vs. centralised institutional oversight, ii) prescriptive regulations vs. general frameworks 
of policy, iii) technocratic deliberations vs. democratic deliberations about policy decisions. 
108
 As we noted above, ambiguity can only be determined at the level of rankings under criteria groups, so 
part of this conclusion is based on analysis that will be provided in sections below. 
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Figure 7.4: Rankings under UK and US bioethicist perspectives  
 
 
The ranking patterns for bioethicists as seen in Figure 7.4 above are similar in 
some respects to those of policy-makers and regulators, with the exception of the ethics-
led governance option. This raises the question of where and how the evaluative criteria 
and option assessments converge and diverge between the two perspectives. This type 
of analysis might be done with an eye towards the literature reviewed earlier in this 
thesis about the rise of a new form of expertise in policy-making – that of bioethicists. 
Further comments in this regard will be made throughout this chapter and the next.  
In addition to this inter-perspective observation, we see some divergence in the 
ranking patterns obtained by UK and US bioethicists. This divergence is interesting 
because it only happens for three of the options, the detailed expert oversight, the mixed 
central/devolved and the ethics-led governance. The other three options all retain the 
same relative patterns across the two national groups. This seems to suggest that under 
this perspective there may something more relatively ‗stable‘ about the latter group of 
options than the former group, leading them to be evaluated in a similar way. 
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Figure 7.5: Rankings under UK and US advocacy group perspectives 
 
 
Figure 7.5 displays the rankings for the different national advocacy group 
perspectives. It was noted earlier that there was a great deal of uncertainty and 
ambiguity expressed in the mixed central/devolved option under this perspective. We 
can see looking at the two national groupings that much of this extended range is due to 
the US advocacy group. In fact, the uncertainty and ambiguity expressed in this option 
ranking under US advocacy perspectives is (at 62 base points), one of the greatest out of 
all perspectives.
109
  
We might recall that the mixed central/devolved option was derived (and 
presented) as analogous to the current US system of governance and the detailed 
centralised oversight option as analogous to the UK governance system. It is interesting 
to note, then, that for the UK advocacy stakeholder group, we also see that the option 
analogous to the stakeholder group‘s own existing national governance system displays 
a relatively high degree of uncertainty and ambiguity. Moreover, this is the first time in 
the analysis presented thus far where this particular option displays such high 
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 Uncertainty at the perspective level for these rankings is shown in Annex J. Ambiguity can only be 
determined under individual issues, and hence is explored later in this chapter. 
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uncertainty and ambiguity – or such low performance relative to other options. Based on 
these findings for both UK and US instances of this stakeholder perspective, we might 
hypothesise that there is something inherent to the particular framings and socio-
political views of advocates which lead them to express more uncertainty and ambiguity 
about governance systems with which they are most familiar.
110
 It may be the case that 
when the focus turns (explicitly) to such systems, advocates are more likely to be 
critically aware of the contingencies affecting both negative and positive outcomes and 
processes of good governance.
111
  
The divergent normative policy positions advocated by different stakeholder 
groups may also be expected to affect option performance. In order to explore this, we 
look to the rankings obtained by subsets of these stakeholder groups concerned with (i) 
patient advocacy, (ii) policy advocacy, and (iii) support of and (iv) opposition to, hESC 
research. This breakdown is shown in Figure 7.6 below. Across all these cases, we can 
see there are marked differences in the ranking patterns, suggesting that resolvable 
distinctions do exist in perspectives on ‗good‘ governance within these groups. 
                                                 
110
 A separate exploration of uncertainty in relation to this point can be found in Annex J. 
111
 This finding cannot be confidently made unless compared with other possible cases. It is only pointed 
out here to raise the possibility, not to claim it as a definitive statement. 
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Figure 7.6: Rankings under patient, policy, opposition and supportive advocacy 
perspectives 
 
 Though the number of participants in the group of advocates opposed to hESC 
research governance is smaller than those in favour of it, we can still explore the 
ranking patterns for systematic differences. Indeed, as with the overall stakeholder 
group as a whole, some of the most notable patterns are found in the differences in the 
evaluation of the detailed centralised oversight, mixed central/devolved and ethics-led 
governance options. In addition, although there are more distinct differences in the 
patterns between those opposed to or in favour of hESC research, there are also some 
similarities worth exploring, such as the consistently higher ranking of the devolved 
authority and detailed centralised oversight options in comparison with the others. All 
of this can be taken to suggest that analytic attention might be paid to these areas 
throughout the chapter. 
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Figure 7.7: Rankings under UK and US industry and professional executive 
perspectives 
 
 
Finally, the last perspective to be presented is that of industry and professional 
executives. Figure 7.7 shows a notably different ranking pattern for this stakeholder 
group by comparison with the perspectives already discussed. As mentioned previously, 
this is the only stakeholder group where the detailed centralised oversight option does 
not have the highest performance ranking. Such differences in the ordinal pattern 
compared with other groups suggests the perspectives on good governance held by 
industry and professional executives might be constituted in distinct ways, or at the very 
least are affected by a more significantly different set of framing assumptions. 
The nation-specific rankings for this stakeholder group also reveal different 
patterns, most notable for US industry and professional executives. Thus, not only are 
the patterns for this perspective different to others at the inter-perspective level, they are 
also more divergent within the perspective, nationally. Though this latter feature has 
been seen throughout the rankings presented thus far, it is perhaps most marked for this 
group. In particular, the fact that US-based industry and professional executives express 
a preference for the two options that highlight both scientific autonomy and the role of 
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expert-based decision-making, indicates a more ‗free market‘ perspective might be held 
by US participants in this group.   
Given the remarkable nature of the different ranking patterns yielded within this 
perspective, it is worth considering other cuts within this group. As Figure 7.8 shows, 
we also find markedly different patterns across the views of executives of professional 
body organisations versus those in industry. In fact, the relatively high degree of overlap 
in the rankings of industry executives perhaps indicates a greater sensitivity to the 
contingencies that affect option performance; while in the professional executives‘ 
perspective clearer distinctions are made. Or, looked at another way, for industry 
executives it seems there is little distinction made between the options at the optimistic 
end, whereas greater distinctions come when considering the pessimistic circumstances 
which may affect option performance. This may be indicative of a view which holds 
that market conditions are variable and, given a positive governance outlook, any 
framework could perform well. 
Figure 7.8: Rankings under industry and professional executive perspectives 
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Though much of the preceding analysis has focussed on differences within 
ranking patterns, we should not lose sight of the similarities across option rankings, 
such as the high performance ranking of the detailed centralised oversight option. This 
suggests that there may be important features of the options themselves which are 
consistent across multiple socio-political viewpoints and perspectives on good 
governance. Attention to both similarities and differences in ranking patterns will allow 
us more fully to understand the normative implications for decision-making in this 
contested area of biomedical science. 
 Having explored the performance rankings for the individual stakeholder groups, 
we can appreciate the complexity and diversity of analysis that must be grappled with. 
In order to better guide the reader through this, Table 7.2 summarises the contrasting 
perspectives that will be discussed in the remaining pages of this chapter for each of the 
initial stakeholder groups. Each perspective is discussed according to the themes of 
good governance resolved in earlier chapters and the basis for the identified 
perspectives was made in a similar way to that described in the previous chapter.
112
 
Those perspectives indicated with a darker shading show particularly strong systematic 
patterns or areas of analytical interest. Thus, these analytical ‗storylines‘ will be the 
main focus of the discussion in this chapter.
113
    
                                                 
112
 See the discussion in Chapter 6, p. 135-136. 
113
 Supporting or tangential information in less prominent storylines is presented in Annex J. 
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Table 7.2:  Contrasting perspectives on themes of good governance
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 Indicates a particularly strong signal from the empirical data and emphasis is placed on these areas in the text. 
 Indicates a clear signal from the empirical data, but findings are not always central to argument. 
 
Indicates some individual points from the analysis were of interest, but overall the findings are not central to the 
argument and, moreover, there was not sufficiently clear signal to merit further analysis. 
 
This table is merely meant to provide an ‗overview‘ for the reader and will not 
be described in any additional detail here. Full discussion under each theme is taken up 
in the text below and we will move directly to that discussion now. The next section, 
7.2, discusses stakeholder perspectives under the theme ‗advancing scientific and 
technological trajectories‘. The analysis will explore the qualities of scientific outcomes 
that are described by stakeholders and the processes of research support that facilitate 
their achievement.  
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 The omitted theme, ‗encourages ethical and moral awareness for hESC research‘ and sub-theme, 
‗characterising policy approaches‘, are analysed and discussed in Chapter 8. 
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7.2 Advancing scientific and technological outcomes 
7.2.1 Overview 
In discussion of this theme in the previous chapter, the perspectives of UK and 
US stakeholders were analysed for overarching patterns in the way that qualities of 
scientific outcomes were characterised and the corresponding processes of research 
support articulated. The focus here remains the same, but the unit of analysis shifts to 
the five main stakeholder groups. As before, the issue is first defined for the purposes of 
making explicit the step in the analysis where individual criteria are grouped because 
they share similar features. 
Advancing the science: Criteria in this issue are distinctive in their concern 
with fostering and advancing the science of hESC research itself. Often 
expressed in an instrumental way, the criteria are concerned with the need for 
the governance framework to facilitate, support and actively advance the 
research, technological and therapeutic trajectories of human embryonic stem 
cell research. 
The criteria that comprise this issue reveal framings about the nature of the science, the 
directions in which it might advance and the qualities of the outcomes it might achieve. 
The criteria also reveal perceptions about what is needed, in ‗good‘ governance terms, 
to facilitate particular outcomes. These needs might include features of financial, social 
or policy support. Evaluation of these factors at the individual stakeholder group level 
will further enrich our understanding of how perspectives on good governance are 
constituted.  
7.2.2 Scientific outcomes and research support 
 The analysis presented in this section will look at the framings of hESC research 
and desired outcomes, be they research-, therapeutic- or commercially-oriented and 
associated processes of research support. This issue is the most frequently mentioned 
amongst all of those analysed and so the findings below are of central importance. We 
will begin by looking at the rankings obtained by the five initial stakeholder groups 
under the issue ‗advancing the science‘, before moving on to the detailed analysis.   
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Figure 7.9: Rankings under stakeholder perspectives for ‘advancing the science’ 
criteria
115
 
 
 
We can immediately see from this chart that there are divergent ranking patterns 
across the perspectives. The strongest pattern seems to be that of systematic divergence 
in the ordinal option rankings. That is, no one option has the highest performance 
ranking under optimistic scores amongst a majority of the stakeholder groups. 
Moreover, different ranking patterns exist in each group. The notable exception to this 
is the performance rankings seen for the stakeholder groups ‗bioethicists‘ and ‗policy 
makers and regulators‘ (with the exception of the ethics-led governance option). This 
finding suggests an intriguing synergy between these two groups which will be explored 
more fully in the following chapter.  
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 As in the previous chapter, when ranking patterns are presented under certain criteria groups (issues), 
only a subset of all criteria may fall within any given grouping. Similarly, not all participants in the 
stakeholder group (perspective) presented may have defined a criterion within the issue, while some may 
have defined several criteria within the issue. Thus, each box in the figure displays information regarding 
the number of participants defining at least one criterion within the issue (e.g., ‗x/x participants‘) and how 
many criteria, in total, comprise the issue within that perspective (e.g., ‗x individual criteria‘). 
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Overall, the tendency towards divergence rather than convergence in ranking 
patterns suggests that there may be relevant distinctions between perspectives in their 
characterisations of salient issues. These may be found both in relation to the framings 
of hESC research outcomes as well as the requisite processes of research support. It is to 
these distinctions that we now direct our attention.  
Looking first to the way in which the criteria are defined and option assessments 
made within the group of policy-makers and regulators,
116
 participants tend to speak 
about scientific outcomes in terms that emphasise support for, alternatively, ‗good‘, 
‗meritorious‘ or ‗the best‘ science. Although some criteria specifically mention 
therapeutic developments as a goal, most were concerned simply with ensuring that 
high quality science is supported. As articulated in a criterion defined by one US-based 
policy-maker,  
meritorious science is science that respected experts consider to be quality 
science... In terms of supporting meritorious science, implicit in that is you are 
not creating unnecessary barriers to the performance of the science itself and 
collaborations between scientists... Doesn't mean you create no barriers, but they 
shouldn't be so high they impede the progress of the science (US policy-maker 
8, #C237). 
Within this single criterion we find a related emphasis both on the framing of hESC 
research outcomes – in terms of good or ‗meritorious‘ science being pursued – as well 
as the processes which should facilitate this – not creating ‗unnecessary barriers‘. It is 
interesting that many participants asserted similar views that the scientific priority 
should be quality science, not specific biomedical applications. As argued by one US 
policy-maker, in order to ―foster scientific breakthroughs and disease therapy 
translation‖ it is necessary to think more about how to support research and less about 
specific outcomes: ―[It‘s about] funding the best science rather than going the disease-
specific route‖ (US policy-maker 6, #C266). Thus, outcomes of hESC research are 
framed in broadly scientific terms, as opposed to therapeutic ones, by policy-makers and 
regulators in this stakeholder group.  
Despite this similarity, there are differences in how UK and US participants in 
this group characterise their criteria. Proportionally,
117
 more of the criteria defined by 
UK members of this group relate to the processes of supporting hESC research, not the 
qualities of outcomes. Conversely, almost half of the criteria defined by US members 
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 The ranking chart comparing UK and US policy-makers and regulators can be found in Annex J. 
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 For UK policy-makers and regulators, seven out of ten criteria in this issue are about processes of 
supporting advances in hESC research, while for US policy-makers and regulators 13 out of 22 criteria of 
this type were defined, leaving just under 50%  discussing the quality of scientific outcomes.  
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focus on the qualities of hESC research outcomes, specifically those where ‗good‘ 
science results. This might be interpreted as being reflective of the greater political 
opposition to hESC research in the US. US policy-makers and regulators may feel more 
acute pressures to justify hESC research by emphasising its purposes, or intended 
outcomes. Conversely, in the UK ‗the purpose of the research‘ is inscribed in legislation 
(UK policy-maker 2, #C137), and so there might be less of a pressure on UK policy-
makers to justify hESC research in the first place. Thus, they may feel more able to 
discuss how to facilitate scientific advances of any and all kinds. Unsurprisingly, then, 
we seem to see a link between the current policy context in each country and the 
associated policy-maker perspectives on good governance. 
We also find national differences in the ways in which processes of research 
support were characterised by UK and US policy-makers and regulators. The following 
quotes are illustrative of the ways each national group made this point. 
The 'go for a coffee' atmosphere is fostered, where regulation is not so 
oppressive that it stifles the science...[it‘s] about governance creating an 
environment that allows science to flourish and scientists not to be put off from 
forming collaborations or trying new things simply because of regulatory 
burdens (UK policy-maker 2, #C140). 
The guidelines that are put forth are meant to be elastic and allow people to fit 
an enormous variety of situations in the framework (US policy-maker 1, #C109). 
These views parallel those identified in the previous chapter where US stakeholders 
tended to refer to a ‗flexible and harmonised‘ space for science, as opposed to the 
‗protected and regulated‘ space advocated for by UK stakeholders. Here, UK policy-
makers and regulators also specify a protected and regulated space that should keep up 
with changing public attitudes. A similar link to that identified for UK perspectives in 
the previous chapter seems to exist between the institutional role of regulation as a 
means of garnering public trust and support for hESC research. This comes through 
very strongly at the individual stakeholder group level for UK policy-makers and 
regulators. We will see in the following analysis that these parallels are not always so 
neat, making it all the more important to note this one here. Such differences in views 
on how to support research reveal certain tensions in the sometimes conflicting realities 
of how the support processes are implemented. Good science cannot progress if it is too 
regulated (as indicated by a lower relative ranking of the detailed expert oversight 
option), but it also should not have too much flexibility (as evidenced by the lower 
ranking of the ethics-led governance option).  
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While UK and US policy-makers and regulators have been shown to have 
slightly diverging perspectives under this theme, this does not seem to be the case for 
UK and US laboratory-based scientists. As shown in Figure 7.10 below, the ordinal 
pattern is the same for UK and US scientists (although there are differences in 
uncertainty and ambiguity), however it is distinct from that of the group of policy-
makers and regulators just analysed.  
Figure 7.10: Rankings under UK and US laboratory scientist perspectives for 
‘advancing the science’ criteria 
 
The rankings above indicate a preference for the ethics-led option, although this 
is much more clearly expressed in the rankings of US than UK scientists. UK scientists, 
in contrast, express greater uncertainty and ambiguity and, as a result, less of a clear 
preference emerges among the three top performing options. Analysis of this 
uncertainty and ambiguity,
118
 reveals that there are differences both in expressions of 
uncertainty between the two groups as well as in the degrees of ambiguity. That is, UK 
scientists are at the same time more individually uncertain about option performance 
and in greater collective disagreement than are US scientists. A more detailed 
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examination of the criteria comprising this issue and their use in evaluation may 
indicate the extent to which these differences are the result of divergent perspectives on 
good governance, or are attributable to some other factor.  
As a group, laboratory-based scientists tend to have a ‗basic research‘ framing of 
the scientific outcomes of hESC research; one where the outcomes are characterised 
primarily in terms of advances in basic biomedical science. ‗Potential‘ therapeutic 
benefits were usually discussed as secondary considerations. 
The therapeutic potential of hESCs is very far away and very hard to 
commercialise... [however] the benefits of understanding disease [from a basic 
science perspective] is huge for society (US scientist 4, #C292).  
Though this concern with the importance of characterising scientific outcomes in more 
research-oriented ways is expressed both by UK and US scientists, there are subtle 
differences in the way the point is articulated. Both groups refer to the need for research 
support processes which provide a guiding framework for science, but UK scientists 
emphasise the need for long-term leadership.  
It is very important to put large amounts of resources into this research as a 
society because the potential to move towards human therapies is so high...But 
it‘s going to be five or ten years before we get there (UK scientist 5, #C319). 
Amongst US scientists, expressions about the processes which should support basic 
science outcomes tend to focus specifically on a desire for standardised oversight. This 
would provide needed stability to the field. In this, US scientists are specific about the 
ill-effects, both scientifically and socially, of a lack of standardisation. Governance 
should ―responsibly allow scientific progress to happen‖ (emphasis added, US scientist 
5, #C57) because ―no government oversight [of this research] is a travesty...it is harmful 
for the research and harmful for the ethical side‖ (US scientist 2, #C66). The purpose, 
then, of a guiding framework as portrayed by US scientists seems intended to show 
respect for the sensitive nature of the science and to help advance the field as a whole.  
Interestingly, neither UK nor US scientists address regulatory burdens when 
discussing good processes of research support. This is particularly interesting because 
most of the other stakeholder groups express concern about the impact of overly 
burdensome regulation on the ability of scientists to pursue their work. Scientists 
themselves, though, discuss only the need for policy frameworks to be ‗flexible‘ or 
‗responsive‘. Rules are a good thing, but they have to be ―responsive, so that they can 
change as the science changes‖ (UK scientist 6, #C314). However, despite not 
addressing such rules explicitly, they seem to implicitly in that the rankings for the more 
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centralised options are lower or equivalent to the more decentralised options. Thus, 
scientists seem most interested in freedom to pursue scientific inquiry, something held 
to be best found in less centralised options.  
As pointed out above, with the exception of the ethics-led governance option, 
the rankings by bioethicists seem similar to those of the policy-makers and regulators 
discussed earlier. However, we do find that the framings that are revealed under this 
perspective vary from those of the policy-makers and regulators in important ways. 
Whereas policy-makers and regulators characterise hESC research outcomes in terms of 
the need to support ‗good‘ science, bioethicists tend to characterise good outcomes of in 
terms of the potential benefits to society. As one US academic bioethicist states, 
―governance must involve an innovative public policy with an optimistic view of the 
future of human societies that fosters more progress and innovation‖ (US bioethicist 4, 
#C277). Other bioethicists make similar points about governance leading to general 
societal benefit.  
It [the governance framework] should start with the assumption that science can 
be good... to appreciate that making changes, hopefully for the better, is what 
makes us humans different (US bioethicist 3, #C44).  
We might say, then, that in line with the disciplinary training bioethicists receive, there 
seems to be a framing of the scientific outcome which relies upon the medical principle 
of ‘beneficence’.119 Under this view, scientific outcomes must not cause net social 
harm, be it to public health or moral fabrics of society.  
Despite these similarities in the framing of the criteria, there are differences in 
the way the assessments of the options were carried out. There is often a greater degree 
of ambiguity (meaning there is disagreement over option performance between one 
participant and another) amongst participants within the stakeholder group.
120
 This is 
possibly explained by looking at the way in which ‗bioethicists‘ themselves are 
characterised, both for this research and as observed in wider literatures. As has been 
pointed out earlier, the composition of national bioethics bodies often cover a wide 
range of individual backgrounds and disciplinary traditions extending well outside 
philosophical inquiry to law, theology, science, social science, medicine and more 
(Gottweis et al., 2009). Though all the individuals in the bioethicist perspective for the 
analysis here had some theoretical or practical grounding in the discipline of bioethics, a 
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 See Annex J for a presentation of charts displaying this finding. 
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variety of primary or secondary backgrounds in different fields from philosophy to 
policy-making were also present.   
This may help explain why two very divergent options have the highest 
performance rankings under this issue. The detailed centralised oversight option is a 
centralised, strongly regulated option whereas the ethics-led governance option has no 
central legislation and individual research institutions enforce their own oversight 
guidelines. Even though there are similar, ‗positive social‘ views on hESC research as 
described above, we do see different framings or assumptions made in relation to its 
‗implementation‘ (i.e., option assessments). For example, one bioethicist working for a 
biotechnology industry group believes centralised systems with prescriptive regulations 
offer an opportunity for governments to guide the research in particular directions so 
that technology and innovation can benefit the public more quickly (US bioethicist 3, 
#A249). Another bioethicist who worked as a policy-maker for the Bush administration 
also believes that a centralised, regulated system could be supportive of hESC research, 
but for different reasons. It is his view that the detailed centralised oversight option has 
a high optimistic assessment under ‗advancing the science‘ criteria because regulatory 
bodies generally get more permissive over time and are more responsive to organised 
scientific interests (US bioethicist 5, #A1387). 
The ethics-led governance option, by contrast, has a more ‗hands-off‘ and 
unregulated approach. In evaluating this option, one academic bioethicist makes the 
assumption that ―if there's a positive ethical stance towards science ... there could be a 
lot of appropriate encouragement of science‖ (UK bioethicist 2, #A1063). Another 
comments that, under his criterion of ‗progress‘, the option scores well because ―experts 
[of any kind] are focussed on progress in the science. So an ethics-led option with high 
levels of expert involvement will do well here and push getting things done‖ (US 
bioethicist 4, #A1590). As both of these individuals taught ethics, the assumptions they 
made seem to reflect the belief that with erudite ethical input, a positive and appropriate 
governance environment that is mindful of societal and public views will emerge. Thus, 
although the criteria characterisations reveal similar framings of scientific outcomes, the 
option assessments reveal that the different assumptions made about option performance 
vary. Moreover, they vary in ways that seem dependent on the individual‘s professional 
background. This affirms recent academic work which questions whether ‗bioethicists‘ 
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are truly objective arbiters of social and moral views (Levidow and Carr, 1997; 
Tallacchini, 2009), or simply introducing a new type of legitimatory ‗expertise‘.121 
In some ways, the perspectives of advocacy groups share certain features with 
those of bioethicists, which is perhaps surprising given that the two groups are often not 
associated. That is, advocates are often known for vociferously arguing for, often 
contending, policy agendas, whereas bioethicists are portrayed within official policy 
discourse as pragmatic deliberators about social values and cultural pluralism, arriving 
independently at common ground (Tallacchini, 2006). Like bioethicists, participants in 
the various advocacy groups tend to frame hESC research in terms of the public benefits 
that can be realised. However, while bioethicists stressed both medical and social good 
in a more substantive way focussed on consensus, advocates seem more inclined to 
frame public benefits in line with their individual goals. One patient advocate pointed 
out that there was a need for ―science in the public interest...with a specific 
purpose...[not] just research for research‘s sake‖ (UK patient advocate 3, #C6), while 
another commented that ―science [itself] is driven by a societal need for medical 
advances‖ (US patient advocate 1, #C252). In both cases, ‗public‘ or ‗societal‘ needs are 
invoked, but in a way that masks the privately-held, more instrumental goals of the 
participants. This was also evident with those who did not support some aspect of hESC 
research or research governance. One policy advocate opposed to hESC research, and 
particularly the governance system in the UK, is concerned that commercial interests in 
governance are too influential. He appeals to public interests in pointing out that such 
commercial intervention could prevent the public from benefiting from research they 
are, in fact, funding (UK policy opposition 6, #C344).
122
  
This all suggests there may be a cross-cutting strategy within this group, 
regardless of the policy objectives being argued, of appealing to a shared sense of 
‘public good’ in order to advance individual policy objectives. It may be for this reason 
that we find (as shown in the performance rankings in Annex J) a consistent pattern 
among all types of advocacy groups of a favourable evaluation of options with 
centralised oversight structures and detailed regulations. In this case, centralised 
regulation would ensure ‗consistency‘ in the outcomes of scientific endeavours. Of 
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 See the discussions in Chapter 5 (pp. 122-124) for the academic background, as well as the discussion 
in Chapter 8 where the empirical and theoretical strands in this regard are combined. 
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 Only two participants opposed to hESC research and governance systems defined criteria that related 
to this issue. The implications of this are incorporated implicitly into the findings above and can be 
observed in terms of option rankings in Annex J. 
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course this is dependent on the governing bodies being in favour of an individual‘s 
policy objectives, and so we see optimistic and pessimistic scores reflecting either 
situation. An example of this is seen in the case of patient advocates, who find the 
‗detailed expert oversight‘ option to have the highest performance ranking under 
optimistic scores. In this option, the approval of research relies on expert-based 
decision-making. Many patient advocates thought experts, with a natural interest in 
science, could facilitate moving it forward, faster. 
Among the views of industry and professional body executives within the issue 
of ‗advancing the science‘, arguments for why science should be advanced seem to 
relate to a notion of ‘scientific freedom’. That is, there seems to be a tendency, either 
within the definition of the criteria or the assessments of the options under the criteria, 
to relate ideas about scientific freedom to the capability of firms or organisations to 
successfully innovate and realise commercial gains. Thus, both the quality of scientific 
outcomes and the process of research support are couched within a particular framing of 
how ‗free‘ individuals (and their companies or professional groups) are to pursue 
research that is commercially or therapeutically promising.  
However, there is some variation in how this was expressed. The UK 
governance framework is permissive of hESC research, but there are many regulations 
that businesses must adhere to. Thus, many UK-based industry and professional 
stakeholders expressed concern over the ―chilling effect‖ (UK industry executive 1, 
#C338) regulations can have on scientific freedom. It is not that stakeholders believe 
there should be no regulation, but rather it is a matter of balance. One industry executive 
who works in a company developing adult stem cell therapies, but looking to move into 
embryonic stem cell therapies, pointed out that: 
The regulatory framework cannot be too rigid now, it needs to be flexible. The 
framework in place needs to be protective enough for safety and responsive 
enough to take future developments into account (UK industry executive 3, 
#C203). 
This seems to suggest a strong relationship between concerns about good governance 
and the governance realities in each country. This also explains for the observed ranking 
differences in the two countries, shown in Figure 7.11 below. UK-based stakeholders in 
this group favour the detailed expert oversight option because they believed the expert-
based oversight processes could give science more of a ‗green light‘, but they do not shy 
away from the regulations required of this option. In contrast, US-based stakeholders 
clearly favour the two options where oversight of the research has little to no central 
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oversight and no formal regulations governing it. Moreover, US industry and 
professional executives express a higher average weighting for this issue of 65%, as 
opposed to the UK average weighting of 39%.
123
 This shows this issue not only to be 
more frequently mentioned by US stakeholders, but also of greater relative importance. 
Again, one explanation for this could be the more restrictive climate for research in the 
US at the time the interviews were conducted. What is ironic, though, is that these 
restrictions only apply to national funding of hESC research. Privately-funded, industry-
led research was not subject to the restrictions. However, the knock-on effects of such a 
policy climate were clearly great enough that US executives felt even more inclined to 
stress the importance of a facilitative governance framework for innovation. 
Figure 7.11: Rankings under UK and US industry and professional body 
perspectives for 'advancing the science' criteria 
 
In addition to these national differences, the analysis presented earlier under all 
criteria suggested that the intra-perspective difference between ‗industry executives‘ 
and ‗professional body executives‘ may offer additional analytical insight into how 
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perspectives on good governance are constructed within the ‗industry and professional‘ 
group as a whole. As shown in Figure 7.12 below, we do see differences in the ordinal 
patterns of rankings between these two sub-perspectives. For the group of professional 
body executives, there is a clear preference for the ethics-led governance and the expert-
led framework options. In contrast, the performance rankings for industry executives 
display a striking amount of similarity in the high end performance rankings under 
optimistic scores, but greater variability in the pessimistic assessments at the low end. 
They also seem to express much greater uncertainty and ambiguity in their 
assessments.
124
 It is worth calling attention to the clear differences between the ranking 
patterns below and those of the national groupings above. These show that very 
different sets of assumptions can be distinguished depending on one‘s affiliation with 
industry, professional bodies, or national contexts.  
Figure 7.12: Rankings under industry and professional body perspectives for 
'advancing the science' criteria 
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The differences in rankings observed above are all the more interesting for the 
fact that, upon qualitative analysis of the criteria comprising the issue, there is little 
difference in the types of criteria from one group to another. Part of the explanation for 
the difference in performance rankings, then, seems to lie in the subtleties of 
participants‘ points of view and assumptions made about the options, both as they relate 
to the work of each individual. Industry executives may be more concerned about the 
‗bottom line‘, that is, whether governance will enable scientific outcomes to translate 
directly into commercialisation opportunities. Their option evaluations seem to illustrate 
the possibility that when looked at solely in terms of outcomes, multiple types of 
governance frameworks have almost equal potentials to enable commercial success. 
However, there are many pessimistic conditions under which this may not be the case.  
Executives of professional bodies, on the other hand, represent a wide range of 
professional interests and views, which may involve diverse commercial or professional 
areas. Their criteria have a slightly greater emphasis on how enabling of innovation the 
processes of research support are, as compared with the industry focus on the outcome 
of innovation, itself. The subtle difference has a big impact on option assessment. For 
participants in professional body, the option assessments indicate a preference for 
governance options where there are fewer perceived roadblocks to advancing the 
science. These roadblocks seem to include regulation, as the two most regulated options 
have the lowest rankings in a ‗best of the worst‘ and ‗worst of the best‘ scenario. This 
seems to give a signal that when the emphasis is on processes that enable innovation, 
clear distinctions in options can be made. When the emphasis is on outcomes, there 
seems to be a view that, optimistically, anything could happen given the right 
conditions. This finding echoes one that will be discussed in Chapter 8 about the 
evaluation of process-based and outcome-based criteria, more generally. The next 
section will summarise all the findings of this section together and draw out the most 
important points.  
7.2.3 Discussion 
The discussion above has shown that for those stakeholder groups on which 
analysis has focused, that it is possible to discern perspectives between which there do 
emerge systematic patterns. These may aid analysis of how perspectives on good 
governance as a whole are constituted. Table 7.3 below summarises the main patterns in 
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perspectives on good governance under the theme ‗advancing scientific and 
technological trajectories of hESC research‘.  
Table 7.3: Summary table of patterns in perspectives under the theme ‘advancing 
scientific and technological outcomes of hESC research’ 
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 Indicates a particularly strong signal from the empirical data and emphasis is placed on these areas in the text. 
 Indicates a clear signal from the empirical data, but findings are not always central to argument. 
 
Indicates some individual points from the analysis were of interest, but overall the findings are not central to the 
argument and, moreover, there was not sufficiently clear signal to merit further analysis. 
 
The distinctions and systematic patterns identified in the preceding analysis and 
summarised in the table above are a strong empirical finding in this area of the analysis. 
The perspectives that emerged under this theme clearly relate both to the qualities of 
scientific outcomes that are seen as ‗good‘ and valued by different stakeholder groups, 
as well as the processes and mechanisms of research support that would facilitate the 
realisation of the outcomes. Not only do these perspectives emerge in a clear manner, 
but they differ systematically across the stakeholder groups. This is especially intriguing 
in the case of policy-makers and regulators and bioethicists, where the evaluations of 
the options share common features, but the perspectives themselves differ.  
The option rankings produced by laboratory-based scientists and industry and 
professional body executives also shared some common features (such as the higher 
performance of the expert-led framework and ethics-led governance options). Both 
groups also spoke generally in terms of scientific freedoms or autonomy to pursue 
promising areas of research. However, laboratory-based scientists focussed on scientific 
outcomes within basic biomedical research, while industry and professional executives 
had an emphasis on commercial applications or therapeutic innovations. Interestingly, 
laboratory-based scientists did not speak very much about regulatory burdens, though 
this concern was expressed by members of all other stakeholder groups.    
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The perspectives of advocates varied the most depending on the particular socio-
political view of the individual, but there were common themes invoking ideas of 
‗public good‘ as an important quality of scientific outcomes. Centralised processes of 
research support for all types of stem cell science would best enable these outcomes. 
This view was especially prevalent among US patient and policy advocates in favour of 
hESC research. One participant explained that it was like when the US waged its ‗War 
on Cancer‘ in the 1970s (US advocate and policy-maker 8). Though the target disease 
was cancer, there was a positive knock-on effect for all of biomedical science.  
Overall, the analysis has revealed important differences in framing and related 
effects of socio-political points of view on option evaluations. We will now turn to the 
perspectives on good governance under the theme of ‗institutions and instruments of 
governance for hESC research‘.  
7.3 Institutions and instruments of governance for hESC 
research  
7.3.1 Qualities of deliberative activities 
 As in the previous chapter, this section will look at the broader rankings of 
governance options under the issue ‗qualities of deliberative activities‘, as well as two 
sub-issues: the ‗role of the public‘ and the ‗nature of expertise‘. Before discussing these, 
we will consider option performance under the issue ‗qualities of deliberative activities‘.  
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Figure 7.13: Rankings under all stakeholder perspectives for ‘qualities of 
deliberative activities’ 
 
 
As we can see in Figure 7.13, some ranking patterns consistently recur. Again 
there is less uncertainty and ambiguity in the rankings of the laboratory-based scientists 
and greater uncertainty and ambiguity for the mixed central/devolved option under 
many of the perspectives. The detailed centralised oversight option has the highest 
performance for all the stakeholder groups, a feature that is particularly notable here in 
the perspective of industry and professional executives (as this option has not performed 
so well for this group under previously discussed issues). In order to best understand 
these patterns, we need to see how perspectives on good governance are constituted 
within this theme. This requires examination of option appraisals under criteria 
concerning different types of deliberative activities.   
7.3.2 Deliberative activities: The role of the public 
 Before considering option rankings under this issue (shown in Figure 7.14), let 
us review the issue definition as it was used to group criteria for the analysis: 
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Role of the public: Criteria in this issue are concerned with how the role of the 
public is conceived of and defined as a part of good governance. The focus is 
both on how public inputs and deliberations might feed into the governance 
process, if at all, as well as the importance of public views on the institutions 
and instruments of governance itself. Thus, issues like public trust and 
confidence are addressed. 
There are 58 criteria identified as relating to this issue and their distribution is fairly 
even across different stakeholder groups. Though, the individual numbers of criteria 
defined within each stakeholder group are relatively small, in each group over half of 
the participants define at least one criterion within the issue. Consequently, though we 
must exercise caution (as in other areas) in over-interpreting patterns arising in analysis, 
there do emerge some intriguing features in cross-perspective comparison.  
Figure 7.14: Rankings under all stakeholder perspectives for ‘role of the public’ 
criteria 
   
Perhaps the most notable feature in the figure above is the consistently high 
rankings of both the detailed centralised oversight and devolved authority options across 
all stakeholder groups (with the exception of laboratory-based scientists in relation to 
the devolved authority option). The fact that both of these options were consistently 
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evaluated so positively in relation to the other options suggests that there may be 
something inherent to these two frameworks that is seen to be critically important to the 
way in which the perspective for this issue is characterised. In addition to this feature, 
there is also a consistent ordinal pattern between the first three options (going down the 
y-axis) for all but one stakeholder group (that of bioethicists). Thus, starting with the 
detailed centralised oversight option and going down, the optimistic performance 
rankings are lower and lower.  
 Examination of the criteria within this issue
125
 reveal differences in the way in 
which stakeholders characterise and conceive of the role of the public in a wider 
governance context. This role is either characterised in terms of the processes of public 
engagement or participation activities and the qualities which make them ‗good‘, or in 
terms of the ‗publicly framed‘ outcomes that institutional mechanisms should achieve. 
With the latter (and as in the previous chapter), the criteria emphasise features of good 
governance that might lead to public support, trust or confidence in hESC science and 
governance activities. Different emphases are placed on these two characterisations 
across the stakeholder groups, with corresponding implications for perspectives on good 
governance and option evaluations.   
 Policy-makers and regulators predominately characterise the issue in terms of 
outcomes that are in turn framed in relation to the public trust and confidence that 
different institutional mechanisms of governance should achieve. Whether discussing 
the importance of ‗transparency‘ (various participants, #C264, #C119, #C171, #C300, 
#C270) or the need to ensure ‗accountability‘ and ‗objectivity‘ in decision-making 
processes (UK regulator 4, #C120, UK policy-maker 3, #C174), most of the policy-
makers and regulators interviewed justify their criteria in the context of public trust and 
legitimacy. As one US policy-maker comments, ‗good‘ governance needs to  
win and maintain popular support as legitimate, safe and appropriate... Popular 
legitimacy [is defined] as the public accepts this is a legitimate way to govern it  
research] (US regulator 4, #C67).  
Another US, state-based policy-maker defines two separate, but inter-related criteria 
about public trust. In this way she emphasises the importance of ―engendering‖ public 
trust both through the governance processes put in place, such as ―appropriate 
representation and consideration of different viewpoints‖ (US policy-maker 8, #C234), 
as well as through the implementation of policies that protect the public from risk. The 
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linking of the two is important and emphasises the outcome focus. ―Even if you have a 
process in place that fosters public trust, it means nothing if the follow-through is not 
there‖ (US policy-maker 8, #C235).  
It is not only the consistently expressed convictions favouring outcomes of 
public trust which characterise this perspective, but also the instrumental way in which 
this is pursued. That is, in seeking public trust as a specific outcome of a governance 
option, policy-makers and regulators reveal an instrumental
126
 imperative in their 
appraisal of governance activities. The perspective of policy-makers and regulators is 
not the only place where this is found.  
Laboratory-based scientists discuss features of public engagement with a clear 
outcome focus and instrumental motivation. However, the outcomes are framed in 
relation to public confidence in the science, not in governance itself. Thus, many criteria 
seem to reflect a view that if engagement is designed so as to make the public feel they 
have a stake in governance decisions, then public trust in both the governance 
framework, and the conduct of the science, will follow. It is important, then, that there is 
not only ‗support from stakeholders‘ (UK scientist 3, #C194) in the governance 
structures, but also that ―society should have some say in setting the guiding principles‖ 
for these structures (US scientist 4, #C287).  
Within this issue, then, laboratory-based scientists are concerned with how 
processes can be designed so as to achieve particular outcomes. With this come clear 
ideas about which governance frameworks best achieve this. In fact, the clear 
distinctions in ranking patterns are quite remarkable and suggest a convergence in views 
amongst the individual participants.
127
 Detailed centralised oversight, with clear rules, 
and a mix of democratically informed expert bodies was the preferred option. Options 
that did not include democratic participation principles or had unclear national rules 
were negatively evaluated. An interesting exception to this is the ranking of the ‗ethics-
led governance‘ option. Although, there is no national oversight, this option is attributed 
high performance under optimistic scores. A possible explanation for this anomaly lies 
in some participants‘ interpretation of the working of ethics bodies. There was a shared 
view that ethics bodies, by their very remit and nature, reflect on public views. It is 
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 See the discussion in Chapter 8 for a full description of the implications of such instrumental 
imperatives. The concept is based on the body of literature introduced in Chapter 3 on p. 52-53. 
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 Though all the criteria defined by this group express ideas about the role of the public in similar ways, 
it should be noted that the majority of the criteria are defined by UK-based laboratory scientists. The 
implications of this for the analysis presented here are not great.  
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therefore seen to follow automatically that any governance based on their guidance 
would be publicly accepted. As was pointed out in earlier discussion,
128
 this suggests 
that the claims of ethics bodies are uncritically adopted by some stakeholder groups and 
perhaps contributes to their perceived legitimacy as a new type of expertise. 
Another stakeholder group that characterises the issue in terms of outcomes 
consists of the industry and professional body executives. Though it is difficult to 
determine any specific patterns in the ways this issue is framed, there is some general 
concern with losing public trust. Thus, some wanted to ensure that public engagement 
happened in some way in order to ―avoid mistrust‖ (UK professional executive 4, 
#C331), or to achieve ―trust and support‖ in the processes of governance already in 
place (UK industry executive 4, #C297). Given the similarities between the ranking 
patterns for this stakeholder group and that of the policy-makers and regulators, it is 
tempting to conclude that their respective perspectives on the role of the public are 
similarly constituted (that governance should foster public trust, confidence or 
acceptance). While this may be the case, the signal is not sufficiently clear to warrant 
much further discussion. 
The final group that shares an outcome-focused perspective concerning the role 
of the public are patient advocates and advocates of permissive hESC research policies. 
Like scientists, participants in this group seem at first to be discussing process-based 
issues about more openness in public engagement, but this is done with the intention of 
ensuring specific outcomes are achieved from them. In the case of patient advocates, 
these outcomes are usually public support for hESC science. There seems an implicit 
expectation that openness in public engagement will lead to greater public support for 
advances in hESC research.  
This is evidence for a more general instrumental tendency to frame notions of 
good governance in terms of more specifically desired policy objectives. For example, 
within the criterion ‗meeting society‘s needs and interests‘, one participant stressed that 
there should be ―room for society to move or drive the research based on their needs, 
[and] by needs of society I mean the needs for medical advancements (US patient 
advocate 1, #C251). Another patient advocate claimed that public trust and engagement 
went hand-in-hand. Trust was needed to push the science forward, but engagement was 
necessary to establish public trust in the first place (UK patient advocate 3, #C1). In 
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both cases, the underlying goal is advancing the science, but the framing is in terms of 
allowing ‗room‘ for society to be engaged on the issues.  
 While the previously discussed stakeholder groups emphasise outcomes over 
process, the perspective of bioethicists is characterised more by process-based concerns, 
often irrespective of the outcomes that might be achieved. This reveals a more 
normative imperative.
129
 With varying emphases on ensuring, for example, that ‗real 
public discourse‘ is integrated into the governance model (US bioethicist 3, #C39) or 
that the ―values of the community are expressed‖ (US bioethicist 2, #C165), criteria 
within this issue all aim (implicitly or explicitly) to ensure there is broad representation 
of social and cultural views.  
However, this desire for pluralism is tempered for some by a note of 
pragmatism. That is, some bioethicists acknowledged the ‗trade-off‘ that needs to occur 
in order to move forward with the policymaking process: 
It‘s about pragmatically striking the right balance between facilitating the 
research whilst maintaining public support for it (UK bioethicist 4, #C128). 
[It‘s about] cultural relativism and pluralism. How you deal with contexts and 
cultures, but recognise that there is a limit to this? Governance should allow for 
this trade-off to occur... (US bioethicist 2, #C165). 
This tension between pragmatism and pluralism is perhaps more apparent in the option 
assessments. There is a more positive assessment of options displaying clear 
mechanisms for public engagement, as well as some element of centralisation and 
regulatory oversight. These latter features help ensure a clear path along which policy 
decisions can eventually be made. Thus, perhaps more explicitly so than other 
perspectives, it seems bioethicists are grappling with the desire to see inclusion of a 
wide range of public views, but not in such a way that paralyses the policy process. 
Finally, policy advocates opposed to hESC research are the only group which 
tends to focus primarily on the importance of openness as a good quality with few 
caveats attached to it. There is a greater tendency to express more ‗normatively‘ derived 
criteria, addressing: i) a ―democratic principle of control‖ where ―as much public debate 
as possible‖ informs the discussions (UK policy opposition 6, # C340); ii) a broad 
―framing‖ that ―ensures no views are excluded at the start of the discussion‖ (UK policy 
opposition 1, #C132); and iii) the need for ―reflective expertise‖ (US policy opposition 
2, #C220) that assumes a balance between democratic voting and expert input.  
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We have seen how patterns in perspectives can be discerned by looking at the 
relative focus on processes or outcomes of public engagement and the role of the public 
in governance.
130
 We will now consider stakeholder views on the nature of expertise 
before drawing together the analysis under this theme of good governance.  
7.3.3 Deliberative activities: The nature of expertise 
 As introduced previously, the issue ‗nature of expertise‘ is used to group criteria 
if they fall within the scope of the following definition: 
Nature of expertise: Criteria relating to this issue are concerned with the 
features and characteristics of expertise within the governance framework. They 
focus on issues like the composition of expert bodies, the quality of advice that is 
provided, the types of deliberations that occur, and the qualities of the processes 
of input themselves as they reflect on the wider role of expertise in a context of 
good governance. 
Figure 7.15 below shows the rankings under this issue for the five stakeholder groups. 
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 Although they were not discussed here, the perspectives of industry and professional executives within 
this issue are included in the summary table and the discussion at the end of this section. However, the 
findings were not deemed to be sufficiently robust or clear to include in the analysis presented above. 
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Figure 7.15: Rankings under multiple perspectives for ‘nature of expertise’ criteria 
 
  
A notable feature of the performance rankings above is the relative number of 
individual criteria defined by each perspective and corresponding mean weightings in 
comparison with the previous issue, ‗the role of the public‘. Table 7.4 below shows the 
mean weightings across the issues within this theme in direct comparison. Laboratory-
based scientists, industry and professional executives and advocates define similar 
numbers of criteria for each issue and assign relatively equivalent importance to each. 
However, both ‗bioethicists‘ and ‗policy-makers and regulators‘ define less than half the 
criteria for the former than the latter and assign relatively less importance to these 
criteria. This finding in and of itself is intriguing. This need not imply that these groups 
marginalise considerations of expertise, but rather that they may frame good governance 
more in terms of the impact and perceptions of the public than on the basis and nature of 
expert advice. Further comments on the implications of other weightings will be made 
in the discussion below. 
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Table 7.4: Criteria and mean weightings for ‘role of the public’ and ‘nature of 
expertise’ 
Criteria 
Type Advocates Bioethicists  
Industry & 
Professional 
Policy-makers & 
Regulators  
Scientists (Labs)  
Role of the 
public 
8/12 participants  
10 criteria;  
Mean weighting 
20% 
8/9 
participants  
11 criteria;  
Mean 
weighting 20% 
8/12 participants  
11 criteria;  
Mean weighting 
14% 
8/12 participants  
13 criteria;  
Mean weighting 
20% 
9/12 participants  
13 criteria;  
Mean weighting 
18% 
Nature of 
expertise 
5/12 participants 
12 criteria;  
Mean weighting 
18% 
5 participants  
5 criteria;  
Mean 
weighting 12% 
7/12 participants  
8 criteria;  
Mean weighting 
15% 
4/12 participants  
4 criteria;  
Mean weighting 
7% 
8/12 participants  
11 criteria;  
Mean weighting 
17% 
Qualities of 
deliberative 
activities 
10/12 
participants  
23 criteria;  
Mean weighting 
40% 
9 participants  
16 criteria;  
Mean 
weighting 32% 
11/12 
participants  
19 criteria;  
Mean weighting 
29% 
9/12 participants  
17 criteria;  
Mean weighting 
27% 
12/12 participants  
24 criteria;  
Mean weighting 
34% 
 
 There are three different ways that participants characterised the ‗nature‘ of 
expertise in criteria under this issue. First, expertise is discussed in terms of what 
qualifies someone as an ‗expert‘ or what the composition of expert decision-making 
bodies should be. Second, expertise is characterised in terms of the processes of expert 
deliberations in the way they consider evidence and make decisions or provide inputs to 
policy-makers. Finally, the nature of expertise is discussed in terms of the outcomes of 
expert deliberations. In this, the focus is not necessarily on specific recommendations, 
but on the content of the evidence, advice or decisions made.  
Advocates display the greatest divergence in ordinal patterns of rankings under 
this issue, compared with the ‗role of the public‘. However, though 12 criteria are 
defined under ‗nature of expertise‘, this is only by five individuals – mostly UK policy 
advocates favouring more restrictive governance of hESC research. Their criteria reflect 
this critical position, pointing out the importance of balanced, representative expertise 
that includes the views of all publics, not just those who support hESC research.
131
  
Discussing criteria in this group, participants are comprehensive – covering in 
each case all three aspects of expertise discussed above. The distinguishing feature of 
many of the criteria and their use in the assessments is an emphasis on the ‗openness‘ of 
the process to multiple points of view. In this, it is seen as important that experts are not 
―captured‖ by special interests, powerful actors or particular ―world views‖ (UK policy 
opposition 6). While some policy advocates were more direct in their criticism of 
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 This point is particularly relevant in the case of the HFEA where, as was noted in the discussion of the 
policy literature in Chapter 5, the only experts allowed to sit on the regulatory body are those who are 
supportive of hESC and other types of embryo research. 
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particular expert inputs,
132
 most express a desire for expertise to be broad, diverse and 
inclusive of lay members (various participants, #C116, #C180, #C130, #C343); provide 
high quality advice based in both science and ethics (various participants, #C197, 
#C198, #C345); and be open to alternative points of view (various participants, #C342, 
#C134, #C135, #C198).  
 While advocates‘ criteria cover all three aspects of expertise, laboratory-based 
scientists‘ criteria focus on the composition of expert bodies, specifying they should be 
broad, multi-disciplinary and representative of public views through the presence of lay 
members. Scientists also focus on the processes of expert inputs in a wider governance 
context. Thus, criteria which alternately discuss the ―balance‖ expert advice needs to 
help achieve in society (UK scientist 3, #C193; US scientist 4, #C288), the 
―responsibility‖ experts have to engage with society about what kinds of science are 
appropriate (UK scientist 5, #C320), the principles of ―accountability‖ experts should 
operate under (US scientist 5, #C61) and the ―freedom‖ from political influence they 
should enjoy (US scientist 1, #C209) all contribute to the notion that expertise plays an 
important, cross-cutting role in good governance.  
 Finally, industry and professional body executives defining criteria within this 
issue all focus in some way on the appropriate composition of expert bodies. This 
emphasis is captured particularly well by one participant in her evaluation of the 
detailed expert oversight option when she asks ―the [real] question is who is an expert?‖ 
(emphasis added, UK professional executive 5, #A874). In considering this, UK 
participants in this group particularly stress the importance of including a commercial 
view on expert bodies. One UK industry executive comments that membership selection 
for regulatory bodies ―doesn‘t necessarily reflect the needs from a business perspective‖ 
(UK industry executive 3, #C204). The three US-based industry and professional 
executives who define a criterion under this issue do not stress the commercial side of 
expertise explicitly, but rather focus on the importance of ‗consistency‘ in composition 
and interpretation (US industry executive 1, #C348), the ‗scientific integrity‘ of the 
experts (US industry executive 4, #C296), and the importance of having ―highly trained, 
currently practicing scientific experts in the room at all times‖ (US professional 
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 For example, one UK policy advocate in describing his criterion about ‗democratic ethics‘ expressed 
his concern that ‗real public ethics‘ weren‘t being taken into account within expert advisory processes: 
“What we currently have is an academic, philosophical kind of bioethics, which is inadequate for dealing 
with the issues that these technologies raise... This type of ethics has evolved to be acceptable to 
governments and scientists and experts who sit on policymaking bodies...” (UK policy opposition 6, 
#C342). 
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executive 5, #C229). This focus on appropriate expert accreditation is also evident in 
option evaluations, with options that specify a ‗balance‘ in experts on decision-making 
bodies attributed higher performance.  
 In summary, although the findings relating to this issue are more tentative for 
some perspectives due to the relatively lower number of criteria and associated 
weightings, there do seem to be clear contrasts in characterisations of the ‗nature of 
expertise‘ across different stakeholder groups. These are most clearly seen within the 
advocates perspective, where the ranking patterns are most divergent. We turn now to a 
general discussion of the theme as a whole before summarising and concluding the 
chapter. 
7.3.4 Discussion 
 Table 7.5 below summarises the main patterns in perspectives on good 
governance under the theme ‗establishes appropriate institutions and instruments for 
hESC research‘. Where the perspective is indicated in italics, conclusions are offered 
tentatively due to the relatively small number of interviews or lack of clear signal as to 
the characterising of the perspective in question. 
Table 7.5: Summary of patterns in perspectives on the theme ‘establishes 
appropriate institutions and instruments for hESC research’ 
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and 
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based: „Who‟ 
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Shading Key: 
 Indicates a particularly strong signal from the empirical data and emphasis is placed on these areas in the text. 
 Indicates a clear signal from the empirical data, but findings are not always central to argument. 
 
Indicates some individual points from the analysis were of interest, but overall the findings are not central to the 
argument and, moreover, there was not sufficiently clear signal to merit further analysis. 
 
 There are a number of clear patterns and points of divergence and convergence 
amongst the perspectives. Criteria about the role of the public divided neatly between a 
process or outcome focus, with outcomes around public trust or support for hESC 
research being emphasised most strongly. However, the articulations of this outcome 
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focus varied. Despite nuances in the perspectives, performance evaluations of the 
governance options under this issue exhibit very similar patterns. This suggests that 
features of the detailed centralised oversight and devolved authority options best fulfil 
this type of good governance criteria, albeit in different ways and with varied emphases 
according to individual perspectives.  
Criteria concerning the ‗nature of expertise‘ fell into three types: composition-
based, process-based, or outcome-based. While some stakeholder groups did not 
comment extensively on this issue, those that did revealed a basis for distinguishing 
perspectives in ways that resonate with those evident under the issue ‗role of the 
public‘. The final discussion will summarise the main patterns in perspectives on good 
governance that have been identified throughout this chapter.  
7.4 Final discussion 
 This chapter has analysed the constituting of stakeholder perspectives on good 
governance of hESC research. In relation to the hypotheses set out at the beginning of 
this chapter, we can now tentatively conclude that: 1) it is possible to discern discrete 
perspectives on good governance across the different types of stakeholder groups; 2) 
criteria definitions and option assessments allow identification of more specific patterns 
within these perspectives; 3) the distinguishing features of these stakeholder 
perspectives contrast with those of either of the overarching national perspectives 
identified in the previous chapter; and 4) these conclusions have implications for wider 
theory-making. Table 7.6 provides a summary of the main patterns in perspectives 
according to the themes of good governance. 
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Table 7.6:  Contrasting perspectives on themes of good governance  
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Shading Key: 
 Indicates a particularly strong signal from the empirical data and emphasis is placed on these areas in the text. 
 Indicates a clear signal from the empirical data, but findings are not always central to argument. 
 
Indicates some individual points from the analysis were of interest, but overall the findings are not central to the 
argument and, moreover, there was not sufficiently clear signal to merit further analysis. 
 
This table summarises the distinguishing, key characteristics of divergent 
stakeholder perspectives on good governance. However, to avoid over-interpreting the 
nuances, complexities and contingencies, this summary focuses only on the principal 
features that have emerged from the discussion. Distinctions between perspectives 
under the first theme (‗advancing scientific and technological outcomes‘) are the 
strongest and most notably divergent amongst the stakeholder groups. Perspectives 
varied in the qualities of scientific outcomes described as desirable, the processes of 
research support required to achieve the outcomes and in the ways each were ultimately 
evaluated in the context of the options. In other words, both the quantitative ranking 
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patterns and qualitative distinctions between perspectives indicate significant contrasts 
in the socio-political framings of this theme employed by different stakeholder groups. 
Perspectives on the theme around ‗establishing appropriate institutions and 
instruments for hESC research‘ also vary, but in less markedly divergent ways from the 
scientific theme. Here, some notable similarities emerge around otherwise contrasting 
perspectives, concerning both ranking patterns and qualitative features of the underlying 
framings. However, distinctions concerning tendencies to adopt an outcome or process 
focus on the role of the public or the nature of expertise are found. In some cases, the 
focus differed between the two types of criteria within a single stakeholder group (as the 
case for laboratory-based scientists), but for others the relative focus was consistent (as 
is the case of advocacy groups).  
Considering all perspectives together, it is possible to make some broader 
observations concerning social and cultural aspects of trust as these relate to general 
notions of good governance in this area. Among policy-makers and regulators, there is a 
consistent tendency to highlight institutionally-based characterisations of good 
governance, involving ‗proportionate regulation‘ or ‗harmonised oversight‘. This is 
associated with a tendency to invoke trust in framing good governance, seemingly in 
order to win support for policy actions. Thus, while criteria about trust were often 
instrumentally motivated in this way, criteria about legitimacy tended to be framed 
more normatively. Concerns such as the representativeness of the process, the fulfilment 
of democratic norms and the objectivity with which policy-makers acted, all were 
expressed without reference to privately desired ends.
133
  
Laboratory-based scientists tend unsurprisingly to be in favour of hESC research 
and frame scientific outcomes correspondingly. Yet they still express an acute concern 
with the public‘s perception of the research they conduct. This exposes a tension 
between engaging the public because it is the ‗right‘ thing to do and engaging so that the 
public can be better educated and more trusting of the work of scientists. Similarly, 
engagement of expertise in regulation was seen as needing to be broad and diverse – 
both as normatively good qualities in their own right, but also because these might lead 
to more ‗informed‘, ‗realistic‘ and generally ‗better‘ regulations for hESC science. 
Thus, for this stakeholder group, it seems that framings of ‗trust‘ and ‗legitimacy‘ 
reflect a faith that independent, evidence-based and informed governance will result in 
the ‗right‘ attitudes and decisions for science.   
                                                 
133
 See the discussion in Chapter 8 for the analysis of these term and their significance for the thesis. 
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Bioethicists invoke ideas about cultural pluralism, whether discussing how best 
to advance the science in accordance with principles of beneficence or in engaging with 
the public. Trust and legitimacy, then, seem to have a basis in the extent to which 
cultural pluralism were seen to be reflected in governance. However, this was 
juxtaposed with a need for pragmatic policy-making. This inter-linkage between 
pluralism and the realities of the policy process has implications which are discussed 
more fully in the next chapter.  
Like bioethicists, the perspectives of various advocates seem to share a similar 
tendency to invoke ‗societal‘ and ‗public‘ interest, but in ways that depend on the theme 
of good governance in question. In some cases, invoking the ‗public interest‘ seems to 
reflect a rhetorical strategy aimed at advancing rather different policy agendas. For 
others, trust and legitimacy are based more on how public good is revealed through the 
‘eye of the beholder’. The finding that the heterogeneous nature of this grouping of 
stakeholders yields the most divergent performance rankings of any perspective, helps 
to confirm the consistency of the other perspectives (relative though this may be). 
Finally, it emerges across all issues that the rankings under industry and 
professional body perspectives tend to diverge the most from those of the other 
stakeholder groups. Industry and professional executives tended to adopt an innovation 
focus, with options favoured by this group being those involving greater 
decentralisation and those which might best afford a ‗license to operate‘. Under this 
view, trust and legitimacy, are based on the extent to which professional and 
commercial needs are accounted for in the governance framework.  
The final discussion chapter, Chapter 8, builds on – and draws together – the 
findings and analytical interpretations introduced in this chapter and the two previous 
ones, as well as introducing some new ones. The main aim is to explore links with 
existing academic literature reviewed earlier and specify the exact theoretical and 
practical contributions of this research.  
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8.  Discussion: bridging the empirical and theoretical 
8.1 Introduction 
 The previous three chapters have explored a variety of empirical grounds for 
discerning contrasting perspectives on good governance within: i) formal US and UK 
policy documents; ii) findings from 57 MCM interviews comparing between US and 
UK perspectives; and iii) findings from 57 MCM interviews comparing between 
different stakeholder perspectives within and across the two national settings. The 
remaining task is to integrate these empirical strands with each other and with 
theoretical issues concerning ‗good‘ governance provided in earlier chapters. This 
chapter will therefore address four main areas which cut across and interlink the 
empirical findings and theoretical literatures. 
In Section 8.2, we consider a recurring theme in the previous three chapters 
concerning distinctions between process- and outcome-based characterisations of good 
governance. We will examine implications of particular rationales and motivations 
behind such characterisations (based on theoretical distinctions discussed earlier 
between normative, instrumental and substantive imperatives in policy appraisal). 
Therefore, we will address a recent and developing body of theory in technology 
appraisal and democratic deliberation.  
In Section 8.3, we will focus in greater detail than hitherto on themes of ethical 
and moral awareness in good governance – and the ways in which these issues were 
more pronounced in findings from the MCM interviews than the policy documentation. 
The normative implications of these findings for policy-making will also be discussed. 
Related to this, Section 8.4 will consider the implications of the patterns and 
relationships observed here between the perspectives on good governance of bioethicists 
(on the one hand) and policy-makers and regulators (on the other). This will offer a new 
empirical basis for returning to theoretical and critical literatures on this issue 
introduced earlier in this thesis.  
Section 8.5 will consider a comparative STS perspective – specifically 
Jasanoff‘s concept of ‗civic epistemologies‘ – concerning the distinct ways knowledge 
is produced in different national contexts. Points of similarity and divergence will be 
explored between these ideas and the empirical findings obtained here. The discussion 
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chapter will end there, but will lead directly into the concluding section of this thesis, 
Chapter 9. Here, a final summary for the thesis is presented, with the main contributions 
of the thesis reviewed,  tentative recommendations offered for policy making in the area 
of hESC research and suggestions for further research made. 
8.2 Exploring normative, instrumental and substantive 
motivations in appraisal 
8.2.1 Introduction 
Stirling (2008) argues that apparently stark dichotomies between expert analysis 
and participatory deliberation tend to mask a series of more nuanced cross-cutting 
contrasts between different imperatives, intentions or motivations for ‗public 
engagement‘ in social appraisal of alternative technology strategies. As was discussed in 
earlier chapters, rather than focussing on these dichotomies (and the implications for 
decision making that might result), he suggests that attention might more fruitfully be 
devoted to improving understanding of the rationales and motivations that lie behind the 
design of different types of appraisal (both expert and participatory). To this end, 
Stirling builds on prior work by Fiorino (1989) and Fineberg et al (1996) to distinguish 
three basic imperatives, or motivations, that may lie behind the design or appreciation of 
social appraisal in technology governance: normative, instrumental and substantive. As 
expressed in the literature, these observations are based on interpretive analysis, rather 
than systematic empirical examinations. Therefore, the characterisations of good 
governance across contrasting stakeholder perspectives in ‗real world‘ settings as 
provided by this thesis may offer valuable insights. The task here, then, is to conduct 
this empirical examination. 
As argued and demonstrated in the preceding discussions, MCM is a method for 
eliciting nuances of framing in the social appraisal of alternative science and technology 
policies (in this case, options for governance of hESC technologies). MCM is therefore 
a suitable tool with which to conduct an original empirical test of the theoretical case 
made by Fiorino, Fineberg et al. and Stirling for the three distinct motivations 
underlying social appraisal, itself. If the distinctions are confirmed as salient across 
contrasting cases and divergent perspectives, then this thesis will have directly 
addressed a significant strand of thinking in recent theoretical literature on technology 
governance. 
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The first of these underlying drivers in social appraisal (to briefly review the 
argument outlined in earlier chapters
134
) are ‘normative’ issues. These focus on 
variously-conceived qualities in the processes of appraisal (Pellizzoni, 2003; also as 
interpreted by Stirling, 2008). They relate in diverse ways to the distinguishing of a 
particular governance framework as ‗good‘ simply on the grounds that certain practices 
or processes involved are judged in and of themselves, in principle, to be inherently ‗the 
right thing to do‘ (for instance, involving democratic inclusion as a self-evidently 
‗good‘ feature of process, irrespective of the outcomes). Accordingly, it was possible to 
identify a subset of participants‘ process criteria as being framed so as to reflect their 
‗normatively‘ good nature, in and of themselves, without regard to the consequences. 
Examples of such normatively-motivated criteria for good governance include features 
like ‗public reason‘, ‗openness‘, ‗legitimacy‘, ‗representativeness‘ and ‗transparency‘.  
The next two types of imperatives are ostensibly concerned with outcomes of 
appraisal (Pellizzoni, 2001; also as interpreted by Stirling, 2008), but they vary in 
important ways. ‘Instrumental’ imperatives are concerned with the realisation of 
particular ends. Here, ‗good governance‘ is judged primarily not by reference to 
process, but in terms of outcomes in the form of prior, privately-defined policy goals. 
Thus, in the context of the present analysis, instrumental framings of good governance 
are (usually implicitly) primarily concerned with achievement of specific organisational, 
policy or scientific ends, and focus not on evaluating the ends themselves, but the means 
by which they may best occur.   
The other outcome-based imperative (the third and final imperative overall) is 
‘substantive’. By contrast with the privately-held objectives driving instrumental 
motivations, substantive imperatives centre on publicly-deliberated and consensual 
societal values such as public health or equity. Thus, though the focus of substantive 
criteria of good governance is also on a set of desired ends, these ends are defined 
(usually more explicitly) in broad societal terms. Though substantive ends may be 
conceived in different ways, they are not usually controversial in broad terms as 
objectives (for example ‗health protection‘ is generally an acceptable aim), in the way 
that instrumental ends often are.  
Against this background, we can pose three broad-based questions which reflect 
the hypotheses of this thesis. First, does the threefold distinction between normative, 
instrumental and substantive imperatives in good governance comprehensively 
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 See the discussion in Chapter 3, p. 52-53. 
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characterise and adequately partition the empirically-elicited criteria? In other words, 
how well does the articulation of criteria by interviewees resonate with the three 
theoretical dimensions? For example, are there significant numbers of ambiguous or 
hybrid criteria, is one category barely represented, or does a fourth category emerge? 
Second, are there differences apparent in performance patterns depending on whether 
governance frameworks are appraised under normative, instrumental or substantive 
criteria? Third, does this conceptual scheme offer a basis for explanatory discussion of 
the drivers of contrasting framings adopted under different perspectives (as explored in 
this thesis)? Depending on the answers to these questions, we may also be able to ask 
whether particular types of perspectives tend to favour normative, instrumental or 
substantive issues and how.  
Some of these questions, particularly the first two, have been previewed in 
earlier chapters when relevant to discussing the perspectives within the themes of good 
governance. However, the issues have not been considered ‗holistically‘ and there has 
not been a critical examination of theory in light of the empirical findings. It is this 
latter point on which the discussion in Sections 8.2.3 and 8.2.4 will most heavily focus. 
The presentation of empirical findings, themselves, will first be done in Section 8.2.2.  
8.2.2 Exploring normative, instrumental and substantive issues  
Beginning with the basic question of whether the three theoretical imperatives 
can be found within the data set, the answer is in the affirmative. Two hundred and 
seventy-six criteria (out of a total of 310 criteria) reveal, under detailed textual 
analysis,
135
 either a distinctively normative, instrumental or substantive motivation in 
the way it was defined. This accounts for approximately 89% of all the criteria defined 
across the MCM interviews. Summary figures for the two countries are presented in 
Table 8.1, while summary data of the number of criteria per issue for the five initial 
perspectives defined in Chapter 7 are presented in Table 8.2. A few comments on how 
the issues are comprised according to the empirical criteria are then given.
                                                 
135
 As discussed in the methodology chapter, detailed textual analysis allows us to make deductions which 
arise from qualitative analysis of both the content of the criteria and the way it was evaluated under each 
option. 
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Table 8.1  Overall criteria matches for UK and US stakeholder perspectives136 
Criteria Type 
Criteria of this type 
among 147 total criteria 
defined by a total of 27 
UK participants? 
Criteria of this type 
among 163 total criteria 
defined by a total of 30  
US participants? 
Criteria of this type 
among 310 total criteria 
defined by a total of 57  
US and UK participants 
Normative 51 criteria  
defined by 21 participants 
Mean weighting: 34% 
49 criteria  
defined by 28 participants 
Mean weighting: 30% 
100 criteria  
defined by 49 participants 
Mean weighting: 32%  
Instrumental 71 criteria defined by  
24 participants 
Mean weighting: 50% 
90 criteria defined by  
30 participants 
Mean weighting: 55% 
161 criteria defined by  
54 participants 
Mean weighting: 52% 
Substantive
137
 9 criteria defined by  
7 participants 
Mean weighting: 7% 
6 criteria defined by  
5 participants 
Mean weighting: 4% 
15 criteria defined by  
12 participants 
Mean weighting: 5% 
No match or 
overlapping 
16 criteria 
Mean weighting: 9% 
18 criteria 
Mean weighting: 10%  
34 criteria 
Mean weighting: 11% 
 
Table 8.2: Criteria matches for principal stakeholder groupings 
Criteria 
type 
Advocates 
(12 
participants) 
Bioethicists  
(9 participants) 
Industry & 
Professional 
(12 
participants) 
Policy-makers 
& Regulators  
(12 
participants) 
Scientists 
(Labs)  
(12 
participants) 
Totals  
(% of total 
criteria) 
Normative 28 criteria 
defined by  
11 participants 
Mean 
weighting: 
45%  
20 criteria 
defined by  
8 participants 
Mean 
weighting: 39% 
14 criteria 
defined by 
9 participants 
Mean 
weighting: 21% 
18 criteria 
defined by 
10 participants 
Mean 
weighting: 29% 
20 criteria 
defined by  
11 participants 
Mean 
weighting: 28% 
100 (32%) 
Instrumental 26 criteria 
defined by 
10 participants 
Mean 
weighting: 
39% 
22 criteria 
defined by 
9 participants 
Mean 
weighting: 45% 
43 criteria 
defined by 
12 participants 
Mean 
weighting: 69% 
38 criteria 
defined by  
12 participants 
Mean 
weighting: 58% 
32 criteria 
defined by 
11 participants 
Mean 
weighting: 49% 
161 (52%) 
Substantive 4 criteria 
defined by 3 
participants 
Mean 
weighting: 7% 
5 criteria 
defined by 4 
participants 
Mean 
weighting: 11% 
1 criteria 
defined by 1 
participant 
Mean 
weighting: 1% 
2 criteria 
defined by 2 
participants 
Mean 
weighting: 3% 
3 criteria 
defined by 2 
participants 
Mean 
weighting: 6% 15 (5%) 
No match or 
overlapping 
6 criteria 
Mean 
weighting: 
8% 
3 criteria  
Mean 
weighting: 5% 
7 criteria 
Mean 
weighting: 8% 
7 criteria 
Mean 
weighting: 9% 
11 criteria 
Mean 
weighting: 17% 
34 (11%) 
Totals 64 criteria 50 criteria 65 criteria 65 criteria 66 criteria 310 (100%) 
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 Some of the mean weightings in the following two tables do not add up to 100 for a methodological 
reason. Six participants chose to define a criterion for their MCM interview they thought was important, 
but they left it unevaluated against the options, either for reasons of time or because they struggled to 
interpret how it would be evaluated against the options (intellectual property is one example as it was not 
addressed in the option definitions and participants felt uncomfortable making assumptions). However, 
they did want to weight the criterion. These ‗partially‘ evaluated criteria thus affect the weightings, but 
not the option rankings. As pointed out in the methodology chapter, they have not figured in much of the 
analysis since they do not impact on the rankings, but there is a small, residual effect on the weightings, 
which is why the phenomenon is observed here. 
137
 The average weightings displayed in this row are reflective of the average weightings across the whole 
perspective, not just those who defined a criterion within this issue. This means that the relative 
importance to the whole perspective is low, as seen in the table, but for those individuals defining a 
criterion within this issue, the relative importance was much higher. The average weightings for these 
individuals is thus, 23% for UK stakeholders and 21% for US stakeholders.  
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Beginning with normative issues, Stirling (2008) argues that normative views 
can take various forms, for instance highlighting democratic principles in participatory 
deliberative processes (Pellizzonni, 2003), or ‗value-free analysis‘ in expert analytic 
procedures. For the purpose of the present analysis, criteria which highlight evidence-
based decision-making, or democratic ideals such as openness, representativeness and 
transparency were all identified as indicating an underlying normative imperative. 
Among these, two distinct normative emphases were identified, relating either to the 
nature of deliberations or to the legitimacy of the deliberative process. The following 
examples are illustrative of the range of meanings: 
Public policy should be based on testable knowledge. We must have evidence-
based development of public policy (US bioethicist 4, #C279). 
Presence of public involvement as an input to governance. It has to be 
transparent, interactive between the public and government. This interaction 
goes both ways, if the public have an opinion it should be considered by 
government (US patient advocate 5, #C303). 
It's about the obligation on the part of government to enable input from as many 
diverse sources as possible and to give it fair consideration (US scientist 3, 
#C196) 
While the first quote reveals a way to secure legitimacy in governance decisions, the 
second two reflect normatively-grounded beliefs about how deliberative activities 
should be conducted, regardless of the ends they might lead to. The middle example is 
particularly interesting in that it seems to express both values of legitimacy and 
deliberative purpose. If public input is an ‗obligation‘ of government, one can infer that 
if it does not happen, government is failing in its obligation to citizens and, thus, loses 
legitimacy.  
Instrumental imperatives, by contrast, focus on outcomes (Pellizonni, 2001). 
These were seen in criteria that discussed education initiatives aimed at public 
understanding, efforts to foster public trust, or the encouragement of specific policy 
climates for technological development. Within these, two main types of instrumental 
issues are identifiable. The first is about how good governance helps facilitate advances 
in the science, while the second reveals an instrumental desire to achieve public trust 
through good governance, particularly as a means to further the autonomy of the 
research system. For example, one criterion about ‗public input‘ seemed at first to 
address normative issues, but actually was defined and used in an instrumental way to 
  
219 
reflect the desire that particular ends were achieved out of such ‗public‘ governance.138 
The following examples represent both types of instrumental criteria identified, the first 
about advancing the science and the second about public trust as a means to this 
(implicit) end. 
Good governance facilitates responsible scientific discovery in the area of stem 
cell research (UK bioethicist 3, #C7). 
[Governance] has to engage with the general public in order to avoid mistrust. 
Represent all opinions, not to edit what gets presented at the end (UK 
professional executive 4, #C331). 
Fifty-four of the 57 participants identified at least one criterion of this instrumental type, 
indicating it was a universally expressed imperative within all perspectives. 
Finally, substantive issues were identified based on whether criteria expressed a 
desire to achieve better ends out of socially-mediated appraisal processes. These 
referred to ideas such as how good governance could, alternatively, ‗maximise 
consensual social benefits‘ (UK scientist 3, C#193), aid in the application of ‗social 
values to innovation‘ (US Bioethicist 4, #C280), or ensure science is ‗driven by a 
societal need for medical advances‘ (US patient advocate 1, C#252). There were only 
15 criteria defined by 12 participants across both national settings that satisfied the 
requirements of identification as a substantive issue. 
Though the majority of the criteria were found to reveal one of the three types of 
imperatives, some did not reveal any particularly strong connotations of a normative, 
instrumental or substantive nature, or were sufficiently ambiguous (or ‗hybrid‘) that no 
attribution could be made. Of the former group, the criteria were deemed to be more 
‗neutral‘ in character. This relative neutrality was often difficult to determine. All 
criteria, to a certain extent, are motivated by the participant‘s desire to reflect upon what 
they consider to be the most important elements of good governance for hESC research. 
In the widest possible interpretation, then, all criteria have some underlying motivation. 
These motivations reflect individual values about good governance and socio-political 
processes, as well as specific ends or outcomes that a governance framework should aid 
in realising.  
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 Such criteria about public trust might legitimately be identified as substantive as mutual trust between 
different sectors of society, governments, publics, scientists and so on, could in itself be a positive quality 
based on consensual social values. However, what makes these criteria more instrumental is that trust is 
presented not as a mutual public value, but as something needed because of a public fearful of science and 
associated institutions. Trust, then, is a means to the privately held, and implicitly expressed, end of 
advancing science. 
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The important point here, though, is whether this motivation was akin to those 
identified in the literature on normative, instrumental and substantive imperatives in 
policy appraisal or public engagement activities. The crucial question that was asked, 
then, was whether the motivations could first be distinguished with respect to individual 
criterion and, second, what the motivation behind each criterion‘s definition and use in 
the context of an MCM appraisal exercise might be. For example, Stirling points out 
that normative imperatives are often associated with particular features of the process of 
appraisal, itself, whereas instrumental and substantive ones are focussed on the 
outcomes (Stirling, 2004, 2006, 2008).
139
 As initially discussed in Chapter 3, in this way 
Stirling is critically building on Pellizzoni‘s distinctions of participant engagement 
along such ‗process‘ or ‗outcome‘ lines (Pellizzoni, 2001, 2003, 2004). While 
developing the notion that process-based features relate to normative democratic 
motivations for engagement, Stirling argues that a singular outcome-based conception is 
insufficient because outcome-based norms can reflect both privately held and publicly 
held views. While theoretically interesting, all of these distinctions can be empirically 
difficult to disentangle. 
In fact, we find that some criteria that are ostensibly about an aspect of an 
appraisal process, are actually used to illustrate how an instrumental, outcome-based 
goal, can be achieved. For example, in discussing how expert advisory bodies should be 
comprised, an ostensibly process-oriented feature of decision-making, one US 
participant commented there should be no clergy or religious views represented on 
expert bodies. This, she believed, could result in governance decisions that were not 
based on scientific facts and could harm the advancement of science (US professional 
body 5, #C229). The motivation revealed, then, was actually rather instrumental. This 
example shows the importance of detailed analysis of both the definition of criteria, as 
well as their use in option evaluation, before assessments of normative, instrumental or 
substantive relevance are made.  
Moreover, it reveals important implications for the theoretical ideas themselves. 
In particular, it may expose crucial limits to the extent to which clear distinctions along 
axes of processes versus outcomes, or indeed normative versus instrumental versus 
substantive, are identifiable in actual stakeholder appraisals. In the discussion above we 
have begun to explore the latter set of these axes, and further comments are made in 
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 See also the discussion in Pellizzoni (2001, 2003). As pointed out in Chapter 3, Stirling‘s aim is to 
critically evaluate the process and outcome-based divide, claiming it is not sufficient and that further 
delineations can be made (i.e. instrumental vs. substantive). 
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Section 8.2.4 on the distinctions within process- versus outcome-based criteria. Our 
initial exploration has highlighted that many shades of grey exist in the motivations of 
stakeholders in appraisal processes. This is first seen in the numbers of ‗unmatched‘ 
criteria that were ambiguous as to a particular motivation along normative, instrumental 
or substantive lines. It is also seen in the complexities in distinguishing motivations 
underlying the criteria definition and use in assessment. In reality, it seems there are 
closely constructed, reflexive and complex relationships between the way stakeholders 
think they approach appraisal, and the way they act when undertaking it. That is, there 
seem to be recursively nested interdependencies among the three rationales that are 
especially evident when real-world appraisals are conducted. For example, normative 
democratic rationales ostensibly about ‗good‘ processes of governance, may also be 
conditioned by substantive motivations about the consensual social values such 
processes should lead to. These conceptual, and empirically-based, contributions are 
further developed in Sections 8.2.4 and 8.2.5. 
8.2.3 Option performance under normative, instrumental and 
substantive issues  
 Having established that the motivations under examination can be distinguished 
in respect of individual criterion, we now move to the second question asked at the 
beginning of this section: do differences exist in option performance based on 
normative, instrumental or substantive motivations in the criteria? The two figures 
below show the performance rankings of the governance options under each issue for 
UK- and US-based participants. 
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Figure 8.1: Rankings under UK-based perspectives for normative, instrumental 
and substantive criteria 
 
Figure 8.2. Rankings under US-based perspectives for normative, instrumental 
and substantive criteria  
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As can be seen from the figures above, differences in rankings by UK and US 
stakeholders do emerge, both across the issues and between the national perspectives. 
This seems to offer an initial indication that different patterns exist in the relative 
prominence of normative, instrumental and substantive criteria. These patterns may 
contribute to our understanding of differences in the ways in which national 
perspectives on good governance are characterised. To this end, some features of the 
patterns should be pointed out.  
First, the reader will have noted earlier and can see here, the low proportion of 
substantive issues within each perspective. This diminishes confidence in conclusions 
concerning ranking patterns under this issue. However, the point is interesting in itself, 
because it suggests that substantive aims behind the definition of good governance are 
either rare, harder to identify, or less consciously acknowledged among participants. 
Despite this, we still see a remarkable similarity between the ranking patterns for 
substantive criteria across UK and US stakeholder perspectives. This suggests we might 
still identify common explanations, for example, a greater potential for fulfilment of 
substantive issues among options with a strongly decentralised component. Such a 
decentralised environment  may open up access to engagement activities around various 
governance issues and provide more transparent and accessible opportunities to public 
deliberation in controversial areas of science policy. Indeed, conclusions of a similar 
nature were drawn by a research team in the US after conducting a national consensus 
conference on the issue of nanotechnology (Philbrick and Barandiaran, 2009). 
Comparing the rankings for each issue within the UK national perspectives in 
Figure 8.1, we see that the ranking patterns for normative and instrumental criteria are 
fairly similar. With some caveats,
140
 these relatively similar rankings seem to indicate a 
particularly close relationship between normative and instrumental motivations. On the 
other hand, looking at US national perspectives in Figure 8.2, we see a ranking pattern 
for the two motivations that is more noticeably different than is the case for the UK. Not 
only are there differences in option performance, but US stakeholders identify almost 
twice as many instrumental criteria as normative ones. This would seem to indicate that 
instrumental framings of perspectives on good governance are more prominent among 
                                                 
140
 The most noticeable difference is the reversal in relative performance rankings of the mixed 
central/devolved option and of the ethics-led option between the two issues normative and instrumental. 
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US- than UK-based participants. We can directly test this by looking at the relative 
importance assigned to the criteria by the individuals themselves.  
Analysis of the average weightings of the different criteria groupings, as 
summarised in Tables 8.1 and 8.2 above, shows this not to be the case. The mean 
weightings of instrumental criteria are actually rather similar for UK and US 
perspectives: 50% (UK) as compared with 55% (US). Thus, we might conclude that the 
two-fold difference is not the result of a greater importance assigned to instrumental 
criteria amongst US perspectives. It is instead indicative of a more nuanced 
distinguishing between different means through which desired (and instrumentally 
framed) ends of good governance are realised. This may be explained by the more 
complicated governance framework present in the US and, thus, more nuanced 
articulations of good governance prevail. 
Further to this, we see in the US rankings that the expert-led framework, ethics-
led governance and detailed centralised oversight options all performed best under 
instrumental criteria. This seems to highlight one of the tensions discussed in previous 
chapters about the desire among US-based participants for scientific autonomy, on the 
one hand, but also stability and harmonised policies, on the other hand. It also reinforces 
the argument about more nuanced descriptions of instrumental criteria of good 
governance. Thus, while the expert-led and ethics-led options feature more 
‗decentralised‘ and ‗hands-off‘ approaches to oversight and may be seen as better at 
fulfilling this perspective, the detailed centralised oversight option may be more able to 
provide stability if the overarching regulatory framework is permissive. 
 When considered across multiple types of stakeholder groups, additional 
patterns are revealed in option performance and perspectives on good governance under 
normative and instrumental issues. Table 8.2 (above) summarised the criteria matches 
for each issue by perspective. Those data suggest that there are (at least superficially), 
some distinguishable patterns across the stakeholder groups. Within these, advocates 
and bioethicists have almost equal numbers of normative, instrumental and substantive 
criteria, whereas the other three perspectives have double to three times as many 
instrumental criteria as normative ones. Figures 8.3 and 8.4 below present the 
performance rankings for the five stakeholder perspectives being analysed under 
normative and instrumental issues, respectively.
141
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 For the reasons discussed above about low numbers of criteria and, therefore, lower confidence in the 
findings, ranking patterns for substantive issues are not presented here, but can be seen in Annex K. 
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Figure 8.3: Rankings under stakeholder perspectives under normative criteria 
 
Figure 8.4: Rankings under stakeholder perspectives under instrumental issues 
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As with the aggregated UK and US perspectives, patterns also emerge from 
comparison of the rankings obtained under disaggregated stakeholder perspectives on 
normative and instrumental criteria. Brief comments will be made here concerning 
possibly salient features for the remaining discussions. Beginning with normative 
criteria, we can see that ranking patterns are rather similar across the perspectives, with 
any ordinal variations being too small to interpret safely. However, it is the case that 
these similarities are most apparent in the assessments of policy-makers and regulators 
on the one hand and the bioethicists on the other. This suggests that these two groups 
share relatively similar perspectives about the normative democratic values that 
characterise good governance. Qualitative analysis does find this to be the case, 
although policy-makers and regulators tend to focus slightly more on normative aspects 
which relate to legitimacy as a feature of governance, while bioethicists focus on 
normative features of deliberation processes like openness, representativeness and ‗real‘ 
public discourse (#C39, US Bioethicist 3). However, despite the similarities, there are 
differences in relative importance assigned to the criteria. Bioethicists having a mean 
weighting of 39% as compared with 29% for policy-makers and regulators. Such a 
subtle difference in expression of importance may reflect upon more deep-seated 
imperatives for good governance which do not otherwise come to the fore. However, 
the implications of the fact that similar ranking patterns of option performance still exist 
is intriguing. This point is taken up in much greater detail in Section 8.4 of this chapter.  
Looking across all perspectives, under normative criteria we see a common 
feature of the detailed centralised oversight option performing best under optimistic 
assessments. However there remain significant variations in the extent to which it is the 
highest ranking, its relationship with other options and associated degrees of 
uncertainty. We might tentatively say, though, that this option displays the highest 
potential to fulfil normative imperatives. 
This is not the case, though, under instrumental criteria. Here, the detailed 
centralised oversight option is less frequently the highest performing option. Moreover, 
when this is the case, it is (on average) by a notably smaller increment than under 
normative issues. This suggests that, when evaluating criteria displaying instrumental 
motivations, there is a greater variability in the types of options and associated 
conditions for positive performance. Since instrumental criteria are more outcome-
based, it may be the case that participants find these types of considerations more 
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amenable to change, whereas normative, process-based motivations are ingrained within 
a system.  
In addition to the observations about ranking patterns, we do see that, subject to 
the same caveats expressed in the analysis of UK and US perspectives as a whole, some 
individual stakeholder groups (policy-makers and regulators, industry and professional 
executives and – to a lesser extent – laboratory-based scientists), all seem to display 
greater tendencies to articulate underlying instrumental (more than normative) 
rationales in their motivations for governance appraisal. In other words, it is among 
these perspectives that instrumental imperatives feature more prominently in terms of 
numbers of criteria defined. These criteria span instrumental motivations which reveal 
imperatives to advance the science (about two-thirds), and to foster public trust, (about 
one-third). When considered with the qualitative content of the interviews, this 
similarity suggests that a key driver of an instrumental framing as observed here is the 
need to engage or work with the public in order to gain trust so that one‘s ‗job‘ – be it 
crafting policy, developing hESC technologies, or conducting research – can continue.  
When we look at the relative importance of the different types of criteria, 
though, we find a contrast to that of the UK and US-based analysis. There, the greater 
number of instrumentally framed criteria amongst US stakeholders did not equate with a 
greater prominence given to them. However, as shown in Table 8.2, the mean 
weightings of each criteria group reveal that relative importance is greater for 
instrumental criteria in the case of policy-makers and regulators, industry and 
professional body executives, and laboratory-based scientists. In these cases, then, the 
greater number of instrumental criteria also corresponds to a greater prominence, as 
indicated by relative importance, of instrumental motivations behind articulations of 
good governance.  
Having now established that normative, instrumental and substantive 
imperatives for appraisal are, indeed, a meaningful way of partitioning the MCM 
criteria and, moreover, that differences in option performance can be distinguished 
depending on the different imperatives, we will now turn to conceptual points about the 
theoretical ideas, themselves. The next section considers distinctions in option 
performance based on outcome or process-based criteria and, after discussing the initial 
findings of such distinctions, compares these to the findings under normative, 
instrumental and substantive imperatives just described.   
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8.2.4 Comparing process and outcome characterisations 
 In Chapter 5, the analysis of UK and US policy documents revealed differences 
of prominence between process- and outcome-based characterisations of policy 
approaches. This, and discussion in preceding sections, suggests that it may be fruitful 
to undertake further analysis of the MCM findings under these issues. This is all the 
more so, given the comments at the end of Section 8.2.2 about the difficulties 
encountered in identifying whether criteria were a) process or outcome-based, b) 
normative or instrumental/substantive, c) if outcome-based whether they were 
instrumental or substantive in nature, or d) ambiguously spanning multiple categories. 
In order to test this point, we need to consider the MCM findings in a different 
way to that discussed so far. If we define outcome-based and process-based issues
142
, 
we can then analyse the rankings and criteria assessments and compare them with the 
analyses of normative, instrumental and substantive criteria. In addition to enhancing 
our understanding of the MCM findings, such consideration will allow us to determine 
whether the empirical findings support, contradict or critically elaborate on the 
theoretical literature reviewed above. The two issues used for the analysis here are 
defined as:   
Process-based: Criteria in this issue are those that relate to features of the 
process of governance. Outcomes may be referenced implicitly or explicitly, but 
the focus of the criteria and option assessments is on how the process of 
governance is characterised.  
Outcome-based: Criteria in this issue are defined in terms of the outcomes good 
governance would achieve. The emphasis is on particular outcomes, with any 
references to the way in which it is achieved being secondary considerations. 
Analysis of this issue below shows that differences in quantitative and qualitative 
patterns of process-based and outcome-based criteria are visible between and within
143
 
the perspectives of US and UK stakeholders and the five stakeholder groups discussed 
in Chapter 7. Figures 8.5 and 8.6 below show the rankings under UK and US 
perspectives for the two issues ‗process-based‘ and ‗outcome-based‘.144 
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 The term ‗issues‘ is used here in the MCM analysis sense of a group of criteria. 
143
 ‗Between‘ means that differences can be seen in the definition and use of the two types of issues when 
compared between the two countries, while ‗within‘ means that differences in the definition and use of 
process-based and outcome-based issues can be seen when compared within each country. 
144
 Performance ranking charts directly comparing UK and US perspectives can be found in Annex K. 
Performance ranking charts directly comparing the five stakeholder groups can be found in Annex K. 
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Figure 8.5. Rankings under US perspectives for ‘process-’ and ‘outcome-based’ 
criteria  
 
 
In the figure above, we can see somewhat distinct ranking patterns under each 
issue, indicating significant contrasts in the constituting and application of process-
based and outcome-based criteria
145
. First, US stakeholders identify almost twice as 
many individual criteria for outcome-based as process-based issues. This prominence is 
supported by an average weighting of these criteria that is higher by more than a third: 
process-based criteria have an average weight of 36%, whereas outcome-based criteria 
have a mean weighting of 63%. This seems to suggest greater concern under US 
perspectives for the outcomes of governance, rather than the ways in which these occur.  
The contrasting ranking patterns noted above arise from a number of discernible 
distinctions. There is more variation in rankings under process issues, with outcome-
based issues displaying an especially pronounced similarity across all options at the 
optimistic ends of the ranking intervals. This suggests a view that all governance 
options are in principle capable of achieving similarly high performance, but that there 
exists greater scope for variation when considering more pessimistic conditions. The 
rankings also reflect the contrast discussed in the previous section concerning normative 
and instrumental criteria, showing the two categories to be highly coincident
146
.  
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 This is indicated by the different ranking patterns and numbers of individual criteria within the issue. 
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 As we have discussed previously, given the relatively low profile of substantive issues we can be all 
the more confident that the coincident findings are most pronounced between process/outcome and 
normative/instrumental categories of criteria, respectively. 
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What is intriguing in the case of this process/outcome comparison, however, is 
that a strongly contrasting pattern emerges when attention turns to UK perspectives. 
Figure 8.6 below compares the ranking patterns under UK perspectives. Here, there are 
much greater similarities between rankings obtained under process and outcome criteria 
than are evident in the US. This suggests systematic differences in the way US and UK 
participants are characterising and defining elements of good governance under this 
theme. Where this degree of contrast arises, some confidence is gained that individual 
patterns are not simple artefacts of the method or option definitions. Moreover, these 
observations echo those from the analysis of the policy literature. We recall from the 
discussions in Chapter 5
147
 that similarities were found between Vogel‘s analysis of UK 
and US regulatory strategies (1986) and the analysis in this thesis of the hESC policy 
documents. Both suggest a greater emphasis on processes, or ‗consensus-seeking‘ 
(Vogel, 1986, p. 269) in the UK approach, as opposed to a more outcome-oriented 
strategy of the increasingly ‗pluralist‘ and ‗interest-based‘ (Ibid, p. 278) US regulatory 
environment. Taken together, these policy document- and empirically-based analytical 
findings suggest an interesting and potentially significant general contrast between 
stakeholder perspectives on good governance in the US and UK. 
Figure 8.6. Rankings under UK perspectives for ‘process-’ and ‘outcome-based’ 
criteria 
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 See the discussion in Section 5.5, and in particular, p. 116. 
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As the figure shows, the relatively tight associations in the UK case between 
rankings under these criteria, suggests a greater inter-linkage, or overlap, in the UK 
between notions of process and associated outcomes of good governance. This is 
corroborated both in the relatively equal mean weightings given to each set of criteria 
(52% for process criteria and 48% for outcome criteria), but also in the qualitative 
evidence from interviews. In the case of UK participants, we did indeed find process 
and outcome-based issues more integrated, with the theoretical and analytical 
distinctions blurred in several of MCM appraisals. For example, the following comment 
was made by a UK patient advocate in assessing the performance of the detailed 
centralised oversight option under his criterion ‗instils real trust‘:   
It‘s about the extent to which the system is transparent and challengeable. It has 
to do with openness of the system and the extent to which public involvement is 
there and public access to the decision-making process (UK patient advocate 5, 
#A1783).   
This criterion is about an outcome of governance decisions, that of fostering public 
trust. However, the assessment focuses on the processes of decision-making through 
which this trust comes about, showing the two to be closely linked. If we look to the 
way this criterion was defined, further ambiguities and implications for the motivations 
behind it arise. The participant says that  
trust should not be blind. It should operate in a system where there are 
mechanisms for looking at the checks and balances, for scrutinising the 
decisions that are made if you want them to be made, [and] where the ...  
operating the processes are public and can be endorsed by people (UK patient 
advocate 5, #C310).  
In one sense this criterion could be interpreted as instrumental in the way Stirling 
defines it (2008). The criterion is about his desire for a system of good governance to 
act in ways that instilled ‗real trust‘. In another sense though, the criterion might be 
interpreted as being substantive. That is, the interviewee favours public discussion and 
attention to what ‗trust‘ means and collective consideration, or ‗endorsement‘ of how it 
is earned. Complicating the picture even more are the elements of ‗good process‘ in 
democratic governance, and hence more normative framings, that are also conditioning 
the criteria‘s definition and use in evaluation.  
Examples of such ambiguity in option assessment and criteria definition further 
support the conceptual points made at the end of Section 8.2.2 that there are both shades 
of grey in understanding stakeholder motivations, as well recursively conditioned 
relationships between the three imperatives in appraisal. This is further evidenced in 
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another participant‘s reflections on his process-based criterion ‗flexibility‘ and its 
evaluation under the devolved authority option:  
At the upper level it's to a degree like what we have in the UK, where we have 
the oversight not as flexible as you might like, but at the local level you might 
have assistance and more flexibility there... you may actually have influence if 
something positive is coming out from local level changes (UK patient advocate 
3, #A24). 
Again, the feature of the governance process being inherently flexible is linked to the 
outcome of having the science advanced and the impact of change at the national level. 
Thus, though it is a process-based criterion under one analysis, the fact the assessment 
was concerned with how that process helps to advance science means it was found to 
reveal more instrumental motivations under the other.  
At the risk of belabouring the point, these distinctions are also borne out when 
the ranking patterns under normative/process-based criteria as well as 
instrumental/outcome-based criteria are compared across the five stakeholder 
perspectives. We find that the patterns between each grouping are similar, but some 
variations are apparent within the finer-grain distinctions according to normative and 
instrumental criteria. We would expect this to be the case on the basis of the heuristic 
distinctions between normative, instrumental and substantive imperatives and their 
relative grounding in process- or outcome-based features of governance. The important 
point, though, is that more fine-grain analysis of key drivers are possible when we look 
at the normative, instrumental or substantive imperatives, as discussed in earlier 
sections. 
Thus, our conclusions from this discussion are two-fold. First, contrasting 
perspectives between UK and US stakeholders were found in the way processes of good 
governance are seen to relate to outcomes of good governance. Second, and more 
directly related to the theoretical literature being empirically tested, is the observation 
that in looking at the findings through the analytical lens of normative, instrumental or 
substantive imperatives versus process or outcome-based characterisations of good 
governance has tangible implications for option performance. Each partitioning 
illuminates distinct features of perspectives on good governance, with associated 
framings and motivations underpinning governance strategies coming to the fore. 
However, the quantitative and qualitative implications highlighted in the analysis reveal 
possible empirical limitations to the theoretically grounded ideas.   
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8.2.5 Discussion 
A growing area of theoretical literature explores the normative, instrumental and 
substantive motivations that might lie behind processes of technology appraisal. This 
literature argues that a focus on understanding the cross-cutting dynamics within both 
participation and analytic appraisal processes, as opposed to focussing on the 
dichotomies between them, might prove more useful in the opening up and 
―empowering of human agency in the deliberate social choice of technological futures‖ 
(Stirling, 2008, p. 286). Thus, identifying the underlying rationales and motivations for 
appraisal as they apply to both the participatory and analytic forms can enable a deeper 
understanding of the reasons for, or conditions under which, the ‗opening up‘ or 
‗closing down‘ of science and technology choice in wider policy discourses148 should, 
or could, occur. While these ideas have been explored theoretically, they have not 
previously been tested empirically.  
In applying the theoretical notions to the empirically generated set of MCM 
criteria, we find the ideas to be substantiated. A detailed analysis reveals not only 
evidence of all three sets of motivations within the criteria (although substantive 
motivations noticeably less so), but different patterns in the performance rankings under 
each issue emerged for different groupings of stakeholders. However, often there were 
overlaps and inter-dependencies in the definition of the criteria, where, for example, 
process-based norms are invoked in instrumental ways, substantive motivations reveal 
normative conditions of process, or normative features of democracy are discussed in 
the context of instrumentally favoured outcomes. Two implications for the theoretical 
ideas emerge from this finding. First, while normative, instrumental or substantive 
rationales may be broadly distinguishable as being process and outcome based, this does 
not always provide a greater level of clarity in distinguishing among more ambiguous 
motivations and rationales. Process and outcome based distinctions of good governance 
reveal a different type of contrast between perspectives on good governance than do 
distinctions based on normative, instrumental and substantive. Second, we have 
contributed conceptually to theoretical insights in the area of technology governance by 
showing that, in addition to the implications of process and outcome distinctions, the 
imperatives themselves are reflexively co-conditioned and mutually constituting in 
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 See the discussions in Section 3.3, in particular p. 52-53. 
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deep-seated ways. The fact that both of these findings are empirically grounded 
reinforces the significance of this contribution. 
This latter point has practical implications for our understanding of why it is 
important to explore the drivers of contrasting framings of good governance. The point 
is to enable understanding of the diverse framings and sensitivities which condition the 
perspectives on different technology choices or governance strategies which are being 
considered. Thus, by finding that such underlying rationales and imperatives can be 
identified in empirical settings, we show specifically how MCM fulfils the requirements 
of the theoretically-grounded concept of ‗opening up‘ technology appraisal.  
8.3 Establishing moral and ethical awareness 
8.3.1 Introduction 
 Moral and ethical concerns surrounding hESC research are never far from the 
centre of policy debates and governance discussions. Certainly in the case of the policy 
literature analysed in Chapter 5, the moral and ethical language used to discuss the 
status of the embryo and conduct of the research featured prominently, and even seemed 
to frame the nature of governance considerations in both the UK and the US settings. 
The question now becomes one of how the perspectives on good governance with 
respect to moral and ethical aspects in hESC research are constituted among the 
different groups of stakeholders interviewed for this research. The analytical MCM 
issue was defined as follows: 
Moral and ethical aspects: Criteria under this issue address moral and ethical 
concerns related to hESC research. Many concern both the need for ethical 
guidance and application of ethical norms to this area of research, as well as 
the need for ethically-based deliberations to inform decision-making. 
 Three distinct types of criteria constitute this issue group: i) criteria relating to 
the moral status of the embryo and the implications of using embryos in research; ii) 
criteria about the ethical principles that should guide the conduct of hESC research; and 
iii) criteria about the need for ethical deliberations to inform these principles and other 
elements of governance for hESC research. While the former adopts a framing based on 
the moral values implicated in hESC research, the latter two adopt a framing based on 
ethical principles.  
The distinction is subtle, yet important both theoretically and conceptually. 
Theoretically, ‗morality‘ refers to an individual‘s or group‘s attempt to ―live out in daily 
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attitudes and actions their vision of the highest good‖ (Young, 2001, p. 163). According 
to Young, moral systems are often tied to particular religious traditions or cultural 
histories. ‗Ethics‘, on the other hand, ―employs a common or public language in 
justifying assertions about prescribed or proscribed attitudes and actions‖ (ibid.). 
Conceptually, in order to use moral arguments in public debate, Young argues one must 
use the ―neutral language of reason‖ and ―appeal to shared societal values‖, thereby 
shifting the preferred rhetoric of the moral system to a more neutral language of ethics 
(ibid.).   
Though a detailed theoretical application of these ideas is beyond the scope of 
this thesis, the distinction is important to bear in mind. There are important insights to 
be gained from appreciating both the ‗unquestioned‘ distinctions between ‗ethics‘ and 
cultural ‗values‘ (Tallacchini, 2006) as well as the more normative implications for 
policy-making that arise from the non-academic application of ‗ethics‘ and ‗morals‘. 
Tallacchini points out one such implication in commenting that  
In moving from academic to institutional settings, moral thought has been 
radically reinvented ... ‗ethics‘ has acquired a quite established soft regulatory 
status consisting in the production of ‗valid ethical knowledge‘ that legitimately 
enters in the legislative process (Tallacchini, 2009, p. 283).  
Analysing the empirical findings with an eye to these theoretically grounded 
distinctions will be a key aim of the following section. In this regard, the analysis below 
will highlight relevant points that emerge from the qualitative analysis of this issue 
group across the various perspectives. However, the performance rankings and 
assessments made by participants will not be presented here.
149
 This is partly due to 
space constraints but is also due to the fact that, in comparison to issues in other themes, 
the number of criteria within this issue is relatively small. Thus, we are somewhat less 
confident about the implications of the option rankings, but nonetheless can make 
meaningful inferences from the qualitative information produced during the interviews. 
8.3.2 Moral and ethical aspects of hESC research: stakeholder 
views 
The point about the relative number of moral and ethical criteria defined, and the 
number of participants defining them, is of interest in itself and is where our analysis 
begins. The review of the policy literature in Chapter 5 found that while the UK policy 
literature adopted a consistent, more technical framing of the embryo (observed through 
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 A full set of analytical charts for the different perspectives can be found in Annex K. 
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coining of the term ‗pre-embryo‘), the US policy literature reveals a rather inconsistent 
framing of the embryo which varies between policy documents. Despite this, in both 
sets of literatures, the moral status of the embryo was an important component of 
governance discussions. 
The fact this framing is central to the discussions in the policy literature makes it 
all the more curious that so few participants specifically address it in their interviews: 
out of 56 moral and ethical criteria across all interviews, only nine criteria (defined by 
eight individuals) specifically discuss the sensitivities of the use of embryos in hESC 
research. Seven of these nine criteria are defined by UK participants (amounting to six 
out of the eight individuals). However, what is even more intriguing, and entirely fitting 
with the importance given to the moral status of the embryo in the policy literature, is 
the fact that seven of the eight individuals who did define a criterion about the moral 
status of the embryo were either policy-makers, or held some position on a government 
advisory panel. This, combined with the fact that six of the eight participants are from 
the UK, suggests that reference to the moral status of the embryo is not only a more 
prominent feature among UK-based participants, but in particular UK-based policy-
makers and regulators.  
Possible explanations for this finding vary. One explanation might be that for the 
very fact that the status of the embryo continues to be so contested in US policy-
making, US stakeholders, including policy-makers and regulators, steer clear of 
mentioning it where possible. Even a participant who is generally opposed to hESC 
research did not explicitly use the term ‗embryo‘ in his evaluations, but rather ‗innocent 
life‘. He entitled his criteria as ‗the defence of human life and dignity‘ and explained it 
in the following way: 
Government is there to protect against violation of certain rights. Government 
itself should not violate these rights. So that means we shouldn‘t pursue policies 
that take innocent life on the one hand, or diminish respect for human dignity... 
It‘s a principle of showing regard for what is unique about individual human 
beings (US bioethicist 5, #C245). 
In further support of this explanation, we find more criteria relate to principles for 
ethical conduct of hESC research (as opposed to ethical deliberations) among US-based 
participants. Thus, it could be that US stakeholders see discussing such issues around 
the ethical conduct of research as more fruitful, since the moral questions relating to the 
embryo get bogged down in incompatible moral framings.
150
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 c.f. Young, 2001 as discussed above. 
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Given this, we might also expect the types of criteria referring to ethical 
principles, more generally, to implicitly refer to the fact that this is an area of science 
rife with moral and social sensitivities. This is, in fact, what we find. Criteria about 
ethical conduct emphasise the need for, variously, ethically-based ‗frameworks‘, 
‗oversight‘ and ‗guidelines‘. This view was particularly prominent among laboratory-
based scientists. The acute awareness of the sensitivities of their work seemed to 
contribute to a clear expression of the importance of thinking through, and being seen to 
think through, the moral and ethical ramifications of conducting hESC research. 
Morality comes into play here... Obviously there needs to be sets of rules 
because some experiments just shouldn‘t be done (US scientist 5, #C58). 
Society needs to determine what is morally correct for itself, and this can be 
difficult to achieve. Good governance would be about facilitating these types of 
discussions throughout society ... listening to society (US scientist 3, #C284). 
The latter of these two quotes illustrates the other type of ethically framed 
criteria, those related to the importance of ethical deliberations. Though the above quote 
is made by a US scientist, criteria about the importance of ethical deliberations were 
mentioned more frequently by UK-based participants (at the national level of 
comparison), as well as by bioethicists and advocates (at the inter-stakeholder level of 
comparison). These criteria relate to the need to actively consider different social, 
ethical and moral views when making decisions about hESC research governance. One 
advocate opposed to hESC research (on the grounds it destroyed human embryos) 
stated,  
Issues like ethics, morality... generally people think a lot of those ideas go 
together, but it‘s about whether it‘s right or wrong in itself. How to reach a 
consensus of what is right or what is wrong is complex and that does involve 
society as a whole (UK opposition policy 2, #C201).  
Another UK-based participant commented that government should ―maximise the 
consensual social benefit.‖  
What one is trying to achieve, in the end, is to maximise consensual benefit from 
this sort of endeavour. This entails two potentially conflicting or opposing 
things. One is that there is a general social interest in improving our general 
understanding of biology and that has specific connotations about managing 
nature. All of that is in favour of doing everything [in terms of the science]. 
Opposing that are certain social and ethical constraints that a society regards as 
reasonable. [Governance] is about trying to find a reasonable blend and balance 
of those conflicting objectives (UK scientist 3, #C193). 
In many ways, this quote illustrates the issues this thesis is exploring in terms of the 
governance challenges posed by biomedical technologies like hESCs. The point is, that 
  
238 
governance decisions cannot occur in a vacuum and social and ethically-based concerns 
must factor into the decision-making process. 
The tables below summarise the characterisations of ‗moral and ethical issues in 
hESC research‘ in the corresponding theme of good governance across the stakeholder 
groups. Table 8.3 displays the main patterns across UK and US stakeholders, as well as 
in comparison to the relevant  national policy literature.  
Table 8.3. Summary of patterns under the theme ‘addresses ethical and moral 
issues in hESC research’ 
 Perspectives from US 
Policy literature vs.  
US stakeholders 
Perspectives from UK 
Policy literature vs.  
UK stakeholders  
Perspectives of  
US stakeholders vs.  
UK stakeholders  
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s
s
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s
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h
 Defines 
principles of 
research 
conduct 
Broadly congruent Slight Divergence Slight Divergence 
Moral status of 
the embryo 
No clear signal Slight Convergence 
Noticeably  
divergent 
Shading Key 
 Noticeably divergent: Distinct differences across the two perspectives are clear and readily identifiable 
 Slightly divergent: Some differences across the two perspectives are clear. Similarities or unclear signals exist. 
 Slightly convergent: Some similarities across the two perspectives are clear. Differences or unclear signals exist. 
 Broadly congruent: Similar patterns across the two perspectives are clear and readily identifiable. 
 
Overall there is a slight divergence between US and UK perspectives on good 
governance within this thematic aspect for principles of research conduct, and stronger 
divergence with regard to how the moral status of the embryo is addressed. In the UK, 
the perspectives on good governance that emerge in this area are less to do with the 
actual conduct of the research and more to do with the ways in which society might 
come to decide on what those principles of conduct might be. The US perspectives on 
good governance are shown to centre largely on criteria related to the types of ethical 
frameworks and guidelines that should be in place in order to ensure that responsible 
scientific discovery can take place. The findings summarised above seem to offer an 
explanation for the differences in UK and US perspectives that relates, in part, to the 
particular policy environments that existed in each country at the time of the interviews.  
Table 8.4 summarises the main patterns in the perspectives across the five main 
stakeholder groups.  
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Table 8.4: Summary of patterns under the theme ‘encourages ethical and moral 
awareness for hESC research’ 
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Principles of 
research 
conduct 
Enforce 
ethical 
compliance 
Establish 
ethical 
guidelines 
Ensure ethical 
inputs 
Balance 
ethical 
guidelines 
and 
deliberations 
Part of 
business 
model 
Moral status 
of the embryo 
Respect for 
social norms 
(5 criteria)  
Respect as 
scientific 
resource  
(1 criterion) 
Respect for 
human dignity 
(1 criterion)
12
 
Respect for 
sensitivity  
(2 criteria)
151
 
No criteria 
expressed 
Shading Key: 
 Indicates a particularly strong signal from the empirical data and emphasis is placed on these areas in the text. 
 Indicates a clear signal from the empirical data, but findings are not always central to argument. 
 
Indicates some individual points from the analysis were of interest, but overall the findings are not central to the 
argument and, moreover, there was not sufficiently clear signal to merit further analysis. 
 
Here we find that the perspectives of individual stakeholder groups also seem to 
reflect the particular social and political environment they encounter on a daily basis. 
Scientists recognise the sensitivities involved with their area of work and the need for 
ethics to play a role in both shaping and informing oversight. Stakeholders from 
industry and professional bodies realise that if ethical sensitivity is not a part of their 
business model, they will lose trust, and therefore, their market. Bioethicists are 
concerned with broad-based ethical deliberations feeding into the development of 
ethical oversight, as are advocates of different types. However, some advocates reveal a 
particularly instrumental motivation in ‗winning‘ public support to their side through 
discussion of ethical principles. Finally, we discussed above how policy-makers and 
regulators, more so than other perspectives, emphasise the moral questions over 
protecting the embryo while grappling with how to translate this into a form of ethical 
compliance that upholds this moral framing in law. We will conclude this section by 
making further links to the academic literature. 
8.3.3 Discussion 
The discussions above have shown that distinctions in the framing of ethical and 
moral perspectives on good governance are evident across various stakeholder 
perspectives. This is observable in the fact that there are few criteria relating to the 
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moral status of the embryo. Those interviewees who do define criteria about the moral 
implications of hESC research are overwhelmingly those involved in developing, 
advising or implementing policy. Among the other stakeholders, issues around moral 
and ethical awareness are framed in terms of the ethical principles that should guide the 
conduct of hESC research and deliberations about its conduct in wider society. There 
are several implications of this for wider theory. 
In relation to criteria about ethical research conduct we may be observing a more 
indirect way of speaking about the moral status of the embryo. In attempting to re-frame 
the question in a way that moves the discussion away from the intractable moral issues 
and towards the ‗grey‘ language of ethics (see the discussion of Young, 2001, as above), 
it could be that stakeholders are forging new paths forward through otherwise seemingly 
intractable governance debates.  
Theoretical and empirical support for this explanation might be found in a 
phenomenon known as ―absent presences‖; a term adopted by Law and observed in a 
recent public engagement study by Felt and colleagues looking at ethical discussions 
around genome research (Law, 2004; as cited in, Felt et al., 2009). In Felt et al.‘s study, 
they hypothesise that participants discuss ‗ethical‘ issues as social or political in nature. 
In so doing, they argue participants seemed to be masking, either from themselves or 
others, the complexities of ethical issues pertinent to the issue of genome research by 
calling them something else. Thus, it might be that a similar ‗absent presence‘ 
phenomenon is observed here. If this is the case, the lack of criteria specifically 
addressing the moral status of the embryo does not suggest it is unimportant, but rather 
it is framed in a different way in order to mask the complexities in the debate, or to 
enable the debate to move forward. 
Under any set of explanations, the empirical finding of such a shift in framing 
from ‗moral status‘ to ‗ethical conduct‘ among the majority of the stakeholders is 
significant. It suggests that those actually advising, crafting or implementing policy are 
operating within a different frame of reference to that of most stakeholders ‗on the 
ground‘. Moreover, these stakeholders may see an entirely different set of issues as 
affecting the ‗problems‘ of policy-making and governance, more generally, in this area. 
Considering this in light of the discussion of the policy literature in Chapter 5, we might 
conclude that the perspectives on good governance extant in formal US and UK policy 
literatures are also framed by rather different sets of problems than are evident in the 
perspectives of stakeholders in the respective countries. That is, ethical and moral 
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elements of good governance in the policy literature may be discussed in less nuanced 
ways and with less breadth than is articulated by the stakeholders themselves. While this 
observation could be a result of a limitation in our ability to deeply explore the policy 
literature to the same extent as an interview discussion allows, the fact that such 
divergent perspectives are found across the stakeholder perspectives at multiple levels
152
 
does seem to suggest that there is merit to our claim.  
Consequently, we can now say with some confidence that it is not only the 
policy literature that tends to dwell strongly – and frame the governance discussion in 
terms of – the moral questions of stem cell research, but evidence of this framing is also 
found among stakeholders who are involved in advising on and crafting policy. This is 
not to say these issues do not feature at all in other stakeholders‘ perspectives on good 
governance – and indeed may be ‗absent presences‘ – but it is the case that the moral 
and ethical criteria defined by the majority of interviewees tend to emphasise the ethical 
conduct of hESC research and application of technologies, as well as the ethical 
deliberations which should inform governance discussions. Therefore, for many 
interviewees, there seem to be a wider set of concerns under the moral and ethical 
umbrella than simply the moral status of the embryo. Thus, we might say that, in 
contrast to the greater use of moral and ethical language to describe governance, and 
frame good governance, in the policy documents, stakeholders interviewed seem more 
concerned with wider socio-political and institutional factors in good governance. This 
dichotomy links to academic literatures relating to the relationship between ‗ethics‘, 
‗bioethics‘ and policy-making and leads us directly into the topic of the next section: the 
emergence of bioethics as a new mode of expertise.  
8.4 Bioethics as a new mode of expertise? 
8.4.1 Introduction 
The implications arising from the discussion in the previous section relate to the 
concerns raised in the academic literature
153
 over the rise of bioethics as a new mode of 
expertise in biotechnology decision-making. This is seen in many ways, including in the 
rise of ―bioethics forums‖ (Gutmann and Thompson, 1997), ―official bioethics‖ 
(Jasanoff, 2005), and ―public bioethics‖ (Kelly, 2003). Many argue that bioethics and its 
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associated rhetorical strategies has emerged as a new source of legitimacy in 
government discussions (Brown and Michael, 2002), and has become the preferred 
language and ‗currency‘ for publics and policy-makers, both nationally and 
internationally, to trade in and negotiate with when developing biomedical technology 
policies (Salter and Salter, 2007; Gottweis et al., 2009).  
In its emergence as a preferred tool for policy-makers (Grove-White, 2001), it is 
argued that governments seem to be seeking 
fresh forms of relationships between science and society – not simply to re-
legitimize scientific advice in the eyes of the wider population, but even to help, 
indirectly, to reconstitute that science in terms which may then be experienced 
as sensitive and relevant to society as a whole (ibid., p. 467).  
Arguments made by Tallacchini (2009) can be interpreted as supporting this statement. 
She calls attention to the ―uneasy‖ relationship between scientific ―facts‖ and cultural, 
ethical or moral ―values‖ in today‘s ―knowledge society‖ (Wynne et al., 2007). Thus, 
ethics is invoked by governments in order to promote shared understandings and 
address feelings of risk and uncertainty which may result from new biotechnologies 
(Tallacchini, 2006). Similarly, in an extensive review Jasanoff convincingly argues that 
in response to the challenges faced by advancements in biotechnology, including hESC 
research, bioethics offers governments the ―promise of bringing order and principle to 
domains previously governed by irrational, emotive and unanalyzed reactions‖ 
(Jasanoff, 2005, p. 172). Thus, in much the same way policy-makers looked to technical 
risk analyses or expert appraisal in previous years when confronted with scientific 
uncertainty, so they look now to the new institutions of bioethical expertise in order to 
‗make sense‘ of developments in biotechnology.  
Thus, it is with some confidence we can argue that public bioethics bodies have 
come to represent an ―appropriate strategy for engaging public disputes about science in 
pluralist democracies‖ (Kelly, 2003, p. 342). As Tallacchini (2009) points out, however, 
the danger is that rather than meaningfully engaging the public and seeking their 
pluralist views, the task of discussing ethics is left to experts. Since bioethics experts 
can, ostensibly, provide ―a predominantly secular, rational, and ‗neutral‘ discourse, not 
unlike the law or science itself‖ (Kelly, 2003, p. 342), bioethical expertise becomes a 
new domain in which ‗objective facts‘ are created, not unlike those of ‗technical‘ 
advisory bodies. The irony is that this objectivity is created in the very ‗subjective‘ 
space that ethical deliberations are intended to explore. This point is important and is 
drawn out further below.  
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The problem, then, as pointed out by the authors just reviewed, lies in an un-
questioning acceptance of the role of ethics in institutional processes. This is not to say 
that ethics should be ignored, indeed the participants in this thesis all indicate that ethics 
does need to be considered as part of a system of ‗good governance‘, but rather there are 
important relationships to explore within the perspectives of bioethicists and policy-
makers in our empirical analysis. Specifically, we might ask how and in what form does 
the relationship between the perspectives of policy-makers and regulators and 
bioethicists take shape, and what are the implications for option performance, or in the 
‗real world‘, policy-making?  
8.4.2 Insights from empirical findings 
The empirical findings of this thesis as compared between policy-makers and 
bioethicists are intriguing, although they may pose more questions than they answer. 
Overall, we find that there are many points of convergence and synergy in the patterns 
of performance rankings across the two perspectives. That is, when analysed 
quantitatively, the ranking patterns between bioethicists and policy-makers and 
regulators reveal several similarities. This is particularly the case in three areas, all 
shown in the set of figures below: i) the mean aggregate rankings (Figure 8.7); ii) under 
criteria related to ‗advancing the science‘ (Figure 8.8); and iii) under criteria relating to 
the ‗qualities of deliberative activities‘ (Figure 8.9).  
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Figure 8.7: Rankings under policy-makers & regulators and bioethicists 
perspectives 
 
Figure 8.8: Rankings under policy-makers & regulators and bioethicists 
perspectives under ‘advancing the science’ criteria 
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Figure 8.9: Rankings under policy-makers & regulators and bioethicists 
perspectives under ‘qualities of deliberative activities’ criteria 
 
 
As we can see from the figures, there are a few exceptions to the similarities and 
convergence in ranking patterns. A notable one is the ordinal ranking of the ethics-led 
governance option, where there is a slight variation in the relative patterns across the 
figures. One might also notice the seeming divergence in rankings under criteria related 
to advancing the science (Figure 8.10), but on closer examination we see that the ordinal 
pattern between the two stakeholder groups is similar (despite the lower relative 
positioning of the rankings for bioethicists). This is due in large part to the fact that 
fewer criteria comprise the issue for the bioethicist group, but also is a factor of the 
lower mean weighting assigned to these criteria by bioethicists (30%) as opposed to 
policy-makers and regulators (48%).  
However, despite the convergence in performance rankings, the analysis 
presented in the previous chapter showed there to be regular and systematic divergences 
in the way perspectives on good governance are expressed, characterised and framed 
between the two stakeholder groups. In Chapter 7 we found that the perspective of 
policy-makers and regulators on the issue ‗advances the science‘ was framed by a view 
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or harmonised policy frameworks. The perspective of bioethicists, in contrast, was 
characterised by a beneficent framing of the quality of scientific outcomes.  
There were differences in the evaluation of the options, indicating some degree 
of ambiguity
154
 was present among the bioethicists, themselves. It was argued this 
might be attributed to the diverse contexts in which the bioethicists worked. Moreover, 
though both groups of stakeholders emphasise the role of the public in their discussions 
of deliberative activities, the perspective of policy-makers and regulators was more 
focussed on how institutional mechanisms of governance might foster public trust. 
Bioethicists, conversely, tended to exhibit a greater degree of pragmatism as to role of 
the public and the need for good governance. That is, there was a feeling that the 
cultural pluralism inherent in societies needed to be respected and addressed, but there 
was also a recognition that the policy process needed to move forward. At some point, 
good governance would need to result in the development of policy solutions.  
8.4.3 Discussion 
The final point made above is worth dwelling on and is where the implications 
for theory-building emerge. Though all the bioethicists participating in this study had 
some level of academic training in bioethics, philosophy or other related disciplines, 
they all worked in different contexts. Some were academics who studied bioethics in the 
area of hESC research, others were policy advisors to national policy-making bodies, 
and still others worked for professional medical or industry organisations. Gottweis, et 
al. (2009) point out that national ‗bioethics‘ bodies themselves are comprised of 
individuals from diverse backgrounds, many of whom have no formal training in 
‗bioethics‘. To call these committees ‗bioethical‘, then, is slightly misleading. As 
bioethics takes on an ever increasing role in policy-making, and as concerns over the 
nature of this role multiply, we need more considered reflection.  
As argued by Tallacchini (Ibid), the emergence of ‗ethics‘ as an ―advisory 
normativity‖ (Tallacchini, 2009, p. 290) in the EU context has several characteristics, 
two of which are particularly relevant for the discussion here. First is the ―expertised 
and technocratic‖ characteristic of EU ethics. This has resulted in a situation where 
ethics is treated as another type of ‗scientific‘ advisory committee. It is one where ethics 
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itself is made objective and the imposition of technocratic values serves to undermine 
the very purpose of exploring the more ethically and morally subjective nature of 
scientific facts, values and technology impacts (ibid., p. 291).  
The second characteristic relates to the problem of ‗outsourcing‘ values (ibid., p. 
295). Here, the problem is still related to the ‗expertisation‘ of ethics, but extends 
beyond this to the problems raised by utilizing ethics as a prescriptive input to policy-
making. In this sense, ethics provides another means through which decisions might be 
‗closed down‘ (Stirling, 2008) through singular, prescriptive appraisal and decision-
making processes. In the case here, the situation is made all the more troubling for the 
fact that ethics is used as a way to argue that citizens are being empowered. According 
to Tallacchini, ethical deliberations merely become a means through which policy-
makers can claim to be considering multiple views. The point is that whether such 
views are, actually, considered becomes irrelevant if the bodies are not set up in such a 
way as to meaningfully foster broad-based discussions.  
In light of the findings reviewed above and in Section 8.3, this view can be both 
supported and critically elaborated upon. It is supported in the sense that the findings 
above seem to suggest that the relative ‗distance‘ of bioethics from policy is not so great 
when it comes to the actual recommendations that emerge from bioethicists‘ 
deliberations. However, the fact that there does seem to be a difference in the 
perspectives on good governance between the two stakeholder groups raises questions 
about the extent to which there may be an inherent failure in bioethical advice, itself.  
Though some bioethicists participating in this study sat on national or 
international bioethics ‗official‘ advisory bodies, not all do. However, all work in some 
way with the policy ‗world‘ – either through their role as bioethics advisors to 
professional member organisations or as informal advisors to policy-makers. Thus, it is 
important to recognise that even amongst academically grounded bioethicists, the 
language and framing of the issues is different, but the governance choices are similar. 
This seems to support Tallacchini‘s arguments that bioethics in a policy-making context 
does not fulfil its mandate of representing cultural pluralism and diversity, but also 
suggests that there is not cause for despair. Instead, the flaw may lie in the extrapolation 
of bioethics into a policy-making context. Therefore, we suggest a more critical and 
cautious stance is needed regarding the relationship between policy-making and the 
legitimatory language of bioethics.  
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 The findings from Section 8.3 further support this assertion. We saw there that it 
is those directly involved in policy-making who are more keen to frame governance in 
the light of moral and ethical language, rather than socio-political and institutional 
factors. This raises the question as to why there seems to be an unwillingness among 
policy-makers to ‗let go‘ of the ethical rhetoric? One possible answer lies in the ideas 
that ground this thesis. The context of hESC research is one where facts are uncertain, 
conditions unknown, assumptions varied and stakes of all kinds are high. Such 
circumstances pose challenges to policy-makers as they grapple with how to approach 
governance and keep apace with the science. As Jasanoff‘s earlier quote points out, and 
as Tallacchini‘s work suggests, bioethics has become one way in which the 
uncertainties and the unknowns seem to become more manageable. Moreover, it is a 
way to respond to the demands for increased public involvement and accountability, 
which have been a rallying cry among publics and academics alike for many years. 
The arguments discussed at the beginning of this section claim that governments 
favour ethical inputs to policy-making because they can lay claim to having considered 
a broad range of societal and cultural values, but without having to show how they have 
considered them. By invoking the language of ‗ethics‘, they are able to claim 
consideration of subjective concerns, but in an ‗objective‘ light which suits their 
pragmatically inclined policy and decision-making orientation. The findings here 
suggest that all is not lost with bioethics as an input to policy-making. The perspectives 
of bioethicists do vary from those of policy-makers, showing that there are new insights 
being brought to bear on tangible governance issues. The challenge, then, lies in 
disentangling bioethics from a policy-making context and thinking more critically and 
cautiously about how to ensure its inputs are truly representative of the cultural and 
social pluralism underpinning our societies.  
8.5 Civic epistemologies 
8.5.1 Introduction 
Jasanoff‘s work on civic epistemologies has been referred to in earlier chapters, 
but it will briefly be reviewed again here. In her book, Designs on Nature (2005), 
Jasanoff covers an immense expanse of ground looking at the ―culturally specific, 
historically and politically grounded, public knowledge-ways‖ (ibid., p. 249) in the field 
of biotechnology. She argues that the implicit public activity of engaging with science 
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forms an ―integral element of political culture in contemporary knowledge societies‖ 
(ibid., p. 249). By classifying this activity according to national tendencies, she uses the 
concept of ‗civic epistemologies‘ to critically examine the way publics assess claims, or 
collectively generate knowledge, about science. Thus, a primary aim of the book is to 
communicate the idea that the ‗politics of biotechnology‘ (ibid.) are deeply intertwined 
and interdependent on the ‗politics of knowledge‘ (Grove-White, 2008). Science and 
technology are shown to be ―central drivers of new ‗knowledge economies‘‖ as they 
become ―ever-more significant agents in the re-shaping of political and institutional 
relationships‖ (ibid., p. 182).  
Over the course of the book, Jasanoff conducts a comparative analysis of three 
countries – the US, UK and Germany – with the aim of identifying broad 
characterisations of each civic epistemology. This is done through detailed case studies 
in each country‘s response to different biotechnology advances. The final chapters 
consider all of the preceding analysis and culminate in a discussion of how six 
―constitutive and interrelated dimensions‖ of civic epistemologies are exhibited in each 
country (emphasis in below added to reflect dimension names, 2005, p. 259):  
• styles of public knowledge-making that are constrained by the specific 
institutional norms and rules of that country;  
• methods of ensuring accountability (and hence the basis for public trust) 
regarding the information and knowledge provided by experts, policy-makers 
and other actors;  
• practices of public demonstration whereby the state acts to demonstrate its 
scientific capabilities and powers in ways that its citizens will accept and relate 
to;  
• preferred registers of objectivity for the state whereby the citizens view the 
knowledge produced and used in policy-making to be ‗true‘ and valid;  
• accepted bases of expertise, meaning the way credibility is conferred upon 
experts in the policy realm; and  
• visibility of expert bodies.  
Jasanoff uses these six areas to broadly characterize the US, UK and Germany as 
having „contentious‟, „communitarian‟ and „consensus-seeking‟ civic epistemologies, 
respectively. Arising out of the six dimensions described above, these civic 
epistemologies provide a window into what we would argue (in the language of this 
thesis) are Jasanoff‘s perception of national perspectives on good governance. That is, 
through her descriptions of how different types of knowledge are co-produced and come 
to be seen as authoritative in each country, she is identifying nation-specific notions of 
what constitutes good governance. What is of interest when considering Jasanoff‘s 
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characterisations of perspectives on good governance in comparison with those 
identified in this thesis, is the way in which each perspective is seen to emerge and 
through which windows of analysis. Insights of this kind may allow us to empirically 
contribute both to the concept of civic epistemologies, but more generally to 
comparative analysis in science and technology studies.     
8.5.2 Dimensions of civic epistemologies; dimensions of good 
governance 
Jasanoff begins with a similar premise to that of this thesis: biotechnologies pose 
unique problems to policy-makers due to their entanglement with a wide array of social, 
cultural and technological values. However, her analysis ends in a place that focuses on 
how these policy problems are ‗known‘, considered and grappled with by different 
national publics. This process of appraising, or coming to ‗know‘, the technologies and 
their co-produced relationship with society, is itself a crucial part of understanding how 
different perspectives on good governance are constituted.  
As this research employs a method of technology appraisal, albeit one that has 
more directly elicited stakeholder views, in comparison with Jasanoff‘s elegantly wide-
ranging and interpretive contribution, it is conceivable that some of the six identified 
epistemologies might reveal themselves within the criteria and option evaluations. If 
this is found to be the case, we might be able to make some comparisons between the 
two sets of findings and hence contribute to an important area in comparative science 
and technology studies. 
As the three previous chapters have alluded to at times, there are some 
resonances between Jasanoff‘s ideas about civic epistemologies and the nature of the 
findings from the analysis here in this thesis. These emerge most strongly in two areas – 
public trust and bases of expertise – and less strongly, but nonetheless worth 
commenting upon, in the dimension of preferred registers of objectivity. Before 
comparisons are made, a note of caution must be sounded. First, it is not our intention to 
claim that our findings are more robustly grounded than Jasanoff‘s, which covers many 
academic disciplines, countries and areas of technology. However, it is also the case the 
study here employed a unique methodology aimed at both opening up the implicit and 
explicit processes through which governance options are socially and technologically 
appraised. Moreover, it does so in a way which allows for distinct socio-political points 
of view to be probed in a symmetrical way and their implications explored. As has been 
  
251 
shown in the analysis, these implications arise at both national as well as individual 
stakeholder group levels. Therefore, though the two data-sets are derived in different 
ways, the aims in understanding the complexities of the relationship between science, 
technology and society and the themes of socio-political governance are broadly the 
same. Thus, we might expect the findings to be mutually enlightening.  
Beginning with public trust, Jasanoff argues that the bases for trust in different 
countries arise from the types of public accountability that are offered. She points to the 
processes of judicial litigation in the US as the primary way in which the credibility of 
scientific claims are established. ―Truth, in this template, emerged only from aggressive 
testing in a competitive forum‖ (Jasanoff, 2005, p. 260). Public accountability in the 
UK, on the other hand, is conferred through the proclamations of official expert bodies. 
This, Jasanoff argues, is due to a more ―insulated‖ regulatory process, which allows for 
experts to gain credibility through years of working in public service. This seems to 
suggest that the basis of trust and expertise are intimately linked in the UK civic 
epistemology.   
The empirical findings in this thesis can be interpreted as supporting and 
critically elaborating on Jasanoff‘s claims. In Chapter 6, we discussed how, for UK 
stakeholders, trust seemed to be heavily dependent upon institutional processes. 
Numerous stakeholders suggested that it was the regulatory process itself which would 
instil public trust. Thus, to the extent that this complements Jasanoff‘s findings that 
public accountability in the UK is related to the insulated regulatory process, we find a 
consistent pattern. However, the findings of this thesis diverge slightly when we 
consider Jasanoff‘s claim that it is the experts themselves who bestow accountability on 
the regulatory process, and hence provide the basis for trust in the regulatory system. 
We argue this may not be exclusively the case. Rather, the participants interviewed for 
this research felt that public accountability resides in the processes themselves, both in 
relation to the individuals involved, but also in relation to the nature of the system. In 
other words, the two are mutually dependent. One could not have corrupt or 
inexperienced individuals on regulatory bodies as this would lead to a loss of 
accountability. However, it is also the case that if the institutions and instruments of 
government were set up to be publicly accountable, the experts on them would not last 
if they were seen to be lacking in a particular key characteristic. It seems, then, that the 
UK-based perspective on trust as characterised in this thesis is grounded in a fuller 
exploration of the multiple foundations of trust that might arise from and within a 
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nation‘s institutional configurations. It is these multiple foundations that serve to 
establish accountability and give rise to the ways in which publics come to bestow their 
trust in government institutions.   
It was difficult to identify a single pattern within the US perspective on public 
trust as analysed in earlier chapters. Despite this, it is clear that litigation as a basis for 
establishing accountability, as argued by Jasanoff, did not actually feature in 
stakeholder perspectives on good governance within this thesis. Rather, there was a 
tension exposed between notionally ‗democratic values‘ which might be expressed 
either through attention to cultural pluralism or establishment of broad-based 
deliberation mechanisms. To this end, we do find some resonance with Jasanoff‘s 
discussion of public trust in the US as being grounded in ‗assumptions of distrust‘. That 
is, government decisions are assumed to be invalid until proven in some way – in her 
argument through the litigation system.  
For the participants interviewed in this thesis, however, assumptions of distrust 
seemed more derived from a dissatisfaction with the current governance system in the 
US and the way it was arrived at. For example, doubt was expressed by some US-based 
stakeholders about the ability of institutions to make the ‗right‘ decisions about good 
governance. This was apparent in the finding that more ‗outcome-based‘ and 
instrumentally motivated criteria dominate the US stakeholder group‘s perspectives on 
good governance. Additionally, others expressed a desire for ‗real public discourse‘ to 
inform governance decisions. However, this criterion was elaborated on by discussing 
how ‗closed‘ the policy-making process for hESC research was within the Bush 
administration and how it did not reflect the majority views of the public. The fact that 
my findings are tangential to Jasanoff‘s claims is not to say they are contradictory. 
Rather, we can only reiterate that legal challenge as a means of addressing distrust was 
not mentioned by interviewees and therefore may not be a dominant mode of generating 
public accountability for this particular area of biotechnology.  
 Expertise is the second dimension of civic epistemologies which we can explore 
in relation to the findings of this thesis. Jasanoff argues experts have a heightened 
importance in the decision-making process for biotechnology, and indeed are 
―indispensable to the politics of knowledge societies. They [experts] tame the ignorance 
and uncertainty that are endemic to modernity...‖ (Jasanoff, 2005, p. 267). Therefore, 
culturally specific ways of identifying and coming to ‗know‘ expertise can be identified. 
Jasanoff argues that the identification of experts rests upon the balance between their 
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formal qualifications and their personal or institutional experiences. In the UK the status 
of expertise is conferred through one‘s history of service to the country, whereas in the 
US expertise comes from one‘s professional status and standing.   
 The findings of this thesis do not reveal anything specific about individual traits 
of experts, so direct comparisons cannot be made on this end. Rather, the perspectives 
on good expertise identified in this thesis focus on more general characteristics of the 
relationship between expertise and good governance. Consequently, there may be an 
important difference in the application of the term ‗expertise‘. For hESC research, the 
view among MCM interviewees in both the US and the UK was that expertise needed to 
be balanced and to represent a wide range of views and types of experts. What differed 
between the two countries was the emphasis on the role of expertise within a wider 
context of good governance. UK-based perspectives tended to emphasise the types of 
experts needed on regulatory bodies, whereas US perspectives tended to emphasise the 
types of inputs and role experts should play in decision-making. In this, the former was 
more process-based – good experts lead to good processes of decision-making – 
whereas the latter was more outcome-based – good inputs lead to the ‗right‘ outcomes 
for hESC research.  
 It seems, then, that in the case of hESC research, the important feature on which 
expertise rests and comes to be seen as reliable is not only the type of knowledge 
individual experts embody, as Jasanoff argues, but the way this knowledge relates to 
governance as a socio-political process. Again, the empirical findings of this thesis, 
display a degree of non-alignment with Jasanoff‘s arguments. Here, it is perhaps the 
case that the dimension of expertise as presented by Jasanoff is simply framed in a more 
narrow way than was conceived of by stakeholders interviewed here. If this is the case, 
we might see further evidence of this within the final civic epistemology dimension of 
‗objectivity‘.  
 The dimension of objectivity is defined by Jasanoff as relating to how publics 
determine whether knowledge is reliable. ―Objective knowledge is by definition reliable 
public knowledge, for such knowledge looks the same from every standpoint in society; 
it is untainted by bias and independent of the claimant‘s subjective preferences‖ 
(Jasanoff, 2005, p. 264). In the US, Jasanoff argues that objective knowledge rests on 
the ―language of numbers‖ (ibid., p. 265). Decisions are made based upon the results of 
quantitative risk assessments, and (despite outcries of the type reviewed in Chapter 3) 
risk assessment and ‗sound science‘ rhetorics came to be linked in the US 
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biotechnology regulatory discourse. In the UK, risk analysis is also a feature of 
objective knowledge, but so too are the experts who are conducting the analyses.  
In [the UK], appropriate political representation remains part and parcel of the 
process of risk analysis, consciously built into the design of expert committees 
and consultative processes... (Jasanoff, 2005, p. 266).  
Both points seem to hold true for the empirical findings presented in this thesis, 
but to varying extents. This is most notable in the case of the US-based perspectives 
identified here, where the endorsement of Jasanoff‘s claims are somewhat mixed. Some 
interviewees expressed a desire to have wider public inputs to ‗objective‘ processes of 
decision-making, seemingly a move away from ‗expert-based‘, technocratic and 
quantitative processes of generating objective knowledge, while others appeared 
staunchly opposed to having anyone except experts sitting on advisory committees and 
making regulatory and policy oversight decisions. One could hypothesise that in the 
case of those asking for more broad-based public deliberations, this was a result of the 
desire to see actual public inputs to decision-making processes, as opposed to the 
―instrumentally selected experts‖ of the Bush administration (Jasanoff, 2005, p. 266). 
Equally, such ‗instrumentally selected experts‘ can be seen as favourable or 
unfavourable depending on one‘s ideological viewpoint. The problem with assertions of 
either type is that ‗ideological bias‘, or ‗objectivity‘, is in the eye of the beholder. Thus, 
though there were calls for ‗evidence-based‘ decision-making, such perceptions of 
objectivity can vary within countries or between stakeholder groups. Jasanoff‘s claims, 
then, while perhaps true in broad terms, may be on shakier ground when considered in 
this way. 
To conclude, the findings of this thesis both support, but also critically elaborate 
on, Jasanoff‘s concept of civic epistemologies. It is in this spirit that we offer a final 
point. The findings of this thesis support the assertion that perspectives on good 
governance are not only discernible at different levels, but they also display systematic 
patterns when compared between national, intra-national and individual stakeholder 
levels. Thus, perhaps more relevant than the national points of comparison in relation to 
Jasanoff‘s concept of civic epistemologies, are the implications of the findings that 
multiple perspectives on good governance reveal different and contrasting socio-
political points of view with implications for assessments of how, and for what reasons, 
different governance options are viewed as favourable. This lends support to the broader 
hypothesis of this thesis that comparative analysis at one level is rarely sufficient for full 
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understanding of the complexities of divergent social, political and cultural 
understandings of good governance.  
8.6 Conclusion 
 This chapter has drawn together the various empirical, theoretical and 
methodological strands of this thesis. We identify contributions to the academic 
literature in four different areas. First, we contribute empirically to, and critically 
elaborate on, an emerging area of theoretically grounded literature relating to the 
different rationales underlying technology appraisal strategies. Normative, instrumental 
and substantive imperatives were found to offer a meaningful way to partition and 
understand key drivers of contrasting perspectives on good governance across multiple 
stakeholder groups. An empirical contribution to recent thinking in technology 
governance literatures is made.  
 Second, the moral and ethical issues relating to good governance are explored. 
We highlight and offer explanations for the greater use of moral and ethical language 
by policy-makers and regulators and within the policy documents themselves to discuss 
governance as compared with the greater focus on socio-political and institutional 
factors by the majority of stakeholders interviewed. This leads to the third contribution, 
that of the increasing role of bioethics in the governance of biomedical technologies, 
especially human embryonic stem cell research. Bioethicists and policy-makers and 
regulators are shown to have divergent, qualitatively-deduced, perspectives on good 
governance, but convergent, quantitatively-identified, assessments of option 
performance. These findings are used to support the idea that in order for bioethics to 
contribute meaningfully to policy and governance in this area, it might cautiously and 
critically evaluate its relationship with, and use of, legitimatory languages of bioethics. 
Finally, Jasanoff‘s seminal concept of civic epistemologies is reviewed and 
comparisons between her theoretical contributions and the empirical findings of this 
thesis are explored. 
 The final chapter will summarise the four overarching contributions of this 
thesis, covering the theoretical, empirical, methodological and policy-relevant 
conclusions that can be drawn. Suggestions for additional research are offered. 
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9. Conclusions, future research and policy implications 
9.1 Overview 
Biomedical technologies like hESCs push the boundaries of how we define 
ourselves as human. Accordingly, they can involve complex and entangled interactions 
between public values, cultural norms, institutional interests, societal expectations and 
technological uncertainties. These entanglements pose serious governance challenges. 
This thesis has therefore addressed ‗good governance‘ of hESC research as both an 
analytical subject and as an imperative for rigorously testing novel forms of 
technological appraisal which might address such challenges. Using one such method 
(MCM), we have explored contrasting perspectives on what constitutes good 
governance for hESC research and asked whether – and what kinds of – systematic 
patterns are discernible between perspectives of UK and US policy actors. These 
perspectives have been empirically investigated through a research framework that 
combines dimensions of qualitative sensitivity and quantitative precision, as well as 
symmetry, transparency and reflexivity, in documenting the nuances of different 
perspectives. In this final chapter, we will review the main contributions of this thesis, 
make suggestions for future research and offer tentative recommendations for policy-
making in the area of hESC research.  
9.2 Summary of findings and theoretical contributions 
In this thesis, we have provided a reflexive explanation of the main drivers 
behind contrasting perspectives of policy actors and have made several interlinked 
theoretical, methodological, empirical and normative contributions to our understanding 
of good governance in the area of hESC research. The contributions in each of these 
areas are summarised below.   
Theoretically, we have examined the wider governance literature and arrived at a 
conception of governance appropriate for the context of this thesis. A social-political 
stance on governance, as introduced in Chapter 3, provided a basis on which we could 
consider the multiple and co-constituting processes involved in governance, the spheres 
in which these processes take place, and the implications of the interactions between 
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them. From there, we moved from the theoretical basis of governance to consideration 
of the normative interpretations of good governance emerging from the wider literature. 
This allowed us to develop three inter-related dimensions of good governance which 
were then used as the basis for the methodological development of the MCM options. 
These dimensions are: 1) the structure of institutional oversight and whether it is 
centralised or decentralised); 2) the processes of negotiation, engagement, and 
deliberation between society and the state in terms of whether they are primarily 
technocratic or democratic, and 3) the types of mechanisms and instruments used to 
govern either as targeted regulations or passive ‘steering’. Further theoretical 
contributions that arise from the empirical findings are discussed below. 
Methodologically, imperatives for good governance have been established as 
theoretical groundings for testing a novel form of appraisal. In using – and further 
developing – the elicitation and analysis method of Multicriteria Mapping, we have 
systematically and symmetrically explored different perspectives on good governance. 
As a method, MCM allows us to harness the strengths of both qualitative and 
quantitative approaches in documenting the divergent socio-political views and 
sensitivities of framing in the appraisal of governance options for contested 
technologies. We found that MCM offered a robust social appraisal method capable of 
engaging a diverse set of participants from contrasting national and stakeholder 
backgrounds.  
We have also made contributions to the development of the methodology in key 
areas. First, we demonstrated how it can be used to triangulate empirical and theoretical 
findings within a wider research framework. The theoretical review identified three 
dimensions of good governance, which were employed within the methodology and 
found relevant across multiple contexts. The empirical, content-based analysis of the 
policy literature identified four themes of good governance which were found, 
independently of direct examination, to be equally salient across the MCM-generated 
assessments of good governance. Quantitative heuristics were then used to identify 
areas of analytical interest, which were explored in great depth in the qualitative 
material underpinning the option assessments and criteria definition. Iterative 
examinations of the data, such as consideration of additional quantitative measures 
(mean weightings or expressions of uncertainty and ambiguity) and qualitative insights 
(explanations of weightings or reasons for uncertainty), were used to confirm or further 
explore earlier hypotheses. Thus, the three areas of analysis relating to ‗good‘ 
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governance were all independently and reflexively conducted, but proved to be mutually 
supporting in their findings.  
Second, in previous uses of the MCM methodology, the process of quantitative 
and qualitative analysis and aggregation of material for presentation tended to be carried 
out by separate parties. The work reported in this thesis involved an unusually large 
number of interviews performed and analysed by a single researcher. Indeed, this is the 
first time that such a detailed quantitative and qualitative MCM analysis has been 
conducted on such a scale (whether for the purposes of a doctoral thesis or otherwise).  
Empirically, we found systematically contrasting patterns in perspectives on 
good governance amongst UK and US policy actors, with equally significant points of 
convergence and divergence. The analysis was structured around four themes of good 
governance that were identified through a review of national policy documents. In brief, 
these themes concerned the extent to which good governance: i) advances scientific and 
technological outcomes and addresses related issues in hESC research; ii) encourages 
moral and ethical awareness of hESC research; iii) establishes appropriate institutions 
and instruments of the oversight for hESC research and iv) is identifiably grounded in 
social and cultural bases. These themes were also found to be salient with regard to the 
MCM findings. 
Thus, within each of the themes, divergent perspectives were found within the 
national policy documents, as well as across and within the different national settings 
and various groupings of stakeholders. While there was often convergence in the MCM 
ranking patterns across the governance options, these commonalities tended to obscure 
the complexities and nuances in framings within the perspectives on good governance. 
The most prominent of these patterns and distinctions were as follows: 
• Contrasting framings of the nature of hESC research in relation to desired 
technological and scientific outcomes were found: (i) between the national 
policy documents of the UK and US; (ii) across broad features of stakeholder 
perspectives in the UK and US; (iii) between stakeholder perspectives within the 
UK and US and, (iv) between some aspects of national policy documents in a 
particular country and corresponding patterns among national stakeholders. 
• Though there were divergent framings of the embryo within national policy 
documents, a general pattern emerged involving greater use of moral and 
ethical language to discuss governance among UK policy documents, policy-
makers or policy advisors. In contrast, less attention was given to the moral 
status of the embryo by the majority of stakeholder interviewees. Instead, there 
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was a greater focus on how institutional and socio-political factors would 
encourage ethical behaviour and awareness in the context of good governance. 
• Further systematic contrasts in characterisations of good governance emerged in 
the more process-based understandings of UK perspectives and the more 
outcome-based views of US perspectives. This was evident in both the national 
policy documents and in the MCM interviews. This seems to parallel claims 
made in some theoretical literatures, notably Vogel‘s study of national styles of 
regulation in the UK and the US (1986). Taken as a whole, then, the finding 
suggests a potentially significant general contrast in characterisations of good 
governance between the UK and US.  
• Reliance on bioethics as a legitimatory policy advisory tool is evident in both 
sets of national policy literatures and similarities were found between the 
ranking patterns of bioethicists and policy-makers within the MCM findings. 
However, divergent socio-political viewpoints are evident in perspectives of UK 
and US stakeholders, especially in terms of the ways scientific outcomes are 
discussed and bases of trust and legitimacy in good governance are established. 
We therefore suggest a critical evaluation of the relationship between policy 
advice and bioethics is needed. 
• A number of key drivers behind contrasting framings of good governance 
adopted under different perspectives were discerned according to underlying 
normative, instrumental or substantive imperatives. These theoretically 
grounded imperatives provided a meaningful way of partitioning the 
empirically-defined criteria and analysing differing option performance patterns. 
Additional comments about the intertwined theoretical and empirical 
contribution made on the basis of this finding are discussed below. 
• Consistent patterns in option performance were found among two of the 
governance options across a remarkably wide array of perspectives. The detailed 
centralised oversight option was one of the highest ranking options across all 
perspectives and under different criteria groupings (or ‗issues‘). The mixed 
central/devolved option often displayed the largest difference between highest 
and lowest rank. This was due to a particularly high degree of uncertainty and 
ambiguity in this option‘s performance, indicating greater diversity in associated 
conditions and assumptions affecting option assessment. These two findings 
have normative implications for policy-making (discussed below). 
From these empirical findings, four further contributions of a more theoretical 
nature emerge.  First, the notion that normative, instrumental or substantive imperatives 
may lie behind the design of different types of technology appraisal is based in a 
developing body of literature. Empirical support for such theoretical ideas had 
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previously been somewhat lacking and the analysis presented in Chapter 8 makes a 
significant contribution in this respect. Second, in contrast to the moral and ethical 
framing of governance problems observed in the policy documents, we find that the 
framings of perspectives elicited from stakeholders are noticeably more socio-political 
and institutional in character. This suggests stakeholders have moved on from the moral 
debate over the status of the embryo to wider concerns about the socio-political 
implications and institutional impacts on the future of hESC science. Third, these 
differences in the use of moral and ethical language, as well as the findings of 
convergent ranking patterns among the perspectives of bioethicists and policymakers, 
raises questions about the reliance on bioethics as a new type of legitimatory expertise. 
This finding adds to a growing discussion in the theoretical literature about the 
limitations of bioethics as an objective arbiter of social and moral views. Finally, the 
identification of systematic patterns in perspectives on good governance across and 
within national and stakeholder groupings supports the conclusion that while national 
comparisons are useful for identifying broad tendencies, they risk overlooking 
important intra-national differences. This suggests, particularly for the area of hESC 
science, that a greater appreciation of the differences in constitutions of good 
governance at multiple stakeholder levels is needed in comparative studies of science 
and technology policy.  
9.3 Suggestions for future research 
 This thesis has critically explored the analytical subject of good governance in 
relation to a specific biomedical technology, hESC research, in two countries, the US 
and the UK. Moreover, it has addressed good governance as an imperative for testing a 
novel form of technology policy appraisal. Suggestions for future research, then, might 
be considered in relation to the subject of the research as well as its methodology. 
 In order to further our understanding of the normative concept of ‗good 
governance‘, it would be useful to examine another area of biomedical technology, or 
even an area of environmental or industrial technology that raises similar conditions of 
risk and uncertainty. It would be useful to see whether – and what kinds of – convergent 
and divergent patterns in perspectives on good governance lie across and within 
different technologies. This would enable us further to understand the normative 
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implications of good governance for policy-making, as well as enable theory-building in 
comparative literatures on science and technology governance. 
 Methodologically, MCM itself has been tested and developed in new ways in the 
course of this research. However, the methodology does have certain limitations and 
further research could be undertaken to test its robustness. To this end, the same 
research could be repeated, but with a different appraisal methodology such as Q-
method (discussed in Chapter 4). Though the purpose of Q method and the resulting 
findings are different from those obtained in an MCM study, the principles of social 
appraisal in an open, participant-led format, are similar. Thus, such findings could be 
used in comparison to the findings here and development of both methodologies might 
result. In addition, further development could be taken to explore the use of statistics 
within an MCM study, as alluded to in Chapter 4. 
9.4 Policy implications 
We are now in a position to address the normative implications of policy-making 
for how good governance of biomedical technologies, specifically hESCs but other 
technologies as well, might be conducted under conditions of risk, uncertainty and 
ambiguity. A note of caution should first be sounded, however, before such implications 
are discussed. The central component of this research has been to explore contrasting 
perspectives on good governance in different national and stakeholder contexts. This 
has required a detailed appreciation of the social, cultural, political and institutional 
factors that influence the framings adopted in different perspectives. The following 
policy-relevant conclusions are offered while at the same time recognising the nuances, 
complexities and sensitivities inherent within national and cultural policy-making 
contexts, as well as between them, that this thesis has sought to explore. However, 
despite the different ‗voices‘ and ‗perspectives‘, common features of good governance 
emerge despite, or perhaps in spite of, the divergences in how these notions of good 
governance come to be constituted and the assumptions, judgements and views that 
frame and condition them. 
The consistently high performance ranking of the detailed centralised oversight 
and more uncertain and ambiguous assessment of the mixed central/devolved option 
suggest there are key features of hESC governance that are favoured across multiple 
contexts and perspectives. Specifically, some type of centralised institutional oversight 
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appears more desirable than other options. Centralised oversight can provide 
consistency and stability for the science, as well as fostering trust among the public in 
ways that were broadly welcomed by a diversity of stakeholders in both the UK and the 
US.  
This is interesting in relation to the US context because there have been many 
state-based initiatives for governing hESC research emerge in recent years. The findings 
here suggest that the presence of such multiple and varied governance frameworks 
within one country may do more harm than good to the progress of hESC research 
because it makes scientific collaboration harder and hinders scientific advance. On this 
basis, we recommend a re-evaluation of this trend in the US and that greater efforts are 
made to standardise funding, regulatory and commercialisation policies across the 
country. This is not to suggest a fundamental re-evaluation of the federal system, but 
rather a greater appreciation of the burdens current governance regimes pose to 
scientific advance.  
In relation to the UK context, the findings suggest that frequently invoked 
complaints about ‗regulatory burdens‘ are, perhaps, exaggerated by some stakeholders. 
Centralisation and strong regulations help to stabilise the platform on which science can 
develop and technological advances are made. Moreover, the perception that science is 
being actively monitored seems to help allay fears of ‗franken-babies‘ and thus fosters 
public trust. This, in turn may help to advance the field by reducing public opposition. 
Future policy-making in the UK should celebrate the strong framework it has 
established over the years in this field, but should also ensure the same attention is paid 
to supporting technological developments from fundamental advances in hESC 
research. 
Though these conclusions are made on the basis of research into hESC 
governance, the basic principles seem to ring true for other areas of biomedical 
research, or indeed other technological areas that carry with them a high degree of 
social and cultural, as well as scientific, uncertainty. Here, as with hESC research, there 
may also be an argument for centralised oversight of scientific advance which can also 
be understood from the two related objectives of scientific advance and public safety. 
But, perhaps more fundamentally, we find it striking that there was a preference among 
all participants for some role of government in the pursuit of ever-more complex 
technologies which pose social and scientific risks, introduce uncertainties and highlight 
ambiguities. We could have found a view that placed scientific advance as an 
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unquestionably ‗good‘ objective in itself and to that end should be left alone by the 
state. Instead, however, we find a much more nuanced discussion prevails in relation to 
the mutually dependent and intertwined roles of the state, the public and science in a 
governance system. 
These nuances are apparent in the findings related to the role of engagement and 
deliberation around technological futures. Attempts to engage the public through 
national dialogue and deliberation about the future of risky and uncertain technologies 
should be made in a manner that is most appropriate for the different cultural and 
historical contexts. For hESC research there were variations in the extent to which this 
was seen as being most appropriately mediated through mechanisms of public 
engagement, or through expert bodies. In either case, there was an interesting preference 
among stakeholders in both countries for devolved governance when assessing criteria 
about the role of the public. This seems to suggest a more general point about the 
importance of ‗locality‘ in governance structures. Though this may seem to contradict 
the earlier finding about centralised oversight, it actually seems to suggest there are 
tangible lessons for the nature and conduct of public engagement. The more local the 
governance system, the more potential there might be for public input to be heard, and 
considered.  
This leads us to a further reflection on the implications for governance of 
biomedical technologies that challenge social and cultural norms. It is our view that 
there are lessons for policy-makers in the need to critically evaluate how and why 
bioethics is used as a policy advisory tool when it comes to the future of biomedical 
technologies. There are benefits to employing principles of ethical and moral thought in 
a technological area rife with conflict on such issues. However, the tendency in policy-
making seems to have been for bioethics to be used more to legitimate difficult policy 
choices and less as a critical tool for engaging with cultural and social pluralism. What 
is presented as a subjective exploration of social views has instead become an exercise 
in translating ‗ethical‘ advice into another form of ostensibly objective technical 
expertise. Policy-makers are not wrong in identifying the potential of bioethics to enrich 
governance discussions and interactions in the area of biomedical technologies, but the 
mechanisms through which this occurs should be examined. To employ the language of 
imperatives used earlier, the danger lies in an instrumental use of bioethical advice for 
the achievement of specific policy ends.  
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To this end, this thesis has shown there is clear potential in the use of social 
appraisal tools like MCM to understand and appreciate the diversity of views and 
sensitivities inherent to different publics, including different ‗experts‘ and policy actors, 
in the consideration of technology policy options. In ‗opening up‘ the reasons for and 
rationales behind different option assessments and appraisal strategies, we are more 
easily able to identify areas of synergy between seemingly divergent points of view and 
stakeholder perspectives, as well as technology choices themselves. To the extent that a 
finding of this thesis relates to the importance of fostering meaningful understanding of 
the implications of divergent views on technology choice within a society, methods of 
appraisal such as MCM provide practical options for widespread policy use at both 
national and local levels. 
 
At some point in the past, it might have been argued that scientific progress took 
place relatively unimpeded by political, cultural and ethical issues. Today, however, a 
host of issues are recognised as both constraints and drivers of scientific advance. This 
is especially so with technologies like human embryonic stem cell research, which 
literally deconstruct and reassemble the building blocks of human life for scientific 
study and medical advance. There is great promise in this biomedical technology, but 
also great uncertainty, as it remains unproven in a therapeutic setting and poses risks 
that extend beyond the medical realm and into the social and cultural. By exploring how 
governance itself is presented in wider academic and political contexts, we have offered 
a critical, reflexive and explanatory view on how different stakeholder perspectives 
believe good governance of human embryonic stem cell research should be constituted. 
We hope to contribute to ongoing debates about how, and in what ways, technological 
advance and cultural sensitivity might mutually reinforce and inform each other in a 
modern world. 
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Annex A – Individual US state policy summaries for 
hESC technologies 
Table A.1: Summary of State-based initiatives in support of hESC technology
155
 
State Summary of support initiative 
California In November 2004, California voters passed Proposition 71 which requires 
California to raise over $3 billion in state bond money that would be 
dedicated to stem cell research. In addition, it amended the state 
constitution to explicitly prohibit human reproductive cloning, but allow for 
human embryonic stem cell research, including nuclear transfer. The 
California Institute of Regenerative Medicine (CIRM) was established to 
administer the research funds and is overseen by an Independent Citizens 
Advisory Committee, which has a detailed set of institutional rules 
governing its actions and activities. 
Connecticut In 2005 a fund was created to support ESC research which would allocate 
£10 million/year over 10 years. An oversight panel reviews research 
applications and makes grant decisions. The first grants were awarded in 
2006.  
Illinois In 2006, an Executive order signed by the Governor authorised £10million 
in funding and set up the Illinois Regenerative Medicine Institute (IRMI). 
The first grants were awarded in 2006. In 2007 state legislature passed bill 
permitting IRMI to conduct stem cell research on cells from any source. 
Indiana The state says that it actively supports adult stem cell research, but this is 
only at one research centre at Indiana University and there is very little 
funding (~$50,000 by 2008 estimates). Legislation passed in 2005 that 
prohibits reproductive and therapeutic cloning.  
Massachusetts In March 2005, the Massachusetts legislature overwhelmingly passed a bill 
clarifying state law on hESC research and therapeutic cloning, ensuring 
both types of research are permitted within a regulatory framework. Though 
the (then) Governor (Mitt Romney) vetoed the legislation, this veto was 
overruled by a further vote in the House and Senate. Despite this, as of 
2006, no state funding had been allocated for hESC research. 
Maryland The Maryland Stem Cell Research Fund was established in 2006 and 
provides grants for both adult and embryonic stem cell research. By the end 
of FY2009, the fund had committed to $56 million across 140 different 
research projects. The projected funding for FY 2010 was $12.4 million.  
Missouri In Missouri, voters have approved a constitutional amendment protecting 
hESC research, but there is little political will in the state legislative bodies 
and nothing has happened in the way of funding the research.  
New Jersey New Jersey was the first state to appropriate funds specifically for adult and 
ESCR. However, a ballot initiative in 2007 which would have created a state 
stem cell fund and provided capital funding for a new research centre was 
voted down. This was attributed to low voter turnout and a state budgetary 
crisis. Not long after the vote, construction on the promised stem cell facility 
was quietly closed down. 
New York In 2007, state legislators created The Empire State Stem Cell Trust. This 
sets aside $100million for fiscal year 2007-08 and $500million, to be 
allocated at $50million per year for 10 years beginning in fiscal year 2008-
09. The approval of research projects and administration of the funds are 
overseen by the Empire State Stem Cell Board. There are several 
committees which sit within this board and have responsibility for approval 
of research, allocation of funds, and ethical oversight. 
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State Summary of support initiative 
Ohio The Center for Stem Cell and Regenerative Medicine was opened in 2003 
with an initial funding of ~$20m. Only human adult stem cells are studied at 
the center and the governor previously has vetoed language prohibiting 
hESC research (2005), but no state funding for lines outside of President‟s 
policy. 
Washington In 2008 the state created a Life Sciences Discovery Fund, however little 
headway has been made since.  
Wisconsin Despite being one of the „birthplaces‟ of hESC research, there is a relatively 
negative political climate in the state legislature, but a very supportive 
Governor. The state previously has provided $750 million in public-private 
investment for biotech, health sciences and SCR. The state legislature has 
tried to prohibit reproductive and therapeutic cloning, but the governor 
repeatedly has vetoed the legislation. 
 
Table A.2: State-by-state summary of legislation on foetal tissue and embryo 
research
156
 
  
 
State 
 
Specifically 
permits 
research on 
fetus/embryo 
 
Restricts 
research on 
aborted fetus/ 
embryo 
 
Consent 
provisions to 
conduct 
research on 
fetus/embryo
3
 
Restricts 
research on 
fetus or embryo 
resulting from 
sources other 
than abortion 
 
Restrictions of 
purchase/sale 
human tissue 
for research 
Arizona 
 
No Yes, prohibits 
research on 
aborted 
living/non-living 
embryo or fetus 
No Yes, prohibits the 
use of public 
monies for cloning 
for research 
No 
Arkansas 
 
No Yes, prohibits 
research on 
aborted live 
fetus 
Yes, consent to 
conduct 
research on 
aborted fetus 
born dead 
Yes, prohibits 
research on 
cloned embryos 
Yes, prohibits 
sale of fetus/fetal 
tissue 
California  Yes, permits 
research on 
adult and 
embryonic stem 
cells from any 
source 
Yes, prohibits 
research on 
aborted live 
fetus 
Yes, consent to 
donate IVF 
embryo to 
research 
Prohibits sale of 
embryos and 
oocytes; prohibits 
payment in 
excess of the 
amount of 
reimbursement of 
expenses to be 
made to any 
research subject 
to encourage her 
to produce human 
oocytes for the 
purposes of 
medical research 
Yes, prohibits 
sale for the 
purpose of 
reproductive 
cloning or for 
stem cell 
research 
Connecticut Yes, on 
embryos before 
gastrulation (a 
process during 
embryonic 
development) 
 No Yes, consent to 
donate IVF 
embryo to 
research 
 No Yes, prohibits 
payment for 
embryos, 
embryonic stem 
cells unfertilized 
eggs or sperm 
donated 
following IVF 
treatment  
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State 
 
Specifically 
permits 
research on 
fetus/embryo 
 
Restricts 
research on 
aborted fetus/ 
embryo 
 
Consent 
provisions to 
conduct 
research on 
fetus/embryo
3
 
Restricts 
research on 
fetus or embryo 
resulting from 
sources other 
than abortion 
 
Restrictions of 
purchase/sale 
human tissue 
for research 
Florida 
 
No Yes, prohibits 
on aborted live 
fetus 
No No No 
Illinois 
 
Yes, permits 
research on 
embryonic stem 
cells, embryonic 
germ cells and 
adult stem cells 
from any source 
Yes, prohibits 
on aborted 
living/ 
nonliving fetus 
Yes, written 
consent to 
perform 
research on 
cells or tissues 
from a dead 
fetus other than 
from an abortion 
Yes, prohibits 
research on 
fetus/fertilized 
embryo; prohibits 
funding under 
E.O. 6 (2005) of 
research on 
fetuses from 
induced abortions 
and the creation 
of embryos 
through the 
combination of 
gametes solely for 
the purpose of 
research 
Yes, prohibits 
sale of fetus/fetal 
tissue; prohibits 
purchase or sale 
of embryonic or 
fetal cadaveric 
tissue for 
research but 
permits 
reimbursement 
for removal, 
storage and 
transportation for 
research 
Indiana 
 
Yes, permits 
fetal stem cell 
research on 
placenta, cord 
blood, amniotic 
fluid or fetal 
tissue 
Yes, prohibits 
research on 
aborted 
living/non-living 
embryo or fetus 
Yes, consent 
required for fetal 
stem cell 
research 
Yes, prohibits 
research on 
cloned embryos 
Yes, prohibits 
sale of human 
ovum, zygote, 
embryo or fetus 
Iowa 
 
Yes, ensures 
that Iowa 
patients have 
access to stem 
cell therapies 
and cures and 
Iowa 
researchers 
may conduct 
stem cell 
research 
No No No Yes, prohibits 
transfer or 
receipt of the 
product of 
human 
reproductive 
cloning 
Kentucky 
 
No No No No Yes, prohibits 
sale of fetus/fetal 
tissue 
Louisiana 
 
No No No Yes, prohibits 
research 
on fetus/embryo 
in utero, in vitro 
fertilized embryo 
No 
Maine 
 
No No No Yes, prohibits 
research on 
fetus/embryo born 
or extracted alive, 
only applies to in 
vitro fertilized 
embryos post-
implantation 
Yes, prohibits 
sale of fetus/fetal 
tissue 
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State 
 
Specifically 
permits 
research on 
fetus/embryo 
 
Restricts 
research on 
aborted fetus/ 
embryo 
 
Consent 
provisions to 
conduct 
research on 
fetus/embryo
3
 
Restricts 
research on 
fetus or embryo 
resulting from 
sources other 
than abortion 
 
Restrictions of 
purchase/sale 
human tissue 
for research 
Maryland 
 
Yes, permits 
research on 
adult and 
embryonic stem 
cells 
 No 
Yes, written 
consent to 
donate unused 
IVF material to 
research 
Yes, prohibits 
donation of 
unused oocytes 
for state funded 
stem cell 
research; cloning 
of an organism 
beyond the 
embryonic stage 
is prohibited 
Yes, prohibits 
valuable 
consideration for 
the donation or 
production of IVF 
material 
Massachusetts 
 
Yes, on 
embryos that 
have not 
experienced 
more than 14 
days of 
development 
(not including 
days frozen) 
Yes, prohibits 
research on 
embryo/live 
fetus 
Yes, written 
consent to 
perform 
research on a 
dead fetus and 
informed 
consent to 
donate egg, 
sperm, or 
unused 
preimplantation 
embryos 
created for IVF 
Yes, prohibits 
research on live 
embryo or fetus; 
also prohibits 
creation of 
fertilized embryo 
solely for 
research 
Yes, prohibits 
sale of neonate, 
embryo or fetus 
for illegal 
purposes; 
prohibits sale of 
embryos, 
gametes or 
cadaveric tissue 
for research 
Michigan 
 
No Yes, live 
embryo/ 
fetus 
Yes, written 
consent of 
mother to 
donate dead 
embryo, fetus or 
neonate to 
research 
Yes, prohibits 
research on a live 
embryo or fetus, 
cloned embryo 
No 
Minnesota 
 
No No No Yes, prohibits 
research on a live 
embryo or fetus 
up to 265 days 
post fertilization 
Yes, permits the 
sale/purchase of 
cell culture lines 
from nonliving 
human 
conceptus 
Missouri No Yes, prohibits 
research on a 
fetus alive pre-
abortion 
No No Yes, prohibits 
receipt of 
valuable 
consideration for 
aborted fetal 
organs or tissue 
Montana 
 
No Yes, prohibits 
research on a 
live fetus 
No No No 
Nebraska 
 
No Yes, prohibits 
research on 
aborted live 
fetus or the use 
of state funds 
for research on 
fetal tissue 
obtained from 
an abortion 
No Yes, limits the use 
of state funds for 
embryonic stem 
cell research; 
restrictions only 
apply to state 
healthcare cash 
funds provided 
by tobacco 
settlement dollars 
Yes, prohibits 
sale, distribution 
or donation of 
viable aborted 
child 
New 
Hampshire 
 
No No No Yes, prohibits the 
maintenance of a 
unfrozen fertilized 
pre-embryo past 
14 days 
Yes 
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State 
 
Specifically 
permits 
research on 
fetus/embryo 
 
Restricts 
research on 
aborted fetus/ 
embryo 
 
Consent 
provisions to 
conduct 
research on 
fetus/embryo
3
 
Restricts 
research on 
fetus or embryo 
resulting from 
sources other 
than abortion 
 
Restrictions of 
purchase/sale 
human tissue 
for research 
New Jersey 
 
Yes No Yes No No 
New Mexico 
 
No No No Yes, prohibits 
research on a 
fetus/embryo born 
or extracted alive, 
only applies to in 
vitro fertilized 
embryos post-
implantation 
Yes, prohibits 
abortion for the 
purpose of 
selling the fetus 
to researchers 
New York  
 
Yes, permits 
research on 
adult and 
embryonic stem 
cells from any 
source 
No No     
North Dakota 
 
No Yes, prohibits 
research on a 
living/non-living 
embryo or fetus 
Yes, requires 
consent to 
conduct 
research on a 
nonliving fetus 
or embryo other 
than from an 
abortion 
Yes, prohibits 
research on a 
fetus born or 
extracted alive; 
cloned embryos 
Yes, prohibits the 
sale of a fetus to 
be used for 
illegal purposes 
Ohio 
 
No Yes, prohibits 
research on a 
living/non-living 
embryo or fetus 
No No Yes, prohibits 
sale of fetus or 
fetal remains 
from an abortion 
Oklahoma 
 
No Yes, prohibits 
research on a 
fetus/embryo 
No No Yes, prohibits 
sale of fetus or 
fetal remains 
Pennsylvania 
 
No Yes, prohibits 
research on a 
live embryo or 
fetus 
Consideration 
may not be 
given to 
mothers 
consenting to 
research; in 
cases involving 
abortion, 
consent must 
be provided 
after decision to 
abort 
No Yes, 
consideration 
may not be given 
to mothers 
consenting to 
research or other 
transferring 
tissue except for 
expenses 
involved in actual 
retrieval, storage, 
etc. 
Rhode Island 
 
No No Yes Yes, prohibits 
research on a 
fetus/embryo born 
or extracted alive, 
only applies to in 
vitro fertilized 
embryos post-
implantation 
Yes, prohibits 
sale of neonate, 
embryo or fetus 
for illegal 
purposes 
South Dakota 
 
No Yes, prohibits 
research on a 
living/non-living 
embryo or fetus 
No Yes, prohibits 
research on 
embryo outside of 
a woman's body; 
research on cells 
or tissues derived 
from an embryo 
outside a 
woman's body 
Yes, prohibits 
sale of embryo 
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State 
 
Specifically 
permits 
research on 
fetus/embryo 
 
Restricts 
research on 
aborted fetus/ 
embryo 
 
Consent 
provisions to 
conduct 
research on 
fetus/embryo
3
 
Restricts 
research on 
fetus or embryo 
resulting from 
sources other 
than abortion 
 
Restrictions of 
purchase/sale 
human tissue 
for research 
Tennessee 
 
No No Yes, consent 
required to 
conduct 
research on 
aborted fetus 
No Yes, prohibits 
sale of aborted 
fetus 
Texas  No No No No Prohibits sale of 
fetus/fetal tissue 
Utah 
 
No No No Yes, prohibits 
research on a live 
fetus, fertilized 
embryo post-
implantation
1
 
Yes, prohibits 
sale of fetus/fetal 
tissue; also 
prohibits sale of 
live unborn 
children, which is 
not defined, but 
are referred to in 
abortion statute
1
 
Virginia 
 
No No No May prohibit 
research on a 
cloned embryo or 
fetus
2
 
Yes, prohibits 
shipping or 
receiving of the 
product of 
human cloning 
for commerce
2
 
Wyoming 
 
No No No No Yes, prohibits 
sale, distribution 
or donation of 
live or viable 
aborted child, 
defined to 
include embryos, 
for 
experimentation 
1. Abortion is defined as a procedure undertaken to terminate a human pregnancy after implantation of 
a fertilized ovum or kill a live unborn child. Therefore, the statute may cover only fertilized ovum. 
2. Virginia law does not expressly prohibit research on cloned embryos, but it is forbidden to possess 
the product of human cloning. Under the state human cloning statute human cloning is defined as the 
creation of or attempt to create a human being by transferring the nucleus from a human cell from 
whatever source into an oocyte from which the nucleus has been removed. Human being is not 
defined as to whether it includes neonates, embryos or fetuses only. 
3. Some states have requirements for consent regarding the disposition of human embryos prior to in 
vitro fertilization that may impact donation to research.  
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Annex B – Development of Multicriteria Mapping 
options 
The Multicriteria Mapping (MCM) options for this thesis are structured 
according to the ‗dimensions of governance‘ which were presented at the end of 
Chapter 3. These dimensions include: 1) is the principal governance mode centralised or 
devolved? 2) do mechanisms for regulatory oversight provide detailed prescriptions or 
general guidance? And 3) are associated deliberative processes ‗democratic‘ 
(participatory) or ‗technocratic‘ (expert-based)? Beginning with these dimensions, the 
option definition process proceeded in an iterative fashion through two independently 
conducted stages. The first of these stages was to develop eight ‗abstract‘ options based 
on the potential combinations of the three central dimensions. 
First, building upon these three dimensions of governance, eight ‗abstract‘ 
options were developed based on the possible combinations of the three central 
dimensions. An example of the working titles of these abstract options are as follows 
and their full descriptions can be found in table B.1 below:  
1. Centralised, democratic, guidelines 
2. Centralised, democratic, prescriptions 
3. Centralised, technocratic, guidelines 
4. Centralised, technocratic, prescriptions 
5. Decentralised, democratic, guidelines 
6. Decentralised, democratic, prescriptions 
7. Decentralised, technocratic, guidelines 
8. Decentralised, technocratic, prescriptions 
To give an idea of how the options were then defined, let us look at one of the 
discretionary options that was ultimately used in the MCM interviews. The following is 
the definition of the option ‗Devolved democratic governance‘ and is analogous to 
working title #6 above:  
Devolved democratic governance through general laws: Oversight of hESC 
research is devolved from the national level to individual jurisdictions. A high 
degree of autonomy is given to researchers within a broad set of general laws. 
Laws are set and interpreted by individual jurisdictions. Both the setting of laws 
and their interpretation are subject to serious provision for deliberations and 
negotiations that include significant public involvement initiatives involving a 
wide range of experts, stakeholders and citizens. 
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As one might observe in reading through the option, the definition is rather 
abstract. Defining a set of core options in this way would both seem to be unwieldy and 
potentially confusing for the interviewee, especially when compounded by an interview 
process which most participants are unfamiliar with. In order to mitigate this, the 
governance options were built around country-specific examples. Thus, the second stage 
of the option definition process was to review national governance frameworks.  
Major countries active in hESC research were identified and their national 
policies reviewed. A particularly useful starting point was the policy report on human 
assisted reproductive technologies delivered by Fukuyama and Furger (2007) which 
extensively reviewed international policies for this area. From this basis, further reviews 
within a relatively distinct body of national policy, theoretical and grey literatures 
discussing regulatory policies for stem cell research were conducted. This review 
confirmed that, as is the case in the Fukuyama and Furger report (2007), there are a core 
group of countries that are discussed most frequently and consistently within these 
literatures. On this basis, the following ten countries were selected for detailed review 
and consideration as candidates on which to base the MCM options: the United States, 
the United Kingdom, Sweden, Germany, Canada, Australia, Italy, Israel, Singapore, and 
Switzerland. A summary of this review can be found in Table B.2 below.    
With the ten countries and the eight abstract options identified, a ‗matching‘ 
process commenced. The aim was to identify a core set of options which were grounded 
in the abstract dimensions, but were based on country-specific models. This was an 
iterative process which simultaneously required ‗operationalising‘ the abstract 
dimensions of governance whilst ‗generalising‘ each country‘s individual governance 
framework. In order to ensure this was done in a systematic manner, several criteria 
were used as a guide:  
 the final set of selected countries needs to cover, to a reasonable extent, all eight 
abstract notions of governance as set out above; 
 it should be reasonable to assume that participants would be knowledgeable 
about the countries selected; 
 the governance features of the selected countries should be sufficiently different 
so that they can be distinctly evaluated; 
 yet the underlying nature of the selected countries should be sufficiently similar 
so as to control for unwanted bias in participant evaluation; 
 the governance frameworks of individual countries should be generalisable in a 
clear and recognisable manner; and 
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  as the US and the UK are the central comparative points of my study, both these 
countries should be included as final core options; 
Based upon these criteria, the abstract options and the country-specific ones came into 
alignment. For example, South Korea was eliminated as a potential country because 
they are a non-Western democracy, while Australia was included because it is a federal 
state with a highly centralised national system of oversight for hESC research, thereby 
rendering it both similar and sufficiently different to the US for comparison. Eventually, 
six core options and three discretionary options were arrived at, covering seven 
countries. The diagram below depicts all nine options and attempts to illustrate the way 
they fill the three-dimensional ‗space‘ created by the dimensions of governance.  
Figure B.1: Schematic representation of option definition process 
US
Centralised
Sweden
Mode of centralisation
Mechanisms of regulation
Deliberations
Israel
Australia
Centralised 
democratic
Devolved 
democratic
Guidelines
Democratic
Technocratic
Devolved
Prescriptions
 
 
 
After this process was completed, a full set of MCM options could be developed. These 
are presented in Annex C.  
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Table B.1: Abstract Governance Options 
Option Title Option Description 
Centralised, 
democratic, passive 
Oversight of hESC research is centralised within a single regulatory 
institution and at a central level of government.  Policy making power 
is vested within that institution, or rests in another centralised 
authority.  The mechanisms for overseeing hESC research are 
passive and scientists and researchers enjoy a large degree of 
autonomy to conduct research; although they may be restricted by 
some overarching norms or formal restrictions.  Negotiations about 
hESC research governance occur between a variety of actors, 
stakeholders and citizens and the governance process is open to 
engagement and participation through many channels.  Deliberations 
that occur within the governance structure are informed by a similar 
variety of views and perspectives and may be expert-based or lay. 
Centralised, 
democratic, 
regulations 
Oversight of hESC research is centralised within a single regulatory 
institution and at a central level of government.  Policy making power 
is vested within that institution, or rests in another centralised 
authority.  hESC research is tightly controlled through specific 
regulatory mechanisms and scientists and researchers must abide by 
these regulations or face consequences.  Negotiations about hESC 
research governance occur between a variety of actors, stakeholders 
and citizens and the governance process is open to engagement and 
participation through many channels.  Deliberations that occur within 
the governance structure are informed by a similar variety of views 
and perspectives and may be expert-based or lay. 
Centralised, 
technocratic, 
passive 
Oversight of hESC research is centralised within a single regulatory 
institution and at a central level of government.  Policy making power 
is vested within that institution, or rests in another centralised 
authority.  The mechanisms for overseeing hESC research are 
passive and scientists and researchers enjoy a large degree of 
autonomy to conduct research; although they may be restricted by 
some overarching norms or formal restrictions. Negotiations occur 
between designated technical experts and policy officials and these 
people set the context and parameters for any deliberations or 
discussions.  These deliberations are informed by selected types of 
technical and scientific advice.  Engagement and participation is fairly 
limited and most open to technical or scientific experts and policy 
officials. 
Centralised, 
technocratic, 
regulations 
Oversight of hESC research is centralised within a single regulatory 
institution and at a national level of government.  Policy making power 
is vested within that institution, or rests in a similarly centralised 
authority.  hESC research is tightly controlled through specific 
regulatory mechanisms and scientists and researchers must abide by 
these regulations or face consequences.  Negotiations occur between 
designated technical experts and policy officials and these people set 
the context and parameters for any deliberations or discussions.  
These deliberations are informed by selected types of technical and 
scientific advice.  Engagement and participation is fairly limited and 
most open to technical or scientific experts and policy officials. 
Decentralised, 
democratic, passive 
Oversight of hESC research is primarily through research institutions 
or at a regional level of government.  Policy making power may be 
dispersed among different government institutions and is not 
centralised at the national level.  hESC research is passively 
regulated, with overarching institutional, disciplinary or regulatory 
norms and mechanisms that might guide hESC research, but a large 
degree of scientific and research autonomy exists.  Negotiations about 
hESC research governance occur between a variety of actors, 
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stakeholders and citizens and the governance process is open to 
engagement and participation through many channels.  Deliberations 
that occur within the governance structure are informed by a similar 
variety of views and perspectives and may be expert-based or lay. 
Decentralised, 
democratic, 
regulations 
Oversight of hESC research is primarily through research institutions 
or at a regional level of government.  Policy making power may be 
dispersed among different government institutions and is not 
centralised at the national level.  hESC research is tightly controlled 
through specific regulatory mechanisms and scientists and 
researchers must abide by these regulations or face consequences.  
Negotiations about hESC research governance occur between a 
variety of actors, stakeholders and citizens and the governance 
process is open to engagement and participation through many 
channels.  Deliberations that occur within the governance structure are 
informed by a similar variety of views and perspectives and may be 
expert-based or lay. 
Decentralised, 
technocratic, 
passive 
Oversight of hESC research is primarily through research institutions 
or at a regional level of government.  Policy making power may be 
dispersed among different government institutions and is not 
centralised at the national level.  hESC research is passively 
regulated, with voluntary or overarching institutional, disciplinary or 
regulatory norms and mechanisms that might guide hESC research, 
but a large degree of scientific and research autonomy exists.  
Negotiations occur between designated technical experts and policy 
officials and these people set the context and parameters for any 
deliberations or discussions.  These deliberations are informed by 
selected types of technical and scientific advice.  Engagement and 
participation is fairly limited and most open to technical or scientific 
experts and policy officials. 
Decentralised, 
technocratic, 
regulations 
Oversight of hESC research is primarily through research institutions 
or at a regional level of government.  Policy making power may be 
dispersed among different government institutions and is not 
centralised at the national level.  hESC research is tightly controlled 
through specific regulatory mechanisms and scientists and 
researchers must abide by these regulations or face consequences.  
Negotiations occur between designated technical experts and policy 
officials and these people set the context and parameters for any 
deliberations or discussions.  These deliberations are informed by 
selected types of technical and scientific advice.  Engagement and 
participation is fairly limited and most open to technical or scientific 
experts and policy officials. 
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Table B.2: Global policies for hESC research 
 
 
Institutional Oversight Processes of 
Negotiation/Deliberation/Engagement 
Mechanisms of Regulation 
Centralisation De-centralisation Technocratic / 
Expert-based 
Democratic / 
Participatory 
Targeted 
regulations  
Passive steering  
United 
States 
 
 
Federal government, 
(the NIH), disperses 
federal research funds 
(subject to restrictions 
such as IRB review); 
Another locus of 
authority operates 
within judicial system 
State governments 
have authority to 
regulate and 
allocate state-based 
research funds; All 
research must 
adhere to federal 
standards. 
Reliance on bioethics 
committees and other 
scientific expertise 
panels to review not 
only policy-based 
decisions, but also 
scientific procedures 
themselves.  
Citizen input through 
appointed experts or 
federal register 
Restrictions at 
federal level on 
funding for HESC 
research; No 
legislative law 
passed, though 
several attempted 
of a „targeted fix‟ 
variety  
No specific hESC 
research oversight of 
private sector; NAS 
„voluntary‟ research 
guidelines; 
Professional codes of 
practice at voluntary 
level 
Summary 
and Notes: 
Equal distribution between each. Level of 
centralisation determined by other two 
dimensions. 
Tendency towards expert-based deliberation 
over democratic and participatory methods of 
engagement. Sits towards the top of this axis. 
Currently no specific prohibitions exist on 
HESC research except federal funding 
restrictions. Passive steering side of axis 
 Institutional Oversight Processes of 
Negotiation/Deliberation/Engagement 
Mechanisms of Regulation 
Centralisation De-centralisation Technocratic / Expert-
based 
Democratic / 
Participatory 
Targeted 
regulations  
Passive steering  
United 
Kingdom 
Central regulatory 
authority 
Some institutional 
oversight once research 
has been approved. 
Decisions on research 
taken through HEFA that 
is comprised of experts 
and lay persons. 
Public consultation 
is integral part of 
operation of HFEA 
and its policy 
decisions 
Specific prohibitions 
are legislated; 
research activities 
are heavily regulated, 
licensed and 
monitored 
Little to no passive 
steering. 
Summary 
and Notes: 
Centralised system at both level of regulatory 
institution and unitary state government 
Both expert-based deliberation and nation-wide 
public consultations that are more participatory 
Research activity has well-defined 
boundaries and controlled operating 
procedures 
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 Institutional Oversight Processes of 
Negotiation/Deliberation/Engagement 
Mechanisms of Regulation 
Centralisation De-centralisation Technocratic / Expert-
based 
Democratic / 
Participatory 
Targeted 
regulations  
Passive steering  
Sweden General ethical 
principles underpin 
HESC policy and 
were formulated by 
central government 
Oversight at 
regional research 
level and through 
institutional / 
scientific review 
boards. 
All seven parties of the 
Swedish Parliament 
reached consensus on 
allowing hESC 
research (although 
unclear how this was 
achieved) 
 Only prohibition is 
on reproductive 
cloning 
Most scientific 
research left 
largely to the 
market with 
ethical regulation 
in place at 
individual 
institutions 
Summary 
and Notes: 
Would place them towards decentralised 
institutional oversight of research 
Parliamentary consensus seems more based on 
expert input 
Very passive environment with research 
with boundaries of research set, but 
otherwise researchers and medical 
professionals given freedom 
 Institutional Oversight Processes of 
Negotiation/Deliberation/Engagement 
Mechanisms of Regulation 
Centralisation De-centralisation Technocratic / Expert-
based 
Democratic / 
Participatory 
Targeted 
regulations  
Passive steering  
Australia ERLC oversees 
embryo research 
licensing 
Regulatory 
enforcement 
through 
professional bodies 
(originally); 
Individual states 
can pass their own 
laws. 
ELRC has expert 
composition with no 
„lay‟ input.  
Democratic and 
participatory input at 
state level; national 
public consultations 
occur. 
Specific 
prohibitions passed 
by Parliament; 
Professional 
standards are 
codified through 
law 
 
Summary 
and Notes: 
Decentralised due to its grounding in 
professional self-regulation and devolved 
power to individual states 
Appears to take a technocratic approach, both 
in developing new policies and in composition of 
advisory bodies 
Would place towards middle of axis. 
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 Institutional Oversight Processes of 
Negotiation/Deliberation/Engagement 
Mechanisms of Regulation 
Centralisation De-centralisation Technocratic / Expert-
based 
Democratic / 
Participatory 
Targeted 
regulations  
Passive steering  
Canada Centralised 
regulatory institution 
has oversight, 
operates at federal 
level, individual 
provinces have little 
authority 
 Oversight body has 
expert-based 
representation 
Wide-ranging public 
engagement on 
development of new 
regulatory structure 
Prohibitions on the 
„ends‟ of research, 
as opposed to the 
means 
 
Summary 
and Notes: 
Centralised authority through federal 
government and newly created Assisted 
Reproductive Agency of Canada 
Due to broad-based public input, tendency 
towards democratic/participatory engagement  
Clearly defined research activity 
boundaries and tightly controlled 
operation of research 
 Institutional Oversight Processes of 
Negotiation/Deliberation/Engagement 
Mechanisms of Regulation 
Centralisation De-centralisation Technocratic / Expert-
based 
Democratic / 
Participatory 
Targeted 
regulations  
Passive steering  
Germany Centralised oversight 
of hESC research 
 Debate was interest 
group driven, less 
participatory 
 Very tight 
regulations  
 
Summary 
and Notes: 
Oversight through legislative bans and strict 
regulatory controls overseen by central 
authority and ethics bodies  
Technocratic tendencies are very strong, debate 
was highly politicized 
No „passivity‟, strict enforcement 
procedures 
 Institutional Oversight Processes of 
Negotiation/Deliberation/Engagement 
Mechanisms of Regulation 
Centralisation De-centralisation Technocratic / Expert-
based 
Democratic / 
Participatory 
Targeted 
regulations  
Passive steering  
Singapore Centralised 
government control; 
Institutional oversight 
within one regulatory 
institution 
 Bioethics Advisory 
Committee made 
principle 
recommendations, but 
did solicit and consider 
broad public inputs 
No specific 
participatory 
engagement except 
for public consultation 
by advisory body 
Boundaries on 
research do exist, 
but at a high level 
 
Summary 
and Notes: 
Would place on centralised end of axis. Would place more towards technocratic/expert-
based negotiation processes 
Within parameters of law, passive 
control seems to be the tendency with 
few specific HESC research regulations 
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 Institutional Oversight Processes of 
Negotiation/Deliberation/Engagement 
Mechanisms of Regulation 
Centralisation De-centralisation Technocratic / Expert-
based 
Democratic / 
Participatory 
Targeted 
regulations  
Passive steering  
Switzerland Centralised control 
and oversight 
through federal acts, 
legislation and 
institutional oversight 
by Federal 
Department of Health 
 Basic principles of law 
developed by Swiss 
National Advisory 
Commission on 
Bioethics;  
Electorate vote on 
whether to allow 
HESC research 
Some prohibitions 
on types of 
research, 
specifically 
therapeutic cloning 
 
Summary 
and Notes: 
Would classify this as centralised control of 
HESC research programmes 
Inputs to the commission do not appear to be 
overtly democratic, but not explicitly 
technocratic in nature 
Due to the fact there are targeted 
regulations on how research can be 
conducted, would place them more 
towards the „left‟ on this axis. 
 Institutional Oversight Processes of 
Negotiation/Deliberation/Engagement 
Mechanisms of Regulation 
Centralisation De-centralisation Technocratic / Expert-
based 
Democratic / 
Participatory 
Targeted 
regulations  
Passive steering  
 Italy Centralised oversight 
by government 
agency to enforce 
legislative restrictions 
 In case of HESC 
research, scientific 
community was not in 
support of current 
policy 
Some public opinion 
polls seem to suggest 
public is generally in 
favour of HESC 
research. 
Specific legislative 
bans on all embryo 
research, including 
HESC research 
On research with 
adult embryos, 
no additional 
controls exist 
Summary 
and Notes: 
Centralised control, enforced through law 
(as under mechanisms) 
As current policy was an act of legislation, 
neither category neatly applies. Certainly does 
not fall under participatory, and some readings 
confirm this.  
Tendency to use targeted controls, 
although only recently with case of 
embryo research. Will need to compare 
with other case study to see if similar 
characteristics of this dimension apply 
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Annex C – Full Text of Multicriteria Mapping 
Governance Options 
The text below is a replica of that provided to all participants prior to their interviews.  
 
Multi-Criteria Mapping Options 
 
Governance of human embryonic stem cell (hESC) research 
 
This interview is looking specifically at the governance of human embryonic stem cell 
research (hESC).  As governance is a widely used term and can mean different things to 
different people, I will define how it is being used in the context of this interview.   
Governance refers to the entire process of defining, developing, engaging, 
deliberating, negotiating, establishing, implementing and reviewing the 
oversight for hESC research.  These processes can happen within and between 
many spheres, for example the public and private, scientific and political, ethical 
and practical, moral and economical.  In other words, governance in this 
context is about the interactions between these multiple processes that are 
involved in governing hESC research in today‟s society.   
 
The following options present different governance scenarios for hESC research that we 
will discuss and evaluate during our MCM interview.  A summary chart can be found 
on page 4 that may help in discerning the key differences between the options. (I will 
provide a colour copy of this at the interview.)  All participants will be asked to evaluate 
the Core Options.  You can also choose to evaluate any of the pre-defined Discretionary 
Options, or to create your own Additional Options.  Further details on the MCM 
interview and the option definition process are given in the MCM Explanatory Note. 
 
Core Options 
 
1. Detailed centralised oversight 
Centralised governance with detailed regulations implemented by an expert 
statutory body that is empowered by legislature and is informed by occasional 
public involvement initiatives. 
This option is broadly analogous to the present governance of hESC research in the UK, 
without necessarily leading to the same outcomes.  Oversight of hESC research is 
centralised.  Primary legislation passed by a national legislature gives powers of 
regulatory oversight to a central statutory body that is comprised of various experts and 
lay representatives.  The statutory body implements detailed regulations that arise from 
the primary legislation and include dedicated approval and licensing processes for hESC 
research.  The main emphasis is on deliberations among experts and policy officials and 
so may be relatively closed to perspectives not represented on expert advisory groups.  
Periodic changes to the hESC governance framework as a whole make serious provision 
for deliberations and negotiations that attempt to engage a wide range of interested 
experts, stakeholders and citizens. 
  
2. Expert-led framework 
Devolved ethical, expert-based oversight subject to central general laws.   
This option is broadly analogous to the present governance of hESC research in 
Sweden, without necessarily leading to the same outcomes.  Policymaking power rests 
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with a central legislature, but oversight of hESC research is devolved to regional ethics 
committees that are comprised equally of appointed experts and lay members.  The 
central legislature defines general laws that guide hESC research, but a high degree of 
autonomy is afforded to researchers within these parameters.  The main emphasis is on 
deliberations within the expert advisory groups and so may be relatively closed to 
perspectives not represented on expert advisory groups.  Periodic changes to the hESC 
research governance framework as a whole involve deliberations and negotiations 
among experts, policy officials and interested policy actors, with few, if any, formal 
public involvement initiatives.   
 
3. Detailed expert oversight 
Centralised, expert governance through detailed regulations established by 
legislature and carried out by central scientific institution. 
This option is broadly analogous to the present governance of hESC research in 
Germany, without necessarily leading to the same outcomes.  Policy making and 
regulatory power is centralised in a national legislature.  Oversight of hESC research is 
delegated to a central research institute of scientific excellence.  All hESC research is 
subject to detailed regulations with dedicated approval and licensing processes.  The 
main emphasis is on deliberations among experts and policy officials and so may be 
relatively closed to perspectives not represented on expert advisory groups.  Periodic 
changes to the hESC research governance framework as a whole involve deliberations 
and negotiations among experts, policy officials and interested policy actors, with few, 
if any, formal public involvement initiatives.   
 
4. Devolved authority 
Devolved legislative authority subject to central detailed regulations and expert 
review with occasional public participation. 
This option is broadly analogous to the present governance of hESC research in 
Australia, though not necessarily leading to the same outcomes. Primary legislation at 
the national level establishes a governance framework for hESC research, but empowers 
individual devolved jurisdictions to pass further legislation implementing the national 
framework. Oversight of hESC research is controlled through detailed regulations.  
There is a centralised expert ethics body that is charged with approval and licensing of 
all research. The main emphasis is on deliberations among experts and policy officials 
and so may be relatively closed to perspectives not represented on expert advisory 
groups. Periodic changes to the hESC research governance framework as a whole 
involve negotiations, deliberations and public involvement among a wide range of 
interested experts, stakeholders and citizens.   
 
5. Mixed central/devolved   
Centralised expert governance with detailed regulation of national public research 
funds, and a variety of devolved governance frameworks. 
This option is broadly analogous to the present governance of hESC research in the 
United States, though not necessarily leading to the same outcomes.  The governance 
framework is mixed, with both central and devolved components.  At a centralised 
level, hESC research is subject to detailed regulation of national research funds.  
Voluntary guidelines for hESC research are in place, but are not enforceable by law.  At 
a decentralised level, devolved governance frameworks exist that include detailed 
regulations or general laws.  In all cases, the main emphasis is on deliberations among 
experts and policy officials and so may be relatively closed to perspectives not 
represented on expert advisory groups.  Periodic changes to the hESC research 
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governance framework as a whole involve deliberations and negotiations among 
experts, policy officials and interested policy actors, but in some cases make serious 
provision for public involvement initiatives, primarily through invited comment, open 
meetings and popular vote (referenda).   
 
6. Ethics-led governance 
Centralised, expert governance through general laws with ethical oversight. 
This option is broadly analogous to the governance of hESC research in Israel, though 
not necessarily with the same outcomes.  Policymaking power rests with a central 
legislature that primarily relies on expert ethical guidance.  Oversight for hESC research 
is guided by a national bioethics committee.  However, within this general framework, a 
high degree of autonomy is given to researchers.  The main emphasis is on deliberations 
among experts and policy officials and so may be closed to perspectives not represented 
on expert advisory groups.  Periodic changes to the hESC governance framework as a 
whole involve deliberations and negotiations among experts, policy officials and 
interested policy actors. 
Discretionary Options 
 
7. Devolved democratic governance 
Devolved democratic governance through general laws. 
Oversight of hESC research is devolved from the national level to individual 
jurisdictions.  A high degree of autonomy is given to researchers within a broad set of 
general laws.  Laws are set and interpreted by individual jurisdictions.  Both the setting 
of laws and their interpretation are subject to serious provision for deliberations and 
negotiations that include significant public involvement initiatives involving a wide 
range of experts, stakeholders and citizens.  
 
8. Centralised democratic governance 
Centralised democratic governance through general laws. 
Oversight of hESC research is centralised.  Primary legislation gives powers of 
oversight of hESC research to a central statutory body.  A high degree of autonomy is 
given to researchers within a broad set of general laws.  These laws are set by a national 
legislature and interpreted by a central statutory body.  Both are subject to serious 
provisions for deliberations and negotiations that include significant public involvement 
initiatives involving a wide range of experts, stakeholders and citizens. 
 
9. Centralised regulatory authority 
Centralised detailed regulation by expert statutory body subject to oversight by 
legislature. 
This option is broadly analogous to the newly established system of governance in 
Canada, though not necessarily with the same outcomes.  Oversight of hESC research is 
centralised, with primary authority resting with the legislature and regulatory oversight 
devolved to a statutory body composed of various expertises.  The statutory body 
enforces detailed regulations with dedicated processes for licensing and approval of 
research.  The main emphasis is on deliberations among experts and policy officials and 
so may be relatively closed to perspectives not represented on expert advisory groups. 
Periodic changes to the hESC research governance framework as a whole may make 
provision for public involvement initiatives, but at present involve deliberations and 
negotiations among experts, policy officials and interested policy actors.   
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Centralisation? Laws and Regulations? Types of Deliberations?
Detailed centralised 
oversight 
(United Kingdom)
Central legislation
Approval by central statutory body
Detailed regulations for approval and licensing
Expert-based with serious provision for 
public involvement
Expert-led framework 
(Sweden)
Central legislation
Approval by devolved regional ethics committees
General laws, ethics approval required Expert-based and ethics review  
Detailed expert 
oversight 
(Germany)
Central legislation
Approval by central research institute
Detailed regulations for approval and licensing Expert-based  
Devolved authority 
(Australia)
Centralised and devolved policies
Approval by central expert ethics body
Detailed regulations for approval and licensing Expert-based with public involvement
Mixed central / 
devolved 
(United States)
Centralised and devolved policies
Approval by mix of central and devolved 
frameworks
Detailed regulation of central public funding, 
Mix of detailed regulations and general laws at 
devolved level
Expert-based with provision for public 
involvement 
Ethics-led governance 
(Israel)
Central legislature
Approval by research institutions
General laws within an ethical framework Expert-based and ethics review  
Devolved democratic 
governance
Devolved legislation General laws Public involvement
Centralised democratic 
governance
Centralised oversight General laws Public involvement
Centralised regulatory 
authority 
(Canada)
Central legislature
Approval by central statutory body
Detailed regulations for approval and licensing Expert-based
Centralised Detailed regulations Public involvement
Mixed Centralisation Mix of general and detailed regulations Mix of deliberations
Decentralised General laws Expert based
D
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Annex D – Example emails and background information 
provided to participants 
Example introductory email to new contact 
The email below is an example of one sent to a new contact who either was 
referred by a previous participant or I had identified through research. 
Dear Dr Smith
157
,  
My name is Molly Morgan and I am a Ph.D. student at the Science and 
Technology Policy Research Institute (SPRU) at the University of Sussex in the 
United Kingdom. I am writing today to invite you to participate in an interview 
for my doctoral research study which is entitled „Governing the constructs of 
life‟. It is a comparative study looking at how 'good' governance for human 
embryonic stem cell (hESC) research is thought about and defined by different 
groups of stakeholders in the US and the UK 
I have been speaking to many leading experts on both sides of the Atlantic for 
this research and all have found it very interesting and timely. It is especially 
important, however, when it comes to the US context of this research that I 
capture perspectives within different states. As your organisation
158
 is an active 
voice in the wider discussions about hESC research, especially in your state
159
, 
it is a crucial point of view to include in my research. Below you will find a brief 
introduction to my study, as well as some details about the interview itself..  
As mentioned above, I am interviewing prominent policy makers, medical 
professionals, scientists, and other expert stakeholders with particular interests 
in the area of hESC research and asking them to evaluate different governance 
and regulatory frameworks that might be used to govern the research. The 
interviews are conducted using an interactive appraisal technique entitled 
Multicriteria Mapping (MCM). MCM provides a way for individuals to appraise 
different possible scenarios for a complex issue. As I am asking participants in 
this study to evaluate different governance frameworks for hESC research, I am 
most interested in the views and perspectives that each participant articulates 
and uses during the evaluation process.  
The interview times can vary, but most take about two hours. I will be in the 
your area in the latter half of would be happy to schedule a time that was most 
convenient for you. I hope you will be able to accept my invitation, however I 
appreciate you have many demands on your time. If you are unable to 
participate, or feel there is another individual within your organisation who is 
more appropriate to contact, I would be grateful for your suggestions. Thank 
you in advance for your time in considering this request and I look forward to 
hearing from you.  
                                                 
157
 This name, and others below, are fictional. 
158
 The organisation was referred to by name at this point in the email, but has been made generic here. 
159
 If the individual was based in an organisation in a particular state or region of the country which was 
relevant to why they were contacted to participate in the interview, this was made known here. 
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Example introductory email to MSc participant  
The email below is an example email of the kind sent initially to those who participated 
in my MSc research in 2004.  
Dear Ms. Smith,  
If you will recall, we met in June 2004 after you kindly agreed to be a 
participant in my Master's dissertation research. That research was looking at 
different options for regulating stem cell research in the US. We met at your 
office in Washington, DC where I interviewed you using an interactive, 
computer-based technique entitled Multi-Criteria Mapping (MCM). The thesis 
was very well received and I won an award for the most outstanding MSc 
dissertation of my year, so thank you again for your participation in that 
research.  
After spending a few years working in science policy for government 
departments in both the United Kingdom and the United States, I am now back 
at the University of Sussex pursuing my Doctorate in Science and Technology 
Policy. My doctoral research is looking at how notions of 'good' governance 
differ in the US and the UK for areas of challenging, and often contested, 
'human' biotechnology research. At this time I am focusing on medical 
biotechnologies, specifically human embryonic stem cell (hESC) research. As 
this research is built on ideas first explored in my Master's thesis, I wanted to 
invite you to participate and provide your expert input to this important and 
topical area of research. Your views and inputs were invaluable to my previous 
work, and would continue to be so in this doctoral study.  
As before, the interviews will use the unique format of MCM to evaluate 
different governance options for hESC research. When I was conducting my 
Master's research, I was fortunate enough to interview distinguished and 
prominent people with an active interest in the area of stem cell research such 
as yourself160. My doctoral research will again seek the views of prominent 
scientists, advocates and representatives from different stakeholder groups in 
the US, and similarly in the UK. 
I hope you are able to participate in this research and share your expert views 
and opinions. I will be conducting interviews in your area during the month of 
January in 2008 and would arrange a time and location that was most 
convenient for you. 
Thank you in advance for taking the time to consider this invitation. I would be 
happy to send through any additional information should you need it. I look 
forward to hearing from you.  
Background information provided to participants before the 
interview 
The text below is identical to that provided to participants prior to their 
interview. It was accompanied by a cover letter which reminded them of the time and 
                                                 
160
 This sentence contained the names of people who had participated in my MSc research and who had 
agreed to have their names shared at that time. These have been deleted for the purposes here. 
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date of their interview and asked that they review the material in the information pack 
prior to our meeting. The documents were sent in hard copy and by email. A copy of the 
cover letter is presented first. 
Dear Professor Smith, 
Thank you for agreeing to participate in my doctoral research project.  Our 
interview is scheduled for Tuesday, 03 June 2008 at 2:30pm.  We will be 
meeting at your office at the address above.  During the interview we will be 
making use of my laptop computer, so it would be best if we could sit side by 
side at a table or desk. Please let me know as soon as possible if this will pose a 
problem or if you need to make any changes to the arranged time. 
This information pack contains two background documents about the MCM 
interview: 1) the MCM Explanatory Note and 2) MCM hESC Governance 
Options.  The first explains the MCM interview process and the second outlines 
the governance options for hESC research that we will be discussing and 
evaluating during the interview.  
I would encourage you to read through at least the summary section of the 
Explanatory Note and try to familiarize yourself with the MCM hESC 
Governance Options. This will help to make the interview more efficient, 
however do not worry if anything is unclear as we will be able to go over 
everything on the day. 
If you have any questions prior to the interview I will be happy to answer them.  
Thank you again and I look forward to meeting you next Tuesday. 
Kind regards, 
 Molly Morgan 
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Multicriteria Mapping Interview Background Documents 
The following section is a replica of the „explanatory note‟ provided to participants 
prior to their interviews 
 
Multicriteria Mapping Explanatory Note: The MCM process explained 
This explanatory note provides an introduction to the MCM interview process.  The 
Summary on this page gives a brief overview of each of the MCM stages. Further detail 
and a worked example of an MCM interview is provided in the additional pages.      
 
Summary  
 
Multi-Criteria Mapping (MCM) is an interactive, decision analysis technique that 
provides a way of appraising a series of different options, or possible ways forward, for 
a complex issue.  It helps individuals to explain their beliefs and views about a complex 
or controversial issue in a structured and systematic way.    
 
An MCM interview has four stages.  The information generated during the MCM 
interview is recorded using a software programme, so we will be working with my 
laptop computer.  If this poses a problem, please let me know as soon as possible.  
 
Stage 1 – defining the options:  There are three types of MCM options that we will 
come across during the interview: Core Options, Discretionary Options and Additional 
Options.  I have already defined 6 Core Options and 3 Discretionary Options for this 
interview.  These are explained in detail in the MCM Options note included in the 
information pack.  It is important you are familiar with these options as we go through 
the interview, so in this stage we will go over the different options and clarify any that 
are unclear.  You may also wish to define Additional Options to evaluate, which can be 
done at this time.  Further information about Additional Options is provided below.  
 
Stage 2 – defining criteria:  In this stage, you will be asked to define 6-8 criteria that 
you will eventually use to evaluate the options from stage 1.  Criteria are the different 
ideas, beliefs, technical judgements or opinions you might use when considering what 
you think about each option.  Criteria are the individual thoughts that might occur to you 
were someone to ask, what do you think of option x and why?  We will go over some 
examples of criteria at the beginning of the interview. 
 
Stage 3 – scoring the options:  During this stage, you will evaluate each option 
according to how well you deem it to „perform‟ under each of the criterion you defined 
in stage 2.  In other words, you are evaluating the extent to which each option would 
allow an individual criterion to be optimally fulfilled.  This is the most detailed part of the 
MCM process, but also one of the most important for the final analysis. 
 
Stage 4 – weighting the criteria:  This stage is different from scoring, where you were 
evaluating each option.  In the weighting stage, you will be asked to evaluate the 
relative importance of each criteria against each other.  Thus, if Criteria A is twice as 
important to you as Criteria B, you will be able to reflect this here.  These weightings, 
together with the scores, will determine the final performance rankings of each of the 
options you have evaluated. 
 
The remainder of this note describes each stage in further detail.  A worked example of 
the MCM stages is provided in the final pages.   
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Stage 1 – Defining the options 
The options represent a range of possible governance scenarios for hESC research.  
MCM uses three types of options: core options, discretionary options and additional 
options.  The Core Options are evaluated by all participants.  Discretionary Options 
have also been pre-defined and you may choose to evaluate some of these, as well.  If 
you feel that none of the existing options capture an aspect of governance that you feel 
is important to discuss, you can then define Additional Options to evaluate.  
 
For the present exercise, I have defined six Core Options and three Discretionary 
Options.  If possible, please familiarise yourself with the Core Options and give some 
thought to any Discretionary or Additional Options you will want to evaluate. A detailed 
description of the core options is included in this information pack, but the headlines 
are listed here: 
 
Core Options 
10. Centralised governance with detailed regulations implemented by an expert 
statutory body that is empowered by legislature and is informed by 
occasional public involvement initiatives.   
11. Devolved ethical, expert-based oversight subject to central general laws. 
12. Centralised, expert governance through detailed regulations established by 
legislature and carried out by central scientific institution. 
13. Devolved legislative authority subject to central detailed regulations and 
expert review with occasional public participation. 
14. Centralised expert governance with detailed regulation of federal public 
research funds, and a variety of devolved governance frameworks. 
15. Centralised, expert governance through general laws with ethical oversight. 
 
Discretionary Options 
16. Devolved democratic governance through general laws. 
17. Centralised democratic governance through general laws. 
18. Centralised detailed regulation by expert statutory body subject to oversight 
by legislature. 
 
Stage 2 – Defining the criteria used to evaluate the options 
If you were asked the question, “What do you think of this option and why?”, criteria are 
the thoughts you might consider when answering.  Criteria are the different ideas, 
assumptions, expert opinions, judgements and issues of importance you may wish to 
use to evaluate the different options.     
 
We will go over some examples of criteria for this specific case of hESC research at 
the beginning of the interview.  However, please jot any thoughts down prior to our 
meeting if you have them.  You will be asked to explain what you mean by each criteria 
and why you have chosen it, so it is important to have a clear idea of the criteria you 
are using and the differences between them.  For purposes of time and efficiency, I 
recommend you restrict yourself to six criteria or less.   
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Stage 3 – Scoring  
Due to the complex nature of scoring and the discussion that ensues, this is the most 
time consuming part of the MCM process.  It is important to understand how it works.  
 
The criteria from Stage 2 will be used to evaluate the different governance options.  
This is done by giving a score to each option as you deem it to „perform‟ under each 
criterion.  This value is entirely up to you to determine.  Often technical judgements, for 
example costs or other quantifiable information, are used to assign a score.  The 
scores are expressed using a scale, for example from one to ten or one to one 
hundred.  The higher the number, the better the performance of the option under a 
particular criterion.   
 
There are two caveats to scoring.  The first occurs when you are uncertain about an 
option‟s performance.  For example, you may think the performance depends on 
certain social or political circumstances, or other assumptions that need to be reflected.  
The MCM process allows you to express this uncertainty through a high and low score 
for each option.  One score reflects the most optimistic end of your judgement of likely 
performance, while the other score reflects the most pessimistic end.   
 
The second caveat applies when you have defined a criterion that reflects an issue of 
principle.  These types of criteria do not lend themselves to scoring.  Instead, these 
criterion simply allow you to state whether an option is acceptable or not under that 
criterion.  In this case, you can simply define an option as either acceptable or 
unacceptable under that „criterion of principle‟. 
 
As you proceed with your scoring, I will ask you to clarify the reasons for your decisions 
of the relative performance of the options under the criterion.  I am interested in the 
justifications for your scores and will use these for comparison in my analysis later on.   
 
Stage 4 – Weighting  
This stage involves assigning a relative order of importance to the criteria.  One way to 
think about this is to decide what number of points from a total of 100 you would assign 
to each criterion.  If one criterion is half as important to you as something else, it will be 
assigned half the number of points.   
 
Weighting is very different from scoring.  Scores reflect relatively technical judgements 
about the performance of options under individual criteria.  Weights are essentially 
subjective judgements about the relative importance of the different criteria themselves.  
Where you have identified a criterion as being an issue of principle, an option is either 
acceptable or not.  For this reason, issues of principle are not a part of the weighting 
exercise.   
 
 
The Outcome 
At the end of the process the software will generate a simple chart of how each option 
performs overall, taking into account all your criteria scores and weightings.  
Embedded in the chart are reflections of your criteria choices, technical judgements of 
the option performance, uncertainties, and priorities concerning the relative importance 
of each criterion.  The final MCM chart will look something like the one below:  
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We will use this chart to discuss how this picture of relative performance fits with your 
general expectations and beliefs about the governance frameworks for hESC research.  
You will also be able to investigate what happens if the weightings you gave are 
changed.  This may aid you in settling on a pattern of weightings which best reflects 
your beliefs and point of view.   
 
A WORKED MCM EXAMPLE – 
THE CASE OF ENERGY GENERATION 
 
The Government wishes to take advice over its policy priorities concerning which 
electricity generating options to encourage and which to discourage.  One specialist 
undertook an MCM exercise as a means of offering her advice. 
 
Stage 1 – Options  
 
The 3 core options were: 
1.  Nuclear power 
2.  Coal burning 
3.  Wind energy 
 
The specialist being interviewed also added „gas generation‟ to the list because of the 
importance of gas to current energy production. 
 
Stage 2 – Criteria  
 
The specialist decided upon the following criteria: 
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 Worker safety: the incidence of fatal or serious injuries or disease across whole 
„fuel cycle‟ (from mining to waste disposal) 
 Public health: incidence of adverse public health effects due to emissions, 
wastes, or accidents (excluding global warming effects) 
 Contribution to global warming: equivalent carbon production taking into 
account whole fuel cycle and material and energy use during construction 
 Electricity cost: taking account of capital costs, fuel cycle costs and waste 
management costs under prevailing market conditions 
 
An additional criterion introduced an issue of principle: 
 Maximum accident: a limit on the maximum extent of acceptable damage 
arising from a single possible accident.  Set at costs in excess of $25 billion or 
total committed public mortality in excess of 10,000 people. 
 
Stage 3 – Scoring  
 
The specialist then scored each criterion under each option.  A high and low score was 
given when it was uncertain how an option might perform.  A scale of 1-10 was chosen, 
with 10 being good and 1 being bad.  The specialist explained some her scoring 
processes this way: 
 
“Worker safety in nuclear power is generally very good, but there can be accidents.  
However, these are very rare.  I‟d score worker safety for nuclear as 6-8.  Worker 
safety for coal is not so good.  Mines can collapse and many miners can be killed.  I‟d 
score worker safety as 4-7 for coal…” 
 
“Nuclear power doesn‟t contribute to global warming unless the energy used in their 
construction is produced by burning carbon.  Therefore, they both score between 9 and 
10.  Coal is the worst and so scores 1-3.  Gas is somewhere in between, scoring 3-5…” 
 
“Nuclear power is the only option that presents a risk of a type of disaster that, although 
very unlikely, is beyond the threshold of what is acceptable to society, so it is ruled out 
on principle in relation to maximum accidents.” 
 
Stage 4 – Weighting  
 
The specialist first ranked the criteria, putting worker safety top, public safety second, 
cost third, and then global warming.   
 
She then thought about how much more important one was then another – to do this 
she thought about how 100 „importance points‟ would be shared between them.  The 
specialist thought worker and public safety were almost equally important and gave 
worker safety 40 and public health 35 points.  Cost was thought to be half as important 
at 18 points, and, because she felt there was little that could be done about global 
warming, gave it a score of 7. 
 
The Outcome 
 
As a result of all these inputs, the final chart shows wind energy generally performing 
best overall, varying between 63 and 97 points on the ranking scale.  Gas generation 
ranks second (between 30 and 76), overlapping with the lower end of the wind scale 
rank.  Coal burning comes third, ranking between 8 and 57 -  presenting quite a large 
overlap with gas, but none at all with wind.  Nuclear power was ruled out under the 
„maximum accident‟ rule.  
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‘Thought Bubble’ diagram given to participants during the MCM interview 
THIS LIST OF ISSUES IS PROVIDED TO HELP YOU THINK ABOUT THE CRITERIA IN MORE DETAIL. 
THESE ARE ONLY PROMPTS, YOU DO NOT HAVE TO USE ANY OF THEM. 
IF YOU WOULD LIKE TO USE THESE PROMPTS, PLEASE DEFINE THEM IN A WAY THAT IS MEANINGFUL TO YOU.
Ethics? 
Culture? 
Risk? 
Politics? 
Engagement? 
Religion? 
Responsibility? 
Trust? 
Progress? Science? 
Accountability? 
Value? 
Flexibility? 
Equality? 
Knowledge? 
Economics 
Gender? 
Technology? Standardisation? 
Research? 
Morality? 
Well-being? 
Society? 
Individuality? 
Harmonisation? 
Safety? 
Commercialisation? 
Ownership? 
Globalisation? 
Employment? 
Interactions? 
Legality? 
Regulation? 
Funding? 
Compliance? 
Objectivity? 
Transparency? 
Legitimacy? 
Expertise? 
Power? 
Media? 
Leadership? 
Feasibility? 
Education? 
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Annex E – Multicriteria Mapping Interviewee Codes 
Table E.1 – Multicriteria Mapping Interviewee Codes 
Interviewee Perspective 
Reference Code in Thesis 
Text 
Member of a genetic rights 
advocacy group 
Advocates UK policy opposition 1 
Member of a reproductive ethics 
group 
Advocates UK policy opposition 2 
Member of a Multiple Sclerosis 
patient advocacy group 
Advocates UK patient advocate 3 
Member of a cancer patient 
advocacy group 
Advocates UK patient advocate 4 
Member of a genetic disease 
patient advocacy group 
Advocates UK patient advocate 5 
Member of an organisation 
concerned with issues about 
biotechnology and society 
Advocates UK policy opposition 6 
Member of an Alzheimer‟s 
disease patient advocacy group 
Advocates UK patient advocate 7
161
 
Member of a medical religious 
advocacy group 
Advocates UK policy opposition 8
162
 
Member of a Parkinson‟s disease 
patient advocacy group 
Advocates US patient advocate 1 
Member of an organisation 
concerned with issues about 
biotechnology and society 
Advocates US policy opposition 2 
Advisor to multiple patient and 
science advocacy groups  
Advocates US policy advocate 3 
Member of a juvenile diabetes 
patient advocacy group 
Advocates US patient advocate 4 
Member of a reproductive 
medicine advocacy group 
Advocates US patient advocate 5 
Member of a Republican party 
woman‟s advocacy group 
Advocates US policy advocate 6 
TOTAL 12 (14)  
Member of a government 
bioethics advisory body 
Bioethicists UK bioethicist 1 
Bioethicist for various 
foundations and government 
advisory bodies 
Bioethicists UK bioethicist 2 
Bioethicist at a UK university Bioethicists UK bioethicist 3 
Bioethicist for a medical 
professional body 
Bioethicists UK bioethicist 4 
                                                 
161
 This participant did not complete a full interview, so they are not included in much of the analysis and 
presentation of ranking charts. 
162
 As above, this participant did not complete a full interview, so they are not included in much of the 
analysis and presentation of ranking charts.  
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Interviewee Perspective 
Reference Code in Thesis 
Text 
Bioethicist at an American 
university 
Bioethicists US bioethicist 1 
Bioethicist at an American 
university 
Bioethicists US bioethicist 2 
Bioethicist for a biotechnology 
industry group 
Bioethicists US bioethicist 3 
Bioethicist at an American 
university 
Bioethicists US bioethicist 4 
Bioethicist for a policy think tank Bioethicists US bioethicist 5 
TOTAL 9  
Chief Executive of a stem cell 
technology company 
Industry and Professional UK industry executive 1 
Chief Executive of a stem cell 
(start-up) technology company 
Industry and Professional UK industry executive 2 
Research Manager and Vice 
President of a stem cell 
technology company 
Industry and Professional UK industry executive 3 
Director of a professional stem 
cell network 
Industry and Professional UK professional body 4 
Research manager of a stem cell 
foundation 
Industry and Professional UK professional body 5 
Director of a professional stem 
cell network 
Industry and Professional UK professional body 6 
Vice President for regenerative 
medicine of a large life sciences 
technology company 
Industry and Professional US industry executive 1 
Vice President for business 
development of a stem cell 
technology company 
Industry and Professional US industry executive 2 
Director for federal affairs of a 
medical college professional 
body 
Industry and Professional US professional body 3 
President of a stem cell (start-up) 
technology company 
Industry and Professional US industry executive 4 
Director of a stem cell foundation Industry and Professional US professional body 5 
President of a technology 
licensing office of an American 
university 
Industry and Professional US industry executive 6 
TOTAL 12  
Research manager of a national 
funding body 
Policy-makers and Regulators UK policy-maker 1 
Policy-maker for a government 
department 
Policy-makers and Regulators UK policy-maker 2 
Policy-maker in a national policy-
making and funding body 
Policy-makers and Regulators UK policy-maker 3 
Member of a national regulatory 
body for stem cell research 
Policy-makers and Regulators UK regulator 4 
Director of a national policy body Policy-makers and Regulators US policy-maker 1 
Director for regulation for a state 
active in stem cell research 
Policy-makers and Regulators US regulator 2 
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Interviewee Perspective 
Reference Code in Thesis 
Text 
Research manager of a national 
policy-making and funding body 
Policy-makers and Regulators US policy-maker 3 
Regulatory advisor for a state 
active in stem cell research 
Policy-makers and Regulators US regulator 4 
Policy-maker in a state active in 
stem cell research 
Policy-makers and Regulators US policy-maker 5 
Policy-maker in a US state active 
in stem cell research 
Policy-makers and Regulators US policy-maker 6 
Policy-maker in US state active 
in stem cell research 
Policy-makers and Regulators US policy-maker 7 
Policy-maker in a US state active 
in stem cell research 
Policy-makers and Regulators US policy-maker 8 
TOTAL 12  
Embryologist at a UK university Laboratory-based scientists UK scientist 1 
Stem cell scientist at a UK 
university 
Laboratory-based scientists UK scientist 2 
Retired professor of genetics and 
biochemistry at a UK university 
and hospital 
Laboratory-based scientists UK scientist 3 
Stem cell scientist working in the 
laboratory of a stem cell 
company 
Laboratory-based scientists UK scientist 4 
Stem cell scientist at a UK 
university 
Laboratory-based scientists UK scientist 5 
Stem cell scientist at a UK 
university hospital 
Laboratory-based scientists UK scientist 6 
Stem cell scientist at a UK 
university 
Laboratory-based scientists UK scientist 7 
Retired professor of genetics and 
biochemistry at a US university 
Laboratory-based scientists US scientist 1 
Stem cell scientist at a US 
medical school  
Laboratory-based scientists US scientist 2 
Stem cell scientist at a US 
medical school  
Laboratory-based scientists US scientist 3 
Stem cell scientist at a private 
research institute 
Laboratory-based scientists US scientist 4 
Stem cell scientist at a US 
university 
Laboratory-based scientists US scientist 5 
TOTAL 12  
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Annex F – Basic summary of Multicriteria Mapping 
interview findings   
Basic summary 
The following sections provide a basic overview of some of the key points 
relating to how MCM was used during the interviews. We will first discuss the 
definition of additional options that were defined by 3 interviewees. We will then look 
at the definition and use of criteria. The three criterion of principle that were defined are 
presented, as well as a brief summary of the use of the bubble handout sheet. The final 
section of this Annex presents all the individual performance rankings across the 57 
MCM interviews.  
 
Additional options defined during the interviews 
 
 The following ‗additional options‘ were defined by interviewees:  
 
1. Centralised, expert governance through general laws with ethical oversight 
(UK Scientist 2). 
 
Policymaking power rests with a central legislature, but they do not legislate on 
specifics of research. National ethics committee with statutory power would 
approve the research. Basically this is the HFEA without government 
interference. 
 
Notes: that relies primarily on expert ethical guidance.  Oversight for hESC 
research is by a national bioethics committee that approves all hESC research.  
However, within these general laws, a high degree of autonomy is given to 
researchers.  The main emphasis is on deliberations among experts and policy 
officials and so may be closed to perspectives not represented on expert advisory 
groups.  Periodic changes to the hESC governance framework as a whole 
involve deliberations and negotiations among experts, policy officials and 
interested policy actors. 
 
2. Centralised representative governance with local oversight and 
implementation (US policy-maker 8).  
 
Centralised policy-making body empowered by legislation with a variety of 
different representation and/or expertise, establishing general, enforceable 
standards with institutional or shared oversight and implementation. Oversight 
mechanism is through contract provisions as opposed to regulations. Meetings 
of the body are open to the public and discussions and decisions are available to 
the public via the internet. 
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Notes: The body is providing input into the policies. Leaves out the enforcement 
mechanism of the board, but is sort of assumed. 
 
3. Centralised democratic governance through general laws and institutional 
oversight (US policy-maker 5 and US policy-maker 6).
163
 
 
Oversight of hESC research is centralised. Primary legislation gives powers of 
oversight of hESC research to a central statutory body. These laws are set by a 
national legislature and interpreted by a central statutory body. The central 
body establishes a schema that institutions have to enforce. Approval is by a 
research institution involving approval by an IRB/ESCRO type of committee. A 
high degree of autonomy is given to researchers within a broad set of general 
laws. The institutional oversight and setting of regulations by a central statutory 
body are subject to serious provisions for deliberations and negotiations that 
include significant public involvement initiatives involving a wide range of 
experts, stakeholders and citizens. 
 
 The evaluations of these options and their final rankings can be found in the 
individual performance ranking summary charts given in the final section of this Annex. 
Summary of criteria use 
Criteria definition 
 In Chapter 4 we introduced the use of the ‗bubble‘ sheet as a guide for the 
participants to use during the criteria definition stage. This sheet can be found in Annex 
D, above. In total, 93 criteria out of the total 310 criteria defined and evaluated in the 
MCM interviews were based on a ‗bubble‘ or group of bubbles from the prompt sheet. 
These 93 criteria were defined by 25 individuals. Therefore, under one-third of all 
criteria were defined using the bubbles as a guide and under half of the individuals 
defined all or some of their criteria from the prompt sheet (14 participants defined all or 
all but one of their criteria using only the prompt sheet).  
 In Chapter 4 we also discussed the various stages of preparation different 
interviewees might have undertaken prior to the interview. Sixteen participants made 
notes prior to the interview and between them 81 criteria were defined prior to the 
actual interview commencing.  
Criterion of principle 
 Three criteria of principle were defined over the course of the MCM interviews 
by two individuals. Two screenshots of the MC Mapper software are shown below 
                                                 
163
 This option was defined by two individuals who participated in an interview together, but had different 
scores for options in places and had different weightings.  
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relating to the two stages specific to criterion of principle. In the first, the criterion of 
principle are shown as diamond shapes in the upper left-hand box. In the second figure, 
the participant has ruled out an option on the basis of it violating one of her criterion. 
The three criterion of principle that were defined by the two participants were defined as 
follows (definitions are paraphrased by the author): 
1. Representation (UK scientist 4): There needs to be full and appropriate 
public representation within the governance framework. Those options that 
don't have public involvement won‟t be acceptable. 
2. Alignment to the laws of the country (UK scientist 4): Needs to align with 
laws and legal code that already exist in the country. If you're choosing to 
set about stem cell research then it's important to abide by what is there in 
the country already. 
3. No influence of religion (US patient advocate 5): Religion should not 
influence the governance framework in any way. 
Only the first criterion of principle was used to rule out an option. The participant 
concluded that because the detailed expert oversight option did not have any provision 
for public involvement within the framework that it violated her principles in this way.  
Figure F.1: Screenshot of criterion of principle 
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Figure F.2: Screenshot of participant ruling out an option based on violation of 
criterion of principle 
 
Individual Participant Ranking Charts 
 In the following pages, the final ranking charts of each individual who 
participated in the MCM interviews are shown. Individuals are coded according to the 
table provided in Annex E. 
Ranks for UK Patient and Policy Advocates 
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Ranks for UK Bioethicists 
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Ranks for UK Laboratory Scientists 
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Ranks for UK Policy-makers and Regulators 
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Ranks for UK Industry and Professional Body Executives 
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Ranks for US Patient and Policy Advocates 
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Ranks for US Bioethicists 
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Ranks for US Laboratory Scientists 
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Ranks for US Policy-makers and Regulators 
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Ranks for US Industry and Professional Body Executives 
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Annex G – MCM Algorithms 
Normalisation and Aggregation Procedures in MC-Mapper  
The Multicriteria Mapping methodology makes use of a normalising formula to 
produce the policy option performance ranks.
164
 This employs a ‗linear additive 
weighting‘ mathematical model based on the simple weight average of option 
performance: 
ri = ∑c sic∙wc 
This equation means that the overall performance rank obtained for the i
th
 choice option 
(ri) is the sum of the performance scores determined for that option under the c
th
 
appraisal criterion (sic) each multiplied by the importance weighting on that criterion 
(wc). The scores are normalised such that: 
sic = (mic – mc,min) / ∑ (mc,max – mc,min) 
This equation means that the performance score for the i
th 
choice option under the c
th
 
appraisal criterion (sic) is the ratio of the difference between the performance measure 
determined for that option (mic) and that for the lowest-performing option (mc,min) with 
the difference between the performance measures determined for the highest  - (mc,max) 
and lowest – (mc,min) performing options under that criterion. 
Calculation of Outputs in MCM Analysis  
 The following sequence of steps provides a narrative explanation of the 
successive steps followed by the MCM Analyst software in calculating the different 
quantitative charts used in an MCM analysis. They are described verbally for clarity. 
The initial calculation steps are as follows: 
1 for each participant in the selected perspective and for each criterion in 
the selected issue: 
2  multiply pessimistic normalised scores by normalised weights (this is 
'pessimistic subrank'); 
3  multiply optimistic normalised scores by normalised weights (this is 
'optimistic subrank'); 
4  subtract pessimistic subrank from optimistic subrank (this is „delta‟); 
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 Taken from Stirling, A and Mayer, S. 1999. Rethinking Risk: A pilot of Multi-Criteria Mapping of a 
genetically modified crop in agricultural systems in the UK. Falmer: University of Sussex. Pp: Annex 3. 
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5  sum half delta with pessimistic subrank (this is 'median'); 
6  divide delta by median (this is 'ratio uncertainty'). 
 
 In order to calculate the mean ratio uncertainty (the measure of uncertainty 
according to the ratio of the absolute difference between optimistic and pessimistic 
scores to the underlying values of the scoring ranges), the following additional steps are 
taken (indicated in successive numerical order to those above): 
7 across each criterion in the selected issue and across all participants in 
the selected perspective: 
8 take mean of ratio uncertainties (this is 'mean ratio uncertainty’). 
 
From here, mean interval uncertainty (the absolute scale of the difference 
between mean optimistic and mean pessimistic scores) is calculated by:  
9 across each criterion in the selected issue and across all participants in 
the selected perspective: 
10 take mean delta (this is 'mean interval uncertainty'). 
 
Finally, mean ambiguity (the measure of how much individuals within a 
perspective disagree with each other) is calculated as follows: 
11 across each criterion in the selected issue and across all participants in 
the selected perspective: 
12  take mean of pessimistic subranks (this is 'mean pessimistic subrank'); 
13 take mean of optimistic subranks (this is 'mean optimistic subrank'); 
14 subtract mean pessimistic subrank from mean optimistic subrank (this is 
'mean ambiguity'). 
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Annex H – Table of all Multicriteria Mapping criteria 
Table H.1: Table of all criteria defined in the MCM interviews 
Criterio
n ID
165
 
Participant Criterion Name 
Criterion 
Weight 
1 UK patient advocate 3 Public trust 35.69 
2 UK patient advocate 3 Open and transparent framework 21.68 
3 UK patient advocate 3 Accountability and monitoring 21.68 
4 UK patient advocate 3 Rigid central guidelines 7.29 
5 UK patient advocate 3 Flexibility, within rigid central guidelines 7.37 
6 UK patient advocate 3 Access to the science 7.29 
7 UK Bioethicist 3 Scientific discovery 28.53 
8 UK Bioethicist 3 Openness 14.41 
9 UK Bioethicist 3 Accountability 16.71 
10 UK Bioethicist 3 Public opinion 7.49 
11 UK Bioethicist 3 Macro and micro 7.20 
12 UK Bioethicist 3 System is respected 18.44 
13 UK Bioethicist 3 Administrative burden 7.20 
14 UK scientist 1 Biological security 26.85 
15 UK scientist 1 Physical security 10.19 
16 UK scientist 1 Ethical governance 18.83 
17 UK scientist 1 Public confidence 15.74 
18 UK scientist 1 Avoiding unnecessary bureaucratic delays 18.52 
19 UK scientist 1 Control of commercial exploitation 9.88 
20 UK policy-maker 1 Keep science at forefront of research 24.10 
21 UK policy-maker 1 Consistency 18.07 
22 UK policy-maker 1 Bureaucracy 15.06 
23 UK policy-maker 1 Acceptable exploitation 21.39 
24 UK policy-maker 1 Prevention of misuse 21.39 
25 UK scientist 2 Broad expertise 17.37 
26 UK scientist 2 Conservative approach 15.37 
27 UK scientist 2 Immune to pressures 17.37 
28 UK scientist 2 Progressive and scientifically astute 17.37 
29 UK scientist 2 Deliberate 17.37 
30 UK scientist 2 Control / Trust 15.17 
39 US bioethicist 3 Real public discourse 14.75 
40 US bioethicist 3 Ethical oversight 14.75 
41 US bioethicist 3 Politics minimized 16.39 
42 US bioethicist 3 Religion plays no role 16.39 
43 US bioethicist 3 Flexibly accommodate new science 11.48 
44 US bioethicist 3 Technology and science friendly 11.48 
45 US bioethicist 3 Transparent 14.75 
46 US policy-maker 3 Scientific merits of research 20.67 
47 US policy-maker 3 Balance of views 20.67 
48 US policy-maker 3 Federal oversight 20.67 
49 US policy-maker 3 Stability 20.67 
50* US policy-maker 3 Intellectual property 6.98 
51 US policy-maker 3 Ownership control 10.34 
52 US policy advocate 6 Funding is allowed from any source 24.92 
                                                 
165
 The reader may note that in some cases the numbers skip ahead and that the final Criterion ID is not 
310, but 349. This is due to the way the data are loaded into the database and some of the errors and ‗re-
loading‘ that had to occur. It is not due to omissions of data. 
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Criterio
n ID
165
 
Participant Criterion Name 
Criterion 
Weight 
53 US policy advocate 6 Presence of a federal framework 20.19 
54 US policy advocate 6 Consistency of oversight 18.93 
55 US policy advocate 6 Ethical and moral framework 6.62 
56 US policy advocate 6 Positive aspects of research brought to forefront 29.34 
57 US scientist 5 Responsibility 17.47 
58 US scientist 5 Accountability 12.91 
59 US scientist 5 Standardised 20.00 
60 US scientist 5 Flexibility 12.91 
61 US scientist 5 Multiple layers of oversight 16.46 
62 US scientist 5 Expert input to policy 20.25 
63 US scientist 2 Ethical framework 25.12 
64 US scientist 2 High standards of conduct 25.12 
65 US scientist 2 Respect for embryo 24.75 
66 US scientist 2 Government oversight 25.00 
67 US regulator 4 Public legitimacy 28.57 
68 US regulator 4 Good science to go forward 28.57 
69 US regulator 4 Minimal resources 14.00 
70 US regulator 4 Check on bad science 23.00 
71* US regulator 4 Public norms 5.90 
72 US industry executive 6 Local control and oversight 18.08 
73 US industry executive 6 Flexibility at central level 18.31 
74 US industry executive 6 Facilitates science moving forward 18.31 
75 US industry executive 6 Ownership 14.65 
76 US industry executive 6 Safety is ensured 9.61 
77 US industry executive 6 Commercialisation 14.42 
78* US industry executive 6 Minimal levels of oversight 6.64 
79 US regulator 2 Constitutional mandate 24.68 
80 US regulator 2 Advance research 18.27 
81 US regulator 2 High ethical standards 15.06 
82 US regulator 2 Issue identification 21.15 
83 US regulator 2 Space for public deliberation 11.86 
84 US regulator 2 Evaluative function 8.97 
97 US patient advocate 5 Non segregation of hESC research 17.42 
98 US patient advocate 5 Informed consent framework 26.48 
99 US patient advocate 5 Safety and transparency ensured 26.48 
100 US patient advocate 5 Public trust and confidence 29.62 
Principle US patient advocate 5 No religion  
101 US bioethicist 1 Meta-guidance 11.57 
102 US bioethicist 1 Local and multi-disciplinary expert guidance 24.04 
103 US bioethicist 1 Feedback 17.80 
104* US bioethicist 1 Collaboration 5.04 
105 US bioethicist 1 Flexibility 17.51 
106 US bioethicist 1 Pluralistic approach 24.04 
107 US policy-maker 1 Science 21.05 
108 US policy-maker 1 Respectful of multiple views 21.05 
109 US policy-maker 1 Flexibility 15.79 
110 US policy-maker 1 Accountability 16.84 
111 US policy-maker 1 Transparency 12.63 
112 US policy-maker 1 Local oversight 12.63 
113 US patient advocate 4 Flexible response to evolving technologies 12.15 
114 US patient advocate 4 Speed of approval 15.79 
115 US patient advocate 4 Consistency of interpretation 27.94 
116 US patient advocate 4 Diverse composition of approving body 19.84 
117 US patient advocate 4 Stable research environment 24.29 
118 UK regulator 4 Public confidence 19.00 
119 UK regulator 4 Transparency 16.33 
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Criterio
n ID
165
 
Participant Criterion Name 
Criterion 
Weight 
120 UK regulator 4 Accountability 16.33 
121 UK regulator 4 Broad expertise 16.33 
122 UK regulator 4 Flexibility 16.33 
123 UK regulator 4 Feasibility and Proportionate Response 16.33 
124 UK bioethicist 4 Scientific progress 22.39 
125 UK bioethicist 4 Minimal bureaucracy 22.39 
126 UK bioethicist 4 Public confidence is fostered 14.93 
127 UK bioethicist 4 Ethical consistency 20.52 
128 UK bioethicist 4 Pragmatic 18.66 
129* UK bioethicist 4 Necessary and useful engagement 1.2 
130 UK policy opposition 1 Expertise 14.42 
131 UK policy opposition 1 Engagement 20.06 
132 UK policy opposition 1 Framing 19.75 
133 UK policy opposition 1 Funding 14.73 
134 UK policy opposition 1 Openness 18.50 
135 UK policy opposition 1 Timing 12.54 
136 UK policy-maker 2 Respect for embryo 22.73 
137 UK policy-maker 2 Embryo research has potential to benefits others 22.73 
138 UK policy-maker 2 Egg donation 22.73 
139 UK policy-maker 2 Proportionate regulation 18.18 
140 UK policy-maker 2 Scientific creativity is fostered 13.64 
141 US policy advocate 3 Objective neutrality 17.27 
142 US policy advocate 3 Ethical guideline of framework 9.60 
143 US policy advocate 3 Leadership 19.19 
144 US policy advocate 3 Funding 9.60 
145 US policy advocate 3 Science dictates policy 17.47 
146 US policy advocate 3 Research is advanced 15.00 
147* US policy advocate 3 Education 11.52 
148 UK bioethicist 1 Accountability 22.16 
149 UK bioethicist 1 Flexibility 20.50 
150 UK bioethicist 1 Consistency 13.85 
151 UK bioethicist 1 Support and trust fostered 27.70 
152 UK bioethicist 1 Responsiveness 15.79 
153 UK professional body 6 Quality assurance 29.08 
154 UK professional body 6 Acceptability 18.30 
155 UK professional body 6 Transparency 18.30 
156 UK professional body 6 Streamlined and minimal bureaucracy 18.30 
157 UK professional body 6 Globalisation 16.01 
158 UK professional body 5 Enables scientific progress 20.83 
159 UK professional body 5 Regulations ensure safety and research ethics 20.83 
160 UK professional body 5 Process is transparent 14.58 
161 UK professional body 5 Have multiple types of expertise 14.58 
162 UK professional body 5 Access 14.58 
163 UK professional body 5 Consistency 14.58 
164 US bioethicist 2 Politics 22.73 
165 US bioethicist 2 Ethics 18.18 
166 US bioethicist 2 Risks 18.18 
167 US bioethicist 2 Globalisation 15.91 
168 US bioethicist 2 Employment 11.36 
169 US bioethicist 2 Ownership 13.64 
170 UK policy-maker 3 Balanced 23.53 
171 UK policy-maker 3 Transparency 17.65 
172 UK policy-maker 3 Responsible 23.53 
173 UK policy-maker 3 Flexibility 5.88 
174 UK policy-maker 3 Objectivity 23.53 
175 UK policy-maker 3 Compliance 5.88 
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Criterio
n ID
165
 
Participant Criterion Name 
Criterion 
Weight 
176 UK patient advocate 4 Public acceptance 13.43 
177 UK patient advocate 4 Science progress 22.00 
178 UK patient advocate 4 Compliance 4.84 
179 UK patient advocate 4 Ethics 24.86 
180 UK patient advocate 4 Expertise 21.72 
181 UK patient advocate 4 Transparency 13.15 
182 UK industry executive 2 Ethics 15.22 
183 UK industry executive 2 Transparency 21.74 
184 UK industry executive 2 Education 19.57 
185 UK industry executive 2 Responsibility 17.39 
186 UK industry executive 2 Regulation 8.70 
187 UK industry executive 2 Feasibility 17.39 
188 UK bioethicist 2 Public debate open 20.00 
189 UK bioethicist 2 Expertise 20.00 
190 UK bioethicist 2 Flexibility 19.80 
191 UK bioethicist 2 Moral sensitivity 20.00 
192 UK bioethicist 2 Encouraging of science 20.00 
193 UK scientist 3 Reasonable balance 33.33 
194 UK scientist 3 Support from stakeholders 25.00 
195 UK scientist 3 Fairness through consistency 25.00 
196 UK scientist 3 Opportunity to express views 16.67 
197 UK policy opposition 2 Knowledge 23.68 
198 UK policy opposition 2 Expertise 15.79 
199 UK policy opposition 2 Legitimacy 26.32 
200 UK policy opposition 2 International sensitivity 7.89 
201 UK policy opposition 2 Morality and ethics 26.32 
202 UK industry executive 3 Smooth regulatory response 31.03 
203 UK industry executive 3 Flexibility 17.24 
204 UK industry executive 3 Breadth of expertise 34.48 
205 UK industry executive 3 Accountability 17.24 
206 US scientist 1 Funding 15.66 
207 US scientist 1 Efficiency of decision-making 19.57 
208 US scientist 1 Harmonisation 19.57 
209 US scientist 1 Freedom from meddling 17.61 
210 US scientist 1 Education 5.87 
211 US scientist 1 Transparency 6.07 
212 US scientist 1 Trust 15.66 
220 US policy opposition 2 Reflective expertise 27.65 
221 US policy opposition 2 Adaptability of framework 16.71 
222 US policy opposition 2 Effective oversight (with minimal bureaucracy) 27.68 
223 US policy opposition 2 Address marginalised communities 27.96 
224 US industry executive 2 Clarity of the rules 20.47 
225 US industry executive 2 Clear authority 16.08 
226 US industry executive 2 Predictability 26.32 
227 US industry executive 2 Participation in rule-making 8.48 
228 US industry executive 2 Extent of freedom to act 28.65 
229 US professional body 5 Informed scientific input 20.00 
230 US professional body 5 Advance and progress the research 20.00 
231 US professional body 5 Guidelines 20.00 
232 US professional body 5 Insulation from politics 20.00 
233 US professional body 5 Advancing therapies 20.00 
234 US policy-maker 8 Engender public trust - processes 22.22 
235 US policy-maker 8 Engender public trust - policies that protect the public 
and individuals 
22.22 
236 US policy-maker 8 Presence of effective oversight and enforcement 
mechanisms 
22.00 
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Criterio
n ID
165
 
Participant Criterion Name 
Criterion 
Weight 
237 US policy-maker 8 Supporting meritorious science 22.22 
238 US policy-maker 8 Flexibility 11.11 
245 US bioethicist 5 Defence of human life and dignity 30.30 
246 US bioethicist 5 Advance scientific research and medical treatment 24.24 
247 US bioethicist 5 Effectiveness 12.12 
248 US bioethicist 5 Avoids divisiveness 18.18 
249 US bioethicist 5 Resolution through democratic processes 15.15 
250 US patient advocate 1 Non-discriminatory 6.23 
251 US patient advocate 1 Meeting society's needs and interests 32.79 
252 US patient advocate 1 Science is advanced 26.23 
253 US patient advocate 1 Ethical compliance 26.23 
254 US patient advocate 1 Congressional oversight 3.28 
255 US patient advocate 1 Flexibility and efficiency 5.25 
256 US professional body 3 Flexibility of system to allow scientific progress 24.04 
257 US professional body 3 Consistency among research tools 8.89 
258 US professional body 3 Vulnerability to political winds 13.22 
259 US professional body 3 Public input 11.54 
260 US professional body 3 Institutional variation 9.38 
261 US professional body 3 Appropriateness of oversight body 9.62 
262 US professional body 3 Credibility and acceptability, consent of the governed 18.99 
263 US professional body 3 Place for State role 4.33 
264 US policy-maker 6 Transparency 19.61 
265 US policy-maker 6 Uniformity and consistency 19.61 
266 US policy-maker 6 Fosters scientific breakthrough 14.71 
267 US policy-maker 6 Economic return to state 9.80 
268 US policy-maker 6 Effectiveness 17.65 
269 US policy-maker 6 Efficiency 18.63 
270 US policy-maker 5 Transparency 15.84 
271 US policy-maker 5 Uniformity and consistency 15.84 
272 US policy-maker 5 Fosters scientific breakthrough 18.81 
273 US policy-maker 5 Economic return to state 9.90 
274 US policy-maker 5 Effectiveness 19.80 
275 US policy-maker 5 Efficiency 19.80 
276 US bioethicist 4 Ethics 21.74 
277 US bioethicist 4 Progress 19.57 
278 US bioethicist 4 Justice 21.74 
279 US bioethicist 4 Science 19.57 
280 US bioethicist 4 Regulation 17.39 
281 US scientist 3 Science advances 20.12 
282 US scientist 3 Flexibility 19.89 
283 US scientist 3 Safety 29.84 
284 US scientist 3 Morality, religion and ethics are discussed 20.23 
285 US scientist 3 Realistic expectations about feasibility of the science 9.92 
286 US scientist 4 Expertise 9.14 
287 US scientist 4 Society sets the standards 9.14 
288 US scientist 4 Balance of expertise and a society 18.28 
289 US scientist 4 Enforceable ethical guidelines 18.28 
290 US scientist 4 International harmonisation 18.28 
291 US scientist 4 Flexibility of oversight 12.25 
292 US scientist 4 Advance biomedical research 14.63 
293 US industry executive 4 Impact on public health 28.93 
294 US industry executive 4 Responsiveness to new knowledge 20.66 
295 US industry executive 4 Balance economic cost/benefit 8.26 
296 US industry executive 4 Scientific integrity 33.06 
297 US industry executive 4 Public opinion 9.09 
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Criterio
n ID
165
 
Participant Criterion Name 
Criterion 
Weight 
298 US policy-maker 7 Broad representation of public and balanced selection 
of decision makers 
28.07 
299 US policy-maker 7 Flexibility 22.81 
300 US policy-maker 7 Transparency 14.04 
301 US policy-maker 7 Harmonisation 7.02 
302 US policy-maker 7 Effective implementation, oversight and monitoring 28.07 
303 UK scientist 7 Public involvement 20.00 
304 UK scientist 7 Advancing the science to full potential 20.00 
305 UK scientist 7 Openness of scientific discovery 20.00 
306 UK scientist 7 Workable legislation 20.00 
307 UK scientist 7 Responsible management of expectations 20.00 
308 UK patient advocate 5 Accommodate uncertainty 18.69 
309 UK patient advocate 5 Achieve balance in research aims 14.95 
310 UK patient advocate 5 Instils real trust 23.36 
311 UK patient advocate 5 Grounded in good science 28.04 
312 UK patient advocate 5 Honouring the gift 14.95 
313 UK scientist 6 Clear rules 19.23 
314 UK scientist 6 Responsiveness 19.23 
315 UK scientist 6 Public involvement 9.62 
316 UK scientist 6 Oversight done by multi-disciplinary experts 13.46 
317 UK scientist 6 Safety and efficacy 19.23 
318 UK scientist 6 Informed consent to the process of deriving stem cell 
lines 
19.23 
319 UK scientist 5 Get the science right 31.25 
320 UK scientist 5 Responsibility 20.83 
321 UK scientist 5 Fosters trust 20.83 
322 UK scientist 5 Strong regulation 12.05 
323 UK scientist 5 Politics 4.17 
324 UK scientist 5 Leadership 10.42 
325 UK scientist 4 Enables quality science 60.00 
326 UK scientist 4 Cost-effectiveness and efficiency 10.00 
327 UK scientist 4 Flexible to change 25.04 
328 UK scientist 4 Transparency 5.00 
Principle UK scientist 4 Representation  
Principle UK scientist 4 Alignment to the laws of the country  
329 UK professional body 4 Enables innovative research 21.98 
330 UK professional body 4 Representative of community at large 13.19 
331 UK professional body 4 Engagement 16.48 
332 UK professional body 4 Protection (safety) 15.38 
333 UK professional body 4 Protection (morality) 10.99 
334 UK professional body 4 Achievable 21.98 
335 UK industry executive 1 Multidisciplinary expertise 22.22 
336 UK industry executive 1 Formality of the governance structure 22.22 
337 UK industry executive 1 Appeals process 11.11 
338 UK industry executive 1 Incentivises research 22.22 
339 UK industry executive 1 Consistency with public policy and public opinion 22.22 
340 UK policy opposition 6 Democratic principle of control 21.05 
341 UK policy opposition 6 Openness 15.79 
342 UK policy opposition 6 Inclusion of 'democratic' ethics 15.79 
343 UK policy opposition 6 Broad public representation 15.79 
344 UK policy opposition 6 Exclusion of commercial interests 15.79 
345 UK policy opposition 6 Quality of scientific advice 15.79 
346 US industry executive 1 Freedom to perform research 42.89 
347 US industry executive 1 Adherence to democratic principles 14.37 
348 US industry executive 1 Consistency of interpretation 14.15 
349 US industry executive 1 Flexibility 28.59 
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Criterio
n ID
165
 
Participant Criterion Name 
Criterion 
Weight 
 UK patient advocate 7
**
 Public involvement  
 UK patient advocate 7 Expert evaluation  
 UK patient advocate 7 Legislative framework  
 UK patient advocate 7 Central licensing authority  
 UK patient advocate 7 Facilitates collaboration  
 UK patient advocate 7 Local oversight  
 UK patient advocate 7 Transparency  
 UK patient advocate 7 Equality  
 UK policy opposition 8
**
 Respect for human life and protection of the weak  
 UK policy opposition 8 Respect for cultural pluralism  
 UK policy opposition 8 Strong regulations  
 UK policy opposition 8 Central research authority  
 UK policy opposition 8 Advance the science responsibly  
 UK policy opposition 8 Investment  
 UK policy opposition 8 Caution  
 
*Criteria indicated with an asterisk next to their Criterion ID are those that were weighted, but options 
were not evaluated under them. 
**These two participants only defined criteria and did not complete a full MCM interview. 
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Annex I – Additional Multicriteria analysis and charts 
for UK and US perspectives as presented in Chapter 6 
Weightings for the issues presented in Chapter 6 
 The table below provides a summary of the average weightings across all the 
issues presented in Chapter 6, namely, ‗advances the science‘, ‗qualities of deliberative 
activities‘, ‗role of the public‘ and ‗nature of expertise‘. The reader is referred to the text 
in Chapter 6 for the significance of the weightings in relation to the analysis presented. 
Table I.1: Table of average weightings for criteria  
Criteria Type 
Criteria of this type among 
147 total criteria defined 
by a total of 27 UK 
participants? 
Criteria of this type among 
163 total criteria defined 
by a total of 30  
US participants? 
Criteria of this type among 
310 total criteria defined 
by a total of 57  US and UK 
participants 
Advances the 
science 
44 criteria  
defined by 23 participants 
Mean weighting: 32.5% 
71 criteria  
defined by 30 participants 
Mean weighting: 44% 
115 criteria  
defined by 53 participants 
Mean weighting: 38%  
Qualities of 
deliberative 
activities 
55 criteria defined by  
25 participants 
Mean weighting: 38% 
39 criteria defined by  
25 participants 
Mean weighting: 24% 
94 criteria defined by  
50 participants 
Mean weighting: 31% 
Role of the 
public 
35 criteria defined by  
21 participants 
Mean weighting: 24% 
23 criteria defined by  
19 participants 
Mean weighting: 13% 
58 criteria defined by  
40 participants 
Mean weighting: 18% 
Nature of 
expertise 
21 criteria defined by  
16 participants 
Mean weighting: 15% 
16 criteria defined by  
12 participants 
Mean weighting: 11% 
35 criteria defined by  
21 participants 
Mean weighting: 13% 
US and UK perspectives under ‘role of the public’ criteria 
 In Chapter 6, Section 6.3, we point out certain features of uncertainty and 
ambiguity in the performance rankings for UK and US perspectives under the ‗role of 
the public‘ criteria. The charts showing how this was analysed are presented below. 
Figure I.1 and I.2 below show the mean ambiguity and mean interval uncertainty 
rankings for US perspectives under the ‗role of the public‘ criteria. The mean ambiguity 
rankings indicate the amount of disagreement between individuals within the 
perspective. We can see from Figure I.1 that the ambiguity is highest for the mixed 
central/devolved option, but otherwise is fairly standard (between 6-8 base points) for 
the other options. A similar pattern is found for the mean interval uncertainty rankings 
in Figure I.2, leading us to be reasonably confident that both uncertainty and ambiguity 
are affecting the larger performance ranking intervals fairly equally. 
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Figure I.1: Mean ambiguity rankings for US perspectives for ‘role of the public’ 
criteria 
 
  
Figure I.2: Mean interval uncertainty rankings for US perspectives and ‘role of the 
public’ criteria 
 
 
 Figures I.3 and I.4, below, show the same sets of rankings for mean ambiguity 
and mean interval uncertainty, but for UK perspectives. The same conclusions as above 
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are drawn about the relative influence of ambiguity and uncertainty on the option 
performance rankings. However, here we compare the charts for the UK perspectives 
with those of the US perspectives. We see that there is a much more even expression of 
ambiguity and uncertainty across all the options for UK perspectives. There is also, on 
average, higher ambiguity expressed by UK perspectives than US perspectives, while 
the relative uncertainty expressed by both groups is fairly similar (with the exception of 
the mixed central/devolved option for US perspectives). These charts thus confirm the 
claims in Chapter 6 that UK participants express greater ambiguity relative to each other 
than US participants when evaluating the options under the ‗role of the public‘ criteria. 
Figure I.3: Mean ambiguity rankings for UK perspectives for ‘role of the public’ 
criteria 
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Figure I.4: Mean interval uncertainty rankings for UK perspectives and ‘role of 
the public’ criteria 
 
Deliberations and trust rankings 
In Chapter 6 the normative and instrumental motivations underlying criteria 
about the ‗nature of deliberations‘ and ‗trust‘, respectively, were discussed. The 
evaluations of these issues are presented in more detail there, but the performance 
rankings are shown in this Annex. First, though, we will briefly describe the definition 
of each issue as it was used in the MCM analysis. 
Deliberations (Normative): Criterion in this issue address exactly how and why 
expert or public input should be constructed in order to ensure sound 
democratic processes are followed. Criteria in this issue distinctly refer to 
particular characteristics and qualities of deliberations that must be present as 
a matter of principle. They are, in and of themselves, simply right elements of 
good governance and are discussed without reference to the ends they may 
achieve, simply the means by which they are implemented.  
Trust (Instrumental): This issue is characterised by criteria that appeal to 
fostering and building public trust and confidence in the governance system. 
Criteria are used in evaluation in such as a way as to determine how much a 
particular option or governance configuration is going to instil or foster strong 
feelings of public trust and confidence in either the regulator, the system, the 
science itself, and so on. Thus, the issue is clearly focussed on the instrumental, 
outcome-based concerns of achieving trust in whatever governance process is in 
place. 
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The two figures below show the rankings and respective counts of criteria within each 
issue.  
Figure I.5: Rankings for UK and US perspectives under ‘normative deliberations’ 
criteria 
 
Figure I.6: Rankings for UK and US perspectives under ‘trust (instrumental)’ 
criteria 
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Annex J – Additional Multicriteria Mapping analysis and 
charts for multiple stakeholder perspectives as 
presented in Chapter 7 
Uncertainty analysis under all performance rankings 
 In Chapter 7 we call attention to the relative uncertainty and/or ambiguity that is 
evident in different performance ranking patterns for the stakeholder groups being 
analysed. While ambiguity can only be determined under individual issues, we can look 
at expressions of uncertainty at the aggregate level of all option scores under all issues 
for different groups of stakeholders. Below are a series of figures for each of the 
stakeholder groups identified in the main text in Chapter 7, Section 7.1.2, where 
uncertainty seemed to be a significant feature of the ranking patterns. For each 
perspective, both ‗mean interval uncertainty‘ and ‗mean ratio uncertainty‘ charts are 
shown, however for the most part the author relied on mean interval uncertainty as the 
main measure of uncertainty for a given perspective or issue. Where there are significant 
differences in the ordinal pattern between mean interval uncertainty and mean ratio 
uncertainty, this indicates that there was a difference in the way participants expressed 
uncertainty in relation the absolute value of the scoring ranges. Were this study to be 
more concerned with how uncertainty is expressed, these differences could be probed in 
further detail. However, the concern here is relative expressions of uncertainty across 
different groups of participants, and so comparisons are made on the basis of relative 
expressions under both measures.  
 Figures J.1 and J.2 below show the mean interval uncertainty and mean ratio 
uncertainty for laboratory-based scientists. We can see a slight difference in the ordinal 
pattern between the charts, but generally we find the greatest expression of uncertainty 
for the mixed central/devolved and ethics-led governance options.  
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Figure J.1: Mean interval uncertainty for laboratory-based scientists 
 
Figure J.2: Mean ratio uncertainty for laboratory-based scientists 
 
  
Figures J.3 and J.4 below show the respective mean interval uncertainty charts for 
UK and US laboratory-based scientists, while Figures J.5 and J.6 show the mean ratio 
uncertainty measures for the two groups. We can see that UK scientists express more 
uncertainty under both measures across all options in comparison to the US scientists, 
therefore supporting the claim made in Chapter 7 in this regard.  
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Figure J.3: Mean interval uncertainty for UK laboratory-based scientists 
 
Figure J.4: Mean interval uncertainty for US laboratory-based scientists 
 
 
  
364 
Figure J.5: Mean ratio uncertainty for UK laboratory-based scientists 
 
Figure J.6: Mean ratio uncertainty for US laboratory-based scientists 
 
 
 Figures J.7 and J.8 below show the uncertainty charts for all advocates 
interviewed. As pointed out in Chapter 7, we can see clearly how under both measures of 
uncertainty the mixed central/devolved option has the highest expression of uncertainty. 
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Figure J.7: Mean interval uncertainty for advocates 
 
Figure J.8: Mean ratio uncertainty for advocates 
 
  
Figures J.9 and J.10 show the mean interval uncertainty for UK and US 
advocates. UK advocates have a more consistent use of uncertainty across all the options, 
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whereas US advocates express relatively less uncertainty for most of the options, with the 
notable exception of the mixed central/devolved option (that most analogous to the US 
governance model). A similar pattern is also seen for mean ratio uncertainty. 
Figure J.9: Mean interval uncertainty for UK advocates 
 
Figure J.10: Mean interval uncertainty for US advocates 
 
  
367 
Figure J.11: Mean ratio uncertainty for UK advocates 
 
Figure J.12: Mean ratio uncertainty for US advocates 
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Mean weightings for criteria discussed in Chapter 7 
Table J.1: Summary table for criteria discussed in Chapter 7 
Criteria 
Type Advocates Bioethicists 
Industry & 
Professional 
Policy-makers & 
Regulators 
Scientists 
(Labs) 
Advances 
the science 
10/12 participants  
22 criteria;  
Mean weighting 
31% 
8/9 participants  
15 criteria;  
Mean weighting 
30% 
12/12 participants  
30 criteria;  
Mean weighting 
52% 
12/12 participants  
32 criteria;  
Mean weighting 
48% 
11/12 participants  
23 criteria;  
Mean weighting 
38% 
Qualities of 
deliberative 
activities 
10/12 participants  
23 criteria;  
Mean weighting 
40% 
9 participants  
16 criteria;  
Mean weighting 
32% 
11/12 participants  
19 criteria;  
Mean weighting 
29% 
9/12 participants  
17 criteria;  
Mean weighting 
27% 
12/12 participants  
24 criteria;  
Mean weighting 
34% 
Role of the 
public 
8/12 participants  
10 criteria;  
Mean weighting 
20% 
8/9 participants  
11 criteria;  
Mean weighting 
20% 
8/12 participants  
11 criteria;  
Mean weighting 
14% 
8/12 participants  
13 criteria;  
Mean weighting 
20% 
9/12 participants  
13 criteria;  
Mean weighting 
18% 
Nature of 
expertise 
5/12 participants 
12 criteria;  
Mean weighting 
18% 
5 participants  
5 criteria;  
Mean weighting 
12% 
7/12 participants  
8 criteria;  
Mean weighting 
15% 
4/12 participants  
4 criteria;  
Mean weighting 
7% 
8/12 participants  
11 criteria;  
Mean weighting 
17% 
Additional analysis under ‘advances the science’ criteria 
Policymakers and regulators 
The figure below shows the option performance rankings for UK and US policy-
makers and regulators which are referred to in Chapter 7, Section 7.2.2.  
Figure J.13: Performance rankings for UK and US policymakers and regulators 
under the ‘advancing the science’ issue 
 
0 5 10 15 20 25 30 35 40 45 50
Performance Rankings
Detailed centralised oversight
Expert-led framework
Detailed expert oversight
Devolved authority
Mixed central/devolved
Ethics-led governance
Detailed centralised oversight
Expert-led framework
Detailed expert oversight
Devolved authority
Mixed central/devolved
Ethics-led governance
Detailed centralised oversight
Expert-led framework
Detailed expert oversight
Devolved authority
Mixed central/devolved
Ethics-led governance
Performance Rankings for UK and US policymakers and regulators perspectives under 
'advancing the science' issues
UK Policymakers 
and Regulators
4/4 participants
10 indiv. criterion
US Policymakers 
and Regulators
8/8 participants
22 indiv. criterion
Policymakers & 
Regulators
12/12 participants
32 indiv. criteria
  
369 
The performance rankings for the UK policymakers and regulators show a 
preference for two highly centralised options: detailed centralised oversight and devolved 
authority. However, there is more uncertainty and ambiguity for the devolved authority 
option and we also see a high level of uncertainty and ambiguity within the mixed 
central/devolved option. This pattern suggests that the UK-based perspective may favour 
options with some degree of centralised oversight and regulation. The rankings for US 
policymakers and regulators seem to reflect the desire to support good science and put 
structures in place which are flexible, effective and foster consistency in oversight. The 
options that are most favoured all have at least one feature of centralisation, thus ensuring 
consistency and harmonisation of policy. Where there is decentralisation, such as seen in 
the expert-led framework with its regional oversight bodies, there is also a high 
expression of uncertainty and ambiguity.   
Uncertainty and ambiguity expressed by laboratory-based scientists 
 The series of figures below show the uncertainty and ambiguity for different 
groups of laboratory scientists under ‗advances the science‘ criteria. They support the 
point made in Chapter 7, Section 7.2.2, about uncertainty and ambiguity within this 
stakeholder group. UK scientists, in particular, are both more uncertain and more 
ambiguous (in relation to each other) in assessing the options than US scientists. This 
point is seen in comparing Figures J.14 through J.17 below. 
Figure J.14: Mean interval uncertainty for UK laboratory scientists under 
‘advances the science’ criteria 
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Figure J.15: Mean ambiguity for UK laboratory scientists under ‘advances the 
science’ criteria 
 
Figure J.16: Mean interval uncertainty for US laboratory scientists under ‘advances 
the science’ criteria 
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Figure J.17: Mean ambiguity for US laboratory scientists under ‘advances the 
science’ criteria 
 
Bioethicists 
 The analysis of the issue ‗advancing the science‘ for bioethicists is presented in 
Chapter 7 in Section 7.2.2. The performance ranking charts for UK and US bioethicists is 
shown in Figure J.18 below.  
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Figure J.18: Rankings for bioethicists under ‘advancing the science’ criteria 
 
 
We can see from this figure that there are real differences in the ordinal pattern of 
performance rankings of UK and US bioethicists. However, the analysis in Chapter 7 
showed that there was little difference in the qualitative analysis of the criteria which 
composed the issue. This seems to support the conclusion that despite the similar framing 
of the criteria within the issue, their evaluations of the options themselves vary. In other 
words, though the framing is similar, the way that the options are interpreted is different. 
The two figures below compare the uncertainty and ambiguity for this stakeholder group 
under ‗advances the science‘ criteria and we do see greater ambiguity evident than 
uncertainty, although the overall patterns are the same, indicating that where there was 
uncertainty, there was also disagreement over option performance, and these patterns 
varied consistently across the options.  
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Figure J.19: Mean interval uncertainty for bioethicists under ‘advances the science’ 
criteria 
 
Figure J.20: Mean ambiguity for bioethicists under ‘advances the science’ criteria 
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Advocates 
In Chapter 7, different types of advocacy groups were analysed. UK and US-
based advocacy groups have similar performance rankings to the ordinal pattern at the 
overall group level and are shown below. 
Figure J.21: Rankings of US and UK advocacy groups under the issue ‘advancing 
the science’ 
 
 
However, there are differences based upon the type of advocate the participant 
was – a patient advocate or a policy advocate – as shown in Figure J.24 below. Rankings 
for participants who advocated for changes to the hESC governance framework because 
they are opposed to it are not shown because only 2 criteria were defined.   
0 5 10 15 20 25 30 35 40 45 50
Performance Rankings
Detailed centralised oversight
Expert-led framework
Detailed expert oversight
Devolved authority
Mixed central/devolved
Ethics-led governance
Detailed centralised oversight
Expert-led framework
Detailed expert oversight
Devolved authority
Mixed central/devolved
Ethics-led governance
Detailed centralised oversight
Expert-led framework
Detailed expert oversight
Devolved authority
Mixed central/devolved
Ethics-led governance
Performance Rankings for UK and US advocacy group perspectives under 'advancing the science' issues
UK Advocacy 
Groups
4/6 participants
6 indiv. criterion
US Advocacy 
Groups
6/6 participants
16 indiv. criterion
Advocates
10/12 participants
22 individual criteria
  
375 
Figure J.22: Rankings of multiple types of Advocates under the issue 'advancing the 
science' 
 
 
First, we can see that under patient advocate perspectives for this issue the 
‗detailed expert oversight‘ option has the highest performance ranking under optimistic 
scores, followed very closely by the expert-led framework (a difference of approximately 
2 base points). Conversely, under policy advocate perspectives the detailed centralised 
oversight option has the higher performance ranking under optimistic scores, followed by 
the devolved authority option (a difference of approximately 5 base points). Under both 
options the ethics-led governance option
166
 and the mixed central/devolved option were 
two of the worst performing options overall.  
A few implications of these different ordinal ranking patterns are highlighted 
here. First, the high performance ranking of the detailed expert oversight option under 
patient advocate perspectives is intriguing because this option has prescriptive 
regulations and centralised oversight. Previous perspectives have found these features to 
                                                 
166
 The extremely small expression of uncertainty seen for the ethics-led option under policy advocate 
perspectives is explained by the fact that only 3 of the 6 participants evaluated this option due to its 
inclusion as a ‗core‘ MCM option after an initial set of interviews had already been conducted (see 
explanation and justification for this as given in Chapter 4). The three participants who did evaluate this 
option, coincidentally, all used very small ranges of uncertainty in their evaluation of the option. 
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translate into a rigid and inflexible option, some of the opposite characteristics from what 
advocates expressed as important components of facilitating a beneficial, therapeutic 
hESC trajectory. However, the option also relies on expert-based decision-making for 
research approval. As we point out in Chapter 7, many patient advocates thought this 
could facilitate moving the science forward, faster.  
Second, as both types of advocates framed the hESC trajectory in terms of social 
and public benefits, it is not entirely unexpected that each group favoured options that 
had centralised oversight and detailed regulations. This, it is believed, ensures 
‗consistency‘ in the science and helps to direct science towards particularly desired goals. 
An explanation for the difference in the type of centralised option each type of advocate 
preferred lies in types of public benefit each group would like to see. Thus, policy 
advocates expressed a preference for the detailed centralised oversight option as opposed 
to the detailed expert oversight option because it had a greater role for public inputs, 
which would prevent the science from being controlled by one group of ‗expert‘ 
interests. Though both groups of advocates had similar motivations for why they favour 
different options, there are clear differences in the way these motivations were revealed 
in the option assessments. 
Industry and professional executives 
 The charts below show the uncertainty and ambiguity charts for various 
groupings of stakeholders within the group ‗industry and professional executives‘. They 
show that industry executives express both greater uncertainty and ambiguity in 
evaluating the options in comparison with participants who are from professional bodies. 
As pointed out in Chapter 7, this could explain the different ordinal ranking patterns 
observed between the two groups. 
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Figure J.23: Mean interval uncertainty for industry executives under ‘advances the 
science’ criteria 
 
Figure J.24: Mean ambiguity for industry executives under ‘advances the science’ 
criteria 
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Figure J.25: Mean interval uncertainty for professional body representatives under 
‘advances the science’ criteria 
 
Figure J.26: Mean ambiguity for professional body representatives under ‘advances 
the science’ criteria 
 
Annex K – Additional Multicriteria Mapping analysis 
and ranking charts for points made in Chapter 8 
Rankings for normative, substantive and instrumental criteria 
In Chapter 8 the normative, instrumental and substantive imperatives which 
were found to be present as underlying rationales affecting option appraisal were probed 
in relation to the MCM empirical findings. Figure K.1 shows the rankings for 
stakeholder perspectives under substantive criteria, the only chart not shown in the main 
text in Chapter 8 in relation to these types of criteria.   
Figure K.1: Rankings for stakeholder perspectives under substantive criteria 
 
Rankings for process and outcome criteria 
The two figures below show the performance rankings for UK and US 
perspectives for the two issues ‗process-based‘ and ‗outcome-based‘: 
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Figure K.2: Rankings of UK and US perspectives on process-based criteria 
 
Figure K.3: Rankings of UK and US perspectives for outcome-based criteria 
 
 The figures below show the rankings for outcome- and process-based criteria 
across the five main stakeholder groups.  
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Figure K.4: Performance rankings of initial stakeholder perspectives under 
process-based issues  
 
Figure K.5: Performance rankings of initial stakeholder perspectives under 
outcome-based issues 
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Rankings for moral and ethical awareness criteria 
 The figures below show the performance rankings for different perspectives 
under ‗moral and ethical awareness‘ criteria.  
Figure K.6: Rankings of UK and US perspectives under ‘moral and ethical 
awareness’ criteria  
 
Figure K.7: Rankings of UK and US perspectives under ‗moral and ethical awareness‘ 
criteria 
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